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Abstract 
Name: Philip Simon Smith 
Title: Molecular genetic investigations of renal cell carcinoma predisposition 
 
Renal Cell Carcinomas (RCC) are a diverse group of histologically and genetically distinct renal 
neoplasms accounting for 2.4% of all cancers worldwide. While a majority of RCC cases are sporadic 
in nature, a proportion are due to genetic predisposition caused by syndromic and non-syndromic 
conditions. Inherited renal cell carcinoma is associated with alterations in genes such as VHL, MET, 
FH, and FLCN and identification of these genes has been critical to understanding the molecular 
biology of both inherited and sporadic RCC, informing both clinical management and treatment. 
Despite the large number of known genes which are linked to RCC predisposition, most individuals 
with features of RCC predisposition do not harbour variants in known inherited RCC genes, 
suggesting additional unknown causes of heritability have yet to be uncovered. This study has 
utilised a range of genomic sequencing methodologies, scaling from single gene to whole genome 
sequencing, on individuals with features of renal cell carcinoma predisposition in order to identify 
novel causes of heritability associated with RCC. Multiple genomic sequencing approaches in these 
individuals has uncovered a range of potential genetic features that could be associated with 
predisposition to RCC, including genes not previously known to be associated with RCC, discovery 
of new molecular mechanisms of genetic inheritance for known RCC predisposition syndromes, and 
provided innovative methods for the identification and characterisation of molecular alterations in 
specific inherited RCC subtypes. 
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1.1 Medical genetics: From Mendel to gene therapy 
1.1.1 Discovery of genetics 
Mendelian inheritance, as first described by Gregor Mendel in 1865 in the Proceedings of the Natural 
History Society of Brünn (1), was the beginning of our understanding of how genetic traits and 
phenotypic features were passed from one generation to the next and is widely considered the birth 
of the field of genetics. Rapid developments in the understanding, models, and theories regarding 
genetics and genetic inheritance led to the identification of genetic alterations, which could confer 
detrimental or beneficial survival advantages, as explored by scientists such as Charles Darwin and 
Thomas Hunt Morgan, amongst many other 20th century geneticists. The application of genetic 
inheritance to human disease traits in the mid to late 20th century transformed our understanding of 
various diseases, demonstrating that diseases could be investigated as underlying inheritable traits 
and their genetic aetiology understood. 
1.1.2 Models of inheritance 
Genetic diseases, defined as a condition that manifests due to a genetic abnormality, occur at 
varying levels of pervasiveness within human populations and at varying clinical severities. While 
many genetic disorders follow Mendelian inheritance, multiple models of inheritance have now been 
defined and implicated in human disease, including but not limited to, X and Y-linked inheritance, 
co-dominant inheritance, mitochondrial inheritance, and polygenic or complex traits. Further 
complexity is added by way of incomplete or partial penetrance of phenotypes, as well as specific 
genotype-phenotype correlations. Penetrance, for example, is the probable likelihood for any given 
genotype to result in a phenotype, where a genotype is considered 100% penetrant when its 
associated phenotype is always present. Genotype-phenotype correlations describe the 
phenomenon of different alterations in one gene loci resulting in different phenotypic presentations, 
for example a lower risk of phaeochromocytomas in Von Hippel-Lindau disease if resulting from a 
truncating mutation in the tumour suppressor gene VHL compared to a missense substitution (2). 
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1.1.3 De novo variants and mosaicism 
De novo genetic events, as a result of newly acquired alterations during zygote formation, can lead 
to disease phenotypes without being inherited from the parental genomes. In fact, all genetically 
inherited diseases will have stemmed from an initial de novo mutational event, with subsequent 
generations inheriting that disease-causing allele. De novo events often lead to increased disease 
prevalence within isolated human populations due to founder effects (e.g. Ellis–van Creveld 
syndrome in Amish populations (3)) as a consequence of increased endogamy and consanguinity 
or, in the case of autosomal recessive sickle cell disease, caused by variants in β-globin (HBB) gene, 
due to the selective advantage conferred in the heterozygous state to malaria infection (4). De novo 
events can also result in mosaic alterations, depending upon which cellular division in embryonic 
development that the alteration occurred in, resulting in two cell populations with differing genotypes 
within the same organism. Mosaicism is subdivided into somatic and germline mosaicism, based on 
the subset of cells affected, with somatic cells unaffected in germline mosaicism. Mosaicism is a 
prevalent mechanism for the occurrence of genetic disease and potential for unusual inheritance 
patterns in the case of germline mosaic variants, as reviewed by Forsberg and Gisselsson (2017)(5). 
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1.1.4 Landscape of genetic alterations 
Genetic aberrations are heterogeneous in nature but include alterations such as chromosomal 
aneuploidy, chromosomal rearrangements (e.g. translocations and inversion), epigenetic and 
imprinting defects, copy number alterations, and single or small nucleotide base errors (e.g. 
nucleotide substitutions, insertions, and deletions). The human genome is highly variable with every 
individual harbouring thousands of inherited alterations and tens of de novo alterations (6), many of 
which confer no phenotype or no known effect. For non-neutral variants, the alterations vary greatly 
in how they mechanistically lead to disease phenotypes but they broadly lead to altered or absent 
protein products either via 1) haploinsufficiency, in which a single functional gene allele is insufficient 
to generate sufficient protein to perform its biological function, 2) recessive variant or bi-allelic 
inactivation of a gene leading to insufficient or inactive protein products, or 3) generation of a 
dominant negative effect in which the affected gene product interferes with wildtype protein functions, 
all of which cause aberrations in downstream molecular pathways resulting in abnormal phenotypic 
presentations. 
1.1.5 Medical genetics in the present 
Understanding genetic alterations and their role in genetic diseases has developed and transformed 
into the field of medical genetics. Medical genetics is now a broad, multi-disciplinary, scientific field 
focused on identifying, classifying, and diagnosing genetic disorders and seeking to provide clinical 
prognoses, counselling, and treatment options for affected individuals and related family members. 
Prognosis of any genetic disorder varies widely based on the disease, ranging from only a minor 
impact on quality of life to severe life-long medical intervention. Genetic disorders, in general, 
intrinsically do not have any known cures (i.e. methods to correct the causative genetic alteration) 
due to the causative alterations being ubiquitous to every cell, though some success has been seen 
in the treatment of genetic autoimmune diseases in bone marrow utilising gene therapy and marrow 
transplants (7).  
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Treatments for genetic disorders focus on methods to alleviate or remove disease symptoms, slow 
the advances of disorders which become progressively worse with time, and provide counselling for 
affected individuals and their families regarding screening and prophylactic options, transplantation 
of the affected organ, as well as family planning in regard to fertility and likely transmission rates for 
offspring. Currently, medical genetics is focused on the application of personalised medicine for 
clinical management and the development of gene therapies, in order to provide a curative option 
for patients afflicted with genetic diseases. Utilisation of genomic sequencing to inform 
pharmacological contraindications and responses (8), potential tolerances and responses to 
treatment plans are already being implemented and used in cancer genomics through analysis of 
tumour sequencing, allowing for targeted use of tumour-specific therapeutics (9).  
Gene therapies are a recent form of therapeutic measures for genetic disorders that aim to directly 
alter the genetics of an affected individual. Gene therapy can be applied by two distinct approaches, 
either somatic or germline, where somatic is by far the most common. Somatic applications could be 
used to fix genetic alterations in specific tissues or organs, such as lung epithelial tissue in cystic 
fibrosis (10), where the effect is not permanent and based on the ability of delivery methods to reach 
the affected cells. Germline methods function identically but occur by altering the DNA of germline 
cells, meaning that alterations are heritable. Most recently, the application of CRISPR-Cas9 
nucleotide base editing has been seen as potential milestone in gene therapy with the ability to 
permanently repair mutations in genes causing diseases, with the resulting change present in 
subsequent cell divisions, but there are a number of ethical and practical concerns, particularly 
regarding germline applications (11). 
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1.2 Cancer: A genetic disease 
Cancer is multi-systemic group of diseases resulting from abnormal and uncontrolled cellular growth 
in any organ within the human body leading to tumour formation. Cancers, in contrast to benign 
tumours, have malignant properties and can invade and metastasise to other tissues, leading to 
organ failure and ultimately death.  
1.2.1 Genetic origin of cancer 
Cancers are, at the most fundamental level, a genomic disease and the occurrence and 
accumulation of genetic alterations or alterations in epigenetic regulation. These alterations lead to 
a cellular environment in which uncontrolled replication can occur, which in turn leads to growth of 
tumour cells in the affected organ. In all cells, mutations and damage to DNA are acquired over time 
through both endogenous and exogenous mechanisms but they are generally either successfully 
repaired (12), detected by cell cycle check points (13), or the alterations are functionally neutral or 
result in no change to fitness (14). 
Genetic alterations in genes leading to cancer development are defined by altering either one of two 
core types of genes, tumour suppressor genes (TSGs) or oncogenes, which function in opposing 
roles in the prevention and promotion of cellular proliferation and survival. TSGs are classically 
associated with the transcription of proteins, which act to negatively regulate pathways involved in 
cell cycle progression, replication, and positive regulation of pathways inducing apoptosis or cellular 
senescence. Tumour suppressor genes are consistently inactivated by genetic alterations in cancer 
cells, resulting in a loss of these functions. Conversely, proto-oncogenes (termed oncogenes after a 
causal genetic alteration has occurred) serve to negatively regulate apoptotic pathways and are 
positive drivers of cell cycle progression and division. Alterations in oncogenes, in contrast to TSGs, 
are not inactivating and act to either increase the function of the transcribed protein, cause 
constitutional protein activity, or elevate transcription rates, leading to further upregulation of their 
target molecular pathways. 
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The identification of both TSGs and oncogenes led to the development of hypothesises on how an 
acquired genetic alteration can specifically result in carcinogenic transformation. Knudson’s two-hit 
hypothesis is regarded as one of the pivotal discoveries in cancer biology stating that loss or 
inactivation of a single TSG allele is insufficient to result in cancer and a secondary ‘hit’ to inactivate 
the remaining wild type allele is needed for cancer to develop (15). As with any rule there are 
exceptions, such as TSGs expressing dominant negative effects or haploinsufficiency (16), but most 
TSGs conform to this theory with secondary hits via additional inactivating variants or chromosomal 
deletions (which result in loss of heterozygosity (LOH)) of the remaining wild type allele. 
Proto-oncogenes typically do not follow the same two-hit hypothesis and most are dominant in 
nature, with a single activating event sufficient to initiate oncogenic processes. In many cases, the 
loss of TSGs and activation of proto-oncogenes act in concert to drive tumour initiation, which 
consequently results in increased clonal expansion and genetic alterations to drive tumour 
evolution through acquired driver mutations. The process of clonal expansion and tumour evolution 
is not dissimilar to evolution that occurs at a species level, with acquired mutations conferring or 
reducing survival advantages for sub-clones of the initiating tumour cell (17). These features of 
tumour development resulted in the emergence of cancer cell traits termed the “hallmarks of 
cancer”, a series of biological processes by which cancers can expand, survive, and resist 
detection and death (18). 
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Lastly, temporal distribution over which the first initiating event and the progression towards 
oncogenic potential occur, has been recently highlighted by the assessment of mutational profiles 
in normal tissues. Evidence for the occurrence of cancer driver mutations found clonally in normal 
tissues, such as skin and oesophageal, have demonstrated that driver mutations in both proto-
oncogenes and tumour suppressors have been found in a large proportion of normal cells, 
increasing with age and exposure to exogenous mechanisms of DNA damage. These mutations 
were observed to have occurred as early as infancy, indicating that initiating event occur and 
persist over large temporal spans but cells harbouring these driver variants lacked additional 
oncogenic features such as higher mutational burden and chromosomal instability seen in cancer 
cells of the respective tissues (19–21). Furthermore, assessment of the timing of mutational events 
seen in clear cell RCC in the TRACERx renal study demonstrated that initial clonal expansion 
consists of only a few hundred cells harbouring a 3p loss initiating event, occurring upwards of 20 
years prior to inactivation of VHL (considered to be the second hit). Following the inactivation of 
VHL, diagnosis of clear cell RCC was not found until between 10-30 years after numerous 
additional driver events had occurred (22). The importance of the temporal distribution of driver 
events is that cancer cells, relative to cancer at a patient-level, have extremely low penetrance and 
rarely result in a tumour. 
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1.2.2 Hallmarks of cancer 
The hallmarks of cancer, as reviewed by Hanahan & Weinberg (2011)(18), are a set of biological 
features that are intrinsically linked to tumour initiation and development, acting to drive tumour 
proliferation or hinder pathways and external mechanisms that would act moderate, attenuate, or 
prevent tumour growth. Different cancers utilise different constituents of the hallmarks, manipulating 
both intracellular pathways and the external surrounding tissues and making use of different 
molecular networks and mechanisms to sustain cellular proliferation, the consequences of which 
drive the diversity in both cancer types, histologies, and prognoses. The hallmarks of cancer are not 
a definitive list of factors that drive cancer but a robust framework that acts to categorise the broadest 
number of molecular features that can drive tumour progression (see 1.2 Figure 1). 
Loss of control of biological processes such as proliferative signalling, induction of replicative 
immortality by activation of telomerases, and the promotion metabolically favourable intracellular 
conditions act to increase cellular growth and replication. In tandem, disruption of cellular 
mechanisms functioning as growth suppressors through cell cycle checkpoints and negative 
feedback loops, resisting cell death via inhibition or inactivation of apoptotic signalling pathways, and 
the avoidance of immune destruction through dysregulation of cell surface markers and extracellular 
signalling, act to reduce cancer cell death by either internal molecular routes or external immune 
detection. Finally, tumours utilise the surrounding stromal tissue to establish a supportive 
environment for growth and development by inducing angiogenesis via activation of angiogenic 
pathways and prompting local inflammatory responses, which aid in tumour development, the 
consequence of which leads to the formation of a tumour microenvironment in which cellular growth, 
clonal expansion and evolution, and tissue invasion can flourish. The ability to be invasive and cause 
metastases is a distinct property of cancers, making this hallmark potentially the most significant in 
terms of disease mortality. While many benign tumours utilise the hallmarks of cancer sustain and 
promote their growth, local and distal invasion through increased motility and large-scale changes 
to underlying cellular subtype, as such the epithelial-mesenchymal transition (EMT), are properties 
only exploited by cancers. These two traits are the greatest contributors to the lethality of cancers 
with almost all cancers showing significant decreases in survival metrics once metastatic disease 
has occurred (23). 
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1.2 Figure 1 
Hallmarks of cancer – 1A Diagram depicting the features that comprise the hallmarks of cancer. Biological 
mechanisms tumours used to promote growth and survival. 1B Diagram demonstrating the newly discovered 
hallmarks of cancer regarding immune evasion and metabolic dysregulation, and non-hallmark characteristics 
which support tumour growth and development. Figure adapted from (18). 
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1.2.3 Genetic inheritance of cancer 
While cancers most frequently occur sporadically, with incidence rates increasing proportionally to 
age in line with random acquisition of genetic variation and exposure to environmental factors, 
familial inheritance of cancers and susceptibility to cancers is well documented. A predisposition to 
cancer is most commonly identified by a strong family history of one or several cancer types within 
a pedigree but is also signified by a reduction in the average age of onset in the presenting 
individuals, or the presentation of multifocal or bilateral tumours. In many cases, these features 
present concurrently, with family histories containing individuals presenting with earlier onset and 
multiple tumours on presentation. 
The mechanism for cancer development in an inherited disease is essentially identical to that of 
sporadic cases in regard to the genetic mechanisms and subsequent biological changes which result 
in oncogenesis, although the age of onset and cancer-specific presentations can differ, for example 
inheritance of a null TP53 allele results in Li-Fraumeni syndrome (24), a syndrome characterised by 
predisposition of a number of rare cancer types. Conversely, sporadic occurrences of TP53 
mutations results in more common cancer types such as small cell lung, oesophageal, and ovarian 
cancers (25). Inheritable cases of cancer arise due to the inheritance, or in some cases de novo 
acquisition, of a constitutional variant in a TSG or proto-oncogene. The stable presence of a non-
wild type TSG allele in all cells has a significant impact on the probability of tumour development; for 
TSGs, the barrier for complete allelic loss (as proposed in Knudson’s two-hit hypothesis) is halved 
as only one somatic inactivating variant is required in the remaining wild type allele, rather than two 
as required in sporadic cases (15). For proto-oncogenes the process is similar; constitutional variants 
in proto-oncogenes overcome the requirements for somatic activation by already being 
constitutionally active and only requiring the loss of additional TSGs or the correct cellular 
environments to allow for tumour progression. Many syndromes associated with cancer risk 
phenotypically display an array of non-cancer pathologies as a result of a non-wild type allele in 
genes with multiple biological functions (26). Conversely, several cancer predisposition phenotypes 
only manifest as a predisposition to cancer development, despite most associated genes having 
functions outside of the remit of a TSG or oncogene, such as BRCA1 DNA repair associated and 
BRCA2 DNA repair associated (BRCA1 and BRCA2) in Hereditary breast–ovarian cancer 
syndrome (27). 
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1.3 Renal cell carcinoma 
1.3.1 Incidence 
Renal cell carcinoma (RCC) is the most frequent form of kidney cancer accounting for more than 
90% of diagnosed cases, the remaining of which includes cancers of the renal medulla and 
transitional cell carcinomas of the renal pelvis. Kidney cancers account for approximately 2% of new 
cancer diagnoses and 1.5% of cancer deaths per year, globally (28). RCC occurs on average at 64 
years of age (29), with age of onset being significantly lowered in individuals presenting with RCC 
predisposition syndromes (30). Life time risk for individuals in the United Kingdom are estimated at 
3% for males and 2% for females (31), with approximately 34% of cases being defined as 
preventable (attributed to lifestyle and environmental factors) (32).  
The primary lifestyle factors attributable to RCC risk are increased body mass index (BMI; kg/m2) 
and tobacco usage. Increased BMI results in combined relative risk increases for both sexes of 28% 
and 77% for overweight and obese individuals, respectively. BMI-linked RCC risk is biased towards 
females with increased risk at 38% compared to 22% in overweight individuals and 95% compared 
to 63% in obese individuals (33). Tobacco usage has also been showed to provide increased risk 
for RCC development with a relative risk increase of 16-36% for tobacco users compared to never-
smokers (34). Other lifestyle and environmental factors for RCC risk include hypertension (35), 
acquired cystic kidney disease (36), diabetes (37,38), non-prescription analgesic usage (39), poor 
dietary choices (40,41), and exposure to specific chemical compounds (42,43).  
Kidney cancer has seen the greatest increase in age-standardised incidence rate (ASIR) among all 
cancers, having seen a 23% increase in incidence between 1990 and 2013. Furthermore, kidney 
cancer occurs more readily in developed countries but has seen a similar increases of 34% and 36% 
in incidence rates between both developing and developed countries, respectively (28). Increases in 
ASIRs for kidney cancer may be attributable to increased rates of obesity (44), particularly in 
developed countries, which is directly linked to poor dietary choices (45), as well as compounding 
other risk factors such as hypertension (46) and diabetes (47). Moreover, kidney cancers have been 
historically difficult to detect due to being relatively asymptomatic until late in tumour progression 
(48), meaning technological advances such as use of abdominal ultrasound imaging, improved 
screening, and increased life expectance may lead to a greater proportion of kidney cancers being 
reported. 
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1.3.2 Major histological subtypes 
Though RCC is broadly discussed as a singular disease, it is more accurately defined as collection 
of renal neoplasms with distinct morphologies, molecular mechanisms, and genetic backgrounds. 
According to the International Society of Urological Pathology (ISUP) more than 15 histological 
subtypes of RCC can be defined but a majority of cases are categorised into three primary groups; 
clear cell RCC, papillary RCC, and chromophobe RCC, which accounts for a vast majority of all RCC 
cases (49) (1.3 Figure 2). 
Clear cell RCC is the most commonly diagnosed histological subtype of RCC with an occurrence 
rate of 63-83% of all RCC cases (50,51). Clear cell RCC occurs more predominantly in males than 
females (1.5-3:1 male to female ratio) and has its highest incidence between 60 and 70 years of age. 
Clear cell RCC is thought to originate from epithelial cells of proximal convoluted tubule and is 
defined by large clear cytosolic cell body due to lipid accumulation (52,53). In term of gross 
morphology, clear cell RCCs are solid, yellow tumours with a high degree of vascularisation (54). 
Clear cell RCC has the worst clinical prognosis compared to both papillary RCC and chromophobe 
RCC, with cancer-specific 5 years survival rates being 68.9%, 87.4%, and 86.7%, respectively (55). 
The most frequent tumour stage at diagnosis in clear cell RCC is stage I but some studies reported 
inconsistently, with stage III in two European studies (54,56) but stage I in a Japanese cohort (57). 
Papillary RCC is the second most common histological subtype of RCC reported, split into two further 
subtypes type 1 and type 2, accounting for 11-18.5% of all RCC (50,51). As discussed in relation to 
clear cell RCC, type 1 papillary RCC have better prognoses and are clinically less aggressive (55), 
where type 2 papillary RCC are similar in clinical presentation. In similarity to clear cell RCC, patients 
most frequently report at stage I and at a median age of 65 (55). The two subtypes are designated 
as basophilic (type 1), due to the presence of small hyperchromatic basophiles with minimal 
cytoplasm, and eosinophilic (type 2) resulting from the presence of tumour cells with abundant 
eosinophilic cytoplasm (58). Morphologically, papillary tumours are solid, well-demarcated with 
minimal vascularity, particularly compared to clear cell RCC, and are slow growing (59). Differences 
between type 1 and type 2 papillary RCC, while they present at similar frequencies, are that type 2 
papillary RCC more frequently present at higher grades and has markedly worse survival outcomes 
compared to type 1 (50). 
25 
 
Chromophobe RCC occurs in 5-6% of reported RCC tumours (50,51) and is considered the least 
aggressive subtype of the three major subtypes (55), with 5-year survival rates as high as 94% (51), 
and metastasis only seen in a small proportion of cases (58). Histologically, chromophobe RCC 
consists of large cells with webbed cytoplasm and haloed nuclei. Conversely to clear cell and 
papillary RCC, chromophobe RCC appears to occur more frequently or equally in females and 
occurs most frequently at lower stages, rarely being diagnosed at stage III or IV (50,55). 
Additional histological subtypes of RCC do occur but most are rare relative to the frequency of the 
three primary types already discussed. These subtypes include, but are not limited to, clear cell 
tubulopapillary RCC, a histological subtype with characteristics similar to that of both clear cell RCC 
and papillary RCC (60). MiT-family translocation RCC, a subtype driven by recurrent somatic 
translocations of Transcription Factor Binding To IGHM Enhancer 3 (TFE3) on Xp11.2 and 
t(6;11)(p21;q12) translocations involving Transcription Factor EB (TFEB), as well as Melanocyte 
Inducing Transcription Factor (MITF) and Transcription Factor EC (TFEC) (61). Mucinous tubular 
and spindle cell carcinoma, subtype with strong similarities to papillary RCC but recently described 
as a distinct histological subtype, reviewed by Zhao et al. (2015)(62). Lastly, succinate 
dehydrogenase (SDH)-deficient RCC tumours, caused by loss of the SDH complex components, are 
a recently classified histological subtype of RCC defined by distinctive eosinophilic inclusions 
corresponding to giant mitochondria (49). 
A histological feature that appears independently of histological subtype but has a substantial effect 
on prognosis is presence or absence of sarcoma-like histology. Approximately 1-5% of RCC tumours 
consist of a sarcoma-like or sarcomatoid histology which is strongly associated with a much poorer 
prognosis compared to other histologies alone (63). While not consistently attributable to a single 
primary histological subtype, sarcomatoid RCC is more frequent in chromophobe RCC histologies 
though comprehensive data is limited (64,65). Sarcomatoid RCC is linked to a shift from an epithelial 
to mesenchymal phenotype (EMT) (66) and EMT is linked with metastatic potential and increases in 
mobility and invasiveness (67), explaining the increase in aggressiveness of RCC tumours with any 
sarcomatoid histology present. 
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1.3 Figure 2 
Histological appearances of the three main tumour types of RCC: 2A Histological presentation of 
clear cell RCC. 2B Histological presentation of type 1 papillary RCC. 2C Histological presentation of 
type 2 papillary RCC. 2D Histological presentation of chromophobe RCC. Images adapted from 
Muglia et al. (2015)(58). 
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1.3.3 Tumour staging 
Typically RCC is staged according to the degree of tumour spread throughout the body, where 
tumour size and invasiveness are taken into account (68). RCC stage is characterised and 
designated by classifications laid out by the American Joint Committee on Cancer as a combinatorial 
function of tumour size (T0-4), lymph node metastasis (NX, N0, or N1), and distant metastasis (M0 
or M1) (69). 1.3 Table 1 describes the TNM system and its associated staging. 
1.3.4 Tumour grade 
The prognostic value of RCC tumour grades has long been recognised and widely utilised as a metric 
for outcome prediction and tumour progression rates (70). Tumour grading based on microscopic 
cellular morphology and differentiation of tumours acts as a surrogate for numerous underlying 
molecular and biochemical processes that influence the prior factors. Classically, RCC tumours have 
been widely graded by the Fuhrman grading system (71) but more recent studies have demonstrated 
that Fuhrman grading inadequately models tumour differentiation and that grading based on 
individual histological subtype is more representative of predicted disease progression (49). 
Current grading of RCC tumours was proposed jointly by the world health organisation (WHO) and 
ISUP in 2012, with clear cell and papillary RCC being graded independently using nucleolar 
prominence and tumour necrosis for clear cell and nucleolar prominence only for papillary (72). Due 
to poor correlation with grading parameters (73) it was suggested that chromophobe grading should 
not be performed (49). With all other histological subtypes, application of ISUP grading guidelines is 
considered challenging due to lack of large enough cohorts to perform stratified analysis to inform 
survival predictions. 
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1.3 Table 1 
Features and classification for staging of RCC tumours 
Stage 
TNM 
classification 
Description 
Stage I T1, N0, M0 
Tumour limited to kidney, less than 7 centimetres in size with no 
lymph node or distant metastasis. 
Stage II T2, N0, M0 
Tumour limited to kidney, greater than 7 centimetres in size with no 
lymph node or distant metastasis 
Stage III 
T3, N0, M0 Tumour expanded to invade large proportion of kidney including 
major veins but with no lymph node or distant metastasis or tumour 
is any size and does not extend to the renal vein but lymph node 
metastasis 
T3, N0, M0 
T2, N1, M0 
Stage IV 
T4, N0, M0 
Tumour extends beyond the kidney tissues into external tissues or 
any kidney tumour with distant metastasis. 
T4, N1, M0 
T1-4, N0-1, M1 
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1.3.5 Survival 
Overall survival rates for kidney cancer are approximately 72.4%, 56.2%, and 49.5% for 1-year, 5-
year, and 10-year survival, respectively. Survival rates for kidney cancers are strongly dependent on 
tumour stage, grade, and histological subtype, as discussed previously. Survival declines sharply if 
diagnosed at stage III or IV, with 5-year survival of 92.6% at stage I compared to 68.7% at stage III 
and only 11.6% at stage IV (29). 5-year survival is also impacted by age of diagnosis where 
individuals diagnosed before 45 years of age have a net survival rate of 87.8% compared to only 
67.5% for those over 65 years of age (29).  
1.3.6 Generalised treatment 
While discussing all potential therapeutic routes and methods currently available for RCC is beyond 
the scope of this thesis, this section covers the general patterns and principles guiding RCC 
treatments as summarised from clinical guidelines (74).Treatment for RCC cases is generally 
directed by tumour stage at presentation, with surgical intervention being the most effective current 
treatment option. Surgical resection by partial, simple, or radical nephrectomy to remove tumour 
tissue with increasing amount of the surrounding normal kidney based on tumour spread, is the first 
line treatment for RCC where a lymphadenectomy is typically performed in stage III cases to remove 
affected regional lymph node tissues (74). In stage IV tumours use of radical nephrectomy is still 
widely used though is usually palliative due to tumour metastasis or tumour embolisms into the 
circulatory system, and where resection of distance metastases is also performed where applicable 
(74).  
Across all stages, targeted therapeutic agents are deployed as both first- and second line treatments 
for RCC. Anti-angiogenic agents, such as sunitinib and pazopanib, which target vascular endothelial 
growth factor receptor (VEGFR), are commonly used in RCC due to known upregulations in 
angiogenic pathways driven by VEGFR and other kinases in RCC tumours (75,76). Most targeted 
therapeutic agents of this type are multi-kinase inhibitors and target VEGFR and its various isoforms, 
as well as epidermal growth factor receptor (EGFR), Platelet-derived growth factor receptor 
(PDGFR), mast/stem cell growth factor receptor (KIT), and hepatocyte growth factor receptor (MET) 
tyrosine kinases (77–79).  
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Further targeted pharmaceutical agents, such as temsirolimus and everolimus, have been design to 
target and inhibit mammalian target of rapamycin (mTOR) (80,81) due to its function in cell growth, 
proliferation, and cell motility via the PI3K-AKT-mTOR pathway which includes proteins coded by 
RCC-associated genes (82). Most recently, the development of Hypoxia inducible factor 2 alpha 
(HIF2-α) antagonists has shown potential in down regulation of angiogenic pathways in metastatic 
RCC with substantial pre-treatment with other agents (83). Phase I clinical trials utilising these 
compounds have demonstrated their tolerability as well as some moderate evidence for disease 
progression attenuation (84). 
Immune therapy utilising monoclonal antibodies have been used as second line treatments for 
individuals with RCC (74). Use of antibodies, such as ipilimumab and nivolumab show increased 
overall survival and act to impair immune checkpoint mechanisms by inhibiting proteins Programmed 
death-ligand 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), resulting in 
reduced cancer immune evasion (85,86). Additional treatments such as bevacizumab have also 
been used to target VEGFR, therefore blocking angiogenic pathways in a manner similar to that of 
sunitinib and pazopanib (87). Cytokine-based therapies have also been used for the treatment of 
RCC to augment immune response to cancer cells. Cytokines such as interferon-α and interleukin-
2 have been widely given as conjunctive first line therapies with targeted therapeutic agents, though 
overall efficacy is modest (74). 
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Though therapeutic routes for many RCC patients are relatively effective, particularly in early stage 
diagnosis with high disease free and overall survival, therapeutic resistance is a well-documented 
outcome in metastatic RCC treatment in both clear cell (88) and non-clear cell subtypes (89). 
Resistance to tyrosine kinase inhibitors, such as sorafenib and sunitinib, which antagonise cell 
surface receptors VEGFR and PDGFR to supress angiogenic response, occurs frequently in 
metastatic RCC after 6-12 months (90), leading to disease progression despite continued treatment. 
While the mechanism of resistance is not fully elucidated, there are several proposed routes by which 
advanced RCC develop therapeutic resistance including drug resistance through reduced uptake or 
lysosomal sequestration (91,92), activation of alternative angiogenic pathways (93), and 
upregulation of pro-angiogenic cytokine Interleukin-8 (94). The effects of the tumour 
microenvironment has also been implicated in resistance through external expression of VEGF via 
pericytes supporting angiogenic growth in surviving endothelial cancer cells (95) and the recruitment 
of pro-angiogenic inflammatory cells to the tumour site (96). More recently, EMT and its associated 
transcriptional and morphological changes have been implicated as a mechanism of tyrosine kinase 
inhibitor resistance, with suppression of EMT-related gene expression resulting in attenuated 
therapeutic resistance in cell models (97). 
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1.4 Genetics of renal cell carcinoma 
A number of Mendelian causes of RCC have been described and there is also evidence for the 
involvement low penetrance susceptibility alleles in RCC predisposition. In this section I will first 
describe Mendelian disorders associated with susceptibility to RCC and the results of GWAS studies 
for susceptibility alleles. 
1.4.1 Inherited renal cancer 
Though a majority of RCC cases are sporadic in origin, an estimated 2-4% of RCC cases are due to 
an inherited disorder (98). This minority of cases has been highly informative in sporadic cases for 
the determination of involved molecular and genetic pathways that are affected in RCC (99), as well 
as potential therapeutic targets for curative or palliative treatment (76,81,100). A summary of the 
different syndromic and non-syndromic RCC predisposing conditions is provided in 1.4 Table 2 and 
are discussed in further detail below. 
1.4.2 Additional genetic risks factors in RCC predisposition 
Family history of RCC is a significant risk factor with a relative risk of RCC incidence being at least 
2.2 fold greater in individuals with a family history of kidney cancer (101). Regardless of familial 
history, early presentation of RCC is a strong indication of predisposition, with early onset being 
predictive of a positive detection of a pathogenic variant in a RCC predisposition gene (102). Lastly, 
presentation of RCC with multiple foci or bilateral occurrence is also a common indication of genetic 
predisposition of RCC with a significantly increased occurrence in comparison to sporadic cases 
(103). In an assessment of heritability of RCC in Icelandic populations, 58% of RCC cases were 
found in families with 2 or more affected family members, with increased relative risk for siblings and 
parents, particularly if incidence was prior to 65 years of age (104). Nordic twin studies have also 
validated the genetic component of RCC within families with a reported heritability of 38% (95% CI, 
21%-55%), with no significant contribution from a shared environment (105). 
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In addition to the rare Mendelian causes of RCC predisposition described above, several studies 
have attempted to identify risk loci through genome wide association studies (GWAS) of RCC 
patients but, in contrast to the large number of susceptibility alleles identified for breast and colorectal 
cancers, there have been a limited number of loci identified as predisposing to RCC. Two SNPs 
(rs11894252 and rs7579899) found at 2p21 were shown to be associated with RCC risk and were 
present within intron 1 of Endothelial PAS Domain Protein 1 (EPAS1; HIF2-α) with an odds ratio 
(OR) = 1.18, a gene with inherent links to carcinogenic mechanisms in RCC (106,107), as well as 
an additional locus at 11q13.3 (rs7105934) associated with reduced risk (108). Fine mapping of the 
region surrounding 2p21 and detailed single nucleotide polymorphism (SNP) imputation, three 
further SNPs (rs4953346, rs12617313 and rs9679290) which were not correlated with the SNPs 
reported previously (108), were associated with RCC risk and suggest a complex haplotype 
surrounding EPAS1 (109).  
A follow-up study, which included meta-analysis of both studies (108,110), confirmed both previously 
described loci as risk loci in RCC on 2p21 and 11q13.3, and suggested two additional SNPs in 
linkage disequilibrium on 12p11.23 (rs718314 and rs1049380) located proximally to the gene Inositol 
1,4,5-Trisphosphate Receptor Type 2 (ITPR2) (110). Analysis of clinical features of individuals 
carrying rs7105934 on 11q13.3 and rs1049380 on 12p11.23 demonstrated increased and reduced 
age of onset in RCC patients, respectively (111). A GWAS study in Icelandic participants further 
elucidated risk loci for RCC, identifying a dinucleotide SNP (rs35252396) on 8q24.1, in the vicinity 
of MYC proto-oncogene, BHLH transcription factor (MYC), conferring an OR = 1.27 which had 
already been associated with other cancer types (112). Several additional studies then identified risk 
loci on 2q22.3, associated with rs12105918 in intron 2 of Zinc Finger E-Box Binding Homeobox 2 
(ZEB2), and on 1q24.1, associated with rs3845536 within intron 4 of Aldehyde Dehydrogenase 9 
Family Member A1 (ALDH9A1) (113,114). Association studies have also identified that risk loci on 
11q13.3 are able to modify the binding of HIF to the transcriptional enhancer of cyclin D1 (CCND1) 
(115) and that SNPs rs1944129 and rs7177 found within CCND1 may contribute towards RCC 
risk in Chinese populations (116). Most recently, association studied have demonstrated an 
association between cumulative SNPs linked to increased leukocyte telomere lengths and risk of 
RCC, implicating several additional loci with RCC risk (117). 
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The calculated population statistics and the limited risk conferred by common SNPs suggests that 
2-4% of RCC cases linked to predisposition is likely an underestimate and there remains a relatively 
large unexplained proportion of heritability. Underestimation of heritability is supported by recent 
assessments of patients meeting genetic referral, where consensus referral criteria provided by the 
American College of Medical Genetics (ACMG) across two independent RCC cohorts resulted in 24-
33.7% individuals in which their clinical features and histological findings would make them eligible 
for genetic testing (118), suggesting that many individuals with heritability may not be referred for 
genetic analysis in the first instance. 
1.4.3 Von Hippel-Lindau disease 
Von Hippel-Lindau disease (VHL; OMIM: 193300) is an inherited, autosomal dominant syndrome 
associated with predisposition to multiple benign and malignant tumour types. Individuals with VHL 
disease are subject to a range of clinical features including haemangioblastomas of the nervous 
system and retina, renal cysts, clear cell RCC, phaeochromocytomas (PCCs), cystadenomas, 
pancreatic neuroendocrine tumours, and endolymphatic sac tumours (119,120). VHL disease is a 
rare condition, at a prevalence of 1:39,000-91,000 and a birth incidence of 1:22,000-42,987 
(121,122). Though VHL disease predisposes to various clinical features and multiple tumour types, 
clear cell RCC has a cumulative lifetime risk of ~70%, at a mean age of 44 years (123,124).  
VHL disease was first described by Treacher Collins in 1894 who described two siblings with 
retinal haemangioblastomas (125). Studies in 1904 by Eugen von Hippel and further 
characterisation by Arvid Lindau in 1927 solidified the clinical features of VHL disease but the 
genetic cause was not uncovered until a century after the initial description. Comparisons made 
between the age of onsets in sporadic RCC cases and VHL disease cases suggested that the 
genetic component responsible for VHL was a tumour suppressor following Knudson’s two-hit 
hypothesis (30), and loss of 3p in RCC was suggestive that this region contained the causal gene 
(126). Subsequent gene mapping, determination of the gene loci from collections of co-segregating 
disease-specific loci, led to the discovery of the gene von Hippel-Lindau (VHL) on the short arm of 
chromosome 3 at 3p25.3 (127). Investigations into mutational patterns in VHL disease patients and 
sporadic RCC cases revealed frequent inactivation of VHL and LOH in tumours, confirming it as a 
primary cause for RCC in both VHL disease and sporadic RCC cases (128,129).  
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A majority of individuals with VHL disease present with a family history of VHL with dominant 
inheritance of the affected VHL allele, though de novo variants and mosaicism is estimated to 
occur in 23% of cases (130,131). Interestingly, pathogenic alterations in VHL are also associated 
with familial erythrocytosis type 2 (ECYT2; OMIM: 263400), an autosomal recessive condition 
caused by homozygous or compound heterozygous specific missense variants in both VHL alleles 
(132) with little to no overlap of the clinical features with those of VHL disease (133). 
Pathogenic variants in VHL are remarkably penetrant at the patient-level (contrary to cellular 
penetrance described earlier) with individuals developing at least one VHL-related cancer before 65 
years of age in approximately 80-90% of cases (122,123). VHL disease is broadly categorised into 
four subtypes, corresponding to differential phenotypic presentations concentrated on presence and 
risk of RCC and phaeochromocytomas. The subtypes are defined as follows: Type 1 – RCC present 
with no phaeochromocytomas, which is further subdivided into high and low RCC risk dependent on 
the absence or occurrence of BRK1 deletions in concert with VHL deletions (134), designated as 
Type 1A and 1B. Type 2A – Phaeochromocytomas with low RCC risk, Type 2B – both 
Phaeochromocytomas and RCC, and Type 2C – Phaeochromocytomas with no RCC (135). Though 
VHL is a well conserved gene, amino acids 1-53 show low evolutionary conservation and non-
truncating variants in these amino acids do not appear to cause VHL disease (136). Variant types 
that lead to inactivation of VHL cover the full spectrum of molecular alterations including nonsense, 
frameshifting insertions and deletions, missense, partial or complete loci deletions (136), and most 
recently synonymous and intronic splice site affecting variants (137). 
36 
 
The VHL gene codes for the von Hippel-Lindau protein (pVHL) which functions in the regulation of 
cellular response to hypoxia. Under normoxic conditions Egl-9 Family Hypoxia Inducible Factor 1, 2 
and 3 (EGLN1, EGLN2 and EGLN3; prolyl hydroxylases; PHDs) act to hydroxylate specific proline 
residues of HIF-α proteins, after which pVHL acts to bind hydroxylated HIF-α as a component of an 
pVHL E3 ubiquitin ligase complex (VCB), resulting in ubiquitin-directed proteolysis (138). During 
hypoxia, the oxygen-dependent hydroxylation of HIF-α proteins by PHDs does not occur, therefore 
the VCB complex does not bind and ubiquitinate HIF-α proteins, leading to an accumulation of 
hypoxia inducible factors (107,139). The translocation to the nucleus and cellular abundance of HIF-
α allow for hetero-dimer formation with HIF1-β subunits which then bind hypoxia response element 
(HRE) motifs upstream of genes associated with hypoxic response (140). This leads to an 
upregulation of transcription of genes associated with growth, angiogenesis, metabolism and stem 
cell like phenotypes, reviewed by Keith et al. (2012)(141). 
Loss of pVHL results in pseudo-hypoxic cellular environment, in which HIF1-α and HIF2-α substrates 
are not targeted for degradation regardless of hydroxylation status, which leads to upregulation of 
hypoxic response genes under normoxic conditions (141), consequentially driving tumour initiation. 
It is worth noting that although both HIF1-α and HIF2-α function in response to hypoxia, they have 
diverging functions and some reports suggest HIF1-α may act in opposition to HIF2-α as a tumour 
suppressor gene (142,143) and loss of HIF1-α is rarely reported somatically (144). 
While pVHL primarily functions in the regulation of hypoxia, pVHL also functions in the regulation of 
cell cycle control, via p27 (145), microtubule organisation and spindle assembly (146), and regulation 
of p53 (147). While these alternative functions are well defined and have functions related to 
preventing tumourigenesis and progression, they are less rigorously studied, and the primary route 
of pathogenesis is presumed to be loss of HIF regulation. Animal modelling of VHL loss have 
provided some evidence to support the current theory regarding VHL-driven tumourigenesis.  
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Though homozygous VHL knockout mice models are embryonic lethal, heterozygous knockouts 
develop haemangioblastoma-like liver growths and VHL disease-like renal cysts (148,149) but 
studies were unable to show RCC development with VHL loss alone and suggest that tumour 
development is not dependent on constitutional activation of HIF pathways (150). This in turn is 
supported by the lack of cancer phenotype in bi-allelic inactivation of VHL seen in erythrocytosis type 
2, where hypomorphic VHL alleles are present in every cell (133), the frequent loss of 3p as a second 
hit somatically (151), and by mouse models which recapitulated human clear cell RCC development 
in kidney-specific deletions of VHL and Polybromo 1 (PBRM1) together but not alone (152). 
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1.4.4 Hereditary leiomyomatosis and renal cell carcinoma 
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC; OMIM: 150800) is an autosomal 
dominant disease resulting in a predisposition to tumours including RCC as well as cutaneous and 
uterine leiomyomas (153,154). The population prevalence of HLRCC syndrome is currently 
estimated to be 1 in 200,000 and relative risk for features of HLRCC have been estimated. HLRCC 
is highly penetrant for non-RCC phenotypes with most affected individuals presenting with 
leiomyomas, but risk for RCC appears to be reduced with occurrence between 15.6-31% (154,155). 
Median age of presentation of RCC in HLRCC cases is 37 years of age (range 10-77) (156), which 
matches to the age of onset described for other RCC predisposition syndromes and cases usually 
present with a limited or single tumour, though multifocal cases have been reported. Most tumours 
tend to be histologically classified as type 2 papillary RCC but also present with features of other 
histological subtypes (157). HLRCC RCC tumours tend to be highly aggressive (grade III or IV) (155), 
in contrast to most papillary RCC tumours which tend to be more latent (158). 
HLRCC is associated with pathogenic variants in the Fumarate Hydratase (FH) gene (155,159,160). 
Most of the reported pathogenic variants within FH are missense mutations (68.2%), the remaining 
being small insertions or deletions, truncating mutations and splice altering variants (155,161). 
Pathogenic FH variants are not found in between 10-15% of HLRCC, suggesting there may be an 
unknown proportion of heritability that may be associated with undiscovered variants in FH (non-
coding variation or copy number alterations) or associated with alterations in genes other than FH 
(155,160). As with VHL, FH is suggested to function as a tumour suppressor gene with bi-allelic loss 
of FH resulting in complete ablation of FH enzyme function (154,159). The FH gene is located at 
1q43 at chr1:241,497,557-241,519,785 and consists of 10 exons which encodes the protein 
Fumarate hydratase, a core enzyme in the tricarboxylic acid (TCA) cycle (162). 
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FH catalyses the reversible hydration of fumarate to malate as part of the TCA cycle (163), driving 
generation of substrates such as purine triphosphates (adenosine/guanine triphosphates; ATP/GTP) 
and nicotinamide adenine dinucleotide (NADH) which are utilised by the electron transport chain for 
oxidative phosphorylation. Loss of FH results in perturbation of the TCA cycle, leading to a loss of 
oxidative phosphorylation and a metabolic switch to aerobic glycolysis to generate energy (164,165), 
in line with the metabolic shift described by the Warburg effect (164) in tumours. PHD enzymes 
function to hydroxylate proline residues of HIF2-α proteins, depending on cellular oxygen levels, and 
regulate hypoxic response (see above). Under normoxic conditions these post-translational 
modifications are added to HIF-α allowing pVHL complex binding and ubiquitination, leading to 
proteolysis of HIF-α (107,138,166). In cells with bi-allelic inactivation of FH, cellular fumarate 
accumulates and act as competitive inhibitors of PHDs which in turn results in the constitutive 
activation of HIF-α, establishment of pseudo-hypoxia, and transcription of genes associated with 
angiogenesis, cell growth, and metabolism (167–169).  
Moreover, loss of FH can increase the number of reactive oxygen species (ROS) present which 
again acts to stabilise HIF2-α via inactivation of PHD proteins by reducing the availability of non-
ROS oxygen molecules (170). Fumarate is able to post-translationally modify Kelch-like ECH 
Associated Protein 1 (KEAP1), a protein associated with a E3 ubiquitin ligase complex which 
regulates the stabilisation of nuclear factor erythroid 2-related factor 2 (NFE2L2) (171). NFE2L2 
transcriptionally regulates genes associated with antioxidant response, upregulating genes which 
encode proteins which function in antioxidant response element (ARE) controlled genes (172). 
Specifically, ARE-controlled genes such as aldo-keto reductase family 1 member B10 (AKR1B10) is 
suggested to be upregulated in both sporadic type 2 papillary RCC and HLRCC type 2 papillary 
RCC, allowing for improved response to oxidative stress and confer a survival advantage, particularly 
given the increased oxidative stress of a Warburg-like or glycolysis driven metabolism (172).  
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This is contrary to previous studies suggesting ROS actively inhibit PHD enzymes. It is likely that the 
increase of intracellular ROS is a genuine consequence of FH loss, as loss of oxidative 
phosphorylation leads to increase oxidative stress (173), but that fumarate both competitively inhibits 
PHD enzymes and modifies KEAP1 directly while ROS themselves confer relatively little to the 
stabilisation of HIF-α proteins. Lastly, accumulation of intracellular fumarate results in the inhibition 
of α-ketoglutarate-dependent diooxygenases involved in histone and epigenetic demethylation, such 
as ten-eleven translocation enzymes (TET) and lysine-specific demethylase (KDM) family enzymes 
(174). Dysregulation of epigenetic modifications by the inhibition of these enzymes, particularly TET, 
were then demonstrated to result in the indirect upregulation of HIF-α via loss of epigenetic inhibition 
of HIF target transcripts (175). 
In similarity to VHL, homozygous or compound heterozygous variants in FH result in a differential 
autosomal recessive disease with limited phenotypic overlap. Bi-allelic inactivation of FH causes 
Fumarase deficiency (FMRD; OMIM: 606812) which manifests as progressive neurological 
dysfunctions including seizures, cerebral atrophy, and metabolic irregularities including lactic, 
pyruvic, and fumaric aciduria (176,177). Phenotypic presentation appears to be variable in severity 
but no FMRD case has presented with features associated with HLRCC, however parents of a FMRD 
case did present with HLRCC (159). Currently, it is suggested that differences in phenotype 
presentation between HLRCC and FMRD is due to gene dosage differences and that a majority of 
FMRD cases have a high rate of mortality before an age at which HLRCC features typically develop. 
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1.4.5 Birt-Hogg-Dubé syndrome 
Birt-Hogg-Dubé syndrome (BHD) is an autosomal dominant syndrome associated with 
fibrofolliculomas, pulmonary cysts, pneumothorax, and renal cancers. BHD is driven by genetic 
aberrations in the folliculin (FLCN) gene. BHD predisposes to renal neoplasms, with between 12-
27% of BHD patients developing renal cancer, often presenting as hybrid chromophobe RCC, 
typically chromophobe/oncocytomas (178–180). In contrast to some other inherited RCC disorders, 
renal cancers in BHD are histologically diverse; though one study reported a majority of BHD-related 
tumours as hybrid chromophobe/oncocytoma or solely chromophobe (84%), with a minority of cases 
being clear cell, oncocytoma, or papillary RCC (9%, 5%, and 2% respectively), other studies have 
reported a majority of tumours were of clear cell subtypes (179). Additionally, there is some isolated 
evidence that tumour histology in BHD cases is determined by the underlying driver variants within 
early tumour clones, with tumours harbouring somatic mutations correlating to the presenting 
histological subtype (i.e. oncocytoma with a secondary FLCN variants, oncocytic papillary RCC 
carrying a MET Proto-Oncogene (MET) variant, and a clear cell RCC tumour harbouring a VHL 
variant) (181). 
Multifocal and bilateral occurrences in BHD-resultant renal cancers have a prevalence of 60% and 
77%, respectively (182), with more recent studies reconfirming that a majority of individuals (83%) 
present with either bilateral or multifocal RCC (183). While the primary clinical manifestation of BHD 
syndrome is fibrofolliculomas, pulmonary cysts, pneumothorax, and RCC, BHD has also been shown 
to be related to several other cancers. BHD has been linked to the development of thyroid tumours, 
parotid tumours, adrenal carcinomas, melanoma, and the development of colorectal cancer (CRC) 
and/or colorectal polyps which have also been suggested to be clinical features of BHD (184–188), 
though further evidence to substantiate the associations is needed. 
42 
 
FLCN is a candidate tumour suppressor gene first identified by genome linkage analysis of BHD 
families to 17p11.2 (189). Subsequently, genetic analysis mapped FLCN to chr17:17,206,924-
17,237,188 coding for a single full-length transcript of 14 exons, the first three of which are non-
coding. FLCN is a highly conserved gene with many pathogenic variants being truncating variants, 
or variants within heavily conserved protein domains and these variants have been demonstrated to 
generate unstable protein products and to be under purifying selection (190). Additionally, FLCN 
contains a mutational “hotspot” at exon 11 due to the high frequency in which BHD patients present 
with truncating variants within this loci (191,192), though frequent deletions of exons 1-3 and exons 
9-14 have also been reported (193,194).  
BHD patients harbouring a single inactivating variant in FLCN are frequently found to have acquired 
a secondary somatic variant in, or LOH of, the wild-type allele of FLCN in RCC tumours (195). 
Conversely, it has been suggested fibrofolliculomas do not appear to display LOH and the 
pathogenesis of fibrofoliculomas seem to be driven by haploinsufficiency (196). Several animal 
models have corroborated this hypothesis; Rat models harbouring a heterozygous germline variant 
in the rat orthologue of FLCN were shown to present with renal tumours, of which 91% presented 
with LOH of the wild type allele and the remaining LOH-negative tumour had deleterious frameshift 
variant within the wild type allele.  
The FLCN protein acts within several cellular pathways to regulate functions related to cellular 
growth, metabolism, and apoptosis. Through interactions with Folliculin interacting protein 1 and 2 
(FNIP1 and FNIP2), FLCN acts to regulate 5' AMP-activated protein kinase (AMPK), which functions 
in the upregulation of hamartin and tuberin in the PI3K-AKT-mTOR pathway, resulting in attenuated 
signalling (197–199). FLCN knockout models have also established increased mTOR activity where 
loss of the wild type allele occurs, demonstrating a mechanism for tumour development in BHD 
patients (200). Furthermore, FLCN and its complex proteins FNIP1 and FNIP2 have been shown to 
inhibit the function of the MITF-TFE3-TFEB complex by reducing nuclear localisation (201), where 
MITF has been shown to regulate both mTOR and HIFα.  
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1.4.6 Hereditary papillary renal cell carcinoma 
Hereditary papillary renal cell carcinoma (HPRCC; OMIM: 605074) is an autosomal dominant 
condition conferring a predisposition to the development of multifocal and bilateral papillary RCC 
tumours (202). HPRCC is associated with type 1 papillary RCC, generally being low grade, well 
differentiated, and is highly penetrant (156,203). The median age of onset for HPRCC tumour is 41 
years of age and HPRCC cases are frequently bilateral or multi focal, but conversely to sporadic and 
other germline causes of RCC, sex appears to be uniformly affected (156,204,205). HPRCC 
tumours, in contrast to many other RCC syndromes, rarely co-occur with renal cysts but microscopic 
lesions do occur proximally to the primary tumours (204,205) and much like sporadic type 1 papillary 
RCC, HPRCC with type 1 papillary RCC are usually indolent in nature (206). 
HPRCC is known to be caused by activating variants in MET and all activating variants have been 
nonsynonymous changes with the MET tyrosine kinase domain (207,208). The MET gene is located 
at 7q31.2 at chromosome co-ordinates chr7:116,672,390-116,798,386 and encodes a 21-exon 
transcript for the C-MET tyrosine kinase receptor (MET). MET functions as a cell surface receptor 
for hepatocyte growth factor (HGF) as it’s only known ligand (209). Binding of HGF to MET allows 
for the transduction of a signal cascade through the PI3K-AKT-MTOR pathway and RAS-ERK 
pathways, leading to upregulation of genes associated with cell survival, proliferation, and motility 
(210), as well as increased HIF1-α and HIF2-α activity through mTOR activation (211). 
Nonsynonymous variants in the tyrosine kinase domain of MET result in a protein with constitutive 
MET auto-phosphorylation without the presence of HGF, resulting in a constant upregulation of the 
pathways, such as PI3K-AKT-mTOR pathway, leading to tumour initiation (208).  
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1.4.7 Succinate dehydrogenase renal cell carcinoma 
Succinate dehydrogenase renal cell carcinoma (SDH-RCC) is a subtype of RCC driven by loss of 
function of the succinate dehydrogenase complex (SDH; electron transport chain complex II). Only 
recently recognised as a distinct subtype of RCC (49), germline pathogenic variants in genes 
encoding components of the succinate dehydrogenase complex leads to a predisposition to RCC in 
an autosomal dominant manner. Inactivation of Succinate dehydrogenase complex, subunits A-D 
via pathogenic variants in SDHA, SDHB, SDHC, and SDHD respectively, are frequently associated 
with paragangliomas (PGLs), PCCs, and gastrointestinal stromal tumours (GISTs) (212).  
Variants in these same genes can lead to RCC predisposition with the most common cause being 
SDHB mutations (213–216), with SDHA mutations having only been demonstrated more recently 
(217,218). SDH-deficient PCC and PGL have also been linked to variants in SDHAF2, which codes 
for an SDH complex assembly factor but no germline variants have currently been described in 
relation to RCC predisposition (219), and evidence for this association is limited. SDH-RCC cases 
are rare compared to the other RCC predisposing syndromes with an incidence rate estimated at 
0.05-0.2% of all RCC cases (220). In similarity to other RCC-predisposition syndromes, age of onset 
is earlier than in sporadic RCC cases with a median of 40-43 years of age and moderately more 
predominant in males compared to females (M:F=1.7-2.3:1) (220,221). Generally SDH-RCC 
tumours are low grade but are frequently observed to be multifocal or bilateral in 26% and harbour 
metastatic potential, with a reported 11-33% of cases developing metastatic disease (220,222).  
While SDH-RCC usually occurs without other malignancies, studies suggest approximately 15% of 
cases will additionally present with PGL and/or wild type GISTs (220). Histologically, SDH-deficient 
tumours do not resemble the classical subtypes seen in other inherited conditions, having a strong 
resemblance to oncocytomas, with cytoplasmic inclusions containing excessive numbers of 
abnormal mitochondria, and features of other histological characteristics also seen (221). The 
difficulties resulting from similarities to other tumour subtypes, particularly non-cancer tumours such 
as renal oncocytomas, is that misdiagnosis of potentially malignant tumours as benign may impact 
clinical treatment. Additionally, SDH-RCC tumours may appear to resemble hybrid 
oncocytic/chromophobe RCC tumours seen in BHD as such confirmation of SDH gene or FLCN 
inactivating variants is critical to inform diagnostics. 
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While estimates for disease penetrance is challenging when assessing SDH-RCC cases, SDHB 
mutation carriers are more frequent than others and lifetime risk for RCC in SDHB variant carriers is 
reported to be up to 14% at 70 years of age (215). However, recent studies employing Bayesian 
estimates of penetrance of pathogenic variants in SDH genes compared to ExAC controls, as well 
as case studies, have provided lower estimates for penetrance rates for SDH genes in PCC/PGL at 
22% for SDHB, 8.3% for SDHC, and 1.7% for SDHA (SDHD was not assessed) (223) and an 
additional study stating a penetrance of between 0.1%–4.9% for SDHA (224). Further assessment 
of RCC risk has been investigated for SDHB and suggested lifetime risk for SDHB mutation carriers 
to be 4.7% by 60 years (225), supporting the limited penetrance of variants in SDH genes, particularly 
given the occurrence of Renal and Phaeochromocytoma/Paraganglioma Tumour Association 
Syndrome (RAPTAS) cases and the strong correlation between PCC, PGL, and RCC (226). 
Loss of any one of the components of the succinate dehydrogenase complex is enough to result in 
destabilisation of the entire complex (227). In a similar manner to HLRCC and inactivation of FH, 
loss of succinate oxidation by SDH into fumarate as part of both the TCA cycle and the electron 
transport chain leads to an accumulation of intracellular succinate (168) as well as a reduction in 
oxidative phosphorylation (228). The accumulated succinate acts identically to fumarate to act as a 
competitive inhibitor of various biological processes related to RCC tumourigenesis. Succinate both 
acts to inhibit the function of PHD proteins, which drive HIF-α destabilisation via pVHL and inhibits 
α-ketoglutarate-dependent demethylases known to result in up-regulation of HIF proteins (175,229). 
Though exceptionally rare, homozygous (or compound heterozygous) alterations to SDH complex 
are profoundly detrimental, resulting in severe metabolic disorder, loss of cardiac function, and infant 
mortality in one case report (230). This is supported by null knock out mouse models in which SDHB, 
SDHC, and SDHD resulted in embryonic lethality (231).  
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1.4.8 Tubular sclerosis complex 
Tubular sclerosis complex (TSC; OMIM: 191100) is an autosomal dominant multi-cancer 
predisposition syndrome which can confer a risk to RCC caused by inactivating variants in TSC 
Complex Subunit 1 (TSC1) or TSC Complex Subunit 2 (TSC2) (232). Patients diagnosed with TSC 
classically present with neurodevelopmental delay and epilepsy (and intracranial hamartomas), with 
cutaneous features such as angiofibromas, cardiac rhabdomyomas, and renal manifestations. The 
most frequent renal manifestations are angiomyolipomas and renal cystics (233). Renal 
angiomyolipomas as an entity are not classed as an RCC subtype as they are benign in nature, but 
both renal cysts and angiomyolipomas are linked to (234,235) and difficult to distinguish from RCC 
(233), respectively. 
In comparison to other RCC-predisposing syndromes, RCC risk is lower in TSC with a prevalence 
estimated at 2-3% in the general population (233). This rate is more significant given that the 
incidence rate of TSC is much higher than many of the other RCC-predisposing syndromes at 
1:6,760–1:13,520 (236), thus increasing the number of individuals going on to develop RCC of the 
total diagnosed with TSC. While the incidence of RCC is low in TSC, an important aspect is the 
molecular biology of the disease and its overlaps with other RCC-predisposing syndromes in genetic 
causes and phenotypic presentation. 
RCC presenting in TSC are observed at a mean age of between 30-42 years of age and, conversely 
to other RCC syndromes, occurs at an inverse sex ratio (1:2.0-2.6: male to female ratio). In 
approximately 47-55% cases present with either multifocal or bilateral RCC, with as many as 20 
individual tumours reported in one case. Metastatic disease is rarely documented in TSC RCC cases 
and prognosis is generally favourable, with most tumours occurring as oncocytic hybrid 
chromophobe-like RCC or papillary-like RCC histologies (232,237). 
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As mentioned previously, TSC is known to be associated with loss of function variants in TSC1 and 
TSC2 which encode the proteins hamartin and tuberin, respectively, mentioned previously in relation 
to BHD. Mutational assessment of genotype-phenotype correlations suggest that pathogenic 
variants in TSC2 result in more severe phenotypes and is also more frequently inactivated than 
TSC1 (238). An estimated 15% of cases are not identified to carry either a coding single nucleotide 
variant (SNV) or copy number variant (CNV) resulting in inactivation of either TSC1 and TSC2, 
though a recent analysis suggested mosaic and intronic variants account for a large proportion of 
the pathogenic variation in TSC (238,239). 
Hamartin and tuberin form a protein-complex, which functions as a tumour suppressor. The 
hamartin-tuberin heterodimer is regulated by RAC-alpha serine/threonine-protein kinase (AKT) (240) 
and is an inhibitor of GTP-binding protein Rheb (RHEB) (241), as components of the PI3K-AKT-
mTOR pathway. RHEB functions upstream of mTOR and primarily acts to upregulate mTOR activity 
through direct interaction or induction of a conformational change in the mTOR complex, leading to 
an increase in mTOR phosphorylation (242). Increased activation of mTOR (and its associated 
complex mTORC1) leads to the same increase in cellular proliferation, motility, survival, and 
autophagy as described in HPRCC and BHD syndromes (82).  
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1.4.9 Cowden syndrome 
Inactivating variants in the Phosphatase and tensin homolog (PTEN) gene are associated with 
Cowden syndrome (CS; OMIM: 158350), an autosomal dominant condition causing some 
neurodevelopmental disorders, as well as both benign and malignant tumours, including RCC. 
Cowden syndrome has an occurrence is estimated at 1 in 200,000 with a significant risk of breast, 
thyroid, endometrial cancers, and RCC. Life time risk of RCC for individuals with CS a reported 34%, 
though estimates are variable given a limited number studies, ranging between 2-34% at age 70 
years, with an elevated risk in women (243–245). A majority cases of CS with RCC exhibited papillary 
RCC tumours, with the remaining presenting as chromophobe RCC, and a majority of the tumours 
showed complete loss of PTEN protein expression under examination by immunohistochemistry 
(246).  
PTEN is a tumour suppressor gene located at chr10:87,863,113-87,971,930, codes for a 9-exon 
protein Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein 
phosphatase (PTEN). PTEN functions in the regulation of the PI3K-AKT-mTOR pathway, via the 
inhibition of Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA). PTEN 
acts to dephosphorylate phosphoinositide molecules, a lipid substrate utilised in Phosphatidylinositol 
by PIK3CA, downstream of cell surface tyrosine kinase receptors like VEGFR. This antagonistic 
response to Phosphatidylinositol signalling attenuates PI3K-AKT-mTOR signalling, reducing 
expression of genes associated with cell growth, proliferation, and angiogenic processes (82). 
Further forms of CS or CS-like syndromes, driven by epigenetic inactivation of Killin, P53 Regulated 
DNA Replication Inhibitor (KLLN) and activating mutations in AKT and PI3KCA, have also been 
associated with RCC development in PTEN negative cases (247,248). The KLLN gene is present at 
the same loci as that of PTEN on 10q23.31, sharing the same transcription start site but transcribed 
in the opposite orientation. Analysis of 123 CS and CS-like cases without germline PTEN variants 
demonstrated hypermethylation of the shared promotor region, which did not impact PTEN 
expression but reduced KLLN expression 250-fold. Individuals with KLLN hypermethylation 
presented with RCC in twice as many cases as those with germline PTEN variants (247). 
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Further assessment of CS and CS-like individuals without PTEN or KLLN alterations by Orloff et al. 
(2013) identified alterations in components of the PI3K-ATK-mTOR pathway in AKT and PI3KCA. 
Of 91 cases sequenced, 11% harboured variants in either AKT or PI3KCA (2 and 8, respectively) 
and two individuals, one carrying an AKT variant and the other a PI3KCA variant, presented with 
RCC at 47 and 32, respectively (248). 
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1.4.10 CDC73-Related disorders 
Inactivating variants in cell division cycle 73 (CDC73; also known as HRPT2) are known to cause a 
series of autosomal dominant genetic disorders including Hyperparathyroidism jaw tumour 
syndrome (HPT-JT; OMIM: 145001) which predisposes affected individuals to a range of renal 
manifestations, including RCC. HPT-JT is characterised by synchronous or metachronous 
presentation of hyperthyroidism, ossifying fibroma of the jaw bones, renal tumours, and uterine 
tumours (249). Penetrance of HPT-JT is estimated to be 83% at age 70 years, with lower penetrance 
in females (250). Approximately 20% of individuals diagnosed with HPT-JT display renal lesions of 
some form, most frequently renal cysts or hamartomas with Wilms tumours, a form of paediatric 
kidney cancer, also occurring in a subset of cases. Though RCC manifestations are rare in HPT-JT, 
papillary RCC has been reported in conjunction with germline CDC73 variants and somatic LOH of 
1q31.2 (251) and the known links between renal cysts and malignant renal phenotypes (234). 
CDC73 on 1q31.2 is a tumour suppressor gene encoding a 17 exon, 531 amino acid protein 
parafibromin, a component of the Polymerase-Associated Factor 1 (PAF1) complex, which has a 
cellular role as RNA polymerase II complex, and has been shown to interact with histone-modifying 
H3K4-methyltransferase proteins (252,253) and is known to function in the regulation of cell cycle 
progression via regulation of cyclin D1 expression (254). Parafibromin has also been shown to act 
to repress the transcription of myc proto-oncogene protein (MYC) via promotor suppression and 
demonstrates a capacity to cause G1 phase cell cycle arrest (255,256), cementing CDC73 as a 
tumour suppressor gene. CDC73 inactivation is also seen regularly in somatic renal tumours 
(including clear cell, papillary, and chromophobe RCC) and inactivation is typically via LOH (257), 
though some studies have demonstrated that hypermethylation and mutations within the 5’ 
untranslated region (UTR) also result in allelic loss (258). 
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1.4.11 Non-syndromic renal cell carcinoma 
In recent years, investigations into the molecular basis of inherited RCC have elucidated some of 
the molecular causes of non-syndromic inherited RCC. The earliest of these occurred prior to the 
identification of VHL with the identification of a large Italian American family with a history of clear 
cell RCC, a high incidence of bilateral presentation, and no age of onset greater than 60 years of 
age (259). This family was found to harbour a t(3;8)(p14.2;q24.2) translocation resulting in disruption 
of Fragile Histidine Triad (FHIT) and Ring Finger Protein 139 (RNF139) at the break point sites, and 
formation of a fusion transcript (260). Further assessment and screening of individuals with RCC 
presenting with features of heritability uncovered a number of other families and individuals carrying 
constitutional translocations, most of which involved chromosome 3, and suggested specific 
constitutional translocations could confer a risk to RCC development (261). In depth review and 
analysis of RCC-associated translocation cases is performed in Chapter 6. 
Several studies assessed germline RCC cohorts and families for the presence of genetic alterations 
in significantly mutated genes in RCC tumours. Studies of patients with co-occurrence of RCC and 
melanoma demonstrated a missense substitution in MITF are associated with higher risk of RCC 
compared to controls (262). Screening of unrelated probands with features of predisposition revealed 
that, although rare, germline variants in BRCA1 Associated Protein 1 (BAP1) segregated with RCC 
phenotype and demonstrated LOH in several tumours as well as somatic VHL loss (263). In an 
assessment of 35 individuals with unexplained family histories of clear cell RCC, one case was 
shown to have a co-segregating frameshift variant in PBRM1 supporting predisposition to RCC 
(264). It should also be noted that germline FLCN and SDHB mutations may also be detected in a 
subset of patients with apparent non-syndromic inherited predisposition to RCC (214,265). 
Lastly, exome sequencing and targeted resequencing of patients with features of familial RCC 
uncovered candidate pathogenic missense variants in Cyclin Dependent Kinase Inhibitor 2B 
(CDKN2B) (266). While the occurrence of variants in MITF, BAP1, PBRM1, and CDKN2B are 
relatively rare, with only a small number of individuals per cohort being affected, they suggest the 
remaining proportion of heritability is likely to be split across many genes at a low percentage, 
rather than the discovery an unknown VHL-like gene, harbouring a large proportion of the 
remaining risk. 
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1.5 Somatic variation in renal cell carcinoma 
Large scale sequencing studies of RCC tumours have been performed to investigate and elucidate 
the genetic causes of RCC and its histological subtypes. As discussed previously, in alignment with 
their histological disparities, the major histological subtypes are genetically heterogeneous and 
numerous genetic and molecular overlaps exist between somatic and germline alterations in RCC. 
1.5.1 Clear cell renal cell carcinoma 
Clear cell RCC, as the most common subtype of RCC, has been extensively characterised by tumour 
profiling studies utilising multi-omic approaches. Copy number variations in clear cell RCC are large 
scale losses or gains of entire chromosome arms, most frequently 3p which carries multiple inherited 
RCC genes as previously discussed, and very few focal events. Loss of 3p occurred in more than 
90% of tumours assessed, with gains of 5q and loss of 14q seen in 67% and 45% of tumours, 
respectively. Whole exome sequencing of tumours revealed VHL, PBRM1, SET Domain Containing 
2 (SETD2), Lysine Demethylase 5C (KDM5C), PTEN, BAP1, MTOR and Tumour Protein 
P53 (TP53) as the most significantly mutated genes. Of note, approximately 20% of tumours 
assessed had no alterations in any of the highly mutated genes, suggesting alternative drivers in 
combination with chromosomal copy number alterations in 3p and 5q. Epigenetic inactivation of VHL 
was demonstrated in 7% of tumours and was mutually exclusive with somatic VHL SNVs. Network 
analysis showed dysregulation pathways for pVHL and its interacting components and chromatin 
remodelling (including genes PBRM1 and AT-Rich Interaction Domain 1A (ARID1A))(267). 
Systematic sequencing of clear cell RCC recapitulated the pivotal role of VHL and hypoxia in 
sporadic clear cell RCC, with 55% of cases harbouring VHL mutations, 82% having upregulation of 
hypoxia pathways, and 87% demonstrating loss of 3p. Further analysis resulted in the identification 
of multiple somatic truncating mutations in histone modifying genes, containing SETD2 which was 
frequently seen in other studies, including KDM5C, Lysine Demethylase 6A (KDM6A), and Lysine 
Methyltransferase 2D (KMT2D) (268). Comprehensive integrative studies across more than 100 
clear cell RCC tumours reiterated other findings but also identified driver mutations in Elongin C 
(TCEB1), TET2, KEAP1, TP53, and MTOR. Of note, mutations in TCEB1 were mutually exclusive 
with VHL variants, which is significant given they both function as part of the VCB complex (269). 
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More recent spatial and temporal sequencing approaches to understand the somatic variation of 
clear cell RCC have uncovered the range and depth of differences because of tumour heterogeneity 
both within and between tumours. Analysis of multi-site & multi-tumour data from the TRACERx renal 
study uncovered that specific driver events or clusters of events are associated with different clonal 
evolution trajectories, branching potentials, and intra-tumour heterogeneity, each of which have 
different prognosis outcomes and responses to clinical treatments (270). These evolutionary 
trajectories of specific sub-clones mirrors and explains the differences seen at the clonal driver 
mutation resolution (such as PBRM1 loss tumours having poorer survival) and why other tumours 
with different drivers respond differently in both progression and response to treatment. 
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1.5.2 Papillary renal cell carcinoma 
Genetic characterisation of papillary tumours reiterated the distinctions found histologically and 
implicates a different subset of genetic loci in tumour development (158). Type 1 papillary RCC, 
harbour frequent copy number gains of chromosome 7 and 17 whereas Type 2 papillary RCC 
tumours are characterised by significantly less copy number losses but two distinct clusters of cases 
with or without a high degree of chromosomal instability and loss of 9p. Whole exome analysis 
revealed that across all papillary RCC cases the most significantly affected genes included MET, 
SETD2, Neurofibromin 2 (NF2), KDM6A, and SWI/SNF Related, Matrix Associated Actin Dependent 
Regulator of Chromatin Subfamily B, Member 1 (SMARCB1). Additional restriction to genes already 
implicated in cancer demonstrated BAP1, PBRM1, and TP53, among others were associated with 
papillary RCC. Lastly, gene fusions of TFE3 and TFEB with various genes occurred in a proportion 
of papillary RCC tumours (10.6%), including HIF1A. 
In regards to specific papillary RCC subtypes, type 1 papillary RCC tumours more frequently 
harboured variants in MET (18.6%), which clustered with known germline predisposition variants 
found in HPRCC, and had increased levels of MET expression compared to type 2 papillary RCC. 
Collectively, given the amplification of MET in cases with chromosome 7 gains, 83% of type 1 
papillary RCC tumours carried MET alterations. In type 2 papillary tumours, Cyclin Dependent 
Kinase Inhibitor 2A (CDKN2A) alterations were more frequent (25%) with focal losses of 9q21, 
mutations, or hypermethylation as the cause. Additionally, SETD2, BAP1, and PBRM1 were 
frequently altered, but in contrast to clear cell RCC, loss of 3p was infrequent. Additionally, CpG 
island methylator phenotype (CIMP) associated tumours, were designated as a subset of type 2 
papillary tumours driven by somatic mutations in FH. In tumours identified with hypermethylation 
profiles, 55.6% carried alterations in FH as well as decreased mRNA expression of FH and increased 
expression genes associated with glycolysis. This agrees with HLRCC caused by germline 
inactivation of FH, where type 2 papillary RCC is most common (155) seen as well as the inhibition 
of epigenetic factors by accumulated fumarate (174). 
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1.5.3 Chromophobe renal cell carcinoma 
Characterisation of chromophobe RCC by Davis et al. (2014) demonstrated the unique genetic 
features of this RCC subtype. Chromophobe RCC carries a distinctive copy number alteration 
pattern with loss of chromosomes 1, 2, 6, 10, 13, and 17 in most cases (86%), with wide spread non-
focal loss of multiple other chromosomes, including chromosome 3 and was shown to have a low 
mutational rate, even compared to other RCC subtypes (approximately 3-fold less than clear cell 
RCC; 0.4 mutations per Mb). TP53 was reported as the most altered gene being mutated in 32% of 
cases assessed, with variants also being present in PTEN (9%), MTOR (3%), and TSC1 or TSC2 
(6%). In general, chromophobe RCC has fewer hypermethylation events in comparison to clear cell 
RCC and demonstrated epigenetic silencing of CDKN2A in 6% of cases. In relation to gene 
expression patterns, upregulation of genes associated with the TCA cycle and electron transport 
chain were seen, counterintuitively to the shift away from oxidative phosphorylation that may be 
expected due to the Warburg effect. In addition to metabolic expression changes, increased 
expression of genes involved with cell cycle progression was also described. Lastly, analysis of 
structural variation demonstrated a significant portion of chromophobe RCC cases have 
chromosomal break points with the telomerase reverse transcriptase (TERT) promotor, associated 
with telomeric end repair, and expression was shown to be elevated in these cases (271). 
Further assessment of RCC tumours as a collective revealed additional focal losses and 
amplifications of genes with associations to germline predisposition cases including loss of SDHD 
and PTEN, as well as amplifications of PIK3CA and sequestosome 1 (SQSTM1) (272), of which 
SQSTM1 is implicated as the driver gene in 5q amplifications (273). Complementary assessment of 
data from the cancer genome atlas (TCGA) cancer study by Ricketts et al. (2018) recapitulated much 
of the previous work with some additional findings. Both type 2 papillary RCC and its subset CIMP-
RCC have increased copy number loss of chromosome 22, which carries the loci for NF2 and 
SMARCB1 and both chromophobe RCC and CIMP-RCC have loss of 13q, which harbours 
retinoblastoma 1 (RB1) and BRCA2. Furthermore, collective assessment of RCC subtypes together 
revealed that TP53 and PTEN were the only significantly mutated genes shared by all RCC tumour 
types as well as deletion or hypermethylation of CDKN2A (274). 
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1.5.4 Epigenetics of renal cell carcinomas 
Epigenetic inactivation is a well-established mechanism of cancer evolution and development (275) 
and analysis of epigenetic alterations in RCC tumours has also been crucial to understanding the 
molecular mechanisms driving tumourigenesis in RCC and its links to predisposition. Discoveries of 
hypermethylation of several genes on 3p, including VHL and Ras association domain Family 
Member 1 (RASSF1A) in sporadic RCC seen in 19% and 26% of cases, respectively (276,277), 
demonstrated the potential for epigenetic alterations to define somatic tumour development. 
Additional genes in the 3p region were demonstrated to be hypermethylated including family with 
sequence similarity 107 member A (FAM107A) (278) and FHIT (279), with further candidate tumour 
suppressors associated with RCC and other cancers also being identified, such as CDKN2A (280), 
cadherin 1 (CDH1) (281), and Ras association domain family member 5 (RASSF5) (282). Various 
further studies have implicated additional genes as downregulated in RCC through hypermethylation 
such as KLLN which is associated with Cowden syndrome (283), secreted frizzled related protein 1 
(SFRP1) a gene related to the downregulation of the Wingless/Integrated (WNT) signalling pathway 
(284), and mutS homolog 2 (MSH2) which is related to DNA repair (285), as well as further genes 
altered across multiple RCC subtypes are detailed in a review by Shenoy et al. (2015)(286).  
Further comprehensive analysis of epigenetic inactivation in RCC tumours has identified a range of 
different genes associated with hypermethylation in RCC, including the characterisation of CIMP 
tumours described previously (287). Initial genome-wide approaches to discover frequently 
hypermethylated promotor regions in RCC identified 9 genes. Of those genes identified, 6 displayed 
reduction in functional expression and activity in in vitro experiments suggestive of cellular roles as 
tumour suppressors (288) and follow-up methylation array studies identified more than 200 
hypermethylated loci compared to normal tissues, including genes solute carrier family 34 member 
2 (SLC34A2), ovo like transcriptional repressor 1 (OVOL1), and somatostatin (SST) in 64%, 40%, 
and 31% of tumours respectively (289). 
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Hypermethylation, outside of promotor-specific methylation, has also been examined where RCC 
samples were characterised by hypermethylation profiles preferentially occurring within coding 
regions. The hypermethylation disproportionately affected both kidney-specific enhancer regions 
associated with histone methylation as well as genes associated with hypoxia, likely as a 
consequence of ongoing dysregulation of hypoxic pathways (290). Finally, use of methylation 
alterations in RCC has been utilised as a biomarker, both diagnostically and predictively in the 
development and progression of RCC tumours which can act to detect recurrent events or predict 
prognostic features in assessed patient, reviewed by Lasseigne et al. (2018)(291). 
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1.6 Inherited and somatic variants in renal cell carcinoma 
In general, somatic alterations in different RCC subtypes are characteristic of that specific histology 
but clear overlaps at a chromosomal level (e.g. loss of 3p in clear cell RCC), but perhaps more 
importantly, at a gene level occur in which a distinct but interconnected pattern of molecular 
pathways is delineated. Genetic alterations in both germline and somatic analysis can be defined 
broadly to being associated with one of three networks; VHL pathway, PI3K-AKT-mTOR pathway, 
and histone modifying and chromatin remodelling network. In both sporadic and inherited cases of 
RCC, the affected entities appear to map to one of these pathways with common proteins and 
metabolic substrates linking them together. 
HIF-α proteins are one of the primary endpoints of both the VHL-driven pathway and the PI3K-AKT-
mTOR pathway. VHL is found to be both inactivated in VHL disease and frequently lost in sporadic 
RCC through inactivating mutations and loss of 3p in clear cell RCC, both acting to drive tumour 
initiation and progression via HIF upregulation and a pseudo hypoxic gene response. Variants found 
in FH in HLRCC and SDHA, SDHB, SDHC, and SDHD in SDH-RCC, while acting to disrupt cellular 
metabolic processes also converge on the VHL pathway indirectly. Accumulation of both succinate 
and fumarate results in pseudo-hypoxic conditions due to the inhibition of PHD proteins and loss of 
HIF1-α and HIF2-α hydroxylation, consequently reducing HIF protein degradation via VHL (168). 
The PI3K-AKT-mTOR pathway drives HIF upregulation as well as mTOR activity, and multiple 
positive and negative regulators and components are implicated in RCC. Activating variants seen in 
MET, as seen in HPRCC and amplification of chromosome 7 in sporadic papillary RCC result in 
constitutional activation of the PI3K-AKT-mTOR pathway at its origin point on the cell surface, 
causing continuous upregulation of all the downstream components, including HIF2-α and VEGFR 
(292). Inactivation of PTEN which acts as an inhibitor of PI3K signal transduction are observed in 
both Cowden syndrome and somatically in both clear cell and chromophobe RCC subtypes, resulting 
in loss of regulated signal transduction through PI3K proteins. 
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Further components of the PI3K-AKT-mTOR pathway are altered including TSC1 and TSC2 
inactivation, as described in TSC and chromophobe RCC, which act to inhibit RHEB directly 
upstream of mTOR. Indirectly, the pathway is perturbed by variation in MITF and FLCN. Inactivation 
of FLCN in BHD syndrome where loss of FLCN results in both the loss of MITF inhibition and AMPK-
driven upregulation of TSC1 and TSC2, though interestingly FLCN variants do not appear to occur 
somatically. Oncogenic alterations in MITF found in a subset of non-syndromic heritable RCC cases, 
as well as in Xp11.2 and t(6;11) sporadic translocation cases via fusion transcripts, cause direct 
upregulation of HIF-α proteins and increased activity of mTOR. 
Finally, the histone and chromatin remodelling pathways are routinely affected somatically with 
components of the SWI/SNF complex, including PBRM1 which is seen in germline predisposition, 
driving RCC through altered transcript and epigenetic alterations. BAP1 is also seen both somatically 
and in heritable cases, resulting in the dysregulation of histone modifications. This final pathway is 
not decoupled from the others entirely though, with accumulations of fumarate and succinate 
resulting in the inhibition of TET and KDM proteins, and subsequently dysregulation of chromatin 
remodelling an epigenetic functions (175,229). 1.6 Figure 3 provides a diagrammatic overview of 
these overarching pathways, components and links to RCC predisposition and tumour formation, 
though it should be noted that this is not fully inclusive of all the genetic components to be implicated 
in RCC pathogenesis, in germline or somatic cases. 
  
 61 
 
1.6 Figure 3 
A diagrammatic representation of the main cellular pathways affected in RCC (adapted from Ricketts et al. 
(2016)(293)). Green components are substrates and/or signalling molecules. Blue components represent 
proteins coded by genes affected somatically in RCC. Orange components represent proteins coded by genes 
affected in germline predisposition to RCC (No key is provided for genes affected in both). Pointed arrows 
demonstrate positive or upregulation of the target component whereas blunted or flat ended arrows demonstrate 
inhibitory or downregulation of the target component. HIF1α and HIF2α are labelled in yellow as the key 
convergence point of multiple RCC-related pathways. 
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1.7 Sequencing in rare diseases 
1.7.1 Sequencing technologies 
The efficiency of identifying genetic alterations that result in disease phenotypes has progressed 
rapidly over the last two decades, with ever decreasing costs and ever-increasing breadth and depth 
of genetic information accurately interrogated by each technological iteration. A milestone in the 
advancement of DNA sequencing was the development of Sanger sequencing (294) and its 
application in automated capillary gel-electrophoresis (295), allowing for the sequencing of the 
complete human genome in 2001 (296).  
Following this breakthrough, rapid development of technologies with greater throughput and lower 
economic and labour costs became the goal of genomic sequencing, culminating in the development 
of high-throughput platforms utilising technologies such as sequencing by synthesis (Illumina, 454, 
Ion Torrent) and sequencing by ligation (Complete Genomics, SOLiD). The widespread adoption of 
2nd generation next generation sequencing (NGS) technologies, particularly Illumina-based 
platforms, resulted in large scale sequencing of thousands of rare disease and oncology cases. 
Additionally, development of sequencing adaptations such as RNA-seq (297), bisulphite sequencing 
(298), ChIP-seq (299), and many others have allowed for the generation of sequencing data in 
numerous “-omics”, leading to multi-dimensional analysis and providing greater biological insights. 
The ability to limit sequencing in 2nd generation NGS technologies to specific target regions (e.g. 
whole exome sequencing and targeted gene panels) has further improved efficacy, increasing the 
biological relevance of the sequenced regions and reducing overall cost compared to whole genome 
sequencing. 
While 2nd generation NGS technologies have revolutionised genomic sequencing, 3rd generation 
sequencing technologies (Pacific Biosciences SMRT sequencing (PacBio SMRT), 10X Genomics 
and Oxford NanoPore Technologies (ONT)) are beginning to move into the spotlight, bringing with 
them unique advantages and disadvantages. Perhaps the greatest disadvantage for 2nd generation 
NGS technologies is the length of reads that are generated. The shorter read lengths limit coverage 
over complex genomic regions, result in difficulties resolving repetitive genomic loci, have poor 
resolution of structural variation, and an inability to perform accurate haplotype phasing. 
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The use of long read lengths overcomes many issues stemming from short reads. Use of long reads 
in all 3rd generation technologies has improved alignment to complex genomic regions and highly 
repetitive loci and has improved the calling and characterising of large structural variations. 
Specifically PacBio SMRT sequencing and 10X Genomics have seen vast improvements in 
haplotype phasing compared to short read sequencing (300,301). Furthermore, 3rd generation 
methods such as PacBio SMRT and ONT have demonstrated the ability to perform innate nucleotide 
base modification detection without the need for prior processing during library preparation 
(302,303), though it is currently restricted to CpG island methylation detection. 
A clear shortcoming of 3rd generation technologies is a large increase in cost for similar sequencing 
throughput, particularly for ONT sequencing, but uptake by the scientific community will drive prices 
down with sufficient demand. A disadvantage to even PacBio and 10X genomic long read 
sequencing is the reliance of genomic centres with the financial and logistical means to provide 
sequencing, each having high costs, maintenance and large machinery requirements to run 
effectively. The development of ONT sequencing provided a reasonably high-throughput, portable 
sequencing option and demonstrated its efficacy in sequencing genomes in infectious disease 
outbreaks such as Ebola and Zika viruses (304,305). Furthermore, read lengths in ONT sequencing 
are only limited on the length of DNA provided to the sequencer after library preparation and physical 
constraints at the sequencing pore, allowing for exceptionally long reads of up to 2 Mb in length 
(306). This advantage has been critical in the use of ONT sequencing for the characterisation of 
structural variation larger than the read lengths of PacBio and 10X genomics (307), and where 
specific loci are known to carry structural variants but the precise nature is not known, including large 
deletions and tandem repeat expansions (308,309). Compared to both 2nd generation short read 
technologies and other 3rd generation methods, ONT has some significant disadvantages, including 
reduced throughput and increased per read error rates, particularly for repetitive regions, but far 
lower cost and ease of use make it highly versatile given the right context. 
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1.7.2 Sequencing technologies - The right tool for the job 
While technologies have rapidly developed and evolved to generate vast quantities of data, no 
technology is without its niche, with Sanger sequencing still seeing ubiquitous use in both clinical 
and research environments for targeted sequencing projects, validation of NGS findings, and clinical 
diagnosis. In all, the selection of a specific sequencing technology relies upon the context in which 
it is being applied. The generation of whole genome sequencing via Sanger sequencing is now an 
absurd idea, resulting in substantially increased economic, labour, and time costs over newer 2nd 
and 3rd generation methods. Conversely, using long read PacBio sequencing for the identification of 
variants in a single exon of one gene is equally unreasoned, providing no practical benefits over 
simple polymerase chain reaction (PCR) amplification and Sanger sequencing. Important selection 
of the most appropriate sequencing method for the question being asked is vital to both maximise 
the biologically relevant data whilst minimising economic, labour, and computational costs. In 1.7 
Table 3, a comparison is made for which sequencing approach is most appropriate to the study 
design being used if only utilising DNA sequencing. 
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1.7 Table 3 
Summary of capabilities of various sequencing technologies for DNA only sequencing given with 
example of case use. Question marks suggest the application is possible but only under specific 
circumstances. 
Sequencing 
technology 
DNA only sequencing 
Example 
SNVs CNVs SVs 
Base 
modifications 
Phasing 
Sanger sequencing      
Sequencing of a single 
exonic region or series of 
SNPs in 50 samples  
Short read sequencing 
(Exome)  ?    
Sequencing of exonic 
regions of 100 genes in 100 
samples 
Short read sequencing 
(Genome)   ?   
Identify coding and non-
coding SNVs and CNVs 
across the entire genome in 
any number of samples 
Pacific Biosciences 
SMRT Sequencing      
Complete characterisation 
of genetic alterations in any 
number of samples 
Oxford Nanopore 
Technologies     ? 
Targeted sequencing of 
SVs and complex regions 
or small genome 
sequencing - single or 
multiple samples 
10X Genomics      
Complete characterisation 
of genetic alterations in any 
number of samples but 
without need for 
methylation 
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1.7.3 Variant detection in rare disease 
The principal function of any sequencing technique is to identify the causal variant or variants 
associated with the disease phenotype being investigated. Given the vast number of variants some 
methods can uncover, filtering and identifying a causal variant can be a substantial challenge. In 
hereditary disease, there are three primary methods for variant identification which are familial 
segregation, trio analysis, and abundance in unrelated probands. Familial segregation is the effective 
presentation of a phenotype within a family pedigree where affected individuals carry the candidate 
genotype, where presentation is variable based on inheritance model and the penetrance of the 
phenotype. For example, in a fully penetrant autosomal dominant pedigree, any given carrier has a 
50% probability of passing the causal variant to their offspring and all carriers are affected.  
A major drawback of segregation analysis is the need for well documented family histories, accurate 
and meaningful phenotype data, as well as issues with identifying segregation in low penetrance or 
complex traits where inheritance patterns may be obfuscated. Use of trio analysis, classically in the 
form of mother-father-offspring trios, are a powerful method for variant detection and segregation. 
Trio analysis can be especially effective when attempting to identify de novo variation in an affected 
offspring, where both parents are unaffected, by removing the variants inherited from the paternal 
and maternal alleles. Trio analysis (or any variation of comparing multiple related individuals) is still 
viable for variants which aren’t de novo provided that phenotypic penetrance is strong enough, as 
unaffected carriers will likely result in the filtering out of the causal variant.  
Assessment of unrelated probands with the same disease can allow for the detection of single 
variants or genes that are associated with the phenotype of interest. By applying statistical 
methodology to allelic frequencies in cases compared to control sets, a calculation can be performed 
as to whether or not a given feature is overrepresented in the case set. This can apply to single loci, 
as is the case in genome-wide association studies (GWAS) studies or utilise more statistically 
complex analyses over fixed genomic regions such as genes, via methods such as variant collapsing 
or burden association tests (310). 
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Lastly, the assumption that any given cancer predisposition phenotype is likely to be autosomal 
dominant, with potentially variable penetrance, is well founded with many cases following this 
inheritance model. Conversely, there is increasing evidence for the role of complex or polygenic 
traits in cancer predisposition, with multiple low risk variants conferring additive cancer risk. In this 
instance, detection of low risk or polygenic traits is restricted to epidemiological studies with large 
enough sample sizes to detect small effect sizes and for rare cancer predisposition, such as those 
seen in RCC, the ability to detect these variants is juxtaposed to the sample size requirements. 
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1.8 Summary 
RCC is complex set of renal neoplasm with distinct morphology, histology, and clinical courses and 
is a prominent cancer in both developing and developed countries, seeing an increased incidence 
globally. While clinical outcomes for stage I and low-grade tumours is favourable, tumours are often 
detected at later stages and as such have a much lower survival rate. Additionally, RCC tumours are 
treatment tolerant, with only moderate efficacies seen without targeted therapies and frequently 
become treatment resistant. Both the early detection, screening frequency and targeted therapies 
hinge on detection and understand the genetic components present both constitutionally and 
somatically. 
Each subtype of RCC are genetically distinct entities with differing somatic and germline mutation 
patterns, as well clear genetic overlaps between causes of inherited RCC and somatic RCC driver 
mutations. While characterisation of somatic mutations across the differing histological subtypes has 
uncovered an array of genes involved in RCC tumourigenesis, understanding of RCC predisposition 
genes has been vital to understanding molecular mechanisms, cellular environments, and genetic 
circumstances which drive sporadic tumours. 
While many genes associated with predisposition to RCC have been discovered, a large proportion 
of the remaining genetic component is currently unknown, with many cases which meet genetic 
screening criteria not carrying pathogenic variation in known RCC predisposition genes. By utilising 
multiple sequencing methodologies on individuals with features of inherited RCC (early onset, 
bilateral or multifocal tumours, and family history), potential candidate genes can be identified as 
associated with RCC predisposition and as such inform investigations in molecular mechanism, 
improve genetic testing and family screening, and provide potential targets for clinical management. 
It is worth noting that while this is a potential source of heritability which is currently not assessed, 
given the historical prior probability of an inherited cases of RCC (2-3%), the power to discover 
additional inherited cases within a cohort with suspected features of predisposition (24-33.7%) has 
low power without large sample numbers. 
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This posterior probability is a frequent challenge in the analysis of rare disease cohorts and 
significantly impacts a studies ability to elucidate new genetic features which are associated with 
RCC predisposition. In spite of this, rare disease studies do not have any robust alternative and a 
failure to perform a given study due to low probability of identifying novel outcomes is not a 
justification for ignoring the clinical and ethical needs of patients and families who present with rare 
diseases, including inherited RCC.  
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1.9 Aims 
 To utilise multiple genomic targets and sequencing technologies to provide evidence to 
support the association of inherited RCC with previously reported genes. 
 Use multiple genomic sequencing approaches and statistical case control analysis methods 
to identify novel genes which are associated with a predisposition to RCC. 
  
 71 
 
2.0 Materials and methods 
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2.0.2 Labour contributions 
All methods described in this section were performed by the author with the exception of patient 
recruitment (performed by Professor Eamonn Maher), sample retrieval and extraction (section 2.1), 
and the contributions described in relation to DNA library preparations (section 2.6.5). 
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2.1 Sample preparation 
2.1.1 Sample retrieval and extraction 
Samples were received from various clinical genetic laboratories and DNA extraction methods will 
vary per recruitment site. Most recruited participants had DNA processed and extracted via either 
Cambridge University Hospital Addenbrookes East Anglian Medical Genetics Laboratory or 
Birmingham Women's Hospital West Midlands Regional Genetics Laboratory. Further subsets of 
samples were prepared at Melbourne, Exeter, Newcastle, King’s College London and sent to 
Cambridge University Hospital Addenbrookes East Anglian Medical Genetics Laboratory for storage. 
2.1.2 Sample source and storage 
All but one sample used was blood serum-derived genomic DNA (one sample was buccal-derived 
DNA and was not found to be detrimental to experimental findings). All stock DNA extractions were 
stored in DNA Lo-bind microcentrifuge tubes (Eppendorf, Germany), sealed with Parafilm M (Bemis, 
United States) or tethered screw cap microtubes with rubber sealed lids (STARLAB, United 
Kingdom). Any samples received in containers not conforming to these storage requirements were 
transferred into the appropriate storage containers. DNA sample dilutions were prepared using 
Nuclease-free water (Qiagen, Germany) to required concentrations and quantified using either Qubit 
Broad Range or Qubit High Sensitivity DNA assay (Invitrogen, United States), depending on 
calculated target concentration (see section 2.2). All sample aliquots were stored at -20°C and 
dilutions were used where possible to reduce freeze-thaw cycling of stock DNA samples. 
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2.1.3 Patient cohort description 
 
Flow chart depicting the patient selection procedure, patient filtering parameters, and sequencing 
methodologies used for each chapter described herein. Patient counts for each stage are denoted by [n = 
patient count]. Initialisms – national health service (NHS); renal cell carcinoma (RCC); cancer gene panel 
(CGP); whole exome sequencing (WES); whole genome sequencing (WGS). 
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2.2 Sample quality control and metrics 
2.2.1 DNA quantification 
DNA quantification was performed with Qubit Broad Range DNA assay (Invitrogen, United States) 
in most circumstances following the manufacturer’s protocol for 2 μl DNA input. In a limited number 
of cases where DNA quantity was low/insufficient or DNA quality was questionable or low 
concentration dilutions were required (e.g. DNA sequencing libraries) DNA aliquots were measured 
by Qubit High Sensitivity DNA assay (Invitrogen, United States) to determine concentration (following 
the manufacturer’s protocol for 2 μl DNA input) and NanoDrop 1000 Spectrophotometer 
(Thermofisher, United States) using 1 μl DNA input to determine sample purity from 260/230 nm and 
280/260 nm absorption ratio (311). 
2.2.2 Whole genome amplification of low quantity samples 
In certain instances, low DNA yield samples limited available DNA for downstream experiments. In 
these cases, DNA was whole genome amplified using REPLI-g Mini kit (Qiagen, Germany) following 
manufacturers’ instructions provided for initial input of 5 μl. Whole genome amplified product 
concentrations were measured using the Invitrogen Qubit Broad Range DNA assay (see section 
2.2.1). Whole genome amplified DNA was not used for high throughput sequencing methods due to 
described base replication errors and region-specific amplification (312). 
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2.3 Polymerase chain reaction (PCR) methods 
2.3.1 Primer design 
Target sequences for designed primers were retrieved using University of California, Santa Cruz 
(UCSC) Genome Browser (313) providing target co-ordinates from Human Genome build 
GRCh38/Hg38 (314). Primers were designed using the Primer3 (315). Primer sets were evaluated 
for non-specific binding and secondary structure formation using National Centre for Biotechnology 
Information’s (NCBI) BLAST (Basic Local Alignment Search Tool) PrimerBLAST (316). 
2.3.2 Short range PCR 
PCR amplification was performed using AmpliTaq Gold DNA polymerase utilising GeneAmp10X 
PCR Buffer II with MgCl2 (Applied Biosystems, United States). In most instances, PCR was 
performed as per the manufacture’s protocol with a standard annealing temperature of 58°C and 30 
cycles. In certain reactions, conditions required optimisation to produce a DNA product for 
downstream steps. The annealing temperature was adjusted with a temperature gradient (53-63°C) 
and the quantity of genomic DNA input required varied depending upon the quality of the DNA, 
increasing incrementally from 10ng/reaction up to a maximum of 50ng/reaction. TaqMan Control 
Genomic DNA (Applied Biosystems, United States) was used in place of patient genomic DNA, 
where appropriate, for optimisations and negative control reactions. Standard PCR protocol is given 
below in 2.3 Table 1. 
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2.3.2 Table 1 
Thermocycler conditions and PCR master mix volumes for a standard short-range PCR reaction 
PCR reaction cycle conditions  PCR reaction mixture (25μl) 
95°C for 10 minutes Initial denaturation  Template DNA 10-50 ng 
95°C for 15 seconds 
x 25-35 cycles 
 AmpliTaq Gold polymerase (5U / 
μl) 
0.125 μl 
55-65°C for 30 
seconds 
(Reaction 
Dependent) 
 
Forward primer (10 μm) 0.5 μl 
72°C for 1 minute / 
Kb 
 
Reverse primer (10 μm) 0.5 μl 
72°C for 10 minutes 
Final extension / 
elongation 
 
dNTP mixture (10 mM) 0.5 μl 
Hold at 4°C  End (Optional) 
 Buffer II with MgCl2 2.5 μl 
 
Nuclease-free H2O 
up to 25 
μl 
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2.3.3 Nested PCR 
For a subset of reactions, initial amplification of PCR targets was complicated by local DNA 
structures or sub-optimal primer designs. As such, expanded PCR amplicons were designed to span 
the original target with additional flanking DNA sequence between 500-2000 bp 5’ and 3’ of the initial 
PCR amplicon. Two PCR reactions as described in section 2.3.2 were performed, the first reaction 
utilising the expanded amplicon primers and the second reaction using the original amplicon primers 
but with the PCR product of former as the input DNA. For larger nested amplicons elongation times 
in the PCR cycling conditions were adjusted as necessary. 
2.3.4 Long range PCR primer design 
Long range PCR primers were designed in accordance with the details of section 2.3.1 with the 
alteration that primers should be purified via high performance liquid chromatography (HPLC) to 
ensure the removal of truncated primer sequences and impurities to reduce possible off target 
effects.  
2.3.5 Long range PCR 
Long range PCR amplicons were generated with the SequalPrep™ Long PCR Kit (Applied 
Biosystems, United States). Stringent optimisation was completed to improve amplicon generation 
via modification of the following conditions; Annealing temperature, concentration of enhancer, 
DMSO concentration & number of PCR cycles. TaqMan® Control Genomic DNA (Applied 
Biosystems, United States) was used for optimisation steps. Cycling conditions and reaction mixture 
set up is given in the 2.3 Table 2 below. 
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2.3.5 Table 2 
Thermocycler conditions and PCR master mix volumes for a standard long range SequelPrep PCR 
  
SequelPrep reaction cycle conditions  SequelPrep reaction mixture (20μl) 
94°C for 2 minutes Initial denaturation  Template DNA 20-50 ng 
94°C for 10secs 
x 10 cycles 
 SequelPrep Long 
polymerase (5U / μl) 
0.125 μl 
55-65°C for 30 seconds 
(Reaction Dependent) 
 
Forward primer (10 μm) 0.5 μl 
68°C for 1 minute / Kb  Reverse primer (10 μm) 1 μl 
94°C for 10 minutes 
x 20-30 cycles 
 10X Enhancer (A or B) 1-2 μl 
55-65°C for 30 seconds 
(Reaction Dependent) 
 
DMSO 0.4 μl 
68°C for 1 minute / Kb 
(+20 seconds / cycle) 
 
10X Reaction Buffer 2 μl 
72°C for 5 minutes 
Final extension / 
elongation 
 
Hold at 4°C  End (Optional) 
 
 Nuclease-free H2O up to 20 μl 
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2.3.6 Gel electrophoresis 
Gel electrophoresis was performed on a wide range of DNA products throughout the experiments 
described in this thesis. This describes a generalised protocol used for all instances in which gel 
concentrations, run times, and applied voltages differ between experiments. Prior to preparing a 
agarose gel, 50X Tris Acetate-EDTA (TAE) stock solution was made by dissolving 242 g Tris-base 
(Fisher Scientific, United States) in 500 ml of water (15 MΩ·cm), adding 37.2 g 
Ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA; Sigma Aldrich, United States), 57.2 
ml glacial acetic acid (Sigma Aldrich, United States), and making total volume up to 1 L, after which 
pH was adjusted to 8.5. This was diluted in 4.9 Litres of water (15 MΩ·cm) forming a 1X TAE buffer 
(40mM Tris, 20 mM acetic acid, 2 mM EDTA). Agarose gel was prepared by adding TAE solution to 
agarose (Sigma Aldrich, United States) to a final agarose gel mass concentration of between 5-30 
mg/ml, depending on the weight of agarose and volume of 1X TAE. 
Agarose gel solutions were cooled to approximately 10-15°C above solidifying temperature and 0.5X 
SYBR Safe DNA Gel Stain (10,000X in DMSO; Invitrogen, United States) was evenly mixed into 
solution. Gels were cast and left to set for 30 minutes, placed into a gel electrophoresis tank, and 
submerged in 1X TAE. Typically, 5 μl DNA product was mixed with 1 μl DNA Gel Loading Dye 6X 
(Thermo Scientific, United States) and loaded into each agarose gel well along with a ladder well 
containing either 2.5 μl GeneRuler 100 Bp Plus, FastRuler Low Range (Thermofisher, United 
States), or Quick-Load 1 kb DNA Ladder (New England Biolabs, United States) depending on 
estimated amplicon size. 
Agarose gels were run for 40-80 minutes at 6-8 V/cm, depending on estimated product size and 
agarose concentration. Agarose gels were visualised using transient ultraviolet (UV) illumination on 
the Gel Doc XR+ Gel Documentation System (BioRad, United States) and gel images were saved 
as both BioRad proprietary 1SC format and standard JPEG format with minimal compression. 
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2.4 Sanger sequencing 
2.4.1 PCR product clean-up 
PCR products generated for Sanger sequencing were cleaned using ExoSAP to remove unwanted 
single-strand sequences and residual dNTPs from the PCR reaction. ExoSAP was prepared by 
mixing Exonuclease I (New England Biolabs, United States) and Shrimp Alkaline Phosphatase (SAP; 
Sigma Aldrich, United States) enzymes at a ratio of 1:2, respectively. Each PCR product had 1 μl of 
ExoSAP added directly to the PCR reaction mixture. ExoSAP-treated reaction mixtures were 
incubated for 60 minutes at 37°C, followed immediately by an inactivating incubation of 80°C for 15 
minutes. 
2.4.2 Sanger sequencing termination reaction 
Sanger sequencing was performed using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems, United States). ExoSAP-purified PCR products were sequenced bi-directionally, 
sequencing both the forward and reverse strands, to improve alignment and sequencing quality 
where possible. Reaction mixtures consisted of 2 μl purified PCR product, 0.75 µl BigDye Terminator 
v3.1 Ready Reaction Mix, 1 μl primer (10 pmol; forward or reverse strand), 2µl 5X BigDye 
Sequencing buffer (Applied Biosystems, United States), and 4.25 µl nuclease-free water (Qiagen, 
United States). The reaction cycling conditions are given in 2.4.2 table 3. 
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2.4.2 Table 3 
Thermocycler conditions for BigDye termination sequencing reaction 
 
  
BigDye termination sequencing protocol 
96°C for 10 seconds 
X 25 cycles 50°C for 5 seconds 
60°C for 3 minutes 30 seconds 
Hold at 4°C  Prior to Isopropanol clean-up 
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2.4.3 Isopropanol clean-up and DNA precipitation 
Isopropanol clean-up was used as a sequence precipitation and clean-up method for removing 
unincorporated dyes and residual termination dNTPs left over from BigDye termination sequencing. 
To each Sanger sequencing reaction, 40µl of freshly prepared 75% v/v isopropanol (Sigma Aldrich, 
United States) was added and mixed gently by pipetting up and down twice. Reactions were then 
incubated at room temperature for 30 minutes and the subsequently centrifuged at 2092 relative 
centrifugal force (RCF) for 45 minutes. The reaction plate was then inverted onto absorbent paper 
and tapped to discard isopropanol, centrifuged for 30 seconds at 33 RCF, and left to air dry for 10 
minutes until all isopropanol has evaporated. DNA pellets were re-suspended in 20 µl of Hi-Di 
Formamide (Applied Biosystems, United States). 
2.4.4 Sequencing analysis 
Sanger termination sequences were loaded onto either a 3730 DNA Analyzer or 3130xl DNA 
Analyzer (Applied Biosystems, United States) where dye terminator sequences were separated by 
capillary electrophoresis and dye florescence was recorded for analysis. Fluorescence 
chromatograms were analysed using Sequencher v5.3 (Gene Codes Corporation, United States), 
aligning sequences to a reference sequence of each targeted variant ±500 base pairs extracted from 
UCSC, as described in section 2.3.1. 
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2.5 Pooled amplicon clean-up 
As part of chapter 3, normalisation of pooled long-range PCR amplicons of variable lengths was 
required prior to DNA library preparation for NGS sequencing. An efficient custom clean up method 
was developed in-house to remove unwanted DNA fragments and contaminants whilst retaining 
size-divergent pooled amplicons. Protocol is a hybridisation of the Agencourt AMPure XP PCR 
Purification Beads (Beckman Coulter, United States) and clean up protocol provided in Illumina 
TruSight Rapid Capture Sample Preparation Guide (Illumina, United States). Both systems 
mentioned above use the AMPure XP magnetic beads for the separation of DNA products (named 
“Sample Purification Beads” in the Illumina documentation). 
A volume of each pooled sample amplicon was mixed well with a pipette and added to a deep-well 
storage plate (minimum volume used was 10 µl as lower volumes resulted in issues with sample 
manipulation whilst in contact with magnetic beads). Subsequently, 1.8 volumes of AMPure XP 
magnetic beads (at room temperature and well mixed) were added to each pooled sample amplicon 
well, sealed with an adhesive plate seal, shaken at 507 RCF for one minute, and left to incubate for 
10 minutes at room temperature. 
The deep-well storage plate was spun briefly to ensure no sample was lost and placed onto a 
magnetic stand for 2 minutes. Whilst remaining on the magnetic stand, supernatant was carefully 
removed without disturbing the pellet, to each well 200 μl of freshly prepared 80% v/v ethanol (Sigma 
Aldrich, United States) was added and incubated at room temperature for 30 seconds after which 
the supernatant was removed. This process was repeated twice for a total of two 80% v/v ethanol 
washes. 
Any remaining ethanol was aspirated off using a 20 μl pipette and air dried at room temperature for 
a maximum of 5 minutes. The deep-well storage was removed from the magnetic stand and 40μl of 
nuclease-free water added to each pool sample amplicon well. Elution-bead mix was then shaken 
at 507 RCF for 1 minute. The deep-well storage plate was spun briefly to ensure no sample is lost 
and placed onto a magnetic stand for 2-10 minutes, with the eluate being subsequently transferred 
to a new labelled 96-well plate without disturbing the pellet. 
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Pooled sample concentrations were measured using the Invitrogen Qubit Broad Range DNA assay 
both before and after clean up to measure levels of DNA loss during the clean-up process (see 
section 2.2.1). Loss of DNA during clean-up is unavoidable using this method due to unbound DNA 
fragments. This protocol had to accommodate a broad range of DNA amplicon sizes – the rate loss 
that was seen typically 10-20% less than the original input (by total mass). Retention of all size 
ranges was confirmed by gel electrophoresis (5 mg/ml agarose gel at 6 V/cm for 60 minutes – See 
section 2.3.6). 
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2.6 DNA sequencing and library preparation 
Full details of manufacturer’s protocols are omitted for brevity but are available online 
(http://emea.support.illumina.com/array/protocols.html). 
2.6.1 Illumina Nextera XT Library preparation and sequencing 
Pooled amplicons underwent DNA library preparation using Illumina Nextera XT (Illumina, United 
States) following the manufacturer’s protocol. All samples were diluted to 5ng/μl and processed 
according to the manufacturer’s protocol. Pooled libraries were quantified by quantitative PCR and 
loaded onto an Illumina MiSeq Sequencer using Illumina MiSeq Reagent v.2 – 300 cycle Kit – paired 
end 150 bp (Illumina, United States). 
2.6.2 Illumina TruSight Cancer library preparation and sequencing 
Samples were prepared using the TruSight Cancer library prep kit (Illumina, United States) following 
the manufacturer’s protocol. All samples were diluted to 5ng/μl and processed according to the 
manufacturer’s protocol. Pooled libraries were quantified by quantitative PCR and loaded onto an 
Illumina MiSeq Sequencer using Illumina MiSeq Reagent v.2 – paired end 150 bp (Illumina, United 
States). 
2.6.3 Illumina TruSeq rapid exome library preparation and sequencing 
Samples were prepared using the TruSeq rapid exome library prep kit (Illumina, United States) 
following the manufacturer’s protocol. All samples were diluted to 5ng/μl and processed according 
to the manufacturer’s protocol. Pooled libraries were quantified by quantitative PCR and loaded onto 
an Illumina HiSeq 2500 Sequencer using Illumina HiSeq Reagent v.2 – paired end 150 bp (Illumina, 
United States). 
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2.6.4 Whole genome sequencing by Novogene 
Whole genome sequencing (WGS) data was generated externally by a third-party company 
Novogene (Beijing, China) from submitted blood-extract DNA. DNA was quantified and quality 
checked as described in section 2.2 prior to submission to WGS. DNA underwent library preparation 
using Illumina Nextera DNA library prep kit and sequenced on the Illumina HiSeq X platform. 
Sequencing output was returned in trimmed and de-multiplexed FASTQ format on an external hard 
drive and transferred to departmental hard drives after MD5 checksums. 
2.6.5 Library preparation labour contributions 
Library preparations of various results chapters discussed within this body of work were not solely 
generated by the author and as such contributions are described as accurately as possible below. 
Library preparation for section 2.6.1 were solely generated by the author and libraries were loaded 
into sequencing flow cells and onto the Illumina MiSeq platform by the stratified medicine core 
laboratory (SMCL) sequencing laboratory.  
Library preparations for section 2.6.2 were performed by Dr Hannah West, Dr Andrea Luchetti, and 
the author divided approximately 40%, 20%, 40% of the total libraries, respectively, and libraries 
were loaded onto sequencing flow cells and onto both Illumina MiSeq and Illumina HiSeq 2500 
platforms by the SMCL sequencing laboratory. 
Library preparations for section 2.6.3, including the sequencing flow cell and Illumina HiSeq 2500 or 
Illumina HiSeq 4000 loading were solely performed by the SMCL sequencing laboratory. 
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2.7 Generalised sequencing pipeline 
 
The diagram visualises the main steps and processes involved in the generation of candidate SNV 
variants. Full details of the sequencing pipeline scripts and runtime parameters are in appendix 
section 9.1. 
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2.8 Variant filtering and annotation 
Variant filtering of NGS data for all chapters was performed using a variant filtering bash script 
(variant_filtering.sh) and an accompanying R script (variant_filtering.R) utilising VCFtools (317). An 
overview of the variant filtering steps are provided here and the full script is provided in appendix 
section 9.1.2. 
Using VCFtools variant sites were filtered to the filter cut-offs described in the summary table below 
unless otherwise specified in the results chapters directly. Per site filters included minimum mean 
read depth across a site, maximum cohort minor allele frequency, site QUAL metric, and maximum 
missingness. Per genotype filters were minimum genotype quality. Minimum genotype quality filters 
were applied prior to maximum missingness as per genotype filters set failed genotypes to missing.  
 
Sites retained after the previously described filtering criteria were left aligned and normalised by 
GATK function ‘LeftAlignAndTrimVariants’ to split multi-allelic sites and present minimum 
representative calls for indels (318)(version 3.7-0-gcfedb67). Variants were annotated using 
Annovar (319) with the following databases; refGene, 1000g2015aug_all, exac03, avsnp150, 
dbnsfp35a, clinvar_20180603, cosmic70, nci60, dbscsnv11, and updated annotation databases 
were used when available.  
Minimum mean 
read depth 
Minimum genotype 
quality 
Maximum minor 
allele frequency 
Maximum 
missingness 
Site 
QUAL 
> 10 > 30 < 0.05 < 0.2 > 100 
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The annotated variants were parsed by the variant_filtering.R script and were then filtered by 
genomic feature (restricted to “exonic”, “exonic;splicing”, or “splicing”) and removed variants 
classified as “synonymous” or intergenic, specified by “unknown”. Variants were filtered by global 
minor allele frequencies present in both the 1000 genomes project (320) and ExAC (321) cohorts. 
Variants were retained if present at less than 1% (0.01 allelic frequency) using an ‘AND’ selection, 
specifying variants should be present at less than 1% in both sets to pass filtering criteria. Variants 
occurring with heterozygous call rates greater than 15% of the total cohort were removed as they 
were considered to be either technical artefacts or undocumented common SNPs. Lastly, allelic 
depth information was extracted for each genotype and alternative allelic depth ratios were 
calculated. Sites in which no single non-reference genotype had an alternative allelic ratio (i.e. 
percentage of supporting reads) great than 0.3 were removed. 
In silico predictive metrics where mentioned in the text refer to the use of Sift (322), PolyPhen (323), 
or CADD (324) applied either independently or collectively. Concordance for a variant being likely 
pathogenic between the software predictions was defined by a prediction of ‘likely pathogenic’ by 
Sift and PolyPhen and a CADD score greater than 25. Concordance for a variant being likely benign 
between the software predictions was defined by a prediction of ‘tolerated’ or ‘benign’ by Sift and 
PolyPhen and a CADD score lower than 10. 
American College of Medical Genetics (ACMG) variant classification criteria (325) were automatically 
applied utilising the default parameters of InterVar (version 2.0.2 20180827)(326) and Annovar (as 
previously discussed). InterVar does not accept or output multi-sample VCF files so was provided a 
pseudo single sample VCF containing all variants present in a given multi-sample VCF with all 
genotypes set to heterozygous. Indels annotated by InterVar were right shifted so post-processing 
was used to reapply left shift and normalisation in InterVar results files. 
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2.9 Oxford Nanopore Technologies sequencing 
2.9.1 Sample preparation and long-range PCR amplicon 
The sample used in Nanopore long read sequencing was prepared and quality controlled as 
described in section 2.2. PCR products for the specific reactions described in the appropriate 
chapters were performed as described in section 2.3.2 and in accordance with any additional 
alterations specified in the chapter 6 materials and methods section referring to this portion of the 
materials and methods chapter (section 6.2.5). 
2.9.2 Nanopore sequencing library preparation 
PCR amplicons were quantified to between 1-1.5 μg of total DNA, as described in section 2.2 and 
libraries were generated using the manufacturer’s protocol (1D Amplicon by ligation SQK-LSK108), 
with adaptation for reduced input fragment size, and loaded onto a FLO-MIN106 flow cell and 
sequenced on a MinION sequencing platform utilising the MinION control software (version 18.12.9). 
Sequencing was run for 1 hour and data was output in FAST5 format. 
2.9.3 Nanopore bioinformatics 
FAST5 read data from Nanopore sequencing was base called using the ONT Albacore Sequencing 
Pipeline Software (version 2.3.3), generating both base called FAST5 output and FASTQ output 
files. FAST5 and FASTQ data was indexed using Nanopolish (version 0.10.2) (327). Sequencing 
quality was assessed by custom R script nano-qc.R, poretools (version 0.6.0) (328), and NanoStat 
(329). Long read FASTQ data was aligned to GRCh38 using Minmap2 (version 2.10-r761) (330) 
using ONT sequencing parameters. Full ONT Nanopore sequencing pipeline nano-pipe.sh is 
included in appendix section 9.1.3. 
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3.0 Sequencing of candidate genes by Sanger and targeted next 
generation sequencing approaches 
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3.1 Introduction 
Current clinical practice utilises targeted sequencing, either using next generation sequencing (NGS) 
panels such as cancer gene panels or ‘clinical’ exomes, or Sanger sequencing for specific genes 
that have been associated with known diseases. The primary benefits of using Sanger sequencing 
and genomic loci-limited NGS sequencing over more comprehensive NGS sequencing methods is 
both a decrease in financial burden, a reduction in the labour required to perform data generation 
and analysis, and an increase in the efficiency of accurate variant identification and assessment by 
reducing the scope of data generated. Genes that are frequently somatically altered in sporadic RCC 
tumours might be candidate targets for inherited disease. This is exemplified by the VHL TSG (99) 
and most recently by PBRM1 and BAP1 which have been implicated in familial and sporadic RCC 
(263,268,331). Assessment of these candidates allow for the selection of additional targets for 
sequencing that are related to the pathways known to be altered in RCC (98). Here, a subset of 
genes related to RCC predisposition or development were targeted by both Sanger and NGS 
techniques in order to identify potential variants of interest in genes associated with RCC. 
3.1.1 – Candidate gene - CDKN2B 
Cyclin-dependent kinase inhibitor 2B (CDKN2B) is a two-exon gene which encodes the protein 
p15INK4B (i.e. Cyclin-dependent kinase 4 inhibitor B) with both a canonical 138 amino acid transcript 
(NM_004936) and a shorter 78 amino acid transcript (NM_078487). CDKN2B shares its genomic 
positions with Cyclin-dependent kinase inhibitor 2B (CDKN2A), which have overlapping loci on 
chromosome 9 (chr9:22002903-22009363 and chr9:21967752-21995301, respectively), along with 
a third associated protein, p14ARF, which is encoded by CDKN2A utilising an alternative reading 
frame.  
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As its namesake suggests, p15INK4B acts as an inhibitor of cyclin-dependent kinase 4 (CDK4), a 
protein associated with cell cycle progression and regulation of proliferation in a protein complex with 
cyclin-dependent kinase 6. CDK4 or CDK6 bind with Cyclin D1 (CD1) and function in the 
phosphorylation of retinoblastoma (RB) proteins which results in the upregulation of gene 
transcription via E2F proteins. Both p15INK4B and p16INK4A act to bind CDK4/CDK6-CD1 complexes 
and inhibit the phosphorylation of RB proteins, which acts to decrease the activity of E2F transcription 
factors (332,333). While the function of p15INK4B and p16INK4A have clear overlaps they are not 
functionally redundant and p15INK4B has distinct functions as a tumour suppressor in the absence of 
p16INK4A (334). 
CDKN2A is reported to be frequently altered somatically across all RCC histological subtypes via 
either promotor hypermethylation or deletion of 9p, correlated with poorer survival (274) and TCGA 
data suggests copy number losses in RCC cases affect both CDKN2A and CDKN2B similarly (25). 
Though inactivating variants in CDKN2B are rare somatically, with only a single inactivating variant 
reported across all RCC samples in TCGA (25), hypermethylation of CDKN2B has been 
demonstrated in RCC and other cancers, including acute myeloid and lymphoid leukaemia (335), 
parathyroid adenomas (336), and colon cancer (337). Additionally, germline variants in CDKN2B 
(amongst other cyclin-dependent kinase inhibitors) were associated with predisposition to multiple 
endocrine neoplasia type 1 (MEN1), though the occurrence rate was low (338). 
A previous study identified a truncating variant in an individual with familial clear cell RCC, and 
subsequent sequencing of a cohort of individuals with features of inherited RCC, without pathogenic 
variants in known RCC predisposition genes, resulted in candidate deleterious variants in CDKN2B 
in up to 5% of assessed samples (95% CI, 0.21%–9.43%) with a significant enrichment compared 
to dbSNP (0.2%) (266). Given the identification of CDKN2B as a candidate familial RCC cohort, 
replication of these findings in an independent RCC cohort would support the hypothesis that 
germline inactivation variants in CDKN2B is associated with RCC predisposition. 
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3.1.2 – Candidate gene - EPAS1 
EPAS1 (also known as HIF2-α) is an enticing candidate gene for potential predisposition given its 
role in the HIF-driven hypoxia response (141) and direct targeting by VHL-dependent ubiquitination 
(107,138). EPAS1 is a 16 exon coding gene at 2p21 which encodes the protein endothelial PAS 
domain-containing protein 1 (EPAS1). Under hypoxic conditions, EPAS1 together with HIF1A and 
HIF1B act to upregulate angiogenic pathways and increase angiogenesis and cellular growth 
through HRE-linked transcription (See 1.4.2 VHL disease).  
Like many oncogenes, truncating or inactivating variants are not predicted to be pathogenic as they 
do not result in constitutional protein activation or increased transcriptional expression. Publications 
regarding EPAS1 have demonstrated that missense mutations in exons 9 and 12 in PCC/PGL 
tumours are oncogenic (339,340), with EPAS1 variant carrying tumours having significantly higher 
EPAS1 expression. In a subset of these cases, the variants were also shown to be present in the 
germline indicating potential predisposition (339). These exons appear to be mutational hotspots, 
co-localising to the hydroxylation site and reducing pVHL binding affinity, respectively, resulting in 
constitutional activation of EPAS1 (341,342). GWAS studies in RCC have also demonstrated the 
presence of a complex risk locus surrounding EPAS1, suggesting potential linkage to functional 
variants in EPAS1 which may increase an individual’s risk for RCC (108,109). 
Given the distinct genetic overlap between RCC and PCC/PGL through conditions such as VHL 
disease, SDH-deficient tumours, and FH-related predisposition, an EPAS1 genotype association 
with PCC/PGL suggested EPAS1 as a candidate for inherited RCC cases and as such exons 9 and 
12 of EPAS1 were selected as candidate sequencing regions in this series of patients with features 
of possible inherited RCC. 
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3.1.3 – Candidate genes - KMT2C and KMT2D 
Somatic alterations frequently found in sporadic cases of RCC may indicate potential sources of 
undiscovered heritability. Large scale sequencing projects such as TCGA (25), amongst others, 
provide reliable data about which genes are frequently somatically altered in specific cancer types. 
Lysine methyltransferase 2C and 2D (KMT2C and KMT2D), are genes that are altered in sporadic 
RCC at frequencies of 5% and 3% respectively in TCGA renal cancer data set (25), with alteration 
rates in chromophobe RCC up to 15%. Investigations into frequently altered somatic genes may 
resolve the presence of germline alterations in those same genes, as is the case with genes such 
as VHL, PBRM1, BAP1, PTEN, and MET. 
Both KMT2C and KMT2D are large coding genes situated at 7q36.1 and 12q13.12, respectively. 
KMT2C is a 59-exon gene encoding a 4,911 amino acid protein and KMT2D is a 54 exon gene 
encoding a 5,537 amino acid protein. Both genes encode Histone lysine-specific N-
methyltransferase enzymes, which primarily act to catalyse the addition of methyl groups to lysine-
4 residues of histone H3, aptly named KMT2C and KMT2D (343). Both KMT2C and KMT2D are 
frequently mutated in multiple cancers, demonstrating both an array of copy number gains, losses 
and SNVs (25). Originally, they were termed MLL2/4 and MLL3 (corresponding to KMT2D and 
KMT2C, correspondingly) due to being part of a family of proteins known as mixed-lineage leukaemia 
(MLL) associated with multiple cancers, including leukaemia (343). KMT2C and KMT2D form protein 
complexes with a series of common, and complex-specific proteins, including KDM6A, a lysine-
specific demethylase dysregulated in clear cell RCC (344,345) and function in histone regulation 
through the addition of H3K4me1 groups to histones particularly in adipogenesis (346), though 
exactly how this promotes tumourigenesis has not been well established. Several studies have 
suggested H3K4me1 groups allow for open chromatin access to enhancer regions of oncogenic 
transcripts, whereas alternative hypothesises suggest H3K4me1 modifications block DNA 
methylation suggesting a loss of transcriptional repression via promotor methylation (347,348). 
KMT2C and KMT2D also appear to have tumour suppressor functions through co-activation of p53 
in DNA repair via the ASCOM protein complex (349). 
 99 
 
Given that PBRM1 and BAP1 are histone modifying and chromatin remodelling genes (350,351) 
frequently altered in somatic RCC (274) and have been recently associated with RCC predisposition 
(263,331), assessing other histone modifying or chromatin remodelling genes such as KMT2C or 
KMT2D may uncover new associations in individuals with predisposition to RCC. Finally, 
unpublished data from whole exome sequencing data identified a nonsense variant in KMT2C 
(NM170606.2: c.2263C>T: p.Gln755Ter: rs201234598) in a blood sample from a patent with familial 
RCC in the absence of any other variants in RCC predisposing genes, raising the possibility that 
germline variants in KMT2C or KMT2D might predispose to RCC. 
Given these factors, sequencing of the full coding region of both KMT2C and KMT2D was performed 
to assess for the presence of pathogenic variants that may confer predisposition. Given the total size 
of the targeted regions standard Sanger sequencing was considered inappropriate and as such 
amplicon-based next generation short read sequencing was utilised to achieve complete coverage 
of the coding regions of both genes. 
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3.1.4 Aims 
 To validate findings of pathogenic CDKN2B variants being associated with RCC 
predisposition in individuals with features of inherited RCC 
 Assess hotspot regions of EPAS1 to identify activating variants which may predispose 
individuals to RCC in a manner similar to that seen in PCC/PGL 
 Evaluate the coding regions of KMT2C and KMT2D for pathogenic variants which may 
predispose individuals to RCC utilising long range PCR and NGS sequencing methods 
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3.2 Materials and methods 
3.2.1 Samples 
Samples selected were individuals with RCC who had been referred to research as having features 
of heritability, as described in section 2.1.3. A total of 166 individual germline whole blood DNA was 
utilised for targeted sequencing of CDKN2B and EPAS1 exon 9 and exon 12. For NGS sequencing 
of KMT2C and KMT2D, a subset of 96 individuals were selected for sequencing from the primary 
cohort of 166 due to issues with sequencing relating to both capacity and economic constraints. 
3.2.2 Sanger sequencing primer design and co-ordinates 
Primers for both standard PCR reactions and long-range PCR reactions were designed as described 
in the main materials and methods (sections 2.3.1). PCR primers for all experiments in this chapter 
are reported in appendix section 9.2.1. 
3.2.3 PCR reactions and Sanger sequencing 
PCR reactions, bi-directional Sanger sequencing, and Sanger sequencing was performed as 
described in main material and methods section 2.3.2, section 2.4. Failed reactions were repeated 
with additional optimisation steps to improve PCR reaction parameters and sample DNA underwent 
quality control to assess potential issues as described in main material and methods (section 2.2). 
Reactions were repeated a maximum of 3 times. 
3.2.4 Long range PCR 
Long range PCR reactions were performed as described in section 2.3.5 of materials and methods 
as input amplicons for next generation sequencing. Long range PCR primers were optimised 
iteratively to a maximum of three iterations, after which regions were designated as poorly optimised 
and not included in long range PCRs downstream. Failed reactions were re-optimised and repeated 
an additional two times prior to being assigned ‘failed’ status. 
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3.2.5 Illumina Nextera XT library preparation for amplicon sequencing 
DNA library preparation for KMT2C/KMT2D long range amplicons, including a custom developed 
amplicon normalisation method, was performed as described in the main materials and methods 
(section 2.5 and 2.6.1). Three individual libraries were prepared for 16 pooled samples for batch 1 
and 2, and 21 samples for batch 3. Batches 1 and 2 were performed using a standard MiSeq flow 
cell whereas batch 3 utilised a MiSeq Nano flow cell. Library loading on to the Illumina MiSeq was 
performed by the SMCL sequencing service. 
3.2.6 Primary bioinformatics 
Primary bioinformatics from BCL to VCF was performed as described in the generalised pipeline in 
the material and methods (sections 2.7) from FASTQ to VCF, BCF to FASTQ and sample de-
multiplexing was performed by the SMCL sequencing service. 
3.2.7 Variant filtering, annotation, and classification 
Variant quality filtering, feature annotation and classification was performed as described in the main 
materials and methods (sections 2.8). 
3.2.8 Sequence identity comparison 
Sequence identity comparison was performed using Emboss Matcher pair-wise sequence alignment 
algorithm to assess sequence similarities (352). FASTA sequences were downloads from NCBI 
(https://www.ncbi.nlm.nih.gov/gene/) and sequence identity compared. Conserved regions were 
generated using coordinate positions of matching sequence regions and converted to BED file format 
prior to plotting. Command line details are provided within the pair-wise sequence alignment results 
in appendix section 9.2.2. 
3.2.9 Statistics 
Fishers exact was performed using the fisher.test() function in stat package using R (version 3.5). 
Binomial proportions and confidence intervals were calculated using bionom.test() in the stats 
package using R (version 3.5). 
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3.3 Results 
3.3.1 Targeted Sanger sequencing - PCR product generation 
A cohort of 166 RCC cases were selected for targeted Sanger sequencing of the coding regions of 
CDKN2B and exons 9 and 12 of EPAS1. DNA was amplified to cover all targeted regions described 
prior, two amplicons were used to cover the two exons from CDKN2B and one amplicon for EPAS1 
exon 9 and 12 each (See 3.3 - Table 1). In total 1328 PCR reactions were performed and amplicons 
were successfully generated for 92.7% (154/166), 97.0% (161/166), 80.7% (134/166), and 97.6% 
(162/166) samples for amplicons CDKN2B-1, CDKN2B-2, EPAS1-exon9 and EPAS1-exon12, after 
PCR product generation was confirmed by agarose gel electrophoresis (3.3 - Figure 1 - Example 
gel). Sequencing was generated by Sanger sequencing for successful amplicons of samples. The 
mean success rate for uni-directional and bi-directional sequencing for all targets was 92.0% and 
80.6%, respectively, where uni-directional sequencing was defined as the successful analysis of 
either the forward or reverse Sanger sequencing trace.  
Overall, only 1.2% (2/166) samples failed to generate any usable PCR products for Sanger 
sequencing, 1.8% (3/166) of samples only generated uni-directional sequencing for EPAS1 exon 12, 
4.2% (7/166) of samples only generated usable sequencing for CDKN2B-2 and EPAS1 exon 12, 
1.2% (2/166) of samples generated sequencing for all amplicons except for EPAS1 exon 12, and a 
larger subset of 12.0% (20/166) failed to generate sequencing for EPAS1 exon 9. In total, 79.5% 
(132/166) and 35.5% (59/166) of samples had uni-directional and bi-directional sequencing, 
respectively, for all amplicons for targets of CDKN2B, EPAS1 exon 9, and EPAS1 exon 12. A 
summary of Sanger sequencing product and trace generation is provided graphically in 3.3 - Figure 
2. 
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3.3 - Table 1 
Amplicons used in targeted Sanger sequencing analysis of CDKN2B and EPAS1 exon 9 & 12 
 
3.3 - Figure 1 
An example of an agarose gel used to confirm the generation of a PCR amplicon for each target 
prior to performing Sanger sequencing. 
  
Amplicon Target region Amplicon size (bp) Primer set name 
CDKN2B-1 Exon 1 597 CDKN2B-1B-PS 
CDKN2B-2 Exon 2 600 CDKN2B-2A-PS 
EPAS1-exon9 Exon 9 565 ORF-EPAS1-Ex9-rep 
EPAS1-exon12 Exon 12 829 ORF-EPAS1-Ex12-rep 
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3.3 – Figure 2 
Schematic heat map-style representation of amplicon sequencing visualising successfully analysed 
Sanger sequencing traces. Heat map is contiguous but split into three sections for clarity. X-axis is 
defined by both Amplicon and strand direction (Referred to by ‘F’ and ‘R’ columns). Green cell 
colouration indicates a trace was successfully analysed whereas red cell colouration indicates a 
trace failed to be analysed.  
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3.3.2 Targeted Sanger sequencing – Variant analysis 
Sanger sequencing traces (bi-directional where available) were aligned to reference sequences for 
the corresponding genomic regions. Across the 164 samples assessed with viable Sanger data, 
variants were identified in 21 samples (12.7%), no sample carried more than a single variant, and 
variants were distributed across the targeted regions with a majority of samples carrying variants in 
EPAS1 exon 12 (CDKN2B = 2, EPAS1 exon 9 = 2, EPAS1 exon 12 = 17)(Sanger traces shown in 
3.3 - Figure 3). Most variants occurred more than once across the sample set, with only 5 unique 
sites altered, 1 in CDKN2B, 2 in EPAS1 exon 9, and 2 in EPAS1 exon 12 (See 3.3 - Table 2). Of the 
identified variants, 2 were classified as common SNPs, occurring in gnomAD (353) at an allele 
frequency of more than 1%. Remaining variants were assessed for pathogenicity based on manual 
annotation of criteria including functional consequence, clinical reporting, and in silico predictive 
metrics. Two individuals carried 1 variant in CDKN2B and two individuals carried variants in EPAS1 
exon 9. Filtered variants, including informative annotation, are described in 3.3 - Table 3. 
EPAS1 exon 9 variants were present in 1.49% (2/134) individuals with available sequence 
information. The two variants present in EPAS1 exon 9 (NM_001430:c.1104G>A: p.Met368Ile and 
NM_001430: c.1121T>A: p.Phe374Tyr) are flagged as likely benign according to ClinVar 
submissions, VUS and likely benign by ACMG interpretation, and in-silico tools SIFT, PolyPhen and 
CADD are in consensus that these missense alterations are unlikely to result in protein dysfunction. 
The remaining variant identified in exon 2 of CDKN2B in two individuals (NM_004936: c.256G>A: 
p.Asp86Asn) occurs at a minor allele frequency 1.22E-03 in the gnomAD dataset and falls within a 
functional domain and in-silico predictive metrics used suggest the variant is detrimental. The 
p.Asp86Asn variant is identical to that reported in the original report regarding RCC predisposition 
related to CDKN2B variants (266) which occurred at a rate of 1.19% (1/84; 95% CI 0.03-6.46%). 
Compared to this series, 1.24% (2/161; 95% CI 0.15-4.42%), the variant distributions are not 
statistically different (fishers exact; p = 1.00).  
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3.3 - Figure 3 
Sanger traces of identified variants from targeted Sanger sequencing – Orange arrows indicate the 
position of the variant and each Sanger trace represents a single individual.  
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3.3.3 KMT2C & KMT2D targeted sequencing – Long range PCR product generation 
For the targeted sequencing of KMT2C and KMT2D, long range HPLC-purified primer pairs were 
designed to cover the all exons and a proportion of intronic regions of both genes of both genes, 
encompassing exons 1-58 of KMT2C and 1-54 of KMT2C for a total targeted sequencing region size 
of 337 Kb. Amplicons were rejected if they failed to generate distinct or single amplicons and 
application of this filtering criteria resulted in no available coverage of 16/112 exons (14.2%) (See 
3.3 - Table 4). Agarose gel containing all optimised long-range PCR amplicons is shown in 3.3 - 
Figure 4. 
For the remaining optimised primer pairs, long range PCR amplification was carried out across 96 
samples, totalling 1824 long range PCR reactions. After repeating long range PCRs, a total of 82.8% 
of reactions successfully generated suitable PCR products for library preparation. The number of 
successful amplicons was higher in KMT2D amplicons than KMT2C amplicons (87% compared to 
81%), with the worst performing amplicon KMT2C exon 53-58 having 54.2% success rate and the 
best performing amplicon KMT2D exon 12-14 successfully generating long range amplicons in 
94.8% of samples (See 3.3 - Figure 5).  
Samples with complete sets of amplicons were batched into libraries for sequencing utilising Illumina 
NexteraXT kit as described in the methods (Section 3.2). Batch 1 and 2 consisted on amplicons for 
both KMT2C and KMT2D whereas batch 3 only contained amplicons for KMT2D due to 
complications discussed later in this chapter. 
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3.3 - Figure 4 
Agarose gel on control genomic DNA for all 19 viable long range PCR amplicons 
 
3.3 - Table 4 
Details of primer optimisation process detailing reaction requirements for long range PCR and 
exclusion criteria 
  
Gene Exon Covered Optimisation 
Product Size 
(bp) 
Annealing Temp. 
(°C) 
DNA Conc. (ng/μl)  Notes 
KMT2C Exon 3 PASS 7854 61 10  
KMT2C Exon 4 - 6 PASS 7457 60 10  
KMT2C Exon 7 PASS 5668 61 10  
KMT2C Exon 15 - 16 PASS 7243 61 10  
KMT2C Exon 17 - 18 PASS 4806 59 10  
KMT2C Exon 19-20 PASS 6219 60 10  
KMT2C Exon 21 - 23 PASS 8008 60 10  
KMT2C Exon 24 - 27 PASS 9375 59 10  
KMT2C Exon 32 - 37 PASS 9205 59 10  
KMT2C Exon 38 - 41 PASS 9776 58 10  
KMT2C Exon 45 - 52 PASS 9169 58 10  
KMT2C Exon 53 - 58 PASS 9896 62 10  
KMT2C Exon 59 PASS 8076 59 10  
KMT2D Exon 1 - 11 PASS 6579 59 10  
KMT2D Exon 12 - 14 PASS 1623 59 10  
KMT2D Exon 15 - 18 PASS 1518 57 10  
KMT2D Exon 19 - 34 PASS 8433 59 10  
KMT2D Exon 35 - 42 PASS 5064 62 10  
KMT2D Exon 43 - 54 PASS 11,150 59 10  
KMT2C Exon 1 FAIL 7909 NA NA Multiple Bands 
KMT2C Exon 8-9 FAIL 7826 NA NA Multiple Bands 
KMT2C Exon 10-14 FAIL 7986 59 10 Multiple Bands 
KMT2C Exon 42-44 FAIL 9047 58 10 Multiple Bands 
KMT2C Exon 2 FAIL 7950 60 10 Multiple Bands 
KMT2C Exon 28 - 31 FAIL 5512 58 10 Wrong Product size 
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3.3 - Figure 5 
Schematic heat map representation of long-range PCR amplicon generation across 96 samples. 
Columns represent individual amplicons and rows correspond to samples. Numeric values on the x 
and y axis are completion percentages for each row/column/group. Green colouration indicates 
success and red indicates failure. 
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3.3.4 KMT2C & KMT2D targeted sequencing – Library preparation and quality control 
Across each batch, the mean number of reads successfully aligned to human genome build GRCh38 
was 99.87% (SD=0.06), 99.78% (SD=0.20), and 98.92% (SD=1.29) and estimates of PCR 
duplicates were calculated with a mean value of 14.3% (range 8.30-17.5; SD=2.52%), 20.7% (range 
10.5-31.2%; SD=4.99), and 3.16% (range 1.5-5.3%; SD=1.06) for batches 1-3, respectively. 
Significant differences were found in PCR duplicate rates across batches (Kruskal-Wallis rank sum 
test; p=8.68E-10) but was solely related to input amplicons used across batches. 
On-target sequencing rates were calculated based on the number of non-PCR duplicate reads 
intersecting within the genomic span of KMT2C and KMT2D. For batches 1-3, the on-target 
sequencing rates were 63.3% (SD=3.98), 60.3% (SD=5.11), and 89.1% (SD=3.81) of reads aligning 
to either the genomic regions of KMT2C or KMT2D, respectively. Significant differences in on-target 
alignment were seen between batches 1-2 and batch 3 (Kruskal-Wallis rank sum test; p=4.10E-09). 
Mean coverage across targeted exonic regions was 353 (SD=63.2), 435 (SD=72.8), and 40.0 
(SD=5.15) for batches 1-3, providing adequate coverage for variant calling. As mentioned previously, 
batch 3 was sequenced on a lower throughput sequencing flow cell and as such has lower mean 
coverage compared to batches 1 and 2. Overall sequencing metrics were deemed to be adequate 
for variant assessment given the sequence coverage levels. High levels of off-target sequence 
alignment were noted, particularly in batch 1 and 2. Sequence alignment and quality control metrics 
are shown in 3.3 - Figures 6-8 with additional sequencing statistics provided in appendix section 
9.2.3. 
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3.3.5 KMT2C & KMT2D targeted sequencing – Variant analysis 
Variant calling was performed as described in material and methods section and called a total of 
23,644 variants prior to filtering and quality control. After filtering called variants for depth, QUAL, 
and genotype quality a total of 1,773 variants were retained. Missingness filters were not applied 
due to no sequencing data being available for KMT2C in 39.6% of samples due to constraints applied 
to library batch 3. 
Variants were annotated and further filtered as described in the methods and a total of 18 sites 
across 14 individuals were retained. After filtering for variants within the span of the coding region of 
KMT2C and KMT2D, 7 variants in 6 individuals were kept, with the remaining proportion being called 
in off-target regions. Variants were functionally annotated utilising Annovar and assessed for 
pathogenicity (See 3.3 Table 5). All variants identified were missense variants, 1 in KMT2C and 6 in 
KMT2D. Of the 7 variants identified in the coding regions of KMT2C or KMT2D, 3 variants were 
classified as variants of unknown significance (VUS) and 4 were classified as likely benign by ACMG 
criteria (325). No variants identified were classed as known pathogenic variants and only missense 
variant p.Gly1425Ser in KMT2C (NM_170606: c.4273G>A: p.Gly1425Ser) in exon 27 had 
consensus pathogenic or damaging in silico predictive metrics. 
  
   3.
3
 -
 T
a
b
le
 5
 
V
a
ri
a
n
ts
 o
c
c
u
rr
in
g
 w
it
h
in
 t
h
e
 g
e
n
o
m
ic
 r
e
g
io
n
s
 o
f 
K
M
T
2
C
 a
n
d
 K
M
T
2
D
 p
a
s
s
in
g
 a
ll 
fi
lt
e
ri
n
g
 c
ri
te
ri
a
 w
it
h
 a
d
d
it
io
n
a
l 
in
 s
ili
c
o
 p
re
d
ic
ti
o
n
, 
A
C
M
G
, 
a
n
d
 C
lin
V
a
r 
a
n
n
o
ta
ti
o
n
s
. 
  C
h
r 
P
O
S
 
rs
ID
 
R
E
F
 
A
L
T
 
G
E
N
E
 
T
ra
n
s
c
ri
p
t 
E
x
o
n
 
c
D
N
A
 
A
A
 
C
O
N
S
E
Q
. 
X
1
0
0
0
G
 
E
X
A
C
 
C
A
D
D
 
S
IF
T
 
P
O
L
Y
 
P
H
E
N
 
A
C
M
G
 
C
L
IN
V
A
R
 
c
h
r7
 
1
5
2
1
9
9
2
7
9
 
rs
7
4
6
2
7
0
7
5
7
 
C
 
T
 
K
M
T
2
C
 
N
M
_
1
7
0
6
0
6
 
2
7
 
c
.G
4
2
7
3
A
 
p
.G
1
4
2
5
S
 
M
is
s
e
n
s
e
 
0
.0
0
E
+
0
0
 
8
.3
5
E
-0
6
 
2
6
.2
 
D
 
D
 
V
U
S
 
N
/a
 
c
h
r1
2
 
4
9
0
4
0
1
0
0
 
rs
1
8
9
8
8
8
7
0
7
 
G
 
A
 
K
M
T
2
D
 
N
M
_
0
0
3
4
8
2
 
3
1
 
c
.C
7
6
7
0
T
 
p
.P
2
5
5
7
L
 
M
is
s
e
n
s
e
 
8
.5
9
E
-0
3
 
8
.5
0
E
-0
3
 
2
3
.4
 
D
 
B
 
L
B
 
B
e
n
ig
n
 
L
ik
e
ly
 b
e
n
ig
n
 
c
h
r1
2
 
4
9
0
3
8
5
9
1
 
rs
7
5
7
7
9
1
5
3
9
 
C
 
T
 
K
M
T
2
D
 
N
M
_
0
0
3
4
8
2
 
3
4
 
c
.G
8
7
6
5
A
 
p
.R
2
9
2
2
Q
 
M
is
s
e
n
s
e
 
0
.0
0
E
+
0
0
 
8
.4
6
E
-0
6
 
2
4
.3
 
T
 
B
 
V
U
S
 
N
/a
 
c
h
r1
2
 
4
9
0
5
1
7
4
3
 
rs
2
0
0
0
8
8
1
8
0
 
G
 
T
 
K
M
T
2
D
 
N
M
_
0
0
3
4
8
2
 
1
0
 
c
.C
1
9
4
0
A
 
p
.P
6
4
7
Q
 
M
is
s
e
n
s
e
 
0
.0
0
E
+
0
0
 
4
.0
0
E
-0
4
 
4
.6
2
2
 
T
 
B
 
L
B
 
C
o
n
fl
ic
ti
n
g
  
in
te
rp
re
ta
ti
o
n
s
 o
f 
p
a
th
o
g
e
n
ic
it
y
 
c
h
r1
2
 
4
9
0
4
2
2
3
2
 
rs
7
5
4
4
2
0
1
0
0
 
G
 
A
 
K
M
T
2
D
 
N
M
_
0
0
3
4
8
2
 
2
8
 
c
.C
5
9
6
6
T
 
p
.T
1
9
8
9
M
 
M
is
s
e
n
s
e
 
0
.0
0
E
+
0
0
 
0
.0
0
E
+
0
0
 
2
3
.9
 
T
 
D
 
V
U
S
 
N
/a
 
c
h
r1
2
 
4
9
0
5
1
5
5
4
 
rs
7
5
8
9
1
2
9
1
9
 
G
 
C
 
K
M
T
2
D
 
N
M
_
0
0
3
4
8
2
 
1
0
 
c
.C
2
1
2
9
G
 
p
.P
7
1
0
R
 
M
is
s
e
n
s
e
 
0
.0
0
E
+
0
0
 
5
.1
8
E
-0
5
 
0
.0
7
3
 
T
 
B
 
L
B
 
N
/a
 
c
h
r1
2
 
4
9
0
5
1
6
0
9
 
rs
2
0
2
0
7
6
8
3
3
 
G
 
T
 
K
M
T
2
D
 
N
M
_
0
0
3
4
8
2
 
1
0
 
c
.C
2
0
7
4
A
 
p
.P
6
9
2
T
 
M
is
s
e
n
s
e
 
1
.4
0
E
-0
3
 
4
.2
0
E
-0
3
 
9
.2
3
3
 
D
 
B
 
L
B
 
B
e
n
ig
n
 
L
ik
e
ly
 b
e
n
ig
n
 
 118 
 
3.3.6 KMT2C & KMT2D Targeted sequencing – Off-target regions and read mapping 
The initial number of called variants (23,644) compared to final filtered numbers resulted in 
investigations in variant calling metrics and quality control and analysis was performed to assess the 
number of total intragenic (within gene region) variants called across the cohort. As variant calling 
was performed genome-wide, a minor fraction would be expected to be present across off-target 
sites due to both mismapping reads, genomic contaminants, and variant calling errors. As expected, 
low levels (< 10 variants) intragenic variants were identified in 46 genes, the majority of which 
occurred within non-coding space but an apparent enrichment of variants was identified in BAGE 
Family Member 2 (BAGE2)(See 3.3 Figure 9). 
Given that called variants are present due to mapped reads supporting a specific allele, analysis of 
read mapping was performed across the BAGE2 coding regions to identify the total proportion of 
reads aligning to the region. Mean percentage of reads aligning within BAGE2 in batches 1 and 2 
was 8.35% (SD=1.16) and 7.67% (SD=1.26), respectively, while batch 3 did not contain any reads 
mapping to BAGE2. The mapping results suggest that alignment of reads with BAGE2, and as such 
variant calling, is due to the presence of KMT2C amplicons given that batch 3 consisted only of 
amplicons for KMT2D. Read alignment rates for BAGE2, KMT2C, KMT2D, KMT2C/D are shown in 
appendix section 9.2.3. 
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3.3 Figure 9 
Variant counts for intragenic regions detected in targeted sequencing data of KMT2C/D prior to 
stringent rarity and consequence filters. 
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3.3.7 KMT2C & KMT2D Targeted sequencing – BAGE2 gene sequence comparison 
The BAGE family of genes consisting of members BAGE1-5, of which only BAGE2 and BAGE5 have 
genomic positions designated in genome build GRCh38, where all others are unmapped and 
designated in chr21p11.1, in proximity to BAGE2 (See Appendix 9.2.4). Since BAGE2 read 
alignments only occur in samples containing KMT2C amplicons, it is likely sequence similarities exist 
between regions of KMT2C and BAGE2, resulting in off-target alignment. Using Emboss matcher, 
the coding sequences of KMT2C (ENSG00000055609) and BAGE2 (ENSG00000187172) resulted 
in a pair-wise alignment sequence similarity of 86.6% and gap presence of 9%. Inverse pair-wise 
alignments resulted in similar levels of sequence identity between KMT2C and BAGE2 (78.7%). Pair-
wise sequence of mRNA sequences for KMT2C (NM_170606) and BAGE2 (NM_182482) also 
demonstrated significant sequence similarity (73%) but a much greater introduction of sequence 
alignment gaps (25.4%), demonstrating lower identity within coding regions. Comparison of 
conserved sequence regions in BAGE2 plotted across KMT2C demonstrated gene-wide 
conservation (See Appendix 9.2 for sequence comparisons, read alignment rates, and conservation 
plots). 
3.3.8 Validation of KMT2C nonsense variant 
Given the issues regarding KMT2C and multiple mapping of reads to BAGE2 and others, DNA for 
the initial index case harbouring the KMT2C nonsense variant (NM170606.2: c.2263C>T: 
p.Gln755Ter: rs201234598) was acquired and Sanger sequencing was used to amplify the region 
containing the KMT2C variant. Sanger sequencing trace resolved a partial mosaic variant at the 
affected site, with a reduced allelic depth estimated at 0.2-0.3 (See 3.3 Figure 10). 
Additional variant data was extracted from ExAC and gnomAD aggregated datasets to assess 
variant statistics related to the nonsense variant site. Both datasets employ a stringent series of filter 
criteria on variants detected within the cohorts and though rs201234598 is reported, it failed random 
forest filtering in both sets, suggesting the variant is artefactual. In addition to failing random forest 
filtering metrics, the variant is present in a large proportion of genomes reported in gnomAD with 
allele frequency reported in gnomAD greater than that in ExAC by an order of magnitude, 2.17E-03 
compared to 4.1E-02. 
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3.3 - Figure 10 
Sanger sequencing trace from affected individual alleged to carry the KMT2C nonsense variant 
(NM170606.2: c.2263C>T: p.Gln755Ter: rs201234598). 
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3.4 Discussion 
Targeted Sanger sequencing of EPAS1 exon 9 and 12 and CDKN2B revealed several potential 
variants of interest, though none were classified as pathogenic or likely pathogenic. Analysis of rare 
variants in EPAS1 exon 9 and 12 identified two missense variants (NM_001430: c.1104G>A: 
p.Met368Ile and NM_001430: c.1121T>A: p.Phe374Tyr) in exon 9 which have previously been 
assessed in relation to polycythaemia and paragangliomas (342). While ClinVar and ACMG criteria 
regard these variants as likely benign or VUS variants, functional studies have demonstrated that 
EPAS1 p.Phe374Tyr results in a gain-of-function, demonstrating increased stability over wildtype 
EPAS1, and protein interaction simulations suggested p.Phe374Tyr-EPAS1 protein disrupted pVHL 
binding to its complex components (342). The second EPAS1 p.Met368Ile variant does not have 
supporting functional data but occurs at a lower allele frequency in reference datasets and in close 
proximity to the p.Phe374Tyr variant, suggesting that the p.Met368Ile variant may alter EPAS1 in a 
similar manner, though functional confirmation would be required. Germline predisposing variants in 
EPAS1 in RCC would be particularly interesting if proven to be a true association given recent clinical 
trials of EPAS1 inhibitors as a treatment for RCC tumours (84), given the potential to attenuate 
EPAS1 function somatically and improve clinical outcome. 
The remaining variant identified in the targeted Sanger sequencing experiment was in exon 2 of 
CDKN2B in two individuals (NM_004936: c.256G>A: p.Asp86Asn) and occurs at a minor allele 
frequency 1.22E-03 and falls within a Ankyrin repeat domain. All in-silico predictive metrics used 
suggest the variant is detrimental and previous publications determined that the variant resulted in 
diminished function by disrupting the interaction between p15INK4B and CDK4 (354). The CDKN2B 
p.Asp86Asn variant, as well as being seen in parathyroid adenomas (355), is identical to the variant 
found in heritable RCC cases profiled previously (266) and supports the hypothesis that rare 
functionally damaging variants in CDKN2B can confer a risk to RCC. However, given the allele 
frequency in control non-cancer populations, high or complete penetrance is unlikely and variants in 
CDKN2B may act similarly to variants in SDHB genes conferring only a low risk of RCC (221), though 
further association data is required. 
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The issue regarding sequence identity between KMT2C and BAGE2 is the primary issue with the 
outcome of the targeted sequencing of KMT2C and KMT2D. The first BAGE gene was originally 
identified due to encoding an antigen present in melanoma (356), after which further BAGE genes, 
including BAGE2, were identified mapping to both chromosome 9, 13, and 21 in juxtacentromeric 
regions and have reported regions of sequence identity between 92-99% in similarity (357). 
Evolutionary analysis of BAGE2 sequence origin revealed that BAGE2 and its related genes are 
formed due to a reshuffling and duplication of regions of KMT2C on chromosome 7, followed by 
further duplications across the chromosomes mentioned previously resulting in multiple BAGE 
sequences across the genome (358). This, in part, demonstrates why many reads generated by 
targeted sequencing of KMT2C produced off-target mapping to BAGE2. 
The failure of amplicon generation of exons 1, 2, 8, 9, 10-14, 28-31, and 42-44 of KMT2C was 
unexpected during primer optimisation, but no primers failed due to an absence of products. Given 
the information regarding BAGE2 and that all primers failing optimisation did so due to either 
incorrect or multiple primary products would suggest that long range primers are annealing to off 
target sites in BAGE2 and its related genes despite rigorous primer design to minimise those factors. 
It cannot be stated that all amplicon primer sets that failed are as a result of BAGE2 sequence 
similarity though, since primers generating multiple products could also be producing PCR amplicons 
outside of BAGE2. Loss of these amplicons resulted in a restriction in the available coding exons of 
KMT2C available for analysis, which included exon 14 in which the nonsense variant (NM170606.2: 
c.2263C>T: p.Gln755Ter: rs201234598) from the index case occurred.  
For the amplicons that successfully passed optimisation, failure to generate products were either 
due to multiple products (as discussed above) or due to an absence of PCR product. In this instance, 
failure to generate products after iterative optimisation steps is likely due to DNA quality and degree 
of fragmentation which are decreased and increased, respectively, during long-term storage and 
freeze-thaw cycles. While a proportion of reads generated by NGS library preparation will map 
incorrectly to BAGE2 due to sequence similarities, it is probable primer design resulted in the direct 
amplification and sequencing of BAGE2 and KMT2C concurrently, with product sizes being 
indistinguishable on standard gel electrophoresis. This is supported by the primer design process 
which selected intronic regions for primer annealing, which are also highly conserved between the 
two genes. 
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The presence of mismapped reads and resulting variant calls is an important consideration when 
discussing variant calling due to the potential for false positive variant calls and is a documented 
pitfall of short read sequencing (359). If reads are misaligned from KMT2C to BAGE2, logically it 
suggests that reads are being conversely misaligned from BAGE2 to KMT2C. For identical regions, 
this results in no detectable variation but if any read contained a sequence variation and aligned 
incorrectly it would suggest an alternative allele at the misaligned loci. Repeated occurrence of this 
process at the same site would provide enough supporting alternative reads to result in false positive 
variant calling. Presence of false positive calls introduced by low mapping quality reads in simulated 
data demonstrated that increase MAPQ filtering nullifies this concern generally (360) but MAPQ 
filtering in this study was already greater than the suggested threshold to eliminate this issue.  
In the case of exome data and the nonsense variant described previously, it is plausible a false 
positive variant call occurred, given the difference in allelic frequencies between exome and genome 
sequencing data sets and the reduced alternative allelic fraction seen in the Sanger sequencing. 
Taken together, this provides informative data to suggest that the nonsense variant initially identified 
results as a consequence of sequence conformity between KMT2C and BAGE2, where PCR 
amplification from both regions results in the inclusion of sequence regions where differences in 
sequence are limited to only a single base. The increased allelic frequency in gnomAD genomes 
compared to exomes is likely due to the removal of biases introduced by exome target probe 
hybridisation. Moreover, this introduces doubt over the reliability of all variant calling within the 
KMT2C coding regions which share sequence identity with BAGE2, and as such caution should be 
taken when assessing variants in this gene. A vast majority of current sequencing projects, 
particularly somatic, utilise WES or capture-based sequencing to generate somatic variant calls. 
Given that somatic calls are typically made at lower allelic fractions than germline calls, mismapping 
in somatic cases could inadvertently result in an enrichment of false positive calls in genes identified 
to be significantly mutated in tumour datasets. 
 125 
 
While KMT2C sequencing harboured major issues regarding off-target effects and data 
misalignment, KMT2D did not display these features and performed well by comparison, with no 
amplicons failing to generate sequencing data and on-target sequencing rates above 80% in all 
samples (See appendix section 9.2.3). One identified issue with sequencing of KMT2D was the 
overrepresentation of amplicons KMT2D Exon 12 – 14 and Exon 15 – 18 which sequenced at far 
greater depth than other targets (mean coverage > 20,000 for both) due to the size discrepancy 
between other amplicons. Both KMT2D Exon 12 – 14 and Exon 15 – 18 are less than 2 Kb in length 
(See 3.3 Figure 4 and Table 4), and as such pmol input of each amplicon, even after normalisation, 
resulted in several fold increases in fragment retention prior to library preparation compared to larger 
amplicons. Though this did not impact results generated in this study due to surplus sequence 
coverage, replication in studies with narrower margins of error for targeted coverage may result in 
disproportionate sequencing of these smaller amplicons, resulting in reduced or inadequate 
coverage of other amplicons. 
Targeted NGS of KMT2C and KMT2D identified several rare missense substitution variants in both 
genes, but a majority occurred within KMT2D for the reasons specified previously. The single variant 
in KMT2C (NM_170606: c.G4273A: p.G1425S) was predicted to be pathogenic by SIFT, PolyPhen 
and CADD and reported with an allele frequency of 8.35E-06. The amino acid change glycine to 
serine is non-conservative, therefore more likely to be damaging to protein structure but the variant 
does not appear to affect any known regulatory or functional protein domain. Both variants KMT2D 
p.P2557L (NM_003482: c.C7670T: p.P2557L) and KMT2D p.P692T (NM_003482: c.C2074A: 
p.P692T) had no evidence to support pathogenicity and occurred at allele frequencies in ExAC at 
marginally lower than 1%, suggesting they are unlikely to be disease-causing. One variant in KMT2D 
(NM_003482: c.C1940A: p.P647Q) was predicted to be benign by in silico tools and had conflicting 
interpretation in ClinVar but on review was reported as causal in an individual affected with Kabuki 
syndrome but no case report was provided and multiple additional reports presented conflicting 
evidence (361,362). The remaining KMT2D variants (NM_003482: c.G8765A: p.R2922Q, 
NM_003482: c.C5966T p.T1989M, and NM_003482: c.C2129G: p.P710R) had contradictory or 
unsupportive in silico metrics but occurred at allele frequencies consistent with the potential to be 
disease causing, though none had any additional evidence to suggest pathogenicity. 
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KMT2C and KMT2D are associated with known autosomal dominant genetic disorders Kleefstra 
syndrome 2 and Kabuki syndrome, respectively, and are associated with heterozygous loss-of-
function variants. Kleefstra syndrome 2 is a recently defined syndromic condition resulting in delayed 
psychomotor development, and dysmorphic anatomical features associated with frameshift, 
truncating and deletions of KMT2C (363). Kabuki syndrome is a well characterised syndrome 
causing cognitive impairment, growth restriction, facial dysmorphisms and cardiac and renal 
anomalies as a result of inactivating or truncating variants in KMT2D (364). 
In this series no known pathogenic or loss of function variants were identified to substantiate the 
hypothesis that pathogenic inactivating variants in in KMT2C or KMT2D might be associated with 
RCC predisposition. For variants in KMT2C, presentation of kleefstra syndrome is typically seen with 
sub-telomeric loss of 9q, including loss of EHMT1 or inactivation of KMT2C on chromosome 7 (365). 
In tumours, inactivating mutations or deletions of KMT2C, alterations have been demonstrated to 
downregulate DNA repair pathways (366), as well as mediate responses to oestrogen in breast 
cancers (367). A potential genotype-phenotype could be hypothesised in which variants in KMT2C 
under which loss of KMT2C can results in epigenetic reprogramming that corresponds with the 
phenotype seen in kleefstra syndrome whilst in the context of cancer, impedance of DNA repair and 
alternative epigenetic alterations could drive oncogenesis and cancer predisposition. While the exact 
mechanism and correlation of such a genotype-phenotype correlation is not known it may currently 
be the most likely hypothesis, particularly given functional links between KMT2C, SMARCB1, and 
the SWI/SNF complex of which several genes are already associated with predisposition to RCC 
(264) and the frequency at which KMT2C is altered somatically (25). 
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Moreover, KMT2D has conflicting evidence regarding its function as a tumour suppressor, being 
shown to upregulate p53 and supress tumour development (349,368) but also functions in an 
oncogenic capacity in maintaining tumour cell proliferation (369). Given that KMT2D has the potential 
to act as either a TSG or an oncogene in a tumour-specific manner it could be hypothesised that 
missense variants in KMT2D might predispose to renal cancer in the absence of Kabuki syndrome 
(if the former were activating mutations and the latter resulted from inactivating mutations). 
Additionally, single cell transcriptome and RNA sequencing data on patient-derived Kabuki 
syndrome cell lines carrying a KMT2D nonsense variant displayed reduced cell cycle progression, 
increased cell death, and most intriguingly demonstrated downregulated genes included an 
overrepresentation of genes containing HRE motifs (370), most commonly activated by HIF complex 
binding as discussed in relation to VHL regulation of hypoxia (138,140), proposing that activating 
mutations in KMT2D could cause constitutional upregulation of HRE-containing genes in a manner 
similar to HIF proteins. Only missense variants were identified in this series and no large deletions 
are observed somatically in KMT2D but significant further analysis and functional assessment of 
both the function of KMT2D in RCC and the identified variants are required before any conclusion 
could be made regarding either the pathogenicity of the identified variants or the role of KMT2D in 
RCC tumourigenesis. 
However, an alternative hypothesis would be that missense variants with a partial loss of function 
effect could cause an attenuated (and unrecognised) form of Kabuki syndrome and predispose to 
renal cancer. Interestingly there are some case reports of tumour development in patients with 
Kabuki syndrome, though there is no evidence of clear increased risk of neoplasia (371–373). 
Furthermore, prostate tumour studies identified loss-of-function alterations in KMT2D in 60% of 
assessed patients and demonstrated attenuation of cell proliferation, invasion and migration in 
KMT2D knockout cell lines (374). 
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3.5 Conclusion 
Targeted sequencing, both via Sanger sequencing and NGS techniques, can provide a robust and 
relatively simple way to adequately genotype a small set of genomic regions but it is clear that issues 
regarding pseudo-genes, DNA amplification rates, and DNA quality can give rise to difficulties in 
experimental design and interpretation of sequencing data. Regardless of the pitfalls encountered 
by the investigations present here, potential predisposition variants in both CDKN2B and EPAS1 
could be of interest but cautious interpretation should be applied before drawing causal relationships 
and a lack of an appropriate control group and technical issues regarding experimental design 
confound drawing any firm conclusions. Clear weaknesses of sequencing a limited number of 
genomic targets across a reduced a pre-screened cohort of samples is a reduction in power to detect 
associations, but alternative methodologies are either more financially demanding or requires a more 
complex analysis. Alterations in KMT2C and KMT2D, though occurring frequently in somatic RCC 
cases are difficult to assess accurately, given the issues that were encountered in this study, but 
several rare and potentially damaging variants were identified. No variants in KMT2C or KMT2D had 
evidence to suggest pathogenicity but without additional genetic or molecular data further 
conclusions cannot be made. In all cases, additional confirmation by co-segregation, validation 
sequencing, or tumour sequencing to assess secondary mutations are required to support that 
variants in KMT2D, CDKN2B or EPAS1 exon 9 are associated with germline predisposition to RCC.  
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4.0 Cancer gene sequencing of individuals with features of inherited 
RCC 
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4.1 Introduction 
Of all diagnosed RCC cases, approximately 3% are familial in nature (98). Molecular genetic studies 
have identified multiple genetic causes for RCC predisposition. As discussed previously, the best 
recognised cause of familial RCC is the dominantly inherited familial cancer syndrome von Hippel-
Lindau (VHL) disease caused by germline mutations in the VHL tumour suppressor gene (99,127). 
Additionally, inactivating mutations in tumour suppressor genes (TSGs) BAP1, FH, FLCN, SDHB, 
SDHD, SDHC, SDHA, PBRM1, and CDKN2B, as well as activating mutations in the MET proto-
oncogene have been implicated in predisposition to renal cancers (98). A majority of RCC with 
suspected predisposition do not carry pathogenic variants in known RCC predisposition genes and 
recent studies suggest between 24-33% of individuals presenting with RCC meet referral criteria for 
genetic testing (118). Taken together, there is an unidentified genetic component to non-syndromic 
RCC cases with features of predisposition. 
As the previous chapter demonstrated, the rate of variant detection in single gene or exon 
sequencing is low and as such high throughput sequencing of high priority targets would enable the 
analyse of multiple genes of interest with reduced labour, at the expense of increased cost, 
computational, and bioinformatic requirements. While initially cancer-associated genes were 
described in relation to a single cancer phenotype, a greater number of genes are being associated 
with several or even a spectrum of cancer predispositions, in both syndromic and non-syndromic 
cases, such as BRCA1 in breast, ovarian, and prostate cancers (27,375). Recently, studies in a 
number of human cancer types have identified pathogenic variants in a wide range of cancer 
predisposition genes than have been traditionally associated with the cancer of interest, as 
exemplified by Whitworth et al (2018) (376). A hypothesis can be proposed that adopting a wider 
testing strategy to a cohort of patients with features that might indicate a cancer predisposition gene 
mutation might improve knowledge of the molecular architecture of inherited RCC. 
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In order to identify new genetic components associated with renal cancer predisposition, 118 
probands presenting with features of non-syndromic inherited RCC with no known pathogenic or 
likely pathogenic variants in VHL, MET, FLCN, SDHB, CDKN2B and BAP1 were investigated and 
targeted sequencing was performed using the Illumina TruSight cancer sequencing panel or virtual 
TruSight cancer sequencing panel on available whole exome sequencing data. The sequencing 
technology applied in each instance was only because of a shift from targeted panel sequencing to 
whole exome sequencing as a laboratory standard operating procedure, not a specific experimental 
design choice. 
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4.1.1 Aims 
 Confirm the lack of pathogenic or likely pathogenic variants in known RCC predisposition 
genes. 
 Identify pathogenic or likely pathogenic variants in genes associated with RCC or other 
cancers through targeted cancer gene and SNP sequencing. 
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4.2 Methods 
4.2.1 Patients 
Patients diagnosed with RCC were assessed for eligibility based on the presence of clinical features 
associated with inherited RCC, as described in section 2.1.3. Patients were recruited if they matched 
one of the following criteria 1) Patient had at least one first or second degree relative with RCC 2) 
Presented with no family history but two or more separate primary RCC before age 60 years, or 3) 
Presenting with RCC at age 45 years or less (age of diagnosis corresponding to less than 10% of 
total cases as defined by SEER(377)). Patients with confirmed or likely mutations in BAP1, FH, 
FLCN, MET, SDHB and VHL were excluded from the study. 
4.2.2 DNA extraction and quantification 
DNA extraction from whole blood lymphocytes, quantification and quality control was performed as 
described in material and methods (section 2.1). 
4.2.3 Library preparations and sequencing 
Cancer gene panel library preparations were performed as described in materials and methods 
(section 2.6.2). WES library preparations were performed as described in materials and methods 
(section 2.6.3) performed by the SMCL sequencing service. 
4.2.4 Sequencing bioinformatics 
Primary bioinformatics (BCL to VCF) was performed as described in materials and methods (section 
2.7) by the SMCL sequencing service. Variants from targeted sequencing panel and exome datasets 
were called independently and a ‘virtual’ panel applied to the exome variants via VCFtools, restricting 
the reported variants to the Cancer gene panel target bed intervals (with an additional 3bp padding) 
4.2.5 Variant filtering and prioritisation 
Variant filtering, annotation, and prioritisation was performed as described in the materials and 
methods (section 2.8) including Intervar variant interpretation using ACMG guidelines (325). Targets 
included in the cancer gene panel are given in appendix section 9.3.1 and were used to filter a virtual 
variant panel in the WES sequencing samples. 
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4.2.6 Statistical Analysis 
Proportion confidence intervals were calculated using R base function binom.test() at CI 95%, using 
R (version 3.5). Two-tailed Fishers exact tests and odds ratios were calculated using the 
‘oddsratio.fisher()’ function in epitools package (version 0.5-10), using R (version 3.5). Confidence 
interval for odds ratio calculation was set to 95%. 
4.2.7 Sanger sequencing 
Primer design and PCR amplicon generation for Sanger sequencing was performed as described in 
the main materials and methods (section 2.3). Sanger sequencing of variants was performed as 
described in the main materials and methods (section 2.4). BRIP1 primer sequences are given in 
the appendix (section 9.3.2). 
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4.3 Results 
4.3.1 Clinical features 
The 118 unrelated individuals with RCC eligible for inclusion were subdivided into three clinical 
subsets: 44 cases with a positive family history and 74 sporadic cases comprising 30 cases with 
multifocal or bilateral disease and 44 cases with early onset RCC only). Median age of onset across 
all cases was 42 years (range 10-74) and 52 years (range 29-74) in the familial cases, 48 years 
(range 31-72) in multifocal/bilateral cases and 33 years (range 10-46) in early onset cases). 
Histological subtype was available for 70 of 118 cases (59.3 %) and comprised 68.6% clear cell 
RCC, 27.1% papillary RCC, and 4.29% chromophobe RCC). Summary of the distribution of clinical 
features are given in 4.3 Table 1. 
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4.3 Table 1 
Summary of clinical features of individuals with suspected inherited RCC where available 
Clinical feature Value 
Sex, Num. (%)  
 Male 71 (60.2) 
 Female 47 (39.8) 
Age, median (range)  
 All 43 (10-74) 
 Familial 52 (29-74) 
 Early onset 33 (10-45) 
 Bi/Multi 48 (31-74) 
Case type, Num. (%)  
 Familial 44 (37.2) 
 Early onset 44 (37.2) 
 Bi/Multi 30 (25.4) 
Family history, Num. (%)  
 1st degree 27 (61.4) 
 2nd degree 8 (18.2)  
 Unspecified 9 (20.5) 
Family history, Num. (%)  
 
clear cell RCC 
48 (68.6) 
 
papillary RCC 
19 (27.1) 
 
chromophobe RCC 
3 (4.29) 
 
non-specified RCC 
48 
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4.3.2 Quality control and variant filtering 
Quality control checks were performed to assess alignment rates, and depth of coverage and PCR 
duplicate rates for both cancer gene panel sequenced samples and WES sequenced samples. Read 
alignment rates a mean of 99.6% (range 92.3 - 99.8%) across all samples, with a mean coverage of 
327X (range 226 - 719) (4.3 Figure 1). Quality control metrics for WES samples match those 
described in chapter 5 section 5.3.2. 
A total of 3,817 variants were called in the targeted sequencing set of 100 samples (3,458 SNVs and 
359 Indels) and 405 variants were called in region-filtered whole exome data of 18 samples (395 
SNVs and 10 Indels). A total of 1,955 and 237 variants passed quality control filtering requirements 
for depth, QUAL, genotype quality, missingness and internal minor allele frequency for targeted 
panel and exome derived data, respectively. After filtering for variants occurring within coding regions 
or splice site consensus sequences, removing synonymous and common variants in 1000 genomes 
and ExAC datasets (>1%), and additional filters, a total of 264 and 38 variants were retained from 
the targeted sequencing and virtual panel sets, respectively. For downstream analysis, variants 
occurring in both sets were merged, consisting of 14 variant genotypes. 
Analysis of the variants identified in this set were divided into three subpanels based on the 
inheritance patterns of the affected genes. 1) Group A genes with a known association with RCC 
predisposition 2) Group B genes in which heterozygous pathogenic variants are known to be 
associated with predisposition to multiple non-RCC tumours and 3) Group C genes which are 
associated with cancer predisposition when there are biallelic pathogenic variants or those which 
have been associated with a single non-RCC tumour phenotype. In broad terms, the three groups 
correspond to differing levels of prior probabilities for detecting an association with RCC (lowest in 
the latter group because non-syndromic RCC is usually inherited in an autosomal dominant manner).  
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Variants passing filtering and meeting selection criteria were then assessed for pathogenicity using 
the InterVar tool (326) for automatic generation of ACMG variant classifications. Of the 288 variants 
assessed, a total of 19 were classified as pathogenic or likely pathogenic (P-LP) variants (5 
pathogenic, 14 likely pathogenic), corresponding to 5 nonsense variants, 3 frameshift deletions, 2 
frameshift insertions, 8 missense substitutions, and 1 splice site variant. The 19 variants were 
observed in a total of 21 individuals, giving an identification rate 21/118 (17.8%; 95% CI: 11.4-25.9) 
across all assessed cases. Pathogenic variants were equally distributed by count across the 
inherited subtypes (8 variants in familial, 6 variants in early onset, and 7 variants in 
bilateral/multifocal). All 19 pathogenic/likely pathogenic variants are described in 4.3 Table 2.  
4.3.3 Detection variants in Group A cancer predisposition genes 
As expected, no P/LP variants were detected in genes that had previously been analysed before 
inclusion in this study (VHL, MET, FLCN, SDHB, CDKN2B or BAP1) and only a single gene identified 
as harbouring a P/LP variant has been previously linked to RCC, either in germline or somatic 
sequencing. A MITF missense variant in (NM_000248: c.952G>A: p.E318K) was identified in an 
individual who presented with clear cell RCC at age 74 years and whose son was reported to have 
presented with clear cell RCC at age 53 years. Sequencing in the individual’s unaffected brother did 
not carry the variant and though this variant had been previously associated with predisposition to 
RCC and melanoma (262), there was no family history of this tumour. 
Three variants in MET (NM_000245: c.T2543C: p.V848A, NM_000245: c.G1406C: p.R469P, and 
NM_000245: c.A1336G: p.I446V) were present at allelic frequencies lower than 8.5E-05, with in 
silico predictions being variable, but none of the variants fall within the tyrosine kinase domain 
associated with constitutional activation of c-MET (204,208), and none had been reported as somatic 
events in sporadic RCC based on data from the catalogue of somatic mutations in cancer 
(COSMIC)(378).  
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Six missense variants were identified in TSC2, associated with tuberous sclerosis complex (MIM: 
613254) which predisposes individuals to renal angiomyolipomas and cysts, as well as hybrid or 
oncocytic RCC in between 2-4% of cases (232,237). Histological information was not available for 
these individuals to assess if they presented with histologies consistent with loss of TSC2. The 
predicted pathogenicity of these missense variants, as well as the allele rarity, is variable but two 
variants (NM_000548 c.G4657T: p.G1553C & NM_000548: c.G5117A: p.R1706H) occur within the 
Rap GTPase activating protein domain implicated in RHEB inhibition (241) and one variant 
(NM_000548: c.C2476A: p.L826M) arises in a Tuberin-type domain, though its direct function is not 
known. None of the 6 variants identified in TSC2 had been reported as somatic events in sporadic 
RCC in COSMIC.  
4.3.4 Detection of variants in Group B cancer predisposition genes  
A total of 6 P/LP variants were detected in the 3 genes in which heterozygous pathogenic variants 
are known to be associated with predisposition to multiple non-RCC tumour types. Two Group B 
genes, BRIP1 and CHEK2, harboured germline P/LP variants in more than one proband. Three 
BRIP1 truncating variants (NM_032043: c.1161dupA: p.Gln388Thrfs*7, NM_032043: c.1871C>A: 
p.Ser624*, and NM_032043: c.2392C>T: p.Arg798*) were identified across four individuals, two of 
which carried a BRIP1 p.Ser624* nonsense variant. The four probands consisted of 2 familial cases 
and 2 multifocal/bilateral cases. Age at diagnosis of RCC was 54, 64, 46, and 39 years and presented 
with papillary, two non-specified, and clear cell RCC, respectively (see 4.3 Table 3). Affected family 
members were available for one individual carrying the NM_032043: c.2698G>A: p.Arg798* and an 
affected second degree relative (clear cell RCC at age 57 years) and also found to harbour the 
NM_032043: c.2698G>A: p.Arg798* nonsense variant. In total, truncating variants in BRIP1 were 
detected in 3.39% (4/118) of sequenced individuals. To compare frequencies to a comparable 
control set the ICR1000UK control set was aligned identically and was analysed for number of 
truncating variants. The ICR1000UK control cohort harboured truncating variants in 0.4% (4/999) 
corresponding to an enrichment of truncating variants in our cases (p=5.92E-03, OR 8.70, 95% CI: 
1.60 – 47.4).  
 142 
 
Evaluation of rare truncating variants in BRIP1 compared to gnomAD revealed an estimated at 
0.24% (123/51,300 (353); carriers were estimated using median allele number where alternative 
alleles were presumed to be mutually exclusive) which results in a significant enrichment in the case 
set (p=2.19E-04, OR 14.6, 95% CI: 3.85 – 39.35). Finally, statistical comparison to data published 
by Easton et al (2016)(379) also demonstrated a statistical enrichment in this series (p=1.21E-04, 
OR 18.2, 95% CI: 4.55 – 53.1) when compared to truncating variants in BRIP1 in breast cancer, 
found at a rate of 0.19% (28/14,526). The BRIP1 truncating variants were confirmed by Sanger 
sequencing (4.3 Figure 2).
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A frameshift deletion in CHEK2 (NM_007194: c.1263delT: p.Ser422Valfs*15) was identified in two 
individuals, both of whom presented with multifocal RCC at age 56 years, though the histology was 
not specified. The frameshift deletion is considered to be pathogenic and has previously been 
detected in both germline sequencing of breast (380) and prostate cancer (381,382). An additional 
CHEK2 missense variant (NM_007194: c.1427C>T: p.Thr476Met) was also identified in one 
individual classified as likely pathogenic by InterVar (though there have been conflicting reports on 
ClinVar (VUS=7, LP=10). The variant falls within the protein kinase domain of CHEK2 and in vitro 
studies demonstrated a loss of kinase activity and loss of DNA repair function (383,384).  
Finally, an individual carried a BRCA1 frameshift deletion in exon15 (NM_007300: c.4563delA: 
p.Lys1521Asnfs*5) which was novel in ExAC and 1000 genomes, as well as not present in the non-
cancer gnomAD data set. The individual presented with early onset papillary RCC at age 40 years. 
4.3.5 Detection of variants in Group C cancer predisposition genes  
A PMS2 nonsense variant was identified in three individuals, purported to occur within the 4th amino 
acid (PMS2: c.11C>G: p.Ser4*) but on review was found only to affect non-canonical isoform 14 
(NM_001322015), resulting in an intronic substitution within the canonical isoforms of PMS2. A P-
LP missense variant in one individual was identified in PMS2, occurring within the canonical 
transcript (NM_000535: c.2066C>T: p.Thr689Ile). The PMS2 missense substitution occurs within 
exon 12 resulting in a Threonine to Isoleucine substitution in a c-terminal dimerization domain. The 
variant occurs as a singleton in the gnomAD data set (353) and is considered to be highly deleterious 
by multiple in silico predictive tools. 
A patient presenting with early onset clear cell RCC at age 39 years harboured a nonsense variant 
in FANCE (NM_021922: c.265C>T: p.Arg89*) within exon 2. The variant was seen only once in the 
gnomAD data set and due to occurring early in the amino acid sequence presumably leads to loss 
of the entire protein product but no further functional evidence was available. 
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Multiple P-LP variants were identified in genes associated with nucleotide excision repair pathways, 
including ERCC2, XPA, and XPC. Three missense variants were identified in ERCC2 (NM_000400: 
c.2084G>A: p.Arg695His, NM_000400: c.1802G>A: p.Arg601Gln, and NM_000400: c.772C>T: 
p.Arg258Trp). Two of these missense variants were only present as singletons within the non-cancer 
gnomAD data set (353) (NM_000400: c.2084G>A: p.Arg695His; AF = 4.22E-06 & NM_000400: 
c.772C>T: p.Arg258Trp; AF = 4.23E-06), with the remaining variant ERCC2 (NM_000400: 
c.1802G>A: p.Arg601Gln) occurring at minor allele frequency of 1.68E-04. All three variants are 
within conserved functional protein domains, occurring within an ATP-dependent helicase C-terminal 
domain, P-loop containing nucleoside triphosphate hydrolase & ATP-dependent helicase C-terminal 
domain, and a DEAD2-type helicase ATP-binding domain, respectively. A nonsense variant in exon 
4 of XPA (NM_000380: c.464delT: p.Leu155*) and a frameshift deletion in exon 2 of XPC 
(NM_004628: c.219delG: p.Val75Trpfs*4) were also found. Both truncating variants occur early in 
the reading frames of both genes and are novel variants not seen in the non-cancer Gnomad data 
set (353). 
Genetic overlaps have been demonstrated between RCC and Pheochromocytomas (PCC) and 
paragangliomas (PGL), with variants in genes such as VHL, SDHB/C/D, and FH predisposing to 
both tumour types (124,155,215,385). Therefore, analysis of genes associated with PCC/PGLs may 
uncover new associations. One variant was present in SDHAF2 and two in RET which are associated 
with predisposition to Phaeochromocytoma (386,387). The SDHAF2 variant (NM_017841: p.R18G) 
is within exon 2, is present at a minor allele frequency of 2.8E-05 in gnomAD, and predictive in silico 
tools suggested it occurred in a conserved amino acid and therefore likely damaging. Two RET 
variants (NM_020975: c.C166A: p.L56M and NM_020975: c.G973A: p.A325T) occurred in one 
individual each with the first being repeatedly flagged as benign by Clinvar. The latter has conflicting 
interpretations of pathogenicity on Clinvar but SIFT, PolyPhen and CADD all suggest the variant is 
not pathogenic in nature, particularly given that RET activating variants are typically clustered in the 
tyrosine kinase domain (388). 
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4.3.6 Analysis of variants of uncertain significance 
Of the 288 variants passing all quality control and filtering parameters, 134 variants were categorised 
as variants of uncertain significance (VUS) by ACMG guidelines applied by InterVar. Of these 
variants 96.3% (129/134) were missense variants, with 3 non-frameshift deletions, 1 nonsense 
variant, and 1 splice site altering variant composing the remaining percentage. For genes harbouring 
VUSs, 40.6% carried only a single variant (26/64 genes), with 25.0% (16/64 genes), 14.1% (9/64 
genes), and 9.37% (6/64 genes) harbouring two, three and four variants across the sample set, 
respectively. The remaining genes each carried five or more variants classified as VUS (CDKN2A = 
13, ERCC5 = 10, ALK = 9, ATM = 9, TSC2 = 6, ERCC3 = 5 and ERCC4 = 5). VUS variants were 
found at a rate of 1.40 per individual (range 0-4). VUS variants occurred less frequently in samples 
harbouring P-LP variants at 1.05 compared to 1.48 variants per sample, though it did not reach 
statistical significance (p=0.08; Student’s t-test). Comparisons of InterVar-assigned pathogenicity to 
Clinvar status reported in the VUS variants identified 10 variants in which Clinvar indicates clear lack 
of pathogenicity, marked as benign or likely benign. Conversely, no variants designated as VUS by 
InterVar were classified as P-LP variant by Clinvar. 
A single missense variant was found in SMARCB1, a gene encoding a component of the SWI/SNF 
complex which contains PBRM1 (389), which is shown to be altered in papillary RCC (158). The 
variant is located in the 4th exon (NM_001317946: c.C497G: p.T166S) and appears to be relatively 
common compared to other VUSs in the set (AF=1.0E-03 nc-gnomAD) and is predicted to be 
tolerated or benign by all in silico predictive tools.  
Several missense VUS variants were present in genes significantly affected in somatic RCC 
sequencing. The variants include two missense variants in EGFR which is amplified in somatic 
papillary RCC as part of chromosome 7 duplications (274). Neither of the EGFR variants fall within 
functional domains or have evidence to suggest they would result in constitutive activation of the 
epidermal growth factor receptor. EGFR variant p.Pro20Arg (NM_005228: c.C59G: p.P20R) is 
reported only once in gnomAD but is predicted to be tolerated or benign by in silico predictive tools 
whereas the second variant (NM_005228: c.G2024A: p.R675Q) is reported more frequently (AF= 
2.1E-04) but predicted to be deleterious by in silico predictive tools. 
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Two additional VUS variants were identified in TP53 and CDKN2A, both of which are described in 
somatic sequencing. The variant in TP53 (NM_000546: c.G124A: p.D42N) is present as a singleton 
in gnomAD and is located in the Cellular tumour antigen p53, transactivation domain 2 region but in 
silico predictive tools suggest the amino acid change is tolerated. Lastly, a missense variant in 
CDKN2A was present in 13 individuals (NM_000077: c.A221C: p.D74A). While passing all filtering 
and quality control criteria, the inflated allele count for this variant is anomalous given the size of the 
cohort sequenced and the expected rarity of causal variants. Review of data regarding this variant 
suggested that it is present as a sequencing artefact and failed random forest filtering, as part of 
ExAC (390) and as such this variant was not evaluated further.  
Several samples carried non-missense VUS variants across multiple genes. An individual carried 
both a BRCA2 non-frameshift deletion and a MSH6 splice site altering variant. The BRCA2 variant 
(NM_000059:exon11: c.4142_4144del: p.1381_1382del) has multiple conflicting interpretations of 
pathogenicity, reported as both likely benign and a VUS. The variant is reported at an allele 
frequency which conforms with potential pathogenicity (AF=8.E-05) and functional studies have 
demonstrated a loss of function of the BRCA2 protein (391) but additional Clinvar submissions report 
co-occurrence with known pathogenic variants reported in breast cancer. The splice site affecting 
deletion in MSH6 (NM_000179: c.4001+12_4001+15delACTA) is present in gnomAD at an allelic 
frequency of 1.2E-03, which is relatively frequent for a pathogenic variant and expert panel review 
in Clinvar regards it as a true VUS without further evidence to support pathogenic or benign 
classification. 
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Two related genes, FANCL and FANCD2, were shown to be present in one individual each. A non-
frameshift deletion in FANCL (NM_001114636: c.1022_1024del: p.341_342del) was classified as a 
VUS but functional studies have demonstrated the variant results in a null allele (392), and 
subsequent incorporation of this data in ACMG shifts the classification for VUS to likely pathogenic. 
The FANCD2 non-frameshift deletion (NM_033084: c.877_885del: p.293_295del) has no published 
studies regarding its likely effect on protein function but it does result in the loss of 3 amino acids 
within a region suggested to interact with FANCE and the variant is only present as a singleton in 
gnomAD. Lastly, an individual carried a nonsense variant in CEBPA. CEBPA is an intronless gene 
with a complex series of differential initiation codons, including both ATG and non-ATG start sites. 
The variant CEBPA (NM_001287424: exon1: c.C16T: p.R6X), is only a stop gain in isoform C, 
resulting in a 5’-UTR variant in other isoforms, making interpretation difficult (393).
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4.3 Table 3 
RCC samples carrying variants identified as pathogenic or likely pathogenic by ACMG guideline 
classifications assigned by InterVar. 
Variants Sex Subtype Histology Age Gene 
SBDS:NC_000007.13:c.258+2T>C 
XPA:c.464delT:p.Leu155* 
F Early onset ccRCC 46 
SBDS 
XPA 
BRCA1:c.4563delA:p.Lys1521Asnfs*5 M 
Early 
onset 
pRCC 40 BRCA1 
CHEK2:c.1263delT:p.Ser422Valfs*15 F Bi/Multi nsRCC 56 CHEK2 
XPC:c.219delG:p.Val75Trpfs*4 M Familial pRCC 44 XPC 
BRIP1:c.1161dupA:p.Gln388Thrfs*7 F Familial nsRCC 64 BRIP1 
SLX4:c.1406dupC:p.Leu470Ilefs*8 F 
Early 
onset 
nsRCC 15 SLX4 
CHEK2:c.1427C>T:p.Thr476Met M Familial nsRCC 58 CHEK2 
ERCC2:c.2084G>A:p.Arg695His F Bi/Multi ccRCC 40 ERCC2 
ERCC2:c.1802G>A:p.Arg601Gln F Familial nsRCC N/A ERCC2 
ERCC2:c.772C>T:p.Arg258Trp F Bi/Multi nsRCC 61 ERCC2 
MITF:c.952G>A:p.Glu318Lys M Familial ccRCC 74 MITF 
CHEK2:c.1263delT:p.Ser422Valfs*15 
MUTYH:c.1178G>A:p.Gly393Asp 
M Bi/Multi nsRCC 56 
CHEK2 
MUTYH 
MUTYH:c.527A>G:p.Tyr176Cys F 
Early  
onset 
nsRCC 45 MUTYH 
PMS2:c.2066C>T:p.Thr689Ile M 
Early 
onset 
nsRCC 27 PMS2 
BRIP1:c.1871C>A:p.Ser624* M Bi/Multi nsRCC 46 BRIP1 
FANCE:c.265C>T:p.Arg89* M 
Early 
onset 
nsRCC N/A FANCE 
PMS2:c.11C>G:p.Ser4* M Familial nsRCC 38 PMS2 
BRIP1:c.1871C>A:p.Ser624* M Bi/Multi pRCC 54 BRIP1 
PMS2:c.11C>G:p.Ser4* F Familial ccRCC 47 PMS2 
PMS2:c.11C>G:p.Ser4* F 
Early 
onset 
nsRCC 34 PMS2 
BRIP1:c.2392C>T:p.Arg798* M  Familial ccRCC 39 BRIP1 
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4.4 Discussion 
In many centres, individuals presenting with confirmed or indicative features of inherited RCC are 
screened for pathogenic germline variants in a panel of RCC-predisposing syndrome genes that will 
typically include VHL, MET, FLCN, FH, and SDHB and more recent studies have identified further 
genes associate with RCC predisposition (SDHC, SDHA, BAP1, and PBRM1). Despite this, many 
individuals undergoing screening harbour no causative variant in known predisposition genes 
suggesting an undiscovered proportion of heritability for RCC.  
Here, a targeted cancer gene sequencing panel, including 94 genes and 284 cancer-related SNPs, 
was used to assess the presence of pathogenic or likely pathogenic variants in individuals with either 
early onset, familial history, or multiple focal / bilateral presentation of RCC. At least one pathogenic 
or likely pathogenic variant was identified in 21 of 118 patient (17.8%), as classified by InterVar using 
the ACMG guidelines (325) including truncating variants in CHEK2, BRIP1, and BRCA1. The results 
reported here conform with recent assessments of clinically relevant pathogenic variants in cancer 
genes in multiple primary tumour cases which identified a comparable number of variants (15.2%), 
in which 42% of those variants did not occur in genes which correlate with the presenting cancer 
(376). 
CHEK2 and BRCA1 variants have been reported in RCC cases previously but no known association 
has been established between pathogenic variants in these genes and RCC predisposition. Single 
cases have reported pathogenic BRCA1 variants (394) and recent results in a Chinese cohort of 
early onset sporadic cases also identified pathogenic variants in BRCA1 (395). In difference to this 
study, the rate of pathogenic variant detection was only 9.5% though this may be due to a reduced 
scope, in terms of genes assessed, and inclusion of known RCC predisposing genes. 
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CHEK2 has been reported as being a multi-cancer susceptibility gene, with variants predisposing to 
a number of different cancers, including RCC, (396,397) but most strongly associated with breast 
cancer (398), though neither of the affected individuals carrying the CHEK2 variants had a family 
history of breast cancer. Interpretation of either BRCA1 or CHEK2 variants is difficult and should be 
assessed conservatively. The lack of demonstrable enrichment of CHEK2 and BRCA1 variants does 
not support the involvement of these genes in RCC predisposition. In particular, the assessment of 
BRCA1 and BRCA2 mutations in have been demonstrated to drive tumourigenesis in BRCA-
associated cancer lineages but biologically neutral in non-BRCA tumour lineages (399). 
The occurrence of BRIP1 rare truncating variants in this series is an interesting finding given that 
inactivating variants in BRIP1 are not currently associated with RCC but have been previously 
implicated in predisposition to ovarian (400) and breast cancer (401), though more recent studies 
have questioned the legitimacy of the association with breast cancer predisposition (379,402). The 
data reported here suggests an association between rare BRIP1 truncating variants, being 
statistically enriched compared to control and disease datasets, and segregating with affected family 
members in one pedigree. Equally, this finding should be interpreted cautiously given the limited 
statistical power and series size and further validation and follow-up in similarly screened 
independent cohorts would be needed to confirm the association. Interestingly, recent publications 
demonstrated no association between breast cancer and BRIP1 truncations (379) and in comparison 
to the studies described in the aforementioned publication, BRIP1 truncations were statistically 
enriched in our series, but again restrained interpretation is necessary. 
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As with previous studies, the assessment of VUS variants continues to be a challenging endeavour. 
Population minor allele frequencies and in silico predictive tools may aid prediction of pathogenicity 
but are not robust enough to reliably state whether a VUS is of consequence. For variants such as 
the FANCL (NM_001114636: c.1022_1024del: p.341_342del) in-frame deletion identified, 
pathogenicity may be ascertained from analysis of functional studies but this is unruly for all identified 
variants and most do not have any additional supporting information to inform classification. Variants 
in genes related to PCC (SDHAF2 and RET) and variants in TSC2 are potentially interesting 
candidates for further assessment given the genotypic overlaps between PCC/PGLs and RCC and 
the occurrence of RCC in Tubular sclerosis complex (232), caused by inactivating variants in TSC1 
and TSC2 (403), but most are categorised as benign and functional studies would be needed to 
confirm loss of function in those with unknown consequences. The nonsense variant in CEBPA 
(NM_001287424: c.C16T: p.R6X) may also be an interesting candidate given its related function to 
the SWI/SNF complex (404), multiple components of which are mutated somatically in RCC and 
includes PBRM1 which is already associated with RCC predisposition (331). 
Further limitations of the experimental design utilised in this chapter include the systematic 
differences in sequencing sensitivity for the detection of variants, inclusion of individuals with non-
white British/Caucasian ethnographic backgrounds, and estimated tolerance to truncating variants 
seen for BRIP1. Targeted panel sequencing had mean number of variants per sample of 38.2, 
whereas variants generated from whole exome sequencing carried 22.5 variants per sample. For all 
intents and purposes, sequencing methodology and bioinformatic processing for both targeted 
sequencing and whole exome sequencing datasets are equivalent, utilising the same hybridisation 
probes and whole exome data limited to genomic regions defined by targeted sequencing loci. As 
such the primary differentiating factor is the read depth coverage for each methodology; Targeted 
sequencing had a mean read depth across all samples of 327X coverage in comparison to 120X 
coverage for exome samples and differing variant calling sensitivity may contribute to the difference 
detection rates seen between targeted and exome sequencing datasets. This is particularly 
important given the statistical comparison between the variants identified in this chapter to control 
datasets generated from whole exome sequencing data. 
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A further limitation is ethnographic backgrounds in this chapter were not elucidated and statistical 
comparisons of genotype rates between non-concordant ethnic groups can lead to confounding 
results due to geography-specific genotypes and allele frequencies. In this instance, prior knowledge 
from further analysis of exome data analysed in chapter 5 negate this limitation, as all of the identified 
pathogenic variants occurred in individuals of European (non-Finnish) decent, but this is an important 
caveat to consider had this study been performed in isolation. 
Lastly, assessment of the likely impact of pathogenicity of truncating variants identified within BRIP1 
is potentially a limitation on the conclusions that can be drawn from an enrichment of truncating 
variants in BRIP1. Computational assessment of BRIP1 and its tolerance for truncating variants 
(propensity to negatively select truncating variants) is that BRIP1 is highly tolerant of truncating 
variants, suggesting that any given truncating variant in BRIP1 is unlikely to result in a phenotypic 
change (pLI = 0) (321). Conversely, caution should be taken when assessing tolerance to inactivating 
variants across an entire gene loci, as specific residues or features can carry greater or less 
tolerance for alterations than the gene region as a whole, as exemplified by assessment of 
constrained regions across the genome (405). 
This assessment of pathogenic or likely pathogenic variants in inherited RCC also highlights the 
current limitations of automated pipelines for the application of ACMG guidelines. With a number of 
VUS variants being known benign variants through ClinVar consensus and misclassification of a 
variant classified as VUS to likely pathogenic (FANCL: NM_001114636: c.1022_1024del: 
p.341_342del) due to published functional studies (392). Discordance within ClinVar is already well 
noted (406) and without proper integration of both in silico metrics, population minor allele frequency, 
known functional studies, and consensus interpretations by other labs then annotation by automated 
pipelines without robust downstream manual assessment will only compound the issue. 
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4.5 Conclusion 
In conclusion, the targeted next generation sequencing of a series of cancer related genes and risk 
SNPs using a pre-built cancer gene panel has uncovered a series of pathogenic and likely 
pathogenic variants in a range of genes associated with both the monoallelic and biallelic 
predisposition. Assessment of pathogenicity is challenging, particularly for VUS variants, without 
functional follow up and additional evidence but familial segregation and statistical enrichment of 
truncating variants in BRIP1 may suggest a new association between individuals with pathogenic 
truncating variants in BRIP1 and RCC predisposition, though additional validation studies would be 
beneficial to corroborate the evidence provided here. Designing of high-throughput functional 
analyses of identified variants, such as effects on DNA repair function by variants in DNA repair-
related genes. Furthermore, large-scale population wide sequencing cohorts (such as Genomics 
England 100K genomes) will greatly increase the ability to improve confidence in potentially 
pathogenic variants by excluding pathogenicity based on population frequency. 
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5.0 Germline whole exome sequencing of individuals with features of 
inherited renal cell carcinoma 
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5.1 Introduction 
Investigations into the missing heritability seen in RCC have largely involved familial co-segregation 
studies or targeted sequencing of known RCC associated genes and while whole exome sequencing 
(WES) methods can be analytically more complex due to increased genomic coverage, that same 
coverage can be leveraged to investigate the entire coding region and perform analyses which are 
impractical in targeted sequencing panels. Utilising a subset of samples investigated in Chapter 4 
(see section 2.1.3), WES was performed to investigate novel causes of RCC predisposition across 
all coding regions and exploit multiple modes of analysis to discover unreported variants and 
mechanisms associated inherited RCC. 
5.1.1 Single nucleotide variant analysis 
As performed with the cancer gene panel sequencing study (chapter 4), detection of rare pathogenic 
variants across all individuals is a first route of investigation in uncovering new associations with 
RCC predisposition. Analysis in this set will attempt to utilise multiple gene clusters to narrow down 
and isolate potentially causal variants while effectively removing the vast number of non-pathogenic 
variants carried in all individuals. Variant analysis will focus on 3 gene clusters; genes altered 
somatically in RCC (after exclusion of known RCC predisposition genes), genes encoding complex 
components of the tricarboxylic acid (TCA) cycle due to links with HLRCC and succinate 
dehydrogenase deficient RCC (SDH-RCC), as well as phaeochromocytomas (PCC) and 
paragangliomas (PGL) (155,212,214), and variant analysis of ultra-rare (AF < 0.001) truncating 
variants (nonsense, frameshift deletions/insertions, or splice-site affecting) to determine if any novel 
genes harbour variants which are most likely to be pathogenic compared to more frequent truncating 
alterations. An allele frequency of 0.001 was selected as most individuals harbour, on average, 90-
100 truncating variants but most occur at non-pathogenic allele frequencies greater than 0.005 in 
the general population (390). This methodology allows for a robust analysis of candidate variants in 
relevant genes whilst maintaining a systematic and repeatable approach to variant detection. 
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5.1.2 Copy number detection 
While a large proportion of genetic variation is attributable to single base variants, small or single 
base insertions and deletions, there is an array of other genomic alterations that can result in a 
disease phenotype. Cytogenetic or sub-microscopic insertions and deletions, chromosome 
translocations and inversions, and copy number alterations all contribute to genetic variance within 
a genome to varying degrees, some of which are pathogenic in nature. Typically, structural and copy 
number alterations are detected and captured through means other than NGS-based sequencing 
platforms, such as comparative genomic hybridisation arrays, due to NGS-based methods having 
restrictive capture/target regions (i.e. whole exome sequencing or panel sequencing). Whilst many 
of these alterations can be detected from whole genome sequencing with high specificity and 
sensitivity, the prohibitive cost of whole genome sequencing and lower sequencing coverage in 
comparison to targeted approaches makes this approach challenging. While whole exome 
sequencing is restrictive in terms of genomic regions available to interrogate, many algorithms have 
been designed to attempt to utilise and leverage the read depth and single nucleotide variant 
information from this data to predict and make copy number variation (CNV) calls across targeted 
regions. XHMM was chosen as the CNV detection tool of choice based on various metrics and data 
availability, including portability, detection rates, and control requirements as reviewed by Tan et al 
(2014) (407). Copy number alteration detection in this series may uncover unreported losses or gains 
in both genes known to be associated with RCC predisposition or novel genes in which an 
association with inherited RCC has yet to be established.  
5.1.3 Gene burden analysis 
With exome-wide sequencing, the amount of alleles genotyped allows for the opportunity to perform 
relatively robust case-control analysis to identify loci which are statistically associated with cases (in 
this instance individuals with features of inherited RCC) compared to a control set of healthy 
individuals. In addition to inferring statistical associations, statistical testing provides an unbiased 
framework for candidate variant detection without a need for gene lists and complex interpretation 
of in silico predictive metrics and biological relevance.  
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Typically, association studies are performed on a genotype scale where individual variants are 
compared by frequency between cases and controls, particularly in genome-wide association studies 
(GWAS) which focus on common SNPs conferring a low risk for the case phenotype. For rare 
disease, genotype-genotype comparisons are often not effective due to low sample numbers and, in 
the case of WES, poor coverage of non-coding variant sites. More recent approaches to overcome 
these limitations in rare disease is the development of collapsing or clustered statistical ‘burden’ 
testing, in which rare variants are assessed over specified genomic features or loci (e.g. genes, 
pathways) to determine the presence of statistical enrichment (i.e. genetic burden) in comparison to 
control sets, increasing the potential statistical power to detect an association.  
Many bioinformatic tools and statistical models have been developed to perform these analyses such 
as Combined Minor Allele test (CMAT) (408) and Combined Multivariate and Collapsing test (CMC) 
(409) which collapse genotypes over a genomic loci into a single ‘score’, or more complex models 
such as statistical kernel association test (SKAT) (310) which function to identify over-dispersion in 
the calculated variance across a given genomic region. Lastly, statistical models have been 
developed which combine the two approaches and include variant weighting (typically by minor allele 
frequency) to improve modelling in assessing potential gene mutational burden, including tests such 
as the optimal statistical kernel association test (SKAT-O) (410), as reviewed by Lee et al (2014) 
(411). 
Gene burden has been effectively used to identify increased occurrences of rare variants in specific 
genes in both non-cancer syndromes (412,413) and germline cancer predisposition cases (414) and 
may prove useful in the identification of novel genes in RCC predisposition which harbour a greater 
mutational burden compared to healthy controls. In this study, the SKAT-O combined gene burden 
and variance test was selected due to having greater statistical power when assessing variant sets 
where causal direction of a given variant is unknown and a low proportion of variant are presumed 
to be causal, though the SKAT-O test is less statistically powerful than either burden or variance-
based tests independently. 
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5.1.4 Additional detection methods 
While not conventionally considered as causes of genetic disorders, particularly in cancer 
predisposition syndromes, the role of mobile genetic elements (i.e. transposons) and short tandem 
repeat expansions are rarely explored in germline sequencing for their potential involvement in the 
disruption of genes associated with cancer predisposition.  
Transposons are mobile DNA sequences which are capable of ‘jumping’ between different genetic 
loci and form a substantial proportion of the human genome (415). Due to the mobile nature of 
transposons, movement of a transposon into a coding region, exonic or intronic, can result in a 
disease phenotype as seen in haemophilia A (416), retinitis pigmentosis (417), and cancer 
predisposition (418) by disrupting the coding region, affecting exon splicing, or interfering with 
promotor regions upstream of transcription start sites (419). Recent bioinformatics tools, such as 
mobile element locator tool (MELT) (420), allow for the detection of common classes of transposons 
in WES data based on reference positions and subsequent mismapping of reads to mobile elements 
which have reinserted themselves into different genomic loci. 
Short tandem repeats are present throughout the human genome (421) and expansion of these 
repeat motifs has been associated with multiple genetic diseases such as myotonic dystrophy type 
2 (422), myoclonic epilepsy (423), and Huntingdon’s disease (424). Only a small number of studies 
have linked germline short tandem repeat expansions to cancer predisposition or gene regulation 
(425), but disruption of intronic or exonic regions by motif expansion or contraction could lead to 
altered gene function. Tools aimed at leveraging short read data have been developed to model and 
estimate known short tandem repeats, such as gangSTR (426), and detect expansion or contractions 
compared to reference repeat numbers. 
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5.1.5 Aims 
 Identify germline alterations in genes associated with somatic alterations in RCC, genes 
associated with TCA cycle, and investigate rare truncating variants as a cause of RCC 
predisposition. 
 Use a hypothesis-free statistical approach to identify potential associations in both genes 
and pathways in order to determine potential causes of RCC predisposition. 
 Explore underutilised methods of WES data analysis to identify novel causes of RCC 
predisposition caused by copy number alterations, mobile element insertions, and repeat 
expansion changes.  
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5.2 Materials and methods 
5.2.1 Patients 
Samples included as part of this study were selected as a subset of the samples analysed in chapter 
4 and as such were selected for the same clinical features as previously described; Patients were 
recruited if they matched one of the following criteria 1) Patient had at least one first or second 
degree relative with RCC 2) Presented with no family history but two or more separate primary RCC 
before age 60 years, or 3) Presenting with RCC at age 45 years or less. Patients with confirmed or 
likely mutations in BAP1, FH, FLCN, MET, SDHB and VHL were excluded from the study. The subset 
of samples from the primary cohort is described in section 2.13, where patients with clinically relevant 
variants from Chapter 4 were excluded. 
5.2.2 DNA extraction and quantification 
DNA extraction from whole blood lymphocytes, quantification and quality control was performed as 
described in material and methods (section 2.1). 
5.2.3 Library preparations and sequencing 
WES library preparations were performed as described in materials and methods (section 2.6.3) 
performed by the SMCL sequencing service. 
5.2.4 Sequencing bioinformatics 
Primary bioinformatics (BCL to VCF) was performed as described in materials and methods (section 
2.7) by the SMCL sequencing service.  
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5.2.5 Variant filtering and prioritisation 
Variant filtering, annotation, and prioritisation was performed as described in the materials and 
methods (section 2.8) including Intervar variant interpretation using ACMG guidelines (325). Gene 
lists were curated as follows; gene lists for TCA cycle genes were obtained from Reactome pathway 
data (427). Genes frequently altered somatically in RCC tumours were selected from genes with 
alterations occurring at a rate of 3% or greater within the TCGA provisional sample sets for clear cell 
RCC, papillary RCC, and chromophobe RCC (25). The list was then assessed by NCG (version 6.0) 
(428) and false positive genes, as flagged by Bailey et al (2018) (429), were removed as well as 
known RCC predisposing genes retaining 41 genes (see appendix 9.4.1). Analysis of all known 
coding genes was excluded as a SNV investigatory route due to a large proportion of uninformative 
gene annotations for many genes. 
5.2.6 Copy number variation detection 
Copy number alterations were detected from BAM file read depth discrepancies identified utilising 
XHMM (430) across WES aligned and sorted BAM files. Additional WES BAM files from other read 
depth matched (mean depth within 1 Standard deviation) were jointly called to improve call rate and 
identification of common CNVs. CNV calling utilising a modified version of the analysis pipeline was 
also performed on all ICR birth control cohort cases to generate a reference set of commonly called 
CNVs (Allele frequency > 0.05) to filter experimental data against. Default CNV calls were modified 
to provide exon-level copy number calls and calls were filtered based on frequency (allele frequency 
< 0.01) and Q_some quality (Q_some > 60), as described in the XHMM documentation (430). 
CNV pipeline calibration was performed against a subset of samples sequenced as part of the 
HapMap / 1000 genomes project with both comparative genomic hybridisation array-based copy 
number calls and WES data (431) (Sample list provided in appendix section 9.4.2). The primary 
script used to run CNV calling with XHMM, xhmm_CNV.sh, is provided in the appendix section 
9.4.3a. Additional scripts, including pre-processing steps to generate reference files and parameter 
files, annotation steps, and plotting is described in appendix section 9.4.3b. HapMap WES data was 
downloaded in FASTQ format from EBI (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/) and aligned to 
GRCh38 as described in materials and methods (section 2.7), after which the CNV pipeline 
described herein was run across all HapMap WES BAM files. 
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Due to the data format of the HapMap calibration set additional pre-processing was required prior to 
CNV analysis. HapMap CNV array data was downloaded from ftp://ftp.ncbi.nlm.nih.gov/hapmap and 
remapped to GRCh38 from hg18 using NCBI remap service, discarding calls that failed to map to 
GRCh38. HapMap CNV array genotypes were called bi-allelically and as such genotypes were 
merged to match the mono-allelic calls provided by XHMM (e.g. -2 to 2 to -1 to 1). Genomic positions 
were merged based on overlapping loci and unique intervals were retained. HapMap CNV data was 
intersected with the genomic exome probe intervals as provided by Illumina to select only CNVs 
overlapping with regions sequenced by WES by 5% or more. Intersected WES targets were then 
filtered to remove regions with only reference or missing calls and the data was coerced into a 
pseudo-XHMM output format for comparison. 
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5.2.7 Population stratification and sample concordance 
Sample population structure and genetic background were calculated and assigned from 
ADMIXTURE software (432) modelling, which allows for a higher resolution decomposition of genetic 
ethnic background. Case variants were merged with high quality genotypes from the 1000 Genomes 
data set which was used as the training set. Genotypes were pruned and separated by a minimum 
of 2000 bp to reduced linkage effects, selecting only bi-allelic sites present in a minimum of 2 
samples, and restricted to autosomal chromosomes. Further restrictions for minor allele frequency 
(MAF > 0.05) and missingness per site (missingness < 5%) were subsequently applied. 
ADMIXTURE algorithm was designated k = 5, corresponding to the number of population groups to 
assign, which is equivalent to 1000 Genomes super population groups (320). Population structure 
scripts, including plotting scripts are provided in the appendix (section 9.4.4). For samples in which 
both WES and cancer gene sequencing had been performed, genotype concordance was performed 
to assess if WES data adequately captured the same genotype information as the previously 
sequenced cancer gene panel. The tool bcftools gtcheck (version 1.8) was used to compare 
genotype calls across the pan-cancer gene panel targets (see chapter 4.2) to determine if 
sequencing between WES and cancer gene panel sequencing were in concordance. 
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5.2.8 Burden analysis 
Genomic region burden analysis was performed across all genes containing genetic variants utilising 
sequence kernel association testing (SKAT) R package (version 1.3.2.1), as described by Wu et al 
(310) utilising allele frequency as the weighting criteria after logistic weight conversion with the 
“optimal” implementation. Principle components (PC) 1 and PC2 were generated using the same 
variant pruning and filtering as discussed in 5.2.7 for ADMIXTURE analysis and were used as 
covariates in the regression model. Cases in this series were joint called using GATK Unified 
Genotyper (see materials and methods section 2.7) with control samples from the ICR UK 1000 birth 
control cohort (433). Given that population structures in both sets should be of non-Finnish western 
European origin PCA components PC1, PC2 and PC3 were used as sample exclusion criteria for 
outliers falling outside of the primary PCA cluster (see section 5.3.9). 
Joint called genotypes were filtered for variant consequence type, minor allele frequency (applied 
independently to both cases, controls and both sets to reduce the interference of batch effects and 
sequencing artefacts), minor allele frequency compared to the ExAC data set (390), genotype 
quality, site QUAL, and missingness. Several iterative analyses were performed utilising differing 
filtering and covariate combinations and burden testing results were assessed based on minimum 
achievable p-value (MAP) adjusted Q-Q plot distributions to determine the best performing test, 
where MAP values are generated during resampling of the burden input data as described by Lee 
et al (2016) (434). Q-Q plots are frequently used as a metric of goodness of fit for association tests, 
principally in GWAS studies (435), to determine if inflation of significance levels is presence between 
the observed p values versus the theoretical p value quantiles and observe confounding features 
such as population stratification. Filtering parameters and covariates for the optimised parameters 
are described in 5.2 Table 1. 
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Results were corrected for multiple testing using false discovery rate adjustment (FDR) and genes 
meeting significance thresholds, either p-value or corrected p-values where specified in the text, 
were assessed for gene ontology and pathway enrichment using WebGestalt (436), Gene 
Ontology/Panther analysis (Panther GO-slim biological process set; fishers exact method) (437), 
and Reactome (427) in order to detect biological function or pathway enrichment in genes with 
significant genetic burden compared to controls. Full burden testing script is provided in appendix 
section 9.4.5. Additional comparisons were made to Network of Cancer Genes database set to 
assess the proportion of genes identified as known or candidate cancer genes (428). 
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5.2 Table 1 
Table of optimised parameters used for gene burden association testing including filtering values 
and included covariates. PC1 = principal component 1. PC2 = principal component. 
Metric   Value 
Minor allele frequency (AF < value) 
 Global (ExAC)   0.0025 
 Internal (Both)   0.05 
 Internal (case)   0.2 
 Internal (control)   0.2 
Site metrics (Metric > value) 
 Genotype quality   30 
 Read depth   15 
 QUAL   100 
 Non-missing   0.9 
Consequences included 
frameshift deletions 
nonsense 
frameshift insertions 
splice site variants 
missense variants 
Covariates included 
 PC1    
 PC2    
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5.2.9 Short tandem repeat detection 
Detection of short tandem repeats was performed using the GRCh38 BAM files with GangSTR 
(version 1.4) using the default parameters as described by Mousavi et al (2018)(426), with only 
adjustments made for non-uniform coverage. Repeat expansion calls were filtered for read depth 
(DP > 10) and Quality metric ‘Q’ (Q > 3). Calls were annotated by gene region and only calls falling 
within known RCC predisposing genes and novel genes identified in this thesis were analysed (see 
appendix 9.4.1). 
5.2.10 Mobile element insertion detection 
Mobile element insertions were detected using the mobile element locator tool (MELT; version 2.1.5) 
across all BAM files to determine the presence of non-reference mobile element insertions into 
coding regions. Analysis was performed against LINE1, ALU, HERVK, and SVA mobile element 
reference sets for GRCh38. Variant calls were filtered by “PASS” status and split read support > 2. 
Calls for mobile insertion types were merged into a single VCF file and filtered against known RCC 
predisposing genes and novel genes identified in this thesis (see appendix 9.4.1). 
5.2.11 Statistical methods 
Q values (FDR corrected p values) after SKAT-O burden analysis were generated using p.adjust() 
function with method “fdr” in base R (version 3.5). Fishers exact test was performed using the 
fishers.test() function in base R (version 3.5). Chi-squared test was performed using function 
chisq.test()in base R (version 3.5). 
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5.3 Results 
5.3.1 Clinical features 
A total of 72 unrelated individuals matching the selection criteria for RCC predisposition and were 
grouped clinically as follows: 33 cases with a family history and 39 cases with either early onset or 
bilateral/multifocal disease (23 and 16 cases, respectively). Median age of onset across all cases 
was 41 years (range 23-74). Median age of onset in familial cases was 51 years (range 24-74), 48 
years (range 31-60) in multifocal/bilateral cases and 34 years (range 23-46) in early onset cases 
only cases.  
Histological subtype was available for 36 of 72 cases (50%) and comprised 25 (69.4%) clear cell 
RCC, 8 (22.2%) papillary RCC and 3 (8.3%) chromophobe RCC, approximately consistent with 
previous assessments of histological frequencies. RCC presentation by sex was consistent with 
sporadic and heritable cases across all individuals and subgroups (male to female ratio 1.5-2.2) 
except for early onset which had significantly different distribution (male to female ratio 0.92; fishers 
exact p=0.004). Summary of the distribution of clinical features are given in 5.3 Table 2. 
Population structure analysis by admixture demonstrated that 66/72 individuals were of European 
origin, with the remaining population being African (1/72), East Asian (1/72), and European-south 
Asian (4/72) by admixture proportions (see 5.3 Figure 1).  
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5.3 Table 2 
Table of clinical features associated with the case series in this chapter. Percentages are calculated 
based on the entire cohort apart from histologies. Percentages for ccRCC, pRCC, and chRCC are 
calculated excluding nsRCC cases. 
Feature Number 
Age, Median (range) 
 
 
All 41 (23-74) 
 Familial 51 (24-74) 
 Early onset 34 (23-46) 
 Bi/Multi 48 (31-60) 
Histology, Number (%) 
 
 
nsRCC 36 (50.0%) 
 
pRCC 8 (22.2%) 
 
ccRCC 25 (69.4%) 
 
chRCC 3 (8.33%) 
Sex, Number (%) 
 
 
M 44 (61.1%) 
 
F 28 (38.9%) 
Type, Number (%) 
 
 
Familial 33 (45.8%) 
 
Early onset 23 (31.9%) 
 
Bi/Multi 16 (22.2%) 
Family history, Num. (%)  
 1st degree 21 (63.6) 
 2nd degree 5 (15.2) 
 Unspecified 7 (21.2) 
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5.3.2 Quality control and variant filtering 
Given the number of variants identified by whole exome sequencing, stringent and appropriate 
variant filtering criteria are required, as well as appropriate quality control metrics for read alignment, 
read depth, and variant calls. Read alignment rates a mean of 99.81% across all samples, with a 
mean coverage of 120X. PCR duplicates across all samples were present at a mean rate of 13.7% 
(range 7.2-30.2%) (5.3 Figure 2-3). 
Comparisons for genotype discordance between samples sequenced on both the pan-cancer gene 
sequencing panel and WES was available for 75.0% (54/72) of sequenced cases, of which no 
samples demonstrated genotype discordance between the two sequencing data sets. The remaining 
proportion had WES data but not pan-cancer sequencing panel data available. 
Variant calling was performed and resulted in 337,021 variant calls (304,231 SNVs and 32,790 
indels) including 12,704 multi-allelic sites with a resulting transition/transversion (Ts/Tv) ratio of 2.23. 
After filtering for variant quality metrics (read depth, QUAL, genotype quality, missingness and minor 
allele frequency), as described in the materials and methods section, and left alignment and 
normalisation the number of variants retained was 194,367 (175,756 SNVs and 18,611 indels), 
demonstrating an increased Ts/Tv ratio of 2.43. Indel size distributions, and variant substitution types 
are shown in 5.3 Figure 4. 
Variant filtering, as described in materials and methods (section 2.8) removed 113,663 variants 
occurring in intergenic regions, intronic regions more than 2 bp from splice site consensus 
sequences, and a further 34,445 variants which resulted in synonymous amino acid changes. 
Variants were filtered for global minor allele frequency in both 1000 genomes and ExAC to exclude 
sites present above 1%, resulting in 25,022 rare protein affecting variants being retained. Allelic 
depth was assessed and variants with insufficient alternative allele depth (AD < 0.3) in at least one 
sample per site were removed, reducing the final number of filtered sites to 22,384. Variants 
identified as part of chapter 4 were excluded from reported variants but included in variant counts 
and association testing. 
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Given the volume of genetic alterations called and meeting default filtering parameters, in-depth 
analysis of all sites is an impractical methodology to determine potential candidate variants in RCC 
predisposition. This is exemplified by applying ACMG classifications to the filtered call set which 
categorises 84.4% (18,884/22,384) of the sites as variants of uncertain significance. As such, SNV 
analysis was segregated into distinct analysis sets; Ultra rare truncating or splice site-affecting 
variants, somatically altered genes in RCC, and genes related to the TCA cycle, as described in the 
methods. 
5.3.3 Truncating and splice site-affecting variants across all genes 
Variants were filtered to retain only the most potentially damaging variant consequences (nonsense 
variant, frameshift insertions or deletion, and splice site-affecting variants) in order to determine if 
any rare or novel truncating variants disrupted genes which may function in predisposition to RCC. 
After filtering a total of 1,134 variants were kept (5.1%), which consisted of 450 nonsense variants, 
145 frameshift insertions, 310 frameshift deletions, and 229 splice site-affecting variants. Due to the 
number of truncating variants identified, further filtering criteria were applied to reduce the candidate 
number including removal of variants present in a non-reference homozygous state, variants 
identified as known benign or likely benign alterations by ClinVar, and reducing the minor allele 
frequency in ExAC to 0.001 which retained 758 variants. ACMG criteria (325) were applied to the 
remaining variants utilising InterVar (326) as previously described and assigned 99 variants as 
pathogenic or likely pathogenic (P/LP) and 608 variants as variants of uncertain significance. A 
residual 51 variants failed to be parsed correctly by InterVar and as such were not assigned ACMG 
classifications. 
For sites designated as P/LP, genes were assessed by the Network of Cancer Genes platform (NCG) 
(428) to determine if they have previously been related to cancer and in what capacity. The 99 
variants contained 94 unique genes, of which 20 genes were suggested to be associated with cancer 
as assigned by the NCG v6.0 analysis (428) (4 genes were flagged as potential false positives in 
cancer and were excluded). This resulted in a final set of 21 sites with truncating alteration in 
candidate cancer genes assigned as P/LP (5.3 Table 3). 
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All variants categorised as ultra-rare truncating variants were present in only a single individual and 
occurred at allele frequencies in ExAC at 8.00E-04 or lower. Interpretation of these variants is highly 
dependent upon gene function and established associations with other genetic disorders. Most In 
silico predictions for these variants were not designated, except for CADD, which suggested all were 
deleterious in nature. Interestingly, all the genes in which variants were identified in this subset were 
altered somatically in RCC on average 1.83% (range 0.1-9%) of cases, though specific selection of 
genes altered in RCC was not performed. Enrichment analysis biological processes associated with 
the genes in this set using Panther gene ontologies did not identify any significantly enriched groups. 
Several variants are worth noting, including the PKHD1 nonsense variant (NM_138694: c.C5323T: 
p.R1775X) which is a known pathogenic variant associated with autosomal recessive polycystic 
kidney disease. The variant is carried by an individual with early onset clear cell RCC. The variant 
occurs midway through the protein coding sequence and is reported as loss of function intolerant by 
gnomAD classifications (353). Lastly, PKHD1 is reported as a frequently altered (3%) across the 
TCGA renal cancer set, though most are VUS missense variants. The truncating variant in DIAPH1 
(NM_005219: c.C1261T: p.R421X) is associated with autosomal dominant deafness. DIAPH1 is 
highly mutated somatically in RCC (9%) but is nearly exclusively amplified and only one truncating 
variant is reported, occurring concurrently with an broad amplification (25). This would suggest that 
truncating variants in DIAPH1 are unlikely to result in RCC predisposition despite the variant being 
likely pathogenic.  
RNF43 which harbours a frameshift deletion (NM_001305544: c.1410delC: p.P470fs) is also 
reported frequently somatically (1.8%) but with a high degree of amplification though it has been 
demonstrated to have tumour suppressor functions complicating variant interpretation in the context 
of RCC predisposition. The splice site variant identified in NUP93 (NM_014669) affects the first base 
of splice donor site after exon 2, potentially disrupting exon splicing. While no reports implicate 
NUP93 in cancer, NUP93 inactivating variants are associated with autosomal recessive nephrotic 
syndrome. 
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5.3.4 Detection of SNVs in sporadic renal cell carcinoma genes 
After variant filtering and quality control, variants were selected based on gene list incorporating 
genes which are described as being frequently altered in sporadic RCC tumours, as described in the 
materials and methods Assessment of variants passing filter identified 331 variants falling within the 
coding regions of genes associated with sporadic RCC tumours (See appendix 9.4.1; excluding 
known inherited RCC genes). Intervar was used to apply ACMG guidelines to all 331 variants and 
found 3 pathogenic or likely pathogenic variants across 3 genes, all of which were previously 
identified in the previous analysis (COL6A3: NM_004369: c.761delG: p.G254fs, DST: NM_001723: 
c.5832_5838del: p.A1944fs, and PKHD1: NM_170724: c.C5323T: p.R1775X) and 227 VUS 
variants. Variants were cross referenced with ClinVar data to remove conflicting reports and variants 
presenting in a non-reference homozygous state were also removed, resulting in a final count of 202 
variants. 
Protein alterations incurred by the variants identified in this set consisted of 194 missense variants, 
2 frameshift deletions, 2 frameshift insertions, 2 non-frameshifting deletions, 2 nonsense variants, 
and 1 stop loss variant. Variants, excluding missense variants, are in 5.3 Table 4. Overall, few non-
nonsynonynmous variants were identified in genes which are frequently somatically altered in RCC 
and of the 7 genes that were identified, 3 were recapitulations of variants identified without somatic 
RCC-specific gene list filtering. The remaining 5 variants, 3 of which were truncating, only revealed 
one variant of particular interest in SETD2 (NM_014159: c.579_587del: p.193_196del) which is one 
of the most frequently somatically altered genes in RCC, though the pathogenicity of this variant is 
uncertain given it does not result in a premature stop codon or frameshift. The deletion of 3 amino 
acids (p193-196) may result in protein dysfunction but does not occur in any known critical functional 
domain.  
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Analysis of VUS assigned missense variants is difficult, particularly given the number identified in 
this instance (194 sites). Application of restraining in silico predictive metrics to filter variants further 
still resulted in a large set of VUS missense variants being retained where selecting variants only 
predicted to be likely pathogenic by SIFT and PolyPhen, as well as a CADD score greater than 25 
was true for 132 variant sites. For the genes identified in 5.3 Table 4, AHNAK2, COL6A3, DST, 
KIAA1109, PKHD1, SETD2, and XIRP2, also harboured rare VUS missense variants after in silico 
filtering parameters were applied (AHNAK2 = 18, COL6A3 = 4, DST = 5, KIAA1109 = 1, PKHD1 = 
1, SETD2 = 2, and XIRP2 = 7). 
Further sub setting of VUS missense variants in the in silico filtered set uncovered missense variants 
in biologically relevant somatic RCC-linked or cancer-associated genes such as ATM, KDM6A, 
KMT2C, KMT2D, MTOR, NF2, and SMARCA4 in addition to SETD2 (See 5.3 Table 5). 
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5.3.5 Detection of SNVs in metabolic genes associated with Krebs cycle 
Variants from the filtered set were demarcated by genes associated with the TCA cycle (see 
appendix 9.4.1) in order to identify novel or rare likely damaging variants in components the genes 
encoding proteins involved in the TCA cycle and its supporting complexes. After gene list filtering 
(22 genes) a total of 13 sites were retained. All sites identified within the genes present on the TCA 
cycle gene list were nonsynonymous variants and InterVar interpretation of clinical significance 
assigned 76.9% (10/13) as VUS variants, with the remaining categorised as likely benign. 
Of the 13 variants identified, 10 sites occurred within known protein domains or functional sites, 
though variants outside of protein domains did not correlate with variants assigned as likely benign. 
Genes carrying variants included direct components of the TCA cycle complexes (ACO1, ACO2, 
DLST, CS, IDH3A, MDH2,) and genes encoding proteins related to complex scaffolds or TCA 
complex-like functions (SUCLG2, OGDHL, and DLD). 
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5.3.6 Copy number alterations - Calibration of copy number pipeline 
In order to assess the necessary changes to default parameters provided by XHMM for the calling 
of CNVs in unmatched whole exome data, calibration was performed on a subset of HapMap 
samples with both whole exome sequencing and CNV calls from comparative genomic array data 
(see materials and methods 5.2).  
Comparisons in calling rate and genotype for overlapping targets in both whole exome and array 
data were performed across 23 samples to assess the calling efficiency, genotyping accuracy, and 
ability to replicate results found in CGH array data, considered the gold standard for high-throughput 
detection of copy number alterations. Analysis was replicated 95 times utilising differential 
parameters regarding target size, target read depth, sample read depth, read depth standard 
deviation, and PCA variance normalisation. Of 95 replicates attempted, 73 successfully produced 
CNV calls and used to generate summary and comparison data. 
5.3.7 Copy number alterations calibration - Evaluation of call rate, type I, and type II errors 
When comparing exome targets which intersected with genomic regions with available array data, 
the true positive rate was 68.53 ± 2.89% when restricted to all experimental iterations for which 
targets were called in both exome data and array data. False positives occurred at a mean rate of 
5.69 ± 0.63% in which XHMM called an alteration in copy number but array data was discordant. 
The remaining percentage was attributable to false negative calls, where XHMM failed to genotype 
a non-neutral copy number alteration identified by the array data at a rate of 25.77 ± 3.30%. 
Distributions across all samples are given in 5.3 Figure 6A. 
A majority of algorithm parameters, independently, had little to no impact on call rates in the 
calibration set with the exception of ‘minimum mean target read depth’, that is to say the threshold 
below which exome targets are excluded on the basis of mean read depth across the analysed 
samples (5.3 Figure 6B). No analysis was performed to assess call rate effects due to combinatorial 
parameter modifications. 
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5.3 Figure 6 
CNV calibration results across all HapMap WES data sets compared to array data. 6A visualisation of the 
relative proportion of calls and the detection rates by colour. True positives (blue), false positives (red), and 
false negatives (green). 6B Line plot grid for each altered XHMM algorithm metric and the change to TP, FP, 
and FN rates over different iterations.  
A 
B 
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5.3.8 Copy number alterations – RCC copy number analysis 
CNV calling utilising the CNV pipeline was performed on all 72 RCC WES cases with an additional 
74 read depth-matched WES samples. The sample set was normalised on the second principle 
component, removing variance up to the 70% threshold, as specified in the XHMM methodology 
(430).  
Initial calling by XHMM called 9,310 copy number altered regions across all samples. After 
annotation and exon extraction, a total of 13,072 exons were called as having altered copy numbers 
across 146 samples equating to 78,942 altered genotypes over all samples. These calls were split 
evenly between deletions and duplications, with 39,378 duplications and 39,564 deletions (deletion 
to duplication ratio = 1.004). The median number of duplication calls was 249 (range 53-780) per 
sample and the mean number of deletions was 249 (range 116-1085). Stringent call filtering (see 
materials and methods 5.2) filtered 7,418 sites and the removal of 27 samples in which no CNV calls 
remained, resulting in the retention of 5,654 individual genotypes, 3,536 (62.5%) were duplications 
and 2,118 (37.5%) were deletions. The mean duplication and deletion call rates across the retained 
samples were 29.7 (range 0-591) and 17.8 (range 0-437), respectively. 
Lastly, samples were subset to exclude the non-case samples used to improve calling. This caused 
2,275 additional sites to be filtered causing a reduction in genotype calls to 3,379 (2,024 duplications 
and 1,355 deletions). Median CNV calls per sample was 23 (range 1-441), with duplications having 
a median of 15 (range 0-337) and deletions a median of 4 (range 0-437). Of the samples assessed, 
5 individuals harboured call rates exceeding 1 standard deviation from the mean rate across all 
samples, and 3 samples exceeded 2 standard deviations. These samples accounted for 46.6% 
(1,576/3,379) of all CNV calls (See 5.3 Figure 7A). 
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Given that germline CNVs should occur at low rates, samples with an excessive number of CNVs 
were excluded on the premise that the CNV calls were artefactual. Samples with CNV calls 
exceeding one standard deviation greater than the cohort mean were removed. Exclusion of these 
outlier samples resulted in attenuated call rates with a total of 5,654 sites called across 56 samples 
for a total of 1,803 genotype calls (5.3 Figure 7B). Removal of the outlier samples resolved to 
stabilise the CNV call rates across all samples with a median of 21 (range 1-127) CNV calls (1,179 
duplications and 624 deletions). Median duplication and deletion rates in the final sample set were 
12.5 (range 0-103) and 3 (range 0-123), respectively. 
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5.3 Figure 7 
Stacked bar plot of exon call types and counts across all RCC samples where duplication proportion 
is indicated in yellow and deletions in blue. Solid line represents the mean count, dotted represents 
the upper standard deviation, and dashed represents two times the upper standard deviation. 7A 
Stacked bar plot including outlier samples which exceeded 2 standard deviations from mean number 
of target exons called. 7B Stacked bar plot identical to that in 7A but after the removal of the outlier 
samples.  
A 
B 
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Analysis of affected genes was performed by first identifying CNV calls in protein coding genes and 
subsequently the application of gene lists as utilised for SNV analysis. Analysis of CNV calls 
discovered copy number duplications in 274 genes and copy number deletions in 137. A total of 18 
genes had both copy gain and copy loss calls and were excluded on the basis that genes carrying 
both duplications and deletions are unlikely to be associated with the same phenotypic presentation.  
Filtering of CNV calls using a broad pan-cancer gene list (572 cancer-related genes curated from 
the COSMIC cancer consensus gene lists (378) reduced the call set to 75 CNV calls which, when 
exon overlapping calls were merged, collapsed to 10 distinct calls in 10 samples (5.3 Table 7). These 
CNV calls were divided into 5 duplications and 5 deletions, 2 were full coding region alterations and 
the remaining calls were partial. All calls occurred only once, detected in a single individual across 
the entire unfiltered sample set. Many calls were partial duplications of known tumour suppressor 
genes and therefore likely to be false positives or not assumed to have functional effects (TSC2, 
CARD11, PMS2), as well as the full coding region of MUTYH. Deletions were broadly partial in 
nature, resulting in copy number losses of a subset of exonic regions and only a single gene 
demonstrated a copy loss of the entire coding region (EP300).  
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5.3 Table 7 
Table of high quality filtered CNV calls made across the RCC set collapsed by gene and copy 
number alteration type. 
CNV Gene Chr Start End 
Size 
(Bp) 
Q 
Some 
Allele 
frequency 
Allele 
count 
Region 
DEL PDE4DIP chr1 149030194 149030314 120 99 6.90E-03 1 Exon 46 
DEL COL2A1 chr12 47976750 47978819 2069 63 6.90E-03 1 Exon 42-48 
DEL NF1 chr17 31358907 31360764 1857 97 6.90E-03 1 Exon 55-56 
DEL EP300 chr22 41117125 41176589 59464 69 6.90E-03 1 Exon 1-30 
DEL HNRNPA2B1 chr7 26197302 26197908 606 79 6.90E-03 1 Exon 2-4 
DUP MUTYH chr1 45329244 45340348 11104 99 6.90E-03 1 Exon 1-16 
DUP TSC2 chr16 2087801 2088671 870 97 6.90E-03 1 Exon 39-42 
DUP APOBEC3B chr22 38982402 38982522 120 76 6.90E-03 1 Exon 1 
DUP CARD11 chr7 2910037 2947799 37762 94 6.90E-03 1 Exon 3-24 
DUP PMS2 chr7 5986697 5990016 3319 88 6.90E-03 1 Exon 10-11 
 
  
 194 
 
5.3.9 Gene burden analysis 
Gene burden analysis was performed utilising 66 cases with features of RCC predisposition and 999 
control samples from the ICR UK exome (433) (as described in materials and methods 5.2). As such, 
patients identified as not having non-Finnish European admixtures were excluded from downstream 
analysis. Burden analysis was restricted to truncating and nonsynonymous variants (excluding in-
frame deletions and insertions, non-coding, intronic, and synonymous alterations) and after filtering 
resulted in 497,138 variants across 1,071 samples. 
PCA was performed to assess for batch effects and determine appropriate covariates to include the 
gene burden model (See 5.3 Figure 8). Further interrogation of the PCA plot and its variance profile 
demonstrated a likely batch effect due to library and data preparation methods between control and 
case samples, driven by variance in PC1 and intra-case variance from both P1 and PC2 collectively. 
In PCA plots utilising principle components 3 or greater, samples broadly overlapped, suggesting no 
variance between cases and controls, or intra-case variability. 
The magnitude of any variance to a single principle component is an important factor when 
determining the degree to which it will affect downstream analysis. A plot of cumulative variance was 
generated for all computed principle components in order to quantify the contributed variance for 
each principle component (see 5.3 Figure 9). Principle component 1 and 2 contributed 1.03% and 
0.55% of total variance derived from the principle component analysis, respectively. All the remaining 
variance was spread equally across all remaining principle components at percentages between 0 - 
0.47% (mean = 0.09%). Formally, the contributed variance for each principle component broadly 
correlated with the amount of variance contributed individually by each sample. Given the minimal 
about of variance contributed by each principle component, downstream analysis was carried out 
with both principle component 1 and 2 as covariates in the SKAT-O model with all remaining principle 
components contributing an increasingly low amount of variance. 
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5.3 Figure 8 
Scatter plots of principle components 1 – 5 grouped by case and control; cases from this study in 
blue, control samples from ICR1958 birth control cohort in red. A) Scatter plot of principle 
component 1 against principle component 2. B) Scatter plot of principle component 2 against 
principle component 3. C) Scatter plot of principle component 3 against principle component 4. D) 
Scatter plot of principle component 4 against principle component 5. 
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5.3 Figure 9 
Contributed variance across all principle components. X-axis presents all principle components 
generated by principle component analysis; y-axis presents the amount of total variance within the 
data contributed by a given principle component. Graphs A and B display the same data but with 
different y-axis scaling. A) Contributed variance with y-axis scaled to the highest amount of 
variance contributed by a single principle component. B) Contributed variance with y-axis scaled to 
100% contributed variance. 
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5.3 Figure 10 
Q-Q plot for the described SKAT-O implementation depicting the quantile p value spread against 
the theoretical quantiles. Upwards deviation of points from the theoretical distribution (centre line) 
indicate an inflation of p values.  
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SKAT-O burden analysis was performed across all genes containing variants with the optimised 
parameters with covariates (5.3 Figure 10 and 5.2 Table 1). Analysis of SKAT-O output revealed 
532 genes with a significant mutational burden compared to controls at p < 0.05 and 180 genes at 
significance p < 0.01 (See appendix section 9.4.6). A single gene was significant after multiple testing 
correction by FDR (FBLIM1, q value = 0.035). The correction was applied across all assessed genes 
(n = 13,959) and the false discovery rate was set to 5%, as such multiple testing correction was 
statistically conservative for false positive associations. Genes occurring with p values < 0.01 
included 12 known cancer associated genes as defined by network of cancer genes (v6.0) (428), 
including HIF1A (p = 3.28E-04). Analysis of the genes associated with mutational burden (p < 0.01) 
by the Network of Cancer Genes (NCG v6.0; (428)) identified a statistical enrichment of known or 
candidate cancer genes in the burden-associated genes compared to global rates with 6.67% 
(12/180) genes in the burden associated set being known or candidate cancer genes compared to 
12.6% (2372/18833) across the genome (χ² test p = 0.040). 
Gene enrichment analysis was performed on various gene set analysis platforms for genes with p 
values < 0.01 in order to identify enriched biological processes, pathways, or regions. Analysis for 
overrepresented gene ontologies (GOs) using WebGestalt detected no enriched GOs after FDR 
correction. Gene enrichment performed by Reactome to detect statistically overrepresented 
pathways did not detect any pathways in which genes (or their protein products) were enriched. It is 
worth noting that Reactome failed to find matching gene identifiers for 70/180 (38.9%) genes despite 
using multiple gene/protein identifiers (NCBI, Entrez gene, gene symbol, and Uniprot) which may 
have impacted pathway enrichment analysis. Lastly, GO enrichment analysis using Panther and GO-
slim biological process ontology set also did not result in any FDR corrected biological processes 
being enriched in genes with p values < 0.01. 
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5.3.10 Short tandem repeat expansion analysis 
Short tandem repeat expansion (or contraction) (STRE) analysis was performed on BAM files for all 
72 individuals in the case set to determine if known tandem repeat alterations could be detected in 
germline sequencing from WES data, and if those alterations could impact genes known to result in 
RCC predisposition. STREs were called at a mean rate of 34,925 calls per sample (median = 33,343; 
range 20,776-69,571). STRE calls were filtered for both read depth and quality (Q) and restricted to 
calls within known RCC predisposition genes (see appendix 9.4.1), as well as BRIP1, as identified 
in chapter 4. 
After filtering and genomic region restriction the mean number of STRE calls per sample was 1.78 
(median = 1.5; range 1-5). Calls across all samples were collapsed into a single VCF resulting in a 
total of 31 STRE calls passing filtering criteria. A further 24 sites were excluded for occurring at an 
allele frequency greater than 5% (allele frequency > 0.05) and were therefore likely to be either false 
positive calls or natural fluctuations in short tandem repeat lengths.  
The remaining 7 sites (5.3 Table 11) occurred in 6 individual samples, with a single individual 
harbouring both large STRE calls in SDHA and TSC1 (chr5:250296 A/(AGG)272 and chr9:132903602 
C/(CAAAA)163). Of the 7 STRE calls made by gangSTR which passed all filtering criteria, 6 were 
present within gene introns and none occurred in the disruption or in proximity to a spice site 
consensus sequence. A single STRE call was present within exon 20 of BRIP1 (chr17:61684053 
T/TTTGT), occurring at amino acid 998 within the BRCA1 binding domain in an individual with familial 
RCC and no other known candidate variants from previous analysis. 
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5.3.11 Mobile element analysis 
Analysis of mobile element insertion was performed using MELT for all 72 samples present in the 
WES data set. Initial calling of mobile element insertions (MEIs) was independently identified per 
sample for each of the 4 transposable element types and jointly genotyped, describe in the materials 
and methods section. Prior to site filtering MEIs the following number of MEIs were detected per 
transposable element type; ALU = 1,645, HERVK = 1, LINE1 = 152, SVA = 73. 
Filtering parameters for MELT calls were applied (PASS status and split read support > 2) to each 
transposable element type resulting in the retention of 35 ALU sites, 0 HERVK sites, 5 LINE1 sites, 
and 1 SVA sites. Transposon-specific VCF files were concatenated and region filtering of calls to 
genes present in known RCC predisposition genes (and BRIP1), as described previously, did not 
result in any sites being retained. Intersection of the sites present in the multi-transposon VCF file 
with all known gene coding regions returned 41 sites with MEI calls. Removal of common (AF > 0.05) 
MEI calls across the sample set retained 18 sites, only 1 of which was within a gene exon, ZNF763 
(5.3 Table 9). 
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5.4 Discussion 
In this study the use of multiple analysis types has been utilised to identify potential candidate genes 
which may be associated with RCC predisposition. Identification of genes with strong associations 
with somatic RCC alterations in histone modifying and chromatin remodelling pathways such as 
SMARCA4, SETD2, KDM6A, KMT2C, and KMT2D are potential candidate genes given the recent 
association of PBRM1 and BAP1 with RCC predisposition (263,264) and in regard to the details 
discussed in chapter 3 section 3.1.3. SMARCA4 encodes a component of the same complex as 
PBRM1 and is frequently somatically altered in RCC and has been reported in predisposition to other 
cancer (439).  
Variants in SETD2, including a non-frameshift deletion, are interesting potential candidates given 
the frequency of somatic alterations in SETD2 seen somatically, with 18% of clear cell RCC cases 
having either copy loss or putative driver mutations (25) and has been demonstrated to act as tumour 
suppressor via epigenetic regulation (440). Histopathological information was available for one of 
the three individuals with SETD2 variants and had multifocal clear cell RCC at age 48 years, which 
would correlate with SETD2 mutational status. Heterozygous loss of function SETD2 mutations have 
been described as a cause of the intellectual disability disorder, Luscan-Lumish syndrome (MIM: 
616831) which is characterised by developmental and speech delay, dysmorphic facial features, 
macrocephaly and autistic features (441,442). Luscan-Lumish syndrome is a rare disorder and 
predisposition to RCC has not been described and, to my knowledge, the individuals in our RCC 
cohort with SETD2 variants did not have features of Luscan-Lumish syndrome. Variants in KMT2C 
and KMT2D have been broadly discussed in previous chapters but they do occur frequently 
somatically and should not be removed from consideration, particularly KMT2C given the sequencing 
issues and potential false positives that may occur, as such further analysis would be necessary.  
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Lastly, KDM6A is a further gene coding a histone modifying protein, lysine demethylase 6A, and is 
also altered somatically, though at a lower rate than the other genes mentioned (1.8%). KDM6A is 
closely linked to KMT2D, both of which are associated with Kabuki syndrome 2 and 1, respectively 
(MIM: 300867 and 147920) and therefore is open to the same points discussed in chapter 3 in regard 
to the inheritance of a variant associated with an autosomal dominant condition. It is worth noting 
that KDM6A is present on chromosome X and demonstrates X linked inheritance which complicates 
variant interpretation. In this case the individual was a female presenting a chromophobe RCC at 
age 27 years so adherence to a two-hit model is still feasible. Overall variants in these genes are 
interesting candidates given the rate of somatic alterations, where 26% of RCC cases across all 
histological subtypes carry at least one alteration in one of the genes discussed. While interesting 
candidates, additional studies to confirm function implication of the variants identified and tumour 
studies to demonstrate LOH which would support their role in RCC predisposition.  
Variants were identified after analysis of genes associated with TCA cycle complex components and 
supporting proteins. Interpretation of these variants in genes such as ACO1 and CS is difficult without 
functional assessment of the variants and effect on the TCA cycle. Variants in these genes may act 
similarly to FH in HLRCC or SDH genes by results in the intracellular accumulation of substrates of 
the TCA cycle and intermediates such as 2-oxoglutarate which result in the disruption of alpha-
ketoglutarate-dependent dioxygenase enzymes such as TET and KDM proteins (229), as well as 
potential inhibition of PHD proteins in a manner similar to that seen with fumarate and succinate 
(175). Histopathology in these cases, where available, was 50% papillary RCC, which would be 
consistent with HLRCC-like tumours if the mechanisms were similar (443). While protein function 
experiments could be labour intensive, metabolic testing of tumours for accumulated metabolites 
has been demonstrated for SDH-deficient and FH-deficient tumours (444) and, in combination with 
immunohistochemistry for the affected TCA complexes, could rapidly confirm or refute the potential 
detrimental nature of the variants in this set. 
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SNV analysis also identified several putative causal variants in genes linked to genetic renal 
diseases known pathogenic variants associated with renal-related autosomal recessive conditions. 
The nonsense variant in PKHD1 (NM_138694: c.C5323T: p.R1775X) which is a known pathogenic 
variant associated with autosomal recessive polycystic kidney disease. While determining if this 
variant is causal for the predisposition seen in this individual, it is interesting that an individual 
harbouring a pathogenic allele for polycystic kidney disease would develop RCC given that cystic 
disease is a risk factor for RCC (36) and a reported increased susceptibility in autosomal dominant 
polycystic kidney disease (445), especially given the rate at which somatic alterations occur across 
RCC tumours (3%). Conversely, whether the loss of the second wild type allele would induce RCC 
or renal cysts only would require further investigation and that this may be an incidental finding of an 
individual who is a carrier for autosomal recessive polycystic kidney disease. Assessed in the same 
manner, the splice variant seen in NUP93 (NM_014669) could, in autosomal dominant inheritance 
pattern, confer a risk to RCC but NUP93 inactivating variants have only been associated with 
autosomal recessive nephrotic syndrome and though nephrotic syndrome has been associated with 
increased cancer risk (446) in affected individuals, carriers have not been assessed for increased 
cancer risk and are infrequently seen somatically. It is also important to note that acquired cystic 
disease can develop in patients with renal failure and is associated with an increased risk of RCC 
(447), as such drawing correlations between inherited renal cystic disease, RCC predisposition and 
renal failure can be difficult. 
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Gene burden association testing demonstrated reasonably robust statistical metrics given the limited 
sample size and case-control size discrepancy. Only a single gene reached statistical significance 
after multiple test correction (FDR) and only a handful of genes were statistically significant prior to 
FDR correction and known to be associated with cancer. Gene ontology analysis of genes with 
significant burden, with or without multiple testing correction, failed to identify any relevant biological 
processes that were enriched in the gene set. The clear limitation in the gene burden analysis is the 
lack of association after multiple testing correction and the presence of an overabundance of genes 
surpassing uncorrected significance level due to the observed p value inflation, seen in 5.3 Figure 
9. Indications from both the gene burden outcomes and gene ontology enrichment suggest that 
underlying issues with statistical power and clear issues regarding control of variance between the 
cases and controls persist. Overall a limited number of conclusions can be drawn from the results 
presented. Conversely, the gene burden analysis was performed on all coding sequence affecting 
variants, utilising differing subsets of variant consequences, such as only missense variants may 
yield different associations though refitting of the model is required. The statistical power of the 
analysis performed here using SKAT-O could be greatly improved with increased sample size which 
may allow for statistical associations to be detected and allow for absolute associations between 
increased gene mutational burden and RCC predisposition. 
Finally copy number, short tandem repeat expansion, and mobile element analyses collectively 
identified very few candidate alterations which could be plausibly linked to RCC predisposition. CNV 
analysis generated only 10 high quality calls, many of which were partial duplications that are unlikely 
to result in an altered phenotype. Remaining calls such as the partial deletion of exons 55 and 56 of 
NF1 are potentially interesting due to links with predisposition to PCC in neurofibromatosis 1 (MIM: 
162200)(448) and the known phenotypic connections between those diseases and RCC (212,385). 
Conversely, the deletion of those specific exons would result in the truncation of the 2nd and 3rd exons 
from the final 57th exon which does not appear to harbour any functional domains, though there are 
two modified phosphoserine residues on the C terminus which may have a function during mitosis 
(449). 
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The full coding region deletion of EP300 due to it encoding the histone acetyltransferase enzyme 
p300 which regulates chromatin structure and truncating mutations are seen relatively frequently in 
somatic RCC (2.8%), although heterozygous inactivating variants in EP300 are associated with 
Rubinstein–Taybi syndrome (450) and offsetting evidence is available for p300 and its function or 
role in cancer. The WES-based CNV pipeline has clear limitations, particularly regarding false 
negatives, which limits this study’s ability to detect CNVs. Additionally, the presence of a significant 
false positive rate means any copy number alteration would need to be validated by conventional 
methods (i.e. array-based of multiplex-ligation dependent probe amplification) and as such should 
be interpreted with caution.  
The exploratory investigations into the potential for short tandem repeat expansions or mobile 
elements to be associated with RCC failed to reveal any substantial results and genetic diseases 
caused by these mechanisms are rare. While these methods did not yield clear and obvious 
associations, exploring all potential avenues to discover the heritability in RCC utilising rare and 
under measured sources of genetic alterations may prove critical to identifying factors linked to 
predisposition which fall outside of the typical paradigms assessed routinely. 
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5.5 Conclusion 
WES analysis of individuals with features of RCC predisposition has uncovered a range of potentially 
pathogenic or likely pathogenic variants outside of those discovered in chapter 4, as well as a series 
of VUS variants in genes associated with somatic RCC, other renal-related diseases, and metabolic 
pathways seen to be altered in both syndromic RCC and PCC. Conversely, case control mutational 
burden analysis and exploration into copy number alterations and other genetic alteration types did 
not reveal strong candidates for causes of inherited RCC. Limitations of reduced genomic coverage, 
poor variant interpretation, and sample sizes have confounded the identification of any robust 
associations. In particular, power to detect associations given the limited sample size and prior 
probability of an individual having a monogenic disorder is the major limiting factor and it is likely that 
only substantially increased sample sizes would be capable of identifying alleles that contribute to 
RCC predisposition at moderate to low risk rates. 
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6.0 Characterisation of RCC-associated constitutional chromosomal 
abnormalities by whole genome sequencing 
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6.1 Introduction 
Constitutional translocations are detected prenatally at a rate of 1 in 109-238 births (0.42-0.92%) 
(451–453), and large structural variants occur relatively frequently in the general population (454). 
Chromosomal translocations are subdivided into 3 primary types; balanced, unbalanced, and 
Robertsonian, each of which result in differential retention or loss of genomic information depending 
upon the size and type of translocation. Though most translocations are not known to cause genetic 
disorders, a subset of translocations, particularly those that are unbalanced, have been associated 
with a number of different diseases including cancer, infertility, neuropsychiatric disorders, and 
Intellectual/developmental disorders (455–458). 
6.1.1 Constitutional translocations in RCC 
Four decades ago, Cohen et al (1979) described a large kindred in which clear cell RCC segregated 
with a constitutional translocation between the short arm of chromosome 3 and the long arm of 
chromosome 8, t(3;8)(p14.2;q24.1) such that the risk of RCC in translocation carriers was estimated 
to be 80% at age 60 years (259). Subsequently, somatic deletions of the short arm of chromosome 
3 (3p) were found to be the most common cytogenetic abnormality in sporadic clear cell RCC 
suggesting the presence of critical renal tumour suppressor genes on 3p (126). These developments 
led to the suggestion that identification of individuals with suspected inherited forms of RCC should 
be screened for constitutional translocations involving 3p and that the characterisation of RCC-
associated translocation breakpoints might lead to the identification of novel inherited RCC genes 
(459). Subsequent research studies have confirmed that chromosome 3p does indeed harbour 
several tumour suppressor genes (TSGs) that are frequently inactivated in sporadic RCC (e.g. VHL, 
PBRM1, BAP1, RASSF1A) (25,128,277,389,460–463).  
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Unlike normal RCC syndromes, which conform to either a two hit hypothesis or constitutional 
activation of an oncogene, constitutional translocations are suggested to cause RCC predisposition 
via a three-hit model. The three-hit model of tumourigenesis in translocation-related renal cell 
carcinomas is theorized as follows: I) presence of constitutional translocations lead to a genomic 
instability, II) Loss of genomic stability results in the loss of the chromosome 3p region on the 
derivative chromosome, III) Secondary loss of an allele from genes on the wildtype 3p region, usually 
VHL, leads to complete loss of one or more tumour suppressor genes. Under this model, initial 
genomic instability is insufficient to induce cancer development and two additional hits are still 
required to induce neoplastic cell growth, frequently including the loss of tumour suppressors (i.e. 
VHL), although the precise mechanism of the genomic instability is not known.  
Translocations may also confer a generalised genomic instability, in which specific loss of 3p is not 
required, and further inactivation of unknown genes are responsible for tumourigenesis. 
Alternatively, translocations may result in positional-effect variegation, resulting in differential 
expression patterns for coding regions under differential chromatin regulation (464). Generalising 
the model to all translocations, particularly those outside of chromosome 3 has proven more 
challenging. The lack of known tumour suppressors, intergenic break points, and no relation to 
commonly lost regions in sporadic RCC cases suggests that other mechanisms are involved in 
predisposition and tumour progression. 
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6.1.2 Constitutional translocations in other cancers 
Constitutional translocations have been documented in leukaemia (465–468). Recently an overlap 
between blood-derived cancers and RCC was described with a report of an individual with both RCC 
and Hodgkin lymphoma concomitantly, in which germline testing identified a constitutional 
t(6;11)(p21;q12) translocation (469), though the clinical significance is difficult to interpret. 
Furthermore, translocations have also been linked with a predisposition to Wilm’s tumours (470–
472) and though translocations are not common in Wilm’s tumours, evidence for a non-stochastic 
mechanism of tumourigenesis via constitutional translocations seems to be present for these cases, 
implicating genes such as HACE1 and BBS9 as a susceptibility genes in Wilm’s tumour development 
(470,472). Many additional studies have shown idiosyncratic presentations of constitutional 
translocations in cases of oncogenesis, including but not limited to, testicular cancer (473), teratomas 
(474), thymomas (475), appendiceal carcinomas (476), rhabdomyosarcomas (477), meningiomas 
(478), retinoblastomas (479), and neuroblastomas (480–482). 
6.1.3 Methods for translocation characterisation 
Classically, translocations have been identified and characterised by performing an admixture of 
techniques (including array painting, comparative genomic hybridisation arrays, flow cytogenetic 
sorting, Fluorescent in-situ hybridisation, and YAC/BAC hybridisation), allowing for a steady increase 
in genomic resolution to a juncture at which break points can be accurately mapped. These 
techniques, whilst reliable, are laborious and have limited utility for further applications outside of 
break point mapping.  
Comparatively, newer techniques utilising next-generation sequencing at whole genome scale have 
been used to identify and characterise constitutional translocations, utilising the increased genomic 
coverage, paired read discordance, and local reassembly to characterise break points (470,483) but 
have been widely underutilised. The significant drawback of these methods is the financial burden 
of parallel sequencing, but further utility is provided in WGS approaches to allow for a greater breadth 
and depth for data interrogation (e.g. single nucleotide variant, structural variation, and copy-number 
aberrations). Clinical diagnostics may well benefit from a personalised but holistic approach to 
genomic analysis by providing a greater volume of genetic information with which to interpret 
disease, including but not limited to detection and analysis of structural rearrangements. 
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6.1.4 Summary 
As discussed above and previously (Introduction section 1.4.10), constitutional translocations have 
previously been associated with a predisposition to RCC having been identified in numerous families 
and individuals harbouring translocations, most frequently chromosome 3 and other chromosome 
partners. Though rare, these translocations have implications for understanding the molecular 
mechanisms of RCC through characterisation of the chromosomal breakpoints, affected genomic 
loci, and subsequent observations in RCC tumours. In this chapter, a review of all known RCC-
associated translocation cases to-date is performed, assessing the clinical and genetic features 
across these cases and characterise the breakpoints and molecular genetics of novel RCC-
associated translocation cases. Lastly, the use of WGS and new bioinformatics approaches is 
explored as a methodology for a robust and efficient method of breakpoint characterisation without 
using techniques used previously in translocation characterisation studies. 
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6.1.5 Aims 
 Determine the clinical, genetic, and molecular features and characteristics of known RCC-
associated translocation cases 
 Perform molecular and clinical characterisation of 5 novel RCC-associated translocation 
cases 
 Assess the viability of WGS-based and 3rd generation NGS methods for translocation 
breakpoint characterisation 
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6.2 Materials and methods 
6.2.1 Literature review 
Reports of cases of RCC with a constitutional chromosome rearrangement were identified through 
a search of PubMed using the search terms “renal cell carcinoma” or “renal cancer” or “kidney 
cancer/tumour” and “rearrangement/inversion/translocation or chromosome” and by searching 
previously published reports. When previous reports had suggested candidate genes that were 
either close to or disrupted by the relevant chromosomal breakpoints, evidence to suggest that the 
genes were implicated in human cancer was sought by reviewing curated data from the Network of 
Cancer Genes data portal (NCG; http://ncg.kcl.ac.uk/ version 6) (428). Where genes were classified 
as either ‘known cancer genes’, ‘candidate cancer genes’, or ‘non-cancer genes’. Genes flagged as 
‘false positive cancer genes’ were designated as ‘non-cancer genes’. 
6.2.2 Clinical studies  
Individuals presenting with RCC and with constitutional rearrangements were ascertained through 
Regional Clinical Genetics Units in the United Kingdom. 
6.2.3 Sequence alignment and variant calling 
DNA from four probands was sequenced at Novogene as described in materials and methods 
section 2.6.4. WGS bioinformatics was performed as described in materials and methods section 
2.7.  
DNA from one proband underwent WGS as part of the NIHR BioResource Rare Diseases study with 
sequencing and primary bioinformatics performed as previously described in Whitworth et al (2018) 
(376). Data in this instance had been aligned to genome build GRCh37 and all subsequent analysis 
was performed identically with appropriate adjustments for differences in genome build. All genomic 
coordinates are reported in GRCh38 and GRCh37 coordinates were remapped using the NCBI 
remap tool (https://www.ncbi.nlm.nih.gov/genome/tools/remap). Called SNVs were processed and 
filtered for various quality control metrics and allelic frequency as described in materials and methods 
section 2.8. 
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6.2.4 WGS Analysis: Candidate gene analysis and Breakpoint identification 
The WGS results were analysed for evidence for rare, potentially pathogenic, SNVs and copy 
number abnormalities in previously reported inherited RCC genes (VHL, MET, FH, SDHB, SDHD, 
SDHC, BAP1, CDKN2B) (98,484). Copy number detection was performed using Canvas Copy 
Number Variant Caller (version 1.39.0.1598) (485), copy number variants were filtered to include 
calls only marked as “PASS” (See appendix section 9.51). Structural rearrangements and 
breakpoints were identified using Manta Structural Variant Caller (version 1.3.1) (486). Manta 
structural variants were filtered to include only calls marked as “PASS”, number of supporting 
spanning/split reads > 5, QUAL > 100, and call frequency (See appendix section 9.5.1. Breakpoints 
called on chromosomes matching cytogenetic reports were visually inspected using Integrative 
Genomics Viewer (IGV - version 2.3.93) to confirm the presence of split and spanning reads (See 
appendix section 9.5.2). 
6.2.5 Nanopore sequencing of translocation breakpoints 
Long read sequencing of translocation breakpoint PCR amplicons was performed as described in 
the materials and methods section 2.9. 
6.2.6 Sanger sequencing 
Sanger sequencing was performed as described in materials and methods section 2.4 using 
breakpoint spanning primer pairs (Appendix section 9.5.3). Primer pairs were constructed for each 
chromosomal breakpoint to span the break point region by inversing the primer pairing (i.e. ChrA-
forward → ChrB-reverse & ChrB-forward → ChrA-reverse), in this instance only PCR products 
specific to the translocation break point should be amplified. Sanger traces are provided in appendix 
section 9.5.3. 
6.2.7 Statistical tests 
All statistical tests were performed using R project for statistical computing (version 3.5). Welch’s t-
test was performed using the package BSDA (version 1.2.0) with the function tsum.test(). Kruskal–
Wallis rank sum test was performed using the base R function kruskal.test(). Fisher’s exact test was 
performed using the base R function fisher.test(). Statistical testing was undertaken on data from 
confirmed translocation carriers only. 
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6.3 Results 
6.3.1 Literature review of previously reported cases 
A total of 17 previously published distinct constitutional chromosome rearrangements were identified 
from searches of the biomedical literature (see 6.3 Table 1) (260,459,495–499,487–494). In 15 
cases (88%) chromosome 3 was involved (all of which were reciprocal translocations) and there 
were a variety of partner chromosomes in the 15 translocation cases (e.g. 3 with chromosome 6, 3 
with chromosome 8 – see 6.3 Table 1 and 6.3 Figure 1). For the RCC-associated chromosome 3 
translocation cases, the breakpoints were almost evenly distributed between the long arm (3q), n=8) 
and short arm (3p; n=7) and were heterogeneous (see 6.3 Figure 2).  
Review of the clinical and pathological data in the previously reported cases demonstrated 9 
kindreds with at least 2 related individuals with RCC. In the 4 cases without a family history and 
available clinical information, multiple RCC was described in 2 individuals. The mean age at 
diagnosis of a renal tumour in those cases known to carry a constitutional chromosomal 
rearrangement was 50 years (range 25-82 years). Histopathological details were available for 43 
cases and clear cell RCC was reported in 42 cases (98%). 
Previous studies have demonstrated that cases of sporadic and familial RCC differ by mean age of 
diagnosis, with RCC presenting earlier in familial cases (30,129). Comparison of the mean age of 
diagnosis of RCC in translocation cases to familial and sporadic RCC cases (as reported previously 
by Maher et al. (30)) were 50.2 (SD=12.7), 48.2 (SD=12.3), and 61.8 (SD=10.8) years of age, 
respectively. Translocation cases have a statistically lower age of diagnosis than those with sporadic 
disease (Welch's t-test, p=9.84x10-7) but no significant difference between translocation and familial 
cases was observed (Welch's t-test, p=0.522). Though age of diagnosis across all affected 
translocation carriers is variable there was no significant difference in age when comparing between 
familial (with 2 or more related individuals) translocation families (Kruskal–Wallis test, p=0.174). 
 219 
 
6.3 Table 1 
Clinical features of RCC in individuals from families with a constitutional chromosome rearrangement. 
Individuals marked (*) were presumed to be carriers of the relevant rearrangement but were not tested.  
Publication(s) Cytology Histology 
Type 
(foci = n) 
Sex Age 
Cohen et al. 
[1979] 
t(3;8)(pl4.2;q24.1) 
clear cell 
RCC 
Bilateral 
(n=2) 
M 37 
  clear cell 
RCC 
Bilateral 
(n=3) 
M 45 
  clear cell 
RCC 
Unilateral 
(n>2) 
M 59 
  clear cell 
RCC 
Unilateral 
(n=3) 
F 46 
  clear cell 
RCC 
Unilateral 
(n=1) 
M 44 
  clear cell 
RCC 
Unilateral 
(n=1) 
F 50 
  clear cell 
RCC 
Bilateral 
(n>3) 
F 41 
  clear cell 
RCC * 
Bilateral 
(n>2) 
M 47 
  clear cell 
RCC * 
Bilateral 
(n=9) 
F 44 
    RCC 
Bilateral 
(n=7) 
F 39 
Kovacs & 
Hoene [1988] 
t(3;12)(q13.2;q24.1) 
clear cell 
RCC 
Unilateral 
(n=1) 
M 50 
Kovacs et al 
[1989] 
t(3;6)(p13;q25.1) 
clear cell 
RCC 
Bilateral 
(n = 5) 
M 53 
Koolen et al. 
[1998] 
t(2;3)(q35;q21) 
clear cell 
RCC 
Bilateral 
(n=3) 
M 54 
  RCC N/a F 53 
  clear cell 
RCC 
Unilateral 
(n=3) 
F 68 
  clear cell 
RCC 
Unilateral 
(n=1) 
M 40 
    
clear cell 
RCC 
Bilateral 
(n=2) 
M 30 
Van Kessel et 
al. [1999] 
t(3;4)(p13;p16) 
clear cell 
RCC 
N/a M 52 
Eleveld et al 
[2001] 
t(3;6)(q11.2;6q13) 
clear cell 
RCC 
Unilateral F 59 
  clear cell 
RCC 
Unilateral F 41 
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  clear cell 
RCC 
Unilateral F 63 
    
clear cell 
RCC 
Unilateral M 67 
Kanayama et al. 
[2001] 
t(1;3)(q32;q13.3) 
clear cell 
RCC 
Unilateral 
(n=1) 
F 79 
  clear cell 
RCC 
Bilateral 
(n=4) 
M 56 
  clear cell 
RCC * 
Unilateral 
(n=1) 
M 70 
    
clear cell 
RCC 
Unilateral 
(n=1) 
M 62 
Podolski et al 
[2001] 
t(2;3)(q33;q21) 
clear cell 
RCC 
N/a M 45 
  clear cell 
RCC 
N/a M 38 
  clear cell 
RCC * 
N/a M 51 
  clear cell 
RCC * 
N/a F 51 
  clear cell 
RCC * 
N/a F 51 
  clear cell 
RCC * 
Bilateral M 51 
    
clear cell 
RCC * 
N/a F 63 
Meléndez et al. 
[2003] 
t(3;8)(p14.1;q24.23) 
clear cell 
RCC 
Bilateral 
(n = 2) 
M 46 
  clear cell 
RCC 
Bilateral 
(n = N/a) 
F 56 
  clear cell 
RCC * 
N/a M 68 
  clear cell 
RCC 
Bilateral 
(n = N/a) 
M 25 
  clear cell 
RCC 
Bilateral 
(n = N/a) 
M 66 
  clear cell 
RCC 
Bilateral 
(n = N/a) 
M 82 
  clear cell 
RCC 
Bilateral 
(n = N/a) 
M 44 
  clear cell 
RCC 
Bilateral 
(n = N/a) 
F 39 
    
clear cell 
RCC 
Unilateral 
(n = N/a) 
F 44 
Bonne et al 
[2007] 
t(3;15)(p11;q21) 
clear cell 
RCC 
N/a F 49 
  ins(3;13)(p24.2;q32q21.2) 
clear cell 
RCC 
N/a N/a 74 
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Foster et al. 
[2007] 
t(3;6)(q22;q16.2) 
clear cell 
RCC 
papillary RCC 
Bilateral 
(n=3) 
M 49 
Poland et al. 
[2007] 
t(3;8)(p14;q24.1) 
clear cell 
RCC 
Bilateral 
(n = N/a) 
F 47 
    
clear cell 
RCC 
Bilateral 
(n = N/a) 
M 39 
Kuiper et al. 
[2009] 
t(3;4)(q21;q31) 
clear cell 
RCC 
N/a N/a 45 
McKay et al 
[2010] 
t(2;3)(q36.3;q13.2) 
clear cell 
RCC 
Bilateral 
(n = 8) 
M 54 
  clear cell 
RCC 
N/a M 50 
    
clear cell 
RCC 
Unilateral 
(n > 1) 
F 35 
Doyen et al 
[2012] 
t(11;22)(q23-24;q11.2-12) 
clear cell 
RCC 
Unilateral 
(n = 1) 
M 72 
Wake et al. 
[2013] 
t(5;19)(p15.3;q12) 
oncocytoma 
chromophobe 
RCC 
Unilateral 
(n = 2) 
F 35 
    
clear cell 
RCC 
chromophobe 
RCC 
oncocytoma 
Bilateral 
(n > 2) 
F 36 
   6.
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The chromosomal rearrangement breakpoints had been mapped in 15 of 17 previously reported 
cases and a total of 10 candidate genes had been reported to be disrupted by the relevant 
rearrangement breakpoints (6.3 Table 2). Additionally, 21 genes found to be in the vicinity of 
translocation breakpoints and cited as relevant genes by the authors of the original report were also 
assessed (6.3 Table 3). The evidence for implicating the various genes in RCC predisposition was 
assessed using NCG data portal (6.3 Table 2 & 3).  
Of the 10 genes directly disrupted by translocation breakpoints, 20% (2/10) are classified as known 
cancer genes (of a total of 2372 curated cancer genes), with all remaining genes having no evidence 
supporting their role in cancer. Regarding genes stated to be in the vicinity of translocation 
breakpoint, 2 were designated as known cancer genes and 4 were classified as candidate cancer 
genes. 
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6.3 Table 2 
Reassessment of genes disrupted by translocation breakpoints in RCC-associated translocations 
reported previously. Genes were categorised according to their current status in NCG v6.0 (428) 
Original publication Affected genes Position (GRCh38) Known cancer gene 
(NCG 6.0) 
Cohen et al. [1979] FHIT chr3:59747587-61251459 Known cancer gene 
Cohen et al. [1979] RNF139 (TRC8) chr8:124474738-124488618 Non-cancer gene 
Kovacs et al [1989] STXBP5 chr6:147204358-147390476 Non-cancer gene 
Koolen et al. [1998] SLC49A4 (DIRC2) chr3:122794795-122881139 Non-cancer gene 
van Kessel et al. [1999] KCNIP4 chr4:20728606-21948801 Non-cancer gene 
Kanayama et al. [2001] LSAMP chr3:115802363-117139389 Non-cancer gene 
Kanayama et al. [2001] RASSF5 (NORE1) chr1:206507530-206589448 Non-cancer gene 
Podolski et al [2001] DIRC1 chr2:188733738-188839420 Non-cancer gene 
Kuiper et al. [2009] FBXW7 chr4:152320544-152536095 Known cancer gene 
Wake et al. [2013] UBE2QL1 chr5:6437347-6496721 Non-cancer gene 
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6.3 Table 3 
Reassessment of genes highlighted as being close to translocation breakpoints in RCC-associated 
translocations reported previously. Genes were categorised according to their current status in 
NCG v6.0 (428) 
Original publication Affected genes Position (GRCh38) Known cancer gene 
(NCG 6.0) 
Meléndez et al 2003 LRIG1 chr3:66378797-66501263 Candidate cancer gene 
Wake et al 2013 CCNE1 chr19:29811898-29824312 Known cancer gene 
Kuiper et al 2009 C3orf56 chr3:127193131-127198185 Non-cancer gene 
Foster et al 2007 PPP2R3A chr3:135965673-136147891 Non-cancer gene 
Foster et al 2007 PCCB chr3:136250306-136337896 Non-cancer gene 
Foster et al 2007 STAG1 chr3:136336233-136752403 Known cancer gene 
Foster et al 2007 MSL2 (RNF184) chr3:136148922-136197241 Non-cancer gene 
Foster et al 2007 EPHB1 chr3:134597801-135260467 Non-cancer gene 
Foster et al 2007 EPHA7 chr6:93240020-93419547 Non-cancer gene 
Podolski et al 2001 HIBCH chr2:190189735-190344193 Non-cancer gene 
Podolski et al 2001 INPP1 chr2:190343470-190371665 Non-cancer gene 
Podolski et al 2001 HNRNPC (HNRPC) chr14:21209136-21269494 Non-cancer gene 
Koolen et 1998 HSPBAP1 chr3:122740003-122793824 Non-cancer gene 
Koolen et 1998 SEMA5B chr3:122909082-123028605 Candidate cancer gene 
Yusenko et al 2010 PDZRN3 chr3:73382433-73624940 Candidate cancer gene 
Yusenko et al 2010 CNTN3 chr3:74262568-74521140 Non-cancer gene 
Yusenko et al 2010 NECTIN3 (PVRL3) chr3:111070071-111275563 Non-cancer gene 
Yusenko et al 2010 HSPB8 chr12:119178642-119221131 Candidate cancer gene 
Yusenko et al 2010 CCDC60 chr12:119334712-119541047 Non-cancer gene 
Cohen et al 1979 TRMT12 chr8:124450820-124462150 Non-cancer gene 
Cohen et al 1979 TATDN1 chr8:124488485-124539458 Non-cancer gene 
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6.3.2 Clinical features of previously unreported cases 
Five previously unreported constitutional chromosomal rearrangements ascertained through a 
patient presenting with RCC were identified through UK genetics services. The cytogenetic, clinical 
features and pathological features of the five probands and (when relevant) their affected relatives 
are described in 6.3 Table 4. There were 4 translocations (involving chromosome 3 in two cases) 
and a pericentric inversion of chromosome 3 (see 6.3 Table 4 and 6.3 Figure 1). Two or more 
individuals developed RCC in 3 kindreds: 
In the kindred with the t(3;14)(q13.3;q22) 5 individuals developed RCC (four of whom were confirmed 
or obligate translocation carriers). The proband presented with bilateral RCC at age 75 years, his 
daughter (an obligate carrier) died from RCC at age 36 years, his mother and two of his brothers 
were reported to have developed RCC at ages 51, 41 and 79 years respectively. The proband’s 
mother and brother with RCC at ages 51 and 79 years were also obligate t(3;14)(q13.3;q22) carriers 
and the son of the latter developed RCC at age 67 years and was confirmed to have inherited the 
t(3;14)(q13.3;q22).  
In the kindred with the t(3;6)(p14.2;p12) rearrangement, the proband presented with RCC at age 72 
years and four relatives were demonstrated to also harbour the translocation. Three had not 
developed RCC (age at last follow up 47-52 years) but one (the proband’s brother) had developed 
bilateral clear cell RCC age 55 years with unilateral recurrent disease and an adrenal metastasis 
age 74 years and his son died from RCC at age 40 years without any record of his status for the 
t(3;6)(p14.2;p12).  
The index case carrying the inv(3)(p21.1q12) was unaffected but was ascertained following a report 
that her cousin had developed clear cell RCC at age 39 and harboured the chromosome 3 inversion. 
Other carriers of the inversion in the family who were reported to carry the inversion, but were 
unaffected, included her paternal aunt and father, whilst her grandfather was also a carrier and died 
of carcinomatosis at age 80 years. The proband’s brother was diagnosed with RCC at age 48 but 
was not tested for the inversion. 
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The t(2q21.1; 17q11.2) was identified in a 37 year old man with a poorly differentiated clear cell RCC 
who died from metastatic disease shortly thereafter. The translocation was maternally inherited and 
was detected in three unaffected family members (mother and two siblings) aged between 30 and 
58 years of age.  
In the kindred with the t(10;17)(q11.21;p11.2) the proband and their sibling were found to have 
features of suggestive Birt-Hogg-Dubé syndrome (BHD; OMIM: 135150) (pneumothoraces, and 
fibrofolliculomas in the proband and multiple pulmonary cysts and fibrofolliculomas in his sister) after 
the diagnosis of RCC in the proband and the detection of the translocation. 
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6.3 Table 4  
Clinical details of families harbouring RCC-related translocations cases in this series 
Patient Carrier Sex Age 
RCC 
histology 
Sanger Break points Additional notes 
t(2;17)(q21;q11.2) Yes M 37 Clear cell RCC Yes 
chr2:130693727 
chr17:28031855 
 
t(2;17)(q21;q11.2) 
Grandfather 
Unknow
n 
M ? RCC  N/a  
t(3;6)(p14.2;p12) Yes M 72 N/a Yes 
chr3:66680663 
chr6:54817716 
 
t(3;6)(p14.2;p12) 
Relative 1 
Yes N/a 55 Clear cell RCC No N/a 
Recurrent RCC 
Adrenal metastasis 
t(3;6)(p14.2;p12) 
Relative 2 
Yes N/a ? RCC  N/a  
inv(3)(p21.1q12) Yes F N/a Unaffected No N/a  
inv(3)(p21.1q12) 
Cousin 
Yes N/a 39 Clear cell RCC  N/a  
inv(3)(p21.1q12) 
Brother 
Unknow
n 
M 48 RCC   N/a   
t(3;14)(q13.3;q22) Yes M 75 Clear cell RCC Yes 
chr3:125771297 
chr14:59009871 
Bladder carcinoma 
t(3;14)(q13.3;q22) 
Nephew 
Yes M 67 RCC Yes 
chr3:125771297 
chr14:59009871 
 
t(3;14)(q13.3;q22) 
Brother-obligate 
Obligate M 41 Clear cell RCC  No N/a  
t(3;14)(q13.3;q22) 
Daughter 
Obligate F 36 RCC No N/a  
t(3;14)(q13.3;q22) 
Brother 
Obligate M 79 RCC No N/a  
CAMB-AL-
GM13.12941 Mother 
Obligate F 51 RCC No N/a  
t(10;17)(q11.21;p11.2) Yes M 53 Clear cell RCC Yes N/a 
Fibrofolliculomas 
Pneumothoraces 
t(10;17)(q11.21;p11.2) 
Relative 
Yes F N/a Unaffected  N/a 
Fibrofolliculomas 
Lung cysts 
Renal cysts 
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6.3.3 Whole genome sequencing and bioinformatics 
Sequencing metrics were assessed to confirm data reliability and suitability for downstream SNV, 
SV, and CNV analysis. Mean sequence alignment rates across all samples was 99.7%, indicating a 
high-quality sequence mapping. WGS coverage analysis demonstrated a mean coverage of 28.9X 
across all genomes, though the genome analysed as part of NIHR Rare diseases bioresource study 
had mean coverage of 35X due to a different sequencing methodology. For variant calling, the 
transition / transversion ratio (Ts/Tv) after minimal genotype filtering (depth > 10 and QUAL > 30) 
was reported as 1.93, suggesting no variant calling bias across the genome. 
6.3.4 Characterisation of constitutional rearrangements in previously unreported cases 
WGS did not identify any plausible likely pathogenic or pathogenic SNVs or CNVs variants in 
previously reported inherited RCC genes (VHL, SDHB, SDHC, SDHD, MET, FLCN, TSC1, TSC2, 
FH, PTEN, PBRM1, BAP1, or CDKN2B) in the four probands who were affected by RCC. A novel 
missense variant of uncertain significance by ACMG criteria (325) was identified in PBRM1 
(NM_018313.4:c.2446A>T p.Asn816Tyr) in the t(3;6)(p14.2;p12) translocation case. DNA from an 
affected individual was not available for sequencing in the family carrying the inv(3)(p21.1q12) 
inversion, as such sequencing was performed solely to identify candidate breakpoints. Candidate 
rearrangement breakpoints were identified from the WGS data by the Manta structural variation 
detection algorithm in all five cases: 
Breakpoints for translocation t(3;14)(q13.3;q22) were resolved to be present at the loci 
chr3:125771297 and chr14:59009871. The candidate breakpoints were supported by 7 and 9 
spanning and split reads, respectively (Appendix section 9.5.4). The candidate breakpoint locations 
identified by WGS differed from those suggested previously by cytogenetic studies: the 3q breakpoint 
at chr3:125771297 is within cytoband 3q21 and the WGS-identified 14q breakpoint at 
chr14:59009871 maps to 14q23.1. Sanger sequencing confirmed the presence of the translocation 
breakpoints. Sanger sequencing in a DNA sample from his affected nephew confirmed identical 
breakpoints to the proband. The 3q breakpoint intersects with LOC105374312, an uncharacterised 
non-coding RNA gene and the 14q breakpoint disrupts the last intron of LINC01500, a long intergenic 
non-coding RNA gene, and is predicted to result in a truncated transcript lacking the final exon.  
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WGS in the second chromosome 3 associated translocation case t(3;6)(p14.2;p12) revealed 
candidate breakpoints at chr3:66680663 and chr6:54817716 within an AT-rich repetitive region. 
Breakpoint calls were supported by 4 and 7 spanning and split read calls, respectively (Appendix 
section 9.5.4). Sanger sequencing confirmed the presence of the translocation breakpoints. The 3p 
chromosomal breakpoint identified by WGS mapped within 3p14.1 and disrupted LOC105377142, 
an uncharacterised non-coding RNA. The 6p breakpoint did not disrupt a predicted gene but was 29 
kb upstream of FAM83B. 
The candidate breakpoints in the inv(3)(p21.1q12) were identified by Manta with 11 spanning and 
11 split reads supporting the presence of this inversion, though the number of reference spanning 
reads was only 2 (Appendix section 9.5.4). The two candidate breakpoints mapped to chr3:59964935 
at 3p14.2 (interrupting intron 7 of FHIT) and chr3:98667603 (3q12), 47 kb upstream of ST3GAL6-
AS1, a non-coding RNA gene. Though cytogenetics and Manta calls support the presence of the 
inv(3)(p21.1q12), Sanger sequencing under multiple experimental conditions failed to generate any 
PCR products and the candidate breakpoints could not be independently confirmed.  
WGS in the first of the two non-chromosome 3 translocations (t(2;17)(q21.1;q11.2)) localised the 
breakpoints to chr2:130693728 (2q21.1) and chr17:28030855 (17q11.2). The translocation 
breakpoint was supported by 9 spanning and 10 split reads as called by Manta (Appendix section 
9.5.4). Sanger sequencing confirmed the genomic coordinates and breakpoint as a single base 
translocation without local rearrangement, insertions, or deletions. The breakpoint present on 
chromosome 2 disrupted the coding region of two overlapping pseudogenes KLF2P3 and FAR2P3, 
as well as interrupting a CpG island spanning chr2:130693485-130693839. The nearest coding 
genes were POTEJ, AMER3, and GPR148 which were 35 kb upstream, 34 kb downstream and 62 
kb downstream, respectively. The junction on chromosome 17 did not disrupt any known coding 
region but was 1.7 kb upstream of a reported H3K27Ac element covering chr17:28,033,593-
28,035,092, and 9.9 kb upstream of the NLK gene. 
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The second non-chromosome 3 translocation t(10;17)(q11.22;p12) underwent sequencing as part 
of the NIHR BioResource Rare Diseases BRIDGE project (see methods 6.2) and was analysed 
previously as part of a multiple primary tumour cohort (34) with a history facial fibrofolliculomas, 
recurrent pneumothoraces and RCC. At that time no abnormality was detected but subsequently 
reanalysis identified candidate translocation breakpoints that were supported by two overlapping 
Manta calls for the chromosome 10 and chromosome 17 breakpoints at chr17:17218211-17218214 
(17p11.2) and chr10:43236047-43236050 (10q11.21) that were supported by 22 spanning and 10 
split reads and a secondary call at chr17:17218216-17218217 and chr10:43236058-43236059 by 
15 spanning and 18 split reads (Appendix section 9.5.4). Given the proximity of the assigned 
breakpoint regions, a single translocation was presumed with an additional nested structural 
variation resulting in divided calling. Sanger sequencing confirmed the presence of the translocation 
breakpoint in the proband. The chromosome 17 breakpoint prediction disrupted the coding region of 
FLCN, falling within intron 9 (ENST00000285071). The chromosome 10 breakpoint disrupted the 
first intron of RASGEF1A (the first exon encodes 5’ untranslated region only proximal to the 
translation initiation site (ENST00000395810). Sanger sequencing of DNA from the proband’s sibling 
(who was known to carry the t(10;17)(q11.22;p12)) confirmed that translocation breakpoint and that 
she had evidence of BHD syndrome (multiple lung and renal cysts and facial fibrofolliculomas). 
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6.3.5 Characterisation of translocation breakpoints utilising Nanopore sequencing 
While Sanger sequencing of translocation breakpoints can effectively confirm the presence or 
absence of a breakpoint, and in some instances provide characterisation of breakpoints, many 
translocation break points are complex or involve additional genomic alterations such as deletions 
and insertions of additional bases, particularly in repetitive regions. Herein demonstrates the utility 
of Nanopore sequencing for the base-level characterisation of one of the newly reported 
translocation cases, t(3;14)(q13.3;q22), which contained an ambiguous region at the break site by 
multiple sequence alignment of breakpoint-spanning PCR products due to increased sequencing 
read sizes. 
Assessment of Nanopore sequencing metrics determined the sequencing run generated 46,431 
reads across the translocation breakpoint with a median read length of 815 bp from 474 of 512 active 
sequencing channels from breakpoint-spanning PCR products. Mean read qualities were most 
frequent at 8-12, suggesting high quality sequencing was generated (6.3 Figure 3). Nanopore 
sequencing was aligned to GRCh38 and generated 75,096 mapped reads. Discrepancy between 
number of sequenced reads and the number of mapped reads is due to the presence of 
supplementary read alignments, which are defined as reads with two distinct but split mapping 
positions, as would be expected from a translocation breakpoint. Of those reads 71,927 (95.8%) 
reads intersected the translocation breakpoints (chr3:125771297 and chr14:59009871) determined 
by Manta.  
Read alignments were visualised using IGV (6.3 Figure 4) which demonstrated the translocation 
breakpoint succinctly, showing aligned reads split evenly between chromosome 3 and 14. 
Comparisons between Nanopore alignments and Sanger sequencing alignments allowed for the 
resolution of a 5 bp deletion on chromosome 14 (5’-ATGTGTGG) at the breakpoint site whereas 
chromosome 3 did not appear to have any additional structural rearrangements. 
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6.3 Figure 3 
Quality metrics from Nanopore sequencing metrics for the t(3;14)(q13.3;q22) translocation 
PCR amplicon. 3A Histogram plot binning the mean read quality for all generated Nanopore 
sequencing reads. 3B Plot shows the cumulative number of Kb of sequencing generated over time 
during Nanopore sequencing until the run was stopped. 3C Histogram plot shows the binning of read 
lengths generated by Nanopore sequencing, most reads match the size of the PCR breakpoint 
amplicon. 3D A channel map of the Nanopore sequencing channels depicting the number of Kb 
generated by each pore/channel. All sequencing metrics shown here are suggestive of high-quality 
sequencing data.
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6.3.6 Computational evaluation of breakpoint-related genes  
The five constitutional rearrangements were confirmed or postulated to disrupt three protein coding 
genes (FHIT, FLCN and RASGEF1A) and to map within 50 kb of four more genes (FAM83B, POTEJ, 
AMER3, NLK). Two of these genes, FHIT and FLCN have been previously implicated as renal 
tumour suppressor genes (191,195) and potential evidence for a role of RASGEF1A, FAM83B, 
POTEJ, AMER3 and NLK in hereditary cancer predisposition and/or somatic tumourigenesis was 
sought from the NCG data portal (6.3 Table 5). On the NCG data portal both FHIT and FLCN were 
classified as “known cancer genes”, RASGEF1A as a “candidate cancer gene” and the other genes 
were categorised as “non-cancer genes”. 
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6.3 Table 5 
Assessment of genes disrupted by (*) or close to breakpoints in RCC-associated rearrangement 
reported in the current series. Genes were categorised according to their current status in NCG 
v6.0 (428) 
Affected genes Position (GRCh38) Consensus (NCG 6.0) 
FHIT * chr3:59747587-61251459 Known cancer gene 
FLCN * chr17:17206924-17237188 Known cancer gene 
FAM83B chr6:54846643-54945099 Non-cancer gene 
POTEJ chr2:130611413-130658448 Non-cancer gene 
AMER3 chr2:130755435-130768134 Non-cancer gene 
NLK chr17:28041737-28205140 Non-cancer gene 
RASGEF1A * chr10:43194533-43266919 Candidate cancer gene 
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6.4 Discussion 
This study reports five previously unreported RCC-associated constitutional chromosomal 
rearrangements that increase the total number of rearrangements reported to 22 and the number of 
cases in which the breakpoints have been characterised to 20. WGS enabled both the identification 
of candidate translocation breakpoints and simultaneously excluded coincidental pathogenic SNVs 
and CNVs in known hereditary cancer genes. With the increasing availability and reducing cost of 
WGS it will become increasingly feasible to characterise the molecular pathology of RCC-associated 
constitutional chromosomal rearrangements. This will improve our understanding of the relevance 
to individual RCC-associated constitutional chromosomal rearrangements to the RCC 
tumourigenesis and we found that the breakpoint location reported on routine cytogenetic analysis 
often did not correspond to the breakpoint locations identified by WGS. 
The majority (21/22, 95.5%) of RCC-associated constitutional chromosomal rearrangements 
reported to date have been associated with the clear cell variant of RCC. This is the most common 
histological subtype of sporadic RCC (75-80%) and is characterised by somatic inactivation of VHL 
and deletions of chromosome 3p (25,128,460,500). The mean age at diagnosis of RCC in the cases 
reported to date (51 years, range 25-82, n=57, SD=13.25) is younger than the average age for 
sporadic RCC (61.8 years) (30). Whilst this is a feature of other forms of hereditary RCC (and many 
other inherited cancer types) there may also be an element of ascertainment bias with early onset 
cases more likely to be investigated for a genetic cause. Given the loss of the derivative 
chromosomes is reported as the potential initiator of tumourigenesis in chromosome 3 
translocations, the loss of der(3) in the t(3;14) translocation would also result in the loss of 14q which 
would include the HIF1A coding region, a candidate 14q TSG (501). 
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In both this series and the previously published literature series, most RCC-associated constitutional 
chromosome rearrangements involved chromosome 3. Whilst this is consistent with the high 
frequency of 3p allele loss in sporadic clear cell RCC, the fundamental role of somatic inactivation 
of the VHL TSG in clear cell RCC and the incidence of somatic mutations of PBRM1, BAP1 and 
SETD2 in RCC, to date most RCC-associated constitutional chromosome 3 rearrangements do not 
appear to disrupt known RCC TSGs mapping to 3p. A potential explanation for this is the observation 
that RCC from individuals with a constitutional chromosome 3 translocation can show a somatic VHL 
mutation on the wild-type chromosome 3 and loss of the derivative chromosome containing 3p 
(resulting in biallelic inactivation of the VHL TSG). 
This mechanism of tumourigenesis would imply that the susceptibility to RCC might have resulted 
from instability of the translocated chromosome rather than disruption of a specific RCC TSG at the 
translocation breakpoint on chromosome 3 (261) and would be consistent with the variability of the 
RCC-associated chromosome 3 rearrangement breakpoints described to date (6.3 Table 1). 
However, it is interesting that the chromosome 3 inversion described it was associated with a 
breakpoint within the FHIT gene. Previously it was demonstrated in two apparently unrelated families 
with a RCC-associated t(3;8)(p14.2;q24.1) harboured breakpoints that disrupted FHIT and RNF139 
(TRC8) on 3p and 8q respectively (16,22). FHIT is listed as a Tier 1 known cancer gene in the Cancer 
Gene Census (https://cancer.sanger.ac.uk/cosmic/census) however the presence of a somatic VHL 
mutation and loss of the translocated chromosome 3 in a previous t(3;8)(p14.2;q24.1)-associated 
RCC was unexpected (259,492) indicating multiple routes of pathogenicity for RCC-associated 
translocations. 
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It is possible that the recurrent involvement of FHIT in RCC-associated chromosome 3 
rearrangements reflects the presence of palindromic AT-rich repeats at the t(3;8)(p14.2;q24.1) 
breakpoint and causes a propensity to recurrent rearrangements at this locus (502), but note that 
only a fraction of chromosome 3 translocations are associated with predisposition to RCC (503). It 
is therefore conceivable that both instability of the translocated chromosome and mono-allelic 
inactivation of FHIT contribute to RCC susceptibility. Other genes that have been previously reported 
to be located at or close to the breakpoints of RCC-associated chromosome 3 rearrangements (see 
6.3 Table 2, 3 and 5) were reviewed to determine which were included in recently compiled lists of 
known cancer genes which are based on the results of recent large scale cancer genomics projects 
and 8 genes (FHIT, LRIG1, FBXW7, CCNE1, STAG1, SEMA5B, PDZRN3, HSPB8) were identified 
as known or candidate cancer genes. In addition, genes that were disrupted (FHIT, FLCN, 
RASGEF1A) or close to (FAN83B, POTEJ, AMER3, NLK) the breakpoints of the novel RCC-
associated translocations reported here were also assessed and the three genes that were disrupted 
were classified as known (FLCN and FHIT) or candidate cancer genes (RASGEF1A) (6.3 Table 5). 
Relatively few RCC-associated constitutional translocations not involving chromosome 3 have been 
reported. In addition to the two novel cases reported here, there are two previously reported cases 
(498,499) and the translocation breakpoints were characterised in only one of these cases. It is 
entirely possible that non-chromosome 3 constitutional translocations and RCC may occur 
coincidentally and, though there was an early age at onset (37 years) in the proband with t(2q21.1; 
17q11.2) and an unconfirmed family history of RCC in his paternal grandfather, the translocation 
was also found in his mother and two siblings who were unaffected at ages 58, 40 and 31 years. 
However, identification of a translocation breakpoint that disrupted the FLCN gene in a patient with 
a t(10;17)(q11.22;p12) illustrated the value of characterising all RCC-associated constitutional 
rearrangements. Inactivating mutations in FLCN cause BHD syndrome which is characterised by 
facial fibrofolliculomas, pulmonary cysts and pneumothorax and RCC (191,504). The occurrence of 
fibrofolliculomas is age-dependent and pneumothorax occur in minority of cases and so BHD may 
present with RCC without other features being present (265), although rarely. However in the family 
reported here the t(10;17)(q11.22;p12) was associated with other evidence of BHD syndrome. To 
my knowledge this is the first description of a constitutional translocation causing BHD syndrome.  
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The other novel translocation case did not disrupt a known cancer gene but occurred close to Nemo-
Like Kinase (NLK) a serine/threonine-protein kinase that has been associated with the non-canonical 
WNT and MAPK signalling pathways. Whilst NLK is currently not designated as a known cancer 
gene, evidence of tumour suppressor activity has been reported (505–507) and a role for NLK protein 
in the stabilisation of p53 has been suggested (508). Interestingly, NLK appears to collaborate with 
FBXW7 in the ubiquitination of c-Myb by enhancing ligation of additional ubiquitin molecules via NLK 
phosphorylation, leading to downregulation of cellular proliferation (509) and previously a RCC-
associated constitutional translocation, t(3;4)(q21;q31), was demonstrated to interrupt FBXW7 (496). 
Furthermore, FBXW7 is a designated tumour suppressor gene that is mutated in multiple types of 
primary cancers (25) and encodes an F-box protein that is part of a SCF complex thought to target 
cyclin E and mTOR for ubiquitin-mediated degradation (510,511). Additionally, it was demonstrated 
FBXW7 interacts with Ubiquitin-conjugating enzyme E2Q-like protein 1 (UBE2QL1), the gene of 
which is known to be disrupted in another previously reported RCC translocation case (499), 
suggesting an interesting connection between multiple interacting gene products in translocation-
related RCC. 
While studies demonstrated complete loss of der(3p) in tumours tested (259,496,512–515), partial 
loss (489,516,517) or no loss of der(3p) in assessed tumours (493,495,518) has also been 
documented. Furthermore, studies including assessment for loss of heterozygosity or inactivating 
mutations in the remaining wildtype allele of VHL have also been conflicted with experimental data 
demonstrating presence in all samples (489,495,496,515), some samples (516,517), and no 
demonstrable loss (493,497,518). 
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The lack of known tumour suppressors, intergenic break points, and no relation to commonly lost 
regions in sporadic RCC cases suggests that other mechanisms are involved in predisposition and 
tumour progression. Translocations may confer a generalised genomic instability, in which specific 
loss of 3p is not required, and further inactivation of unknown genes are responsible for 
tumourigenesis. Alternatively, translocations may result in positional-effect variegation, resulting in 
differential expression patterns for coding regions under differential chromatin regulation (464). It is 
reasonable, given the atypical presentations and lack of familial history for non-chromosome 3 
cases, that pathways responsible for oncogenesis in these individuals are case-specific and no 
generalised model exists. Given the atypical presentations and lack of familial history for non-
chromosome 3 cases, that pathways responsible for oncogenesis in these individuals are case-
specific and no generalised model exists. 
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6.5 Conclusion 
In conclusion, this study reports five new cases of RCC-associated constitutional chromosome 
rearrangements characterised by WGS. These include the first example of a chromosome 3 
inversion associated with RCC, the first case of a major inherited RCC gene disrupted by a 
translocation and a third example of an RCC constitutional chromosome rearrangement that disrupts 
FHIT. Review of the five novel cases reported here and previously reported cases demonstrates that 
RCC-associated constitutional chromosome rearrangements: 1) mostly involve chromosome 3 but 
rearrangements that solely involve other chromosomes may also be causally linked to RCC, 2) may 
predispose to RCC by a variety of mechanisms including disruption of a tumour suppressor gene 
(e.g. FLCN) and/or chromosomal instability (as with chromosome 3 translocations), 3) can be 
efficiently characterised by WGS and 4) can identify candidate pathways for RCC tumourigenesis. 
For chromosome 3 translocations it is unclear why most cases that are not ascertained because of 
a personal or family history of RCC appear to be associated with a very low risk of RCC (493). In 
those translocations that do predispose to RCC there may be a combination of factors involved 
including instability of the translocated chromosome during cell division together with disruption of a 
TSG (e.g. FHIT) and/or polygenic effects that increase RCC susceptibility. 
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7.0 Discussion 
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The set of studies presented in this thesis have focused on the heritability of RCC and the proportion 
of undiscovered genetic inheritance which exists in families and individuals with features of 
predisposition (early onset, family history, or multifocal or bilateral presentation), but in which no 
genetic cause can be determined based on known RCC predisposition syndromes and genes. Each 
chapter has concentrated on specific genetic sequencing technique, successively increasing in 
scope and coverage; beginning with single gene and exon sequencing with Sanger sequencing and 
ending with whole genome sequencing and 3rd generation sequencing methods, exploiting the 
advantages of each method when used in the correct context. 
7.1 Results chapters: Consequences, associations, and limitations 
Chapter 3 utilised target Sanger sequencing and small scale amplicon-based WGS in order to 
identify putative pathogenic variants in genes frequently altered in somatic RCC, genes in genetically 
linked phenotypes, and replicate associations seen in more recent germline RCC studies (266). The 
study effectively recapitulated previous findings for CDKN2B and its potential role in RCC 
predisposition and findings of functionally detrimental variants in EPAS1 are strong candidates given 
the role of EPAS1 in PCC and PGL and GWAS SNP associations in RCC, where a phenotypic 
expansion of EPAS1 variants to include RCC would not be unexpected (111,339,342), but limited 
inferences can be made in regard to the variants identified in KMT2C and KMT2D without additional 
functional investigations and replication studies (and detailed clinical phenotyping). The most 
demonstrable limitation of the targeted sequencing studies is the lack of a comparable control sets 
to compare allele frequencies between RCC cases and the general population. Additionally, 
selection criteria for patients recruited into this chapter were more broad than the selection criteria 
for chapters 4, 5, and 6, which allows for individuals with lesser or minimal features of predisposition 
to be present within the case cohort and reduce the detection of potentially pathogenic variants. 
Further limitations include sequencing failures, stemming from methodical limitations or the intrinsic 
nature of DNA sequencing. PCR amplification success rates are typically determined by various 
factors, including primer design, reaction mixture constituents, cycling conditions and DNA template. 
In this study, the limitations were derived from the latter in which the nature of the region assessed 
(KMT2C) or the DNA integrity itself (CDKN2B and EPAS1) prevented optimal application of the 
proposed methods. 
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It is important to note that the methods applied in this chapter are effective and reliable when used 
in conjunction with high quality DNA, genomic regions without increased alignment complexity, such 
as that seen with KMT2C and the BAGE genes (519), and an appropriate comparison to control 
datasets. These methods reduce the necessity for large scale targeted or whole genome sequencing 
which complicate bioinformatic and analytical approaches and make Sanger sequencing or small 
scale amplicon-based NGS sequencing projects ideal for validation studies or clinical genetic testing 
where reliability, replicability, and efficiency are critical. 
Targeted sequencing of a panel of genes and SNPs associated with cancer used in Chapter 4 
unveiled potentially the most intriguing result from the perspective of unreported heritability in RCC. 
Through assessment of 118 individuals, the identification of an enrichment of pathogenic truncating 
variants in BRIP1 indicate that BRIP1 may be a new RCC predisposition gene in subset of rare 
inherited RCC cases. The statistical enrichment of BRIP1 truncation carriers compared to both 
healthy control sets (ICR birth control cohort, gnomAD and ExAC non-tcga (321,433)) and disease 
sets with known associations provide strong evidence for a legitimate genetic link between RCC 
predisposition and BRIP1 which is strengthened further by the co-segregation of the truncating 
variant in one of the assessed families (though extensive kindreds were not available). Though the 
evidence is persuasive for the demonstrated association, caution should still be taken before 
causally implicating heterozygous BRIP1 truncating variants in non-syndromic inherited RCC. As 
BRIP1 functions in DNA double strand break repair (520), and as such acts as a tumour suppressor, 
confirmation of LOH or inactivation of the remaining wildtype allele in tumours from the affected 
carriers would add additional support and demonstration that the initial variants do in fact result in 
protein ablation or functional loss, as not all truncating variant result in complete loss of protein 
function. This especially relevant given that BRIP1 truncating variants were initially associated as 
low penetrance risk alleles in breast cancer (401) but more recent epidemiological studies have cast 
doubt on that affiliation, suggesting truncating BRIP1 variants do not confer any risk to breast cancer 
(379).  
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The investigation into a subset of the same samples selected for matching criteria of features of RCC 
predisposition utilising WES methods in chapter 5 provided an increased scope for the identification 
of novel candidate variants and genes but also introduced additional complications. The study 
identified potentially pathogenic truncating variants, as well as variants in both frequently somatically 
altered genes and genes involved in the TCA cycle but the interpretation of these variants and 
determining their impact in RCC predisposition is difficult without functional studies, segregation 
within large families, or statistical enrichment in comparison to a control data set. Case-control 
analysis performed well based on the model metrics assessed considering the prior assumptions 
and innate limitations of the case data set. The case control testing over genomic regions failed to 
identify any associations after multiple testing correction and genes genes demonstrated a trend 
towards significance failed to demonstrate any enrichment in biological pathways. The major 
limitation to this approach is that given the number of cases, the likely risk associated with variants, 
and the requirement for conservative statistical association mean that the number of cases required 
to have reasonable power to detect a causal variant greatly exceeds the number of cases that could 
be reasonably ascertained from public genetic referral services. For example, given the incidence 
rates of RCC in the general population, estimated occurrence of inherited RCC, and a variant effect 
size (OR) of 2, the number of cases required to be powered at 80% is in excess of 1200 under liberal 
false discovery correction. 
Variants identified within genes associated with TCA cycle components are potentially the most 
viable candidates for functional assessment given the recent use of metabolite concentrations as a 
proxy for SDH complex function (444) and whether or not this could be applied to other TCA cycle 
components is an intriguing and potential clinically useful application of this methodology as well as 
uncovering pathogenicity of missense variants, particularly given most of these variants were not 
classified as pathogenic or likely pathogenic. 
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Exploratory analysis of WES data utilising algorithms and bioinformatic tools for the identification of 
copy number alterations, short tandem repeats, and mobile elements did not result in substantial 
findings across the examined cohort which could be due to several factors. Detection of these genetic 
alterations is limited by the bioinformatic tools, experimental design, and sequencing method used. 
In particular, the copy number calling was limited by complications conferred by unmatched WES 
data without the presence of internal controls to account for read depth variability and a high rate of 
false negative calls, an issue which is compounded by limited genomic coverage in WES data. Copy 
number detection in WGS is more reliable and replicable which was aptly demonstrated in the use 
of WGS copy number analysis in chapter 6 (485). Additionally the tool used, XHMM, is widely utilised 
for copy number calling including in large scale projects such as ExAC (321) but more recently 
developed methods have since improved on calling rates and handling of sample and target 
normalisation, including development of simulation pipelines and comparison benchmarks to 
establish optimal calling parameters (521,522). The alternative hypothesis is that these types of 
genetic alterations are rare causes of RCC predisposition, like that of chromosome 3 translocations, 
and cases are likely to be infrequently detected in unrelated proband studies compared to specific 
analysis of large pedigrees. Compared to copy number alterations, short tandem repeats and mobile 
element insertions are very rarely causes of genetic disorders in general and identification of any 
pathogenic alteration specifically in RCC predisposition was low, especially given the sample size. 
More investigations have continued to sequence unrelated individuals with or without clinical features 
of RCC predisposition utilising cancer gene panels or whole exome sequencing with variable 
outcomes. Assessment of advanced RCC patients without selection for features of heritability 
showed 16% carried germline variants in genes not otherwise associated with RCC predisposition, 
such as CHEK2, APC, MUTYH, BRCA2, and RECQL4, amongst others. Additionally, it reiterated 
previous investigations, identifying pathogenic variants in SDHA and BAP1, which currently have 
limited support and require further validation (523). An investigation in a Chinese cohort of early 
onset RCC cases documented 9.5% carried germline pathogenic variants, most of which (66%) were 
in known RCC predisposition genes (VHL, TSC1, TSC2, FH, FLCN, BAP1, PBRM1), with the 
remaining variants in BRCA2, BRCA1, and CDKN2A, though only BRCA1 demonstrated LOH in the 
tumour (395).  
 250 
 
These most recent investigations were recapitulated by the results of the cancer gene panel 
sequencing and WES studies described in this thesis. The number of potential new candidates 
identified appears to be limited, particularly when focused on SNVs, and variants identified as 
potentially associated with RCC predisposition are occurring in genes with known associations to 
other cancer predisposition (e.g. BRCA1, BRCA2, CHEK2 with breast cancer (27,383)) or genes 
altered somatically at high frequency, supporting the results described by Whitworth et al (2018)(376) 
in multiple primary malignant tumours which pathogenic variants found in individuals with unrelated 
cancer type suggests a phenotypic expansion, which may be the case in inherited RCC as well.  
Furthermore, while the identification of candidate genes has been limited this is the largest cohort of 
pre-screened individuals with features of inherited RCC to be sequenced and interrogated for 
putative genetic factors that are causal in RCC predisposition. Other sequencing projects have 
utilised selection criteria (e.g. early onset, advanced disease, family history) (395,523) but none 
previously implemented comprehensive pre-screening for known RCC predisposition genes. The 
application and removal of individuals identified with pathogenic variants in known RCC genes is in 
some respects a double-edged sword in that it potentially enriches novel genetic factors linked to 
RCC predisposition but simultaneously reduces the number of available samples for analysis in an 
already rare sample set.  
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Lastly, the study and review of RCC-associated translocation cases both previously published and 
investigated in this thesis in chapter 6 reconfirmed and strengthened the link between specific 
chromosomal alterations and RCC risk and determined the specific clinical characteristics of RCC-
associated translocation cases. While the identification and characterisation of constitutional 
translocations in this study did not identify any likely novel candidate genes associated with RCC 
predisposition, it did discover several novel occurrences not previously reported in other RCC 
translocation studies. Firstly, a translocation interrupting FLCN was the most clinically relevant 
finding which demonstrated BHD syndrome can be because of a translocation break point within the 
FLCN coding region in an individual with classical features of BHD syndrome. This is the first 
reported case of BHD syndrome caused by a translocation and may be important in assessing 
additional individuals with features of BHD who do not demonstrate obvious pathogenic SNVs or 
copy number alterations. Secondly, the identification of a chromosomal inversion, also involving 
chromosome 3, is the first non-reciprocal balanced chromosomal alteration described in RCC-
associated chromosomal alteration cases. Finally, the study established a framework for the 
identification and characterisation of translocation break points utilising WGS and 3rd generation 
sequencing methodologies or Sanger sequencing to reduce the required workload to resolve 
karyotyping reports to the base pair resolution, as well as providing genetic alterations to rule out 
additional causes of inheritance such as pathogenic SNVs, CNVs, or other structural variants. 
Utilising this analytical pipeline should reduce analysis cost and improve interrogation of further 
samples identified as RCC-association chromosomal alteration cases. 
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7.2 General limitations in next generation sequencing projects  
The results of this thesis are limited by a series of features which are common to all genetic 
association studies, as well as limitations which are specific to targeted next generation sequencing 
methodology. Primarily, the sample size in any given rare disease study is a limiting factor in the 
ability to identify novel causes of genetic disorders, particularly in unrelated proband studies which 
are unable to rely on familial segregation. By increasing sample sizes, statistical power and case 
control analyses can be more effectively leveraged and identification of rarer idiosyncratic 
presentations of predisposition can be detected.  
This limitation is present across rare disease studies and germline cancer predisposition but is 
particularly difficult in RCC. In comparison to the assessment of heritability of cancers such as 
colorectal and breast cancers, which are relatively common, RCC is a rarer cancer subtype. Only an 
estimated 12,500 new cases of RCC are diagnosed in the UK per year (31) which, when combined 
with the low prevalence of heritability, currently estimated at 3% of cases (98), it limits the potential 
UK wide cases to less than 400 individuals as a maximum sample size and that is without screening 
for known RCC predisposition genes. Recent studies into the application of genetic referral criteria 
suggest that the number of individuals eligible for genetic testing may be greater than previously 
estimated which may improve the available samples for research study recruitment but closer 
integration of clinical and research studies, as well as global collaboration efforts, are needed to 
facilitate larger sample sizes to improve detection and discovery rates of the factors associated with 
RCC predisposition. Additional benefits could be gained from clinical follow up and detailed 
phenotyping of individuals with candidate variants and use familial segregation to determine if the 
disease phenotype segregates with the putative variant in question. 
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One of the larger issues faced in large scale next generation sequencing projects such as the cancer 
gene panel sequencing study and the whole exome sequencing study is the inability to resolve the 
variant consequences of rare variants occurring across the genome and in candidate RCC 
predisposition genes. This issue is exemplified by the WES study which, as stated in the study 
results, identified more than 18,000 variants of uncertain significance, almost all of which were 
missense variants. Use of ClinVar as a source of additional variant pathogenicity evidence can be 
useful but availability is limited for most variants and many variants consist of conflicting or 
uncorroborated reports (406,524). The development of the ACMG variant classification framework, 
including its improved derivatives, have allowed for a more stringent and systematised approach for 
variant interpretation (325,525). High-throughput tools such as InterVar have allowed for the rapid 
application of those described classification (326), but the framework is limited and often inadequate 
when not accompanied by additional evidence from functional molecular studies, incorporation of 
reliable in silico predictive metrics, and integration of previously published data. Manual classification 
of variants utilising these frameworks can be more effective but manual curation of publications and 
functional studies for thousands of variants is unrealistic.  
While thorough and detailed functional investigations into all known variants present in the human 
genome would be the ultimate resource for variant interpretation, the scale and cost of even a fraction 
of such an endeavour would be unobtainable. Integration of in silico predictive tools such as SIFT, 
PolyPhen, and CADD amongst many others, could improve automated ACMG classifications but 
their prediction accuracy has been shown to be unreliable in certain instances. Outside of variant 
classification based on conservation and function consequence to the amino acid sequence, several 
recently published features of genetic inheritance and mutational selection could prove useful for 
future interpretation of variant pathogenicity and high-throughput functional experiments for subsets 
of variants are being proposed.  
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Use of genomic features like genetic constraint, in which specific regions are under positive or 
negative selection pressure, have been used across genes to predict intolerance or tolerance (353) 
but constraint averages over an entire coding region may mask specific conserved domains or 
regions with the coding space, including intronic regions. More recent developments and increased 
whole genome sequencing datasets have enabled the calculation of base pair scale assessments 
of mutational constraint (405) independent of gene loci, which may be a more representative proxy 
for evolutionary purifying selection in regions that are presumably more critical to gene function. By 
filtering variants in regions of low constraint (i.e. loci not under purifying selection) it may act to reduce 
candidate variants to only those present in regions were constraint is high and identify variants more 
likely to result in a functional alteration and assist in the interpretation of synonymous and intronic 
variants in relation to disease.  
Minor allele frequencies of variants in control populations are commonly used as a first pass filter for 
the removal of SNPs and low-quality variants. This process is effective at removing many biologically 
irrelevant variants but a vast majority of variants in any given individual are rarer than the standard 
allele frequency cut-offs such as 5% and 1% and thus many rare non-pathogenic variants are 
retained (526). Even assessment of ‘ultra-rare’ variants in chapter 5 at a minor allele frequency of 
0.1% discovered many more variants than could be easily assessed for pathogenicity. Furthermore, 
allele frequency filtering cut-offs are not disease specific, the likely allele frequency of a variant 
causing a common disorder is likely different to that of one causing a rare disorder. Use of maximal 
population allele frequencies, described by Whiffin et al (2017), which estimate the maximum 
tolerated allele frequency at which a causal variant could occur in a control population and still be 
disease causing may provide disease-specific allele frequency filtering thresholds (527), though the 
model requires accurate estimates of population prevalence and likely genetic variability, allelic 
variability, and likely penetrance which can be challenging to estimate in rare diseases.  
Lastly, the development of systems such as CRISPR-Cas9 have enabled high capacity, high-
throughput screening libraries using gene specific RNA guides and cell line libraries. More recent 
attempts are aimed at identifying therapeutic targets for specific cancer tumour types but an 
extension of this system would be feasible and may help prioritise candidate genes more effectively 
based on the effect of induced truncation in specific cell lines (528), allowing for the integration of in 
vitro functional data into variant interpretation. 
 255 
 
7.3 Future directions for the detection of heritability in RCC 
In this series of studies, several interesting candidate variants, genes, and mechanisms were 
discovered in association with RCC predisposition but only a small number of individuals carried 
putative predisposition variants or presented with rare inherited subtypes (i.e. RCC-associated 
translocation). The ability to identify candidate variants in individuals with features of RCC 
predisposition echoes previous studies and results seen in clinical diagnostic labs in which 
pathogenic variants are not identified in most tested individuals. While some of this missing 
heritability could be due to the difficulties in variant interpretation, as described above, a proportion 
may be missed due to not interrogating the genomic regions, variant consequences, or alterations 
that are truly responsible for heritability in RCC and several other factors may help form future studies 
which are able to effectively capture the heritable traits of RCC predisposition. Here I summarise a 
non-exhaustive list of potential research directions and experimental study designs that could be 
utilised to identify these genetic features which does not rely on solely increasing sample numbers, 
which would be the most effective method of improving detection rates. 
This thesis focused on the assessment of protein-affecting variant and excluded synonymous 
variants and intronic variants which are becoming more established as disease causing even in 
known RCC predisposition genes such as VHL (137). Variants in regulatory elements such as 
promotor and enhancer regions, as well as intergenic regions could also be sources of heritability in 
RCC and should be investigated. Use of WGS would allow for the discovery of variants in these 
genomic areas but interpretation of pathogenicity is potentially more difficult than protein-affecting 
variants. The advantage of WGS is that it would allow the exploration of structural and copy number 
alterations with a much greater degree of accuracy and coverage than that provided by targeted 
sequencing.  
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Combinatorial analysis of WES for SNV detection and low coverage WGS, which has been 
demonstrated to be effective in the detection of copy number variants even at coverages as low as 
1X to 5X (529), could provide significant computational and economic savings compared to full 
coverage WGS. Conversely, a more comprehensive sequencing method, such as WGS long read 
sequencing (e.g. PacBio SMRT sequencing), would allow for the examination of multiple DNA 
alterations and remove many of the limitations of 2nd generation short read sequencing methods (see 
Introduction chapter section 1.7) and allow for comprehensive SNV, structural, CNV, and phasing 
data across the entire genome. Additionally, the assumption is that inheritance of RCC predisposition 
is autosomal dominant and the likelihood that a proportion of inheritance is due to low penetrance or 
polygenic traits is becoming relatively high. Investigations into these features, while complex, should 
be performed to ascertain the proportion of heritability which can be attributed to complex polygenic 
traits and risk loci which may help develop methods for assessing polygenic risk scores as utilised 
in breast cancer (530). 
An alternative to increased genomic coverage is the integration of different “–omics” and tumour 
mutational, metabolic, and expression data to improve variant prioritisation and interpretation. Use 
of epigenetic data, such as promotor methylation, may uncover germline methylation defects in 
known or novel genes which are associated with RCC predisposition. Though inactivation of RCC 
genes is frequently reported somatically (280,283,531), very few investigations have fully assessed 
the methylation status of genes constitutionally. By identifying hypermethylation of promotor regions 
or key regulatory elements which correlate with RCC heritability it may demonstrate new genetic 
features involved in inherited RCC which would not be detected through DNA sequencing alone. 
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Inclusion of tumour SNV data would allow for the validation of candidate variant by assessing 
features such as LOH, which provides support for two-hit hypothesis driven loss of tumour 
suppressors, and tumour mutational signatures which may help identify if putative variants in genes 
involved in DNA repair pathways, among others, result in the mutational signatures associated with 
dysfunction in those pathways (532). The availability of fresh frozen tumour material collected 
prospectively during study recruitment would also enable the use of immunohistochemistry and 
metabolic investigations to determine and assess germline variant pathogenicity, improving 
interpretation and reducing ambiguity when attempting to assess variants in genes with functions in 
metabolism, such as those present in the TCA cycle. Integration of multiple “–omic” types could be 
further expanded to the use of tumour RNA expression data which would enable the correlation of 
transcript and allele-specific expression with the presence of putative pathogenic variants, where 
pathogenicity could be refuted or supported based on whether that allele is expressed in tumours. 
Counterintuitively, a proposal could be made for the reduction of study design from large scale 
genomic sequencing of unrelated probands to family only studies. Studies focused detailed 
phenotyping and genotyping of specific families may uncover pedigree-specific associations which 
may then more readily be detected in unrelated individuals. By exploiting familial analysis and the 
ability to co-segregate variants with disease status candidate variants can be more confidently 
determined, after which unrelated proband cohorts can be screened for the genes identified. In fact, 
several of the last genes associated with RCC predisposition, PBRM1 and BAP1 (263,331), were 
discovered through unrelated proband screening but the variants were discovered in individuals with 
strong family histories of RCC and retrospective analysis demonstrated co-segregation. By reversing 
this approach and assessing individuals with particularly strong family histories, it may more 
efficiently uncover associations which may be missed in unrelated proband studies. 
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7.4 Conclusion 
This study has uncovered limited evidence for further associations with new genetic features and 
RCC predisposition. Though cautious interpretation is needed, once confirmed these findings could 
be utilised to inform clinical management through genetic counselling, increasing screening 
procedures, or the development of targeted therapeutics. Furthermore, progressive molecular 
sequencing methodologies were applied to improve detection and characterisation of causal events 
in RCC predisposition which may act to increase the efficiency and analysis strategies of genomic 
data in both research and clinical environments. While much of the genetic components related to 
predisposition of RCC remains undiscovered, the results of this body of work may act as a foundation 
for follow up studies which might lead to confirmation of the findings, or novel associations derived 
from, those results described within this thesis. 
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9.0.2 Notes on appendix data 
The appendix figures, tables, lists, and data provided in this chapter are given in a context-free 
format and are intended to be read as supplemental components to the other chapters in this 
thesis. For scripts and code, script language is given in square brackets (e.g. [BASH]) and scripts 
are provided in a minimally functional state and as such most code comments, user interface 
components, software and server environment variables, and help utilities are removed for reduce 
the number of pages generated by indiscriminate copying of scripts and pipelines into the 
appendix. 
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9.1 Chapter 2 materials and methods 
9.1.1 Next generation sequencing pipeline – FASTQ to VCF 
FASTQ alignment - BWA mem (version 0.7.15-r1140) [BASH] 
bwa mem -c ${BWAC} \ 
    -r ${BWAR} \ 
    -t ${CORES} -R "@RG\tID:${RG}\tLB:WGS_RCC\tSM:${SAMPLE}\tPL:ILLUMINA" \ 
    ${SAMPLE}_1.fq.gz ${SAMPLE}_2.fq.gz | samtools sort -O bam -l 0 -T . \ 
    -o ${SAMPLE}.sorted.bam 
Remove duplicates - samtools (version 1.6-12-gc7b2f4f) [BASH] 
samtools rmdup ${SAMPLE}.sorted.bam ${SAMPLE}.sorted.rmdup.bam 
samtools index ${SAMPLE}.sorted.rmdup.bam 
Indel realignment - GATK IndelRealigner (version 3.7-0-gcfedb67) [BASH] 
java -Xmx40g -jar GenomeAnalysisTK.jar \ 
 -T RealignerTargetCreator \ 
 -R ${REFERENCE}.fa \ 
 -o ${SAMPLE}.merge.sorted.list \ 
 -I ${SAMPLE}.merge.sorted.bam \ 
 -nt ${CORES} \ 
 --allow_potentially_misencoded_quality_scores 
 
java -Xmx40g -jar /data/Resources/Software/Javas/GenomeAnalysisTK.jar \ 
 -I ${SAMPLE}.merge.sorted.bam \ 
 -R ${REFERENCE}.fa \ 
 -T IndelRealigner \ 
 -targetIntervals ${SAMPLE}.merge.sorted.list \ 
 -o ${SAMPLE}.merge.sorted.realigned.bam \ 
 --allow_potentially_misencoded_quality_scores 
Base quality recalibration - GATK BaseRecalibrator (version 3.7-0-gcfedb67) [BASH] 
java -Xmx40g -jar GenomeAnalysisTK.jar -l INFO \ 
 -R ${REFERENCE}.fa \ 
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 -I ${SAMPLE}.merge.sorted.realigned.bam \ 
 -T BaseRecalibrator \ 
 -o ${SAMPLE}.merge.sorted.realigned.table \ 
 -knownSites All.vcf.gz \ 
 -nct ${CORES} \ 
 --allow_potentially_misencoded_quality_scores 
java -Xmx40g -jar GenomeAnalysisTK.jar -l INFO \ 
 -R ${REFERENCE}.fa \ 
 -I ${SAMPLE}.merge.sorted.realigned.bam \ 
 -T PrintReads \ 
 -BQSR ${SAMPLE}.merge.sorted.realigned.table \ 
 -o ${SAMPLE}.merge.sorted.realigned.recal.bam \ 
 -nct ${CORES} \ 
 --allow_potentially_misencoded_quality_scores 
Final sort and index - samtools (version 1.6-12-gc7b2f4f) [BASH] 
samtools sort -@ ${CORES} \ 
 -m 4G \ 
 -O bam -l 9 \ 
 -T . \ 
 -o ${SAMPLE}.sorted.final.bam ${SAMPLE}.merge.sorted.realigned.recal.bam 
samtools index ${i}.sorted.final.bam 
Variant calling - GATK unified genotyper (version 3.7-0-gcfedb67) [BASH] 
java -Xmx60g -jar GenomeAnalysisTK.jar -glm BOTH -R ${REFERENCE}.fa \ 
 -T UnifiedGenotyper \ 
 -D All.vcf.gz \ 
 -o ${COHORT}.vcf \ 
 -stand_call_conf 30.0 \ 
 -A Coverage \ 
 -A AlleleBalance \ 
 --max_alternate_alleles 46 \ 
 -nt ${CORES} \ 
 -I bam.list \ 
 --allow_potentially_misencoded_quality_scores \ 
 -ip 100 \ 
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 -dcov 1500 \ 
 -rf MappingQuality \ 
 --min_mapping_quality_score 30 
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9.1.2 Next generation sequencing pipeline – VCF filtering and annotation 
Variant filtering – variant_filtering.config [BASH] 
MEANDP 30 
MAF 0.2 
GQ 30 
MISSING 0.8 
G1000 0.01 
EXAC 0.01 
CADD 0 
HET 15 
ADEPTH 0.30 
QUAL 30 
SAMP_NUM 1400 
Variant filtering – variant_filteringsh [BASH] 
#!/bin/bash 
BUILD="hg38" 
ANNO="/home/pss41/resources/annovar/" 
GATK="/data/Resources/Software/Javas/GenomeAnalysisTK.jar" 
REF="/data/Resources/References/hg38.bwa/hg38.bwa.fa" 
## config argument settings 
MEANDP=$(grep MEANDP ${CONFIG} | cut -f2) 
MAF=$(grep MAF ${CONFIG} | cut -f2) 
GQ=$(grep GQ ${CONFIG} | cut -f2) 
MISSING=$(grep MISSING ${CONFIG} | cut -f2) 
G1000=$(grep G1000 ${CONFIG} | cut -f2) 
EXAC=$(grep EXAC ${CONFIG} | cut -f2) 
CADD=$(grep CADD ${CONFIG} | cut -f2) 
HET=$(grep HET ${CONFIG} | cut -f2) 
ADEPTH=$(grep ADEPTH ${CONFIG} | cut -f2) 
QUAL=$(grep QUAL ${CONFIG} | cut -f2) 
SAMP_NUM=$(grep SAMP_NUM ${CONFIG} | cut -f2) 
 
## Run folder setup and config file availability 
if [[ ! -d ${OUTPUT}${PROJECT}_variantfiltering ]]; then 
 mkdir ${OUTPUT}${PROJECT}_variantfiltering 
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else 
 echo -e `date +[%D-%R]` "## Variant Filter Script ## - Project folder already 
exists - Overwritting content" | tee -a variantfilter.log 
fi 
## Migrate required ref files, config and logs to working directory 
cp ${CONFIG} ${OUTPUT}${PROJECT}_variantfiltering/variant_filtering.config 
cp variant_filtering.R ${OUTPUT}${PROJECT}_variantfiltering/variant_filtering.R 
cp RVIS_Unpublished_ExACv2_March2017.tsv \ 
 ${OUTPUT}${PROJECT}_variantfiltering/RVIS_Unpublished_ExACv2_March2017.tsv 
cp GDI_full_10282015.tsv \ 
 ${OUTPUT}${PROJECT}_variantfiltering/GDI_full_10282015.tsv 
mv variantfilter.log \ 
 ${OUTPUT}${PROJECT}_variantfiltering/variantfilter.log 
cd ${OUTPUT}${PROJECT}_variantfiltering 
 
## Filter all sites containing ref/ref for all positions & on provided filters 
cp ${INPUT} variant_orig.vcf 
vcftools --vcf variant_orig.vcf \ 
  --non-ref-ac-any 1 \ 
  --min-meanDP ${MEANDP} \ 
   --max-maf ${MAF} \ 
  --minGQ ${GQ} \ 
  --max-missing ${MISSING} \ 
  --recode --out variant_orig  
mv variant_orig.recode.vcf variant_filtered.vcf 
 
## Splitting of multi-allelic sites 
java -jar ${GATK} -T LeftAlignAndTrimVariants -R ${REF} \ 
  --variant variant_filtered.vcf \ 
  -o variant_filtered.bi.vcf \ 
  --splitMultiallelics > /dev/null 2>&1 
 
## Removing header command & generating intermediate files with bcftools 
vcftools --vcf variant_filtered.bi.vcf \ 
  --max-indv 0 \ 
  --recode --out annotate > /dev/null 2>&1 
sed -n '/#CHROM/,${p}' annotate.recode.vcf > variant.table 
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## bcftools to extract depth/genotype/INFO_field information 
bcftools query --print-header \ 
  -f '%CHROM\t%POS\t%REF\t%ALT[\t%GT]\n'  
  -o genotype.table variant_filtered.bi.vcf 
sed -i 's/\[[0-9]\+\]//g' genotype.table 
 
bcftools query --print-header  
  -f '%CHROM\t%POS\t%REF\t%ALT[\t%DP]\n' \ 
  -o sitedepth.table variant_filtered.bi.vcf 
sed -i 's/\[[0-9]\+\]//g' sitedepth.table 
 
 
bcftools query --print-header \ 
  -f '%CHROM\t%POS\t%REF\t%ALT[\t%AD]\n' \ 
  -o allelicdepth.table variant_filtered.bi.vcf 
sed -i 's/\[[0-9]\+\]//g' allelicdepth.table 
 
bcftools query --print-header \ 
  -f '%CHROM\t%POS\t%REF\t%ALT[\t%GQ]\n'  
  -o genoqual.table variant_filtered.bi.vcf 
sed -i 's/\[[0-9]\+\]//g' genoqual.table 
 
## Removing incorrect #CHROM to CHROM for R input 
sed -i 's/# CHROM/CHROM/' genotype.table 
sed -i 's/# CHROM/CHROM/' sitedepth.table 
sed -i 's/# CHROM/CHROM/' allelicdepth.table 
sed -i 's/# CHROM/CHROM/' genoqual.table 
sed -i 's/#CHROM/CHROM/' variant.table 
 
## Removing bcftools tags 
sed -i 's/:GT//g' genotype.table 
sed -i 's/:DP//g' sitedepth.table 
sed -i 's/:AD//g' allelicdepth.table 
sed -i 's/:GQ//g' genoqual.table 
 
## Generating annovar-annotation file for use as table 
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${ANNO}convert2annovar.pl -format vcf4old annotate.recode.vcf \ 
  --outfile annovarform > /dev/null 2>&1 
 
${ANNO}table_annovar.pl annovarform ${ANNO}humandb/ \ 
  -buildver ${BUILD} \ 
  -out annotated \ 
  -remove \ 
  -protocol 
refGene,1000g2015aug_all,exac03,avsnp150,dbnsfp35a,clinvar_20180603,cosmic70,nci60,dbscs
nv11 \ 
  -operation g,f,f,f,f,f,f,f,f \ 
  -nastring -9 > /dev/null 2>&1 
mv annotated.${BUILD}_multianno.txt annovar.table 
 
## Index all the files with header ID followed by var1-var(nrows-1) 
awk -F'\t' -v OFS='\t' 'NR == 1 {print "ID", $0; next} {print "Var"(NR-1), $0}' \ 
  variant.table > awk.table 
mv awk.table variant.table 
 
awk -F'\t' -v OFS='\t' 'NR == 1 {print "ID", $0; next} {print "Var"(NR-1), $0}' \ 
  genotype.table > awk.table 
mv awk.table genotype.table 
 
awk -F'\t' -v OFS='\t' 'NR == 1 {print "ID", $0; next} {print "Var"(NR-1), $0}' \ 
 genoqual.table > awk.table 
mv awk.table genoqual.table 
 
awk -F'\t' -v OFS='\t' 'NR == 1 {print "ID", $0; next} {print "Var"(NR-1), $0}' \ 
  allelicdepth.table > awk.table 
mv awk.table allelicdepth.table 
 
awk -F'\t' -v OFS='\t' 'NR == 1 {print "ID", $0; next} {print "Var"(NR-1), $0}' \ 
  sitedepth.table > awk.table 
mv awk.table sitedepth.table 
 
awk -F'\t' -v OFS='\t' 'NR == 1 {print "ID", $0; next} {print "Var"(NR-1), $0}' \ 
  annovar.table > awk.table 
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mv awk.table annovar.table 
 
###Run R script to filter variants  
wd=$(pwd) 
Rscript variant_filtering.R ${wd} > /dev/null 2>&1 
Variant filtering – variant_filtering.R [R] 
args = commandArgs(trailingOnly=TRUE) 
setwd(args[1])  
require("stringr") 
 
## Import data tables from bash script 
ad <- read.table("allelicdepth.table", 
  header = TRUE, 
  stringsAsFactors = FALSE) 
anno <- read.table("annovar.table", 
  header = TRUE, 
  sep = "\t", 
  stringsAsFactors = FALSE, quote="") 
gt <- read.table("genotype.table", 
  header = TRUE, 
  stringsAsFactors = FALSE) 
dp <- read.table("sitedepth.table", 
  header = TRUE, 
  stringsAsFactors = FALSE) 
config <- read.table("variant_filtering.config", 
  stringsAsFactors = FALSE) 
vv <- read.table("variant.table", 
  comment.char = "", 
  header = TRUE, 
  stringsAsFactors = FALSE) 
## Read in genetic intolerance lists 
rvis <- read.table("RVIS_Unpublished_ExACv2_March2017.tsv", 
  sep="\t", 
  header = TRUE, 
  stringsAsFactors = FALSE, 
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  quote="") 
gdis <- read.table("GDI_full_10282015.tsv", 
  sep = "\t", 
  header = TRUE, 
  stringsAsFactors = FALSE) 
 
## Remove columns that aren't needed 
ad <- ad[,-(2:5)] 
gt <- gt[,-(2:5)] 
dp <- dp[,-(2:5)] 
vv <- vv[,-(8:10)] 
rvis <- rvis[c(1,4)] 
gdis <- gdis[c(1,3)] 
 
## Rename rs id col to something other than "ID" for safety - Rename cols in genetic 
intolerance data 
names(vv)[4] <- "rsID" 
names(rvis) <- c("GENE","RVIS_Pct") 
names(gdis) <- c("GENE","GDIS_Phred") 
 
## Add annotation cols to variant file 
vv$GENE <- anno$Gene.refGene 
vv$TYPE <- anno$Func.refGene 
vv$AA <- anno$AAChange.refGene 
vv$CONSEQUENCE <- anno$ExonicFunc.refGene 
vv$X1000G <- anno$X1000g2015aug_all 
vv$EXAC <- anno$ExAC_ALL 
vv$CADD <- anno$CADD_phred 
vv$SIFT <- anno$SIFT_pred 
vv$POLYPHEN <- anno$Polyphen2_HVAR_pred 
vv$CLINVAR <- anno$CLNSIG 
 
## AF - making novel results = 0 and not -9 for freq calculations 
vv$X1000G[vv$X1000G == "-9"] <- 0 
vv$EXAC[vv$EXAC == "-9"] <- 0 
 
## Import config file settings 
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X1000g <- config$V2[config$V1 == "G1000"] 
exac <- config$V2[config$V1 == "EXAC"] 
CADD <- config$V2[config$V1 == "CADD"] 
HET <- config$V2[config$V1 == "HET"] 
ADEPTH <- config$V2[config$V1 == "ADEPTH"] 
QUAL <- config$V2[config$V1 == "QUAL"] 
SAMP_NUM <- config$V2[config$V1 == "SAMP_NUM"] 
 
## Filter variants to those occuring in exonic regions and splice sites 
exonic.ft <- as.data.frame(anno$ID[grepl("^exonic$",anno$Func.refGene) 
                 | grepl("^splicing$",anno$Func.refGene) 
                 | grepl("^exonic;splicing$",anno$Func.refGene)]) 
## rename col to match other ID cols 
names(exonic.ft)[1] <- "ID" 
## filter by functional consequence 
vv.ft <- vv[vv$ID %in% exonic.ft$ID,] 
 
## filtering on functional consequnce - ExonicFunction.refGene 
func.ft <- as.data.frame(vv.ft$ID[!grepl("^synonymous SNV$",vv.ft$CONSEQUENCE) 
                 & !grepl("^unknown$",vv.ft$CONSEQUENCE)]) 
                  
## rename col to match other ID cols 
names(func.ft)[1] <- "ID" 
## filter by functional consequence 
vv.ft <- vv.ft[vv.ft$ID %in% func.ft$ID,] 
 
## filter by qual 
qual.ft <- as.data.frame(vv.ft$ID[vv.ft$QUAL > QUAL]) 
names(qual.ft)[1] <- "ID" 
vv.ft <- vv.ft[vv.ft$ID %in% qual.ft$ID,] 
 
## corce gt data.frame into a matrix and replace non-numeric format with numeric 
genotypes 
gt <- gt[gt$ID %in% vv.ft$ID,] 
gtm <- as.matrix(gt) 
gtm[gtm == "0/0"] <- 0 
gtm[gtm == "0/1"] <- 1 
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gtm[gtm == "1/1"] <- 2 
gtm[gtm == "./."] <- -9 
gt <- as.data.frame(gtm) 
 
## apply function to sum the number of missing, het, hom and ref sites 
refHOM <- apply(gtm,1, function(x) sum(x == 0)) 
HETp <- apply(gtm,1, function(x) sum(x == 1)) 
nonHOM <- apply(gtm, 1, function(x) sum(x == 2)) 
miss <- apply(gtm, 1, function(x) sum(x == -9)) 
## addition of raw counts of HET/HOM 
vv.ft$HET_val <- HETp 
vv.ft$HOM_val <- nonHOM 
## form matrix for pct calculations 
calc <- cbind(refHOM,HETp,nonHOM,miss) 
 
## calculate hetpct & hompct (excluding missing sites) and missingness over all sites 
hetpct <- ((calc[,2] / (calc[,1] + calc[,2] + calc[,3]))*100) 
hompct <- ((calc[,3] / (calc[,1] + calc[,2] + calc[,3]))*100) 
misspct <- ((calc[,4] / length(gt[1,-1])*100)) 
## append values to new columns in vv.ft  
vv.ft$HET_rate <- hetpct 
vv.ft$HOM_rate <- hompct 
vv.ft$MISS_rate <- misspct 
 
## filter variant ids that are below values for both 1000g & exac_all 
rarity.ft <- as.data.frame(anno$ID[anno$X1000g2015aug_all < X1000g & anno$ExAC_ALL < 
exac]) 
names(rarity.ft)[1] <- "ID" 
 
## filter variant ids that are above cadd 
cadd.ft <- as.data.frame(anno$ID[anno$CADD_phred > CADD | anno$CADD_phred < 0]) 
names(cadd.ft)[1] <- "ID" 
 
## filter by rarity 
vv.ft <- vv.ft[vv.ft$ID %in% rarity.ft$ID,] 
 
## filter by cadd score 
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vv.ft <- vv.ft[vv.ft$ID %in% cadd.ft$ID,] 
 
###filter by het/hom ratio and het rate (het > 0 & no het rate in cohort above 15%) 
hethom.ft <- as.data.frame(vv.ft$ID[vv.ft$HET_rate < HET]) 
names(hethom.ft)[1] <- "ID"  
#log number of variants - Het/Hom 
varcount <- paste("##Variant Filter Script ## R-script Log - Variants matching Het/Hom 
thresholds:",nrow(hethom.ft)) 
write(varcount, file = "R_log.txt", append = TRUE) 
 
###Extract variants based on filtered list 
vv.ft <- vv.ft[vv.ft$ID %in% hethom.ft$ID,] 
###tidy variables and tables 
###performing allelic depth transformation to allele percent 
###make copy of allelicdepth(ad) 
af <- ad[ad$ID %in% vv.ft$ID,] 
af[af == "."] <- NA 
## Indexing and generation of percent allelic depth info 
af_index <- af[1] 
af_mat1 <- as.data.frame(apply(af[2:ncol(af)], c(1,2), 
  FUN = function(x) str_split_fixed(x, ",",2)[,1])) 
af_mat2 <- as.data.frame(apply(af[2:ncol(af)], c(1,2), 
  FUN = function(x) str_split_fixed(x, ",",2)[,2])) 
af_mat1[af_mat1 == ""] <- NA 
af_mat2[af_mat2 == ""] <- NA 
## conversion to matrix and perform matrix arithematic 
af_mat1 <- as.matrix(apply(af_mat1,2,function(x) as.numeric(x))) 
af_mat2 <- as.matrix(apply(af_mat2,2,function(x) as.numeric(x))) 
ad_pct <- af_mat2 / (af_mat1 + af_mat2) 
af <- cbind(af_index, ad_pct) 
## filter on variants with no af rate above threshold 
af.ft <- data.frame(x=rep(0,nrow(af))) 
for(i in 1:nrow(af)){ 
  if(max(af[i,2:ncol(af)], na.rm = TRUE) > ADEPTH){ 
    af.ft[i,1] <- af[i,1]} 
  else{ 
    af.ft[i,1] <- NA 
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  } 
} 
names(af.ft)[1] <- "ID" 
af.ft <- subset(af.ft, (!is.na(af.ft[,1]))) 
vv.ft <- vv.ft[vv.ft$ID %in% af.ft$ID,] 
 
## Add genotype information for remaining variants 
if(ncol(gt) > SAMP_NUM){ 
 gt.ft <- gt[gt$ID %in% vv.ft$ID,] 
 vvgt <- vv.ft 
 clock <- as.character(Sys.time()) 
 names(gt.ft)[1] <- "Id" 
 write.table(gt.ft,file = "variant_filtering_results_GT.tsv", 
  sep = "\t", 
  row.names = FALSE, 
  quote = FALSE) 
} else { 
 gt.ft <- gt[gt$ID %in% vv.ft$ID,] 
 vvgt <- merge(vv.ft,gt.ft, sort = FALSE) 
} 
## rename ID col - issues with opening files in excel with "ID" as the first value 
names(vvgt)[1] <- "Id" 
names(af)[1] <- "Id" 
 
## Col trimming for final tables 
drop_col <- c("HET_rate","HOM_rate") 
vvgt <- vvgt[ , !(names(vvgt) %in% drop_col)] 
## write filtered table out 
write.table(vvgt,file = "variant_filtering_results.tsv", 
  sep = "\t", 
  row.names = FALSE, 
  quote = FALSE) 
write.table(af,file = "variant_filtering_results_AD.tsv", 
  sep = "\t", 
  row.names = FALSE, 
  quote = FALSE) 
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9.1.3 ONT Nanopore sequencing pipeline  
ONT Nanopore pipeline – nano-pipe.sh [BASH] 
#!/bin/bash 
## BED HANDLING 
if [[ ! -z "$BED" ]]; then 
 if [[ -f "$BED" ]]; then 
     #echo -e "${BED} is a file" 
     if [[ $(cat "$BED" | wc -l) -lt 2 ]]; then 
         #echo -e "${BED} is a file with one region" 
         BED=$(cat ${BED} | sed 's/\(\S\+\)\t\(\S\+\)\t\(\S\+\)/\1:\2-\3/') 
   BED_TYPE="SINGLE" 
  else 
   BED_TYPE="BED" 
  fi 
 fi 
else 
 BED_TYPE="REF" 
fi 
 
## Output directory structure and overwrite protection 
cd ${OUTPUT_FOLDER} 
 
## Base calling 
if [[ "$BASE_CALLING" == "TRUE" ]]; then 
 cd ${OUTPUT_FOLDER}${PROJECT} 
 if [[ ! -d "base_calls" ]]; then 
  mkdir base_calls  
 fi 
 cd base_calls 
 
 
 
 
## Albacore base calling 
 if [[ "$BASE_CALLER" == "ALBACORE" ]]; then 
 read_fast5_basecaller.py --flowcell ${FLOWCELL} \ 
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   --recursive \ 
   --kit ${KIT} \ 
   -n 0 \ 
   --output_format fast5,fastq \ 
   --input ${INPUT_FOLDER}/ \ 
   --save_path ${OUTPUT_FOLDER}${PROJECT}/base_calls/ \ 
   --worker_threads ${CORES} \ 
   --disable_pings 
   cat workspace/pass/*.fastq > ${PROJECT}_merged.fastq 
   if [[ ! -d "fast5_syms" ]]; then 
       mkdir fast5_syms 
         cd fast5_syms 
         find ${OUTPUT_FOLDER}${PROJECT}/base_calls/workspace/ -type f \ 
    -name "*.fast5" | xargs -n1 -I {} ln -s {} . 
         cd .. 
      fi 
 fi 
## Indexing FAST files for variant calling 
 ${NANOPOLISH_PATH}nanopolish index \ 
  -s ${OUTPUT_FOLDER}${PROJECT}/base_calls/sequencing_summary.txt \ 
  -d ${OUTPUT_FOLDER}${PROJECT}/base_calls/fast5_syms/ \ 
  ${OUTPUT_FOLDER}${PROJECT}/base_calls/${PROJECT}_merged.fastq  
fi 
 
## Base calling QC 
if [[ "$BASE_QC" == "TRUE" ]]; then 
    if [[ "$LOCAL_PYTHON" == "TRUE" ]];then 
        source ${PYTHON_ENV}activate 
    fi 
 cd ${OUTPUT_FOLDER}${PROJECT}/base_calls 
    if [[ ! -d "base_QC" ]]; then 
        mkdir base_QC 
    fi 
    cd ${OUTPUT_FOLDER}${PROJECT}/base_calls/base_QC 
 Rscript ${INSTALL_FOLDER}nano-qc.R \ 
  ${OUTPUT_FOLDER}${PROJECT}/base_calls/fast5_syms ${PROJECT} \ 
  ${OUTPUT_FOLDER}${PROJECT}/base_calls/base_QC 
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 if [[ -f "${OUTPUT_FOLDER}${PROJECT}/base_calls/sequencing_summary.txt" ]]; then 
  NanoStat --summary \ 
   ${OUTPUT_FOLDER}${PROJECT}/base_calls/sequencing_summary.txt \ 
   --readtype 1D 
 fi 
 
## Alignment 
if [[ "$ALIGNMENT" == "TRUE" ]]; then 
 cd ${OUTPUT_FOLDER}${PROJECT} 
    if [[ ! -d "alignment" ]]; then 
  mkdir alignment 
 fi 
    cd alignment 
##MINIMAP2 Alignment 
 if [[ "$ALIGNMENT_TYPE" == "MINIMAP" ]]; then 
 minimap2 -ax map-ont \ 
   ${REFERENCE} \ 
   ${OUTPUT_FOLDER}${PROJECT}/base_calls/${PROJECT}_merged.fastq > \ 
   ${PROJECT}_basecalled.sam 
 samtools view -b \ 
   -q ${MAP_Q} \ 
   ${PROJECT}_basecalled.sam | samtools sort \ 
   -O bam -l 0 -T . -o ${PROJECT}_basecalled.sorted.bam 
 samtools index ${PROJECT}_basecalled.sorted.bam 
 fi 
fi 
ONT Nanopore pipeline – nano-qc.R [R] 
args = commandArgs(trailingOnly=TRUE) 
library(rhdf5) 
library(poRe) 
library(ggplot2) 
library(reshape2) 
library(dplyr) 
library(gridExtra) 
## Set environment  
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setwd(dir = args[3]) 
project <- args[2] 
reads_info <- read.fast5.info(dir = args[1]) 
## Set Nanopore channel layout 
layout <- function(){ 
 p1 = data.frame(channel=33:64, row=rep(1:4, each=8), col=rep(1:8, 4)) 
 p2 = data.frame(channel=481:512, row=rep(5:8, each=8), col=rep(1:8, 4)) 
 p3 = data.frame(channel=417:448, row=rep(9:12, each=8), col=rep(1:8, 4)) 
 p4 = data.frame(channel=353:384, row=rep(13:16, each=8), col=rep(1:8, 4)) 
 p5 = data.frame(channel=289:320, row=rep(17:20, each=8), col=rep(1:8, 4)) 
 p6 = data.frame(channel=225:256, row=rep(21:24, each=8), col=rep(1:8, 4)) 
 p7 = data.frame(channel=161:192, row=rep(25:28, each=8), col=rep(1:8, 4)) 
 p8 = data.frame(channel=97:128, row=rep(29:32, each=8), col=rep(1:8, 4)) 
 q1 = data.frame(channel=1:32, row=rep(1:4, each=8), col=rep(16:9, 4)) 
 q2 = data.frame(channel=449:480, row=rep(5:8, each=8), col=rep(16:9, 4)) 
 q3 = data.frame(channel=385:416, row=rep(9:12, each=8), col=rep(16:9, 4)) 
 q4 = data.frame(channel=321:352, row=rep(13:16, each=8), col=rep(16:9, 4)) 
 q5 = data.frame(channel=257:288, row=rep(17:20, each=8), col=rep(16:9, 4)) 
 q6 = data.frame(channel=193:224, row=rep(21:24, each=8), col=rep(16:9, 4)) 
 q7 = data.frame(channel=129:160, row=rep(25:28, each=8), col=rep(16:9, 4)) 
 q8 = data.frame(channel=65:96, row=rep(29:32, each=8), col=rep(16:9, 4)) 
 map = rbind(p1, p2, p3, p4, p5, p6, p7, p8, q1, q2, q3, q4, q5, q6, q7, q8) 
 map.matrix = acast(map, row ~ col, value.var = "channel") 
 return(map.matrix) 
} 
channel.layout <- layout() 
channel.layout <- melt(channel.layout) 
## functions 
## qual_plot fucntion 
qual_plot <- function(input){ 
 dat <- input[which(colnames(input) %in% c("tmq","cmq","mq2d"))] 
 #dat <- dat[!is.na(dat$tmq),] 
 
 qual_melt <- melt(as.matrix(dat)) 
 qual_melt$Var2 <- as.character(qual_melt$Var2) 
  
 names(qual_melt) <- c("Var1","read type","mean quality") 
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 qual_melt$`read type`[qual_melt$`read type` == "tmq"] <- "template" 
 qual_melt$`read type`[qual_melt$`read type` == "cmq"] <- "complement" 
 qual_melt$`read type`[qual_melt$`read type` == "mq2d"] <- "2d" 
  
 qual_melt$`read type` <- factor(qual_melt$`read type`, 
     levels = c("template","complement","2d")) 
  
 lim <-round(max(hist(qual_melt$`mean quality`[qual_melt$`mean quality` > 0])$counts),-
3) 
  
 
 ggplot(data = qual_melt,aes(x = `mean quality`,fill = `read type`)) +  
 geom_histogram(bins = 30,color = "grey25") + 
   facet_grid(. ~ `read type`) + 
   labs(title = "Distribution of mean read qualities", 
   fill = "Read type", 
   y = "Frequency", 
   x = "Mean quality") + 
   theme_light() + 
   scale_y_continuous(limits = c(0,lim),expand = c(0,0)) + 
   scale_fill_manual(values=c("#53B400", "#C49A00","#F8766D")) + 
   scale_x_continuous(limits = c(0,NA))  
} 
 
## length_plot fucntion 
rlength_plot <- function(input){ 
 dat <- input[which(colnames(input) %in% c("tlen","clen","len2d"))] 
 dat <- dat[!is.na(dat$tlen),] 
  
 rlength_melt <- melt(as.matrix(dat)) 
 rlength_melt$Var2 <- as.character(rlength_melt$Var2) 
 #qual_melt <- qual_melt[qual_melt$value > 0,] 
  
 names(rlength_melt) <- c("Var1","read type","read length") 
 rlength_melt$`read type`[rlength_melt$`read type` == "tlen"] <- "template" 
 rlength_melt$`read type`[rlength_melt$`read type` == "clen"] <- "complement" 
 rlength_melt$`read type`[rlength_melt$`read type` == "len2d"] <- "2d" 
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 rlength_melt$`read type` <- factor(rlength_melt$`read type`, 
     levels = c("template","complement","2d")) 
 lim <- round(max(hist(rlength_melt$`read length`[rlength_melt$`read length` > 
0])$counts),-3) 
  
 ggplot(data = rlength_melt) +  
  geom_histogram(aes(x = `read length`,fill = `read type`), 
   bins = 50,color = "grey25") + 
    facet_grid(. ~ `read type`) + 
    labs(title = "Distribution of read length", 
   fill = "Read type", 
   y = "Frequency", 
   x = "Mean length") + 
     theme_light() + 
    scale_y_continuous(limits = c(0,lim),expand = c(0,0)) + 
    scale_fill_manual(values=c("#53B400","#C49A00","#F8766D")) + 
    scale_x_continuous(limits = c(0,NA)) 
} 
##yield plot fucntion 
yield_plot <- function(input){ 
 dat <- input[!is.na(input$read_start_time),] 
 
 dat$TIME_SUM <- (as.numeric(dat$exp_start +  
   dat$read_start_time) –  
   min(as.numeric(dat$exp_start + dat$read_start_time))) 
 dat <- dat[order(dat$read_start_time),] 
 dat <- dat[which(colnames(dat) %in% c("tlen","clen","len2d","read_start_time"))] 
 dat$len2d <- cumsum(dat$len2d) / 1000 
 dat$tlen <- cumsum(dat$tlen) / 1000 
 dat$clen <- cumsum(dat$clen) / 1000 
  
 yield_melt <- melt(data = dat,id.vars = c("read_start_time")) 
 yield_melt$variable <- as.character(yield_melt$variable) 
  
 names(yield_melt) <- c("time","read type","cumulative kbs") 
 yield_melt$`read type`[yield_melt$`read type` == "tlen"] <- "template" 
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 yield_melt$`read type`[yield_melt$`read type` == "clen"] <- "complement" 
 yield_melt$`read type`[yield_melt$`read type` == "len2d"] <- "2d" 
  
 yield_melt$`read type` <- factor(yield_melt$`read type`, 
    levels = c("template","complement","2d")) 
 ggplot(data = yield_melt) +  
  geom_line(aes(x = `time`,y = `cumulative kbs`,color = `read type`)) + 
    facet_grid(. ~ `read type`,scales = "free") + 
    labs(title = "Cummulative kbases / time", 
   x = "Time", 
   y = "Cumulative data (Kbases)", 
   color = "Read type") + 
    theme_light() + 
    scale_y_continuous(expand = c(0.01,0)) + 
    scale_color_manual(values=c("#53B400","#C49A00","#F8766D")) + 
    scale_x_continuous(limits = c(0,NA)) 
} 
## channel kb function 
channel_stats_plot_tkb <- function(input){ 
 numeric_cols_sum <- c("len2d","tlen","clen","tcevents","channel") 
 dat_sum <- input[which(colnames(input) %in% numeric_cols_sum)] 
 dats <- dat_sum %>% group_by(channel) %>% summarise_all(sum) 
 merged_channel <- merge(channel.layout,dats,by.x = "value",by.y = "channel",all.x = T) 
 merged_channel$tlen <- merged_channel$tlen / 1000 
 merged_channel$len2d <- merged_channel$len2d / 1000 
 merged_channel$clen <- merged_channel$clen / 1000 
 names(merged_channel) <- c("channel","Var1","Var2","2d kbases (total)", 
    "template kbases (total)", 
    "complement kbases (total)", 
    "template events (total)") 
 merged_out <- melt(merged_channel,id.vars = c("channel","Var1","Var2")) 
 ggplot(merged_out[merged_out$variable=="template kbases (total)",],aes(x = Var2,y = 
Var1)) + 
    geom_point(shape = 21,size = 9, 
   color = "grey25",stroke = 0.5, 
   aes(fill = value)) + 
    geom_text(aes(label=channel),size = 3) +  
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    scale_y_reverse() + 
    scale_fill_continuous(low = "grey95", high = "#53B400",na.value = "white", 
     limits = c(0, 
    max(merged_out$value[which(merged_out$variable %in%  
    c("2d kbases (total)", 
     "template kbases (total)", 
     "complement kbases (total)"))]) 
   )) + 
    labs(title = "Template reads - KBases / channel",y = "Channel number", 
   fill="Kbases") + theme_light() + 
    theme(panel.background = element_blank(),plot.background = 
element_blank(), 
       panel.grid = element_blank(),axis.line = element_blank(), 
       axis.title.x = element_blank(),axis.ticks = element_blank(), 
       axis.text = element_blank(),panel.border = element_blank() 
     ) 
} 
## channel events function 
channel_stats_plot_tevn <- function(input){ 
 numeric_cols_sum <- c("len2d","tlen","clen","tcevents","channel") 
 dat_sum <- input[which(colnames(input) %in% numeric_cols_sum)] 
 dats <- dat_sum %>% group_by(channel) %>% summarise_all(sum) 
  
 merged_channel <- merge(channel.layout,dats,by.x = "value", 
   by.y = "channel", 
   all.x = T) 
 merged_channel$tlen <- merged_channel$tlen 
 merged_channel$len2d <- merged_channel$len2d 
 merged_channel$clen <- merged_channel$clen 
 names(merged_channel) <- c("channel","Var1","Var2", 
    "2d kbases (total)", 
    "template kbases (total)", 
    "complement kbases (total)", 
    "template events (total)") 
 merged_out <- melt(merged_channel,id.vars = c("channel","Var1","Var2")) 
  
ggplot(merged_out[merged_out$variable == "template events (total)",], 
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  aes(x = Var2,y = Var1)) + 
    geom_point(shape = 21, 
   size = 9, 
   color = "grey25", 
   stroke = 0.5,  
   aes(fill = value)) + 
    geom_text(aes(label=channel),size = 3) +  
    scale_y_reverse() + 
    scale_fill_continuous(low = "grey95",high = "blue2",na.value = "white") + 
    labs(title = "Events / channel",y = "Channel number", fill="Events") + 
    theme_light() + 
    theme(panel.background = element_blank(), 
   plot.background = element_blank(), 
       panel.grid = element_blank(), 
   axis.line = element_blank(), 
   axis.title.x = element_blank(), 
   axis.ticks = element_blank(), 
   axis.text = element_blank(), 
   panel.border = element_blank() 
  ) 
  
} 
## Chnanel mean kb function 
channel_stats_plot_tmeankb <- function(input){ 
 numeric_cols_mean <-c("len2d","tlen","clen","channel") 
 dat_mean <- input[which(colnames(input) %in% numeric_cols_mean)] 
 datm <- dat_mean %>% group_by(channel) %>% summarise_all(mean) 
  
 merged_channel <- merge(channel.layout,datm,by.x = "value",by.y = "channel",all.x = T) 
 merged_channel$tlen <- merged_channel$tlen / 1000 
 merged_channel$len2d <- merged_channel$len2d / 1000 
 merged_channel$clen <- merged_channel$clen / 1000 
 
 names(merged_channel) <- c("channel","Var1","Var2", 
    "2d kbases (mean)", 
    "template kbases (mean)", 
    "complement kbases (mean)") 
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 merged_out <- melt(merged_channel,id.vars = c("channel","Var1","Var2")) 
  
 ggplot(merged_out[merged_out$variable == "template kbases (mean)",],aes(x = Var2,y = 
Var1)) + 
  geom_point(shape = 21,size = 9,color = "grey25",stroke = 0.5, aes(fill = value)) + 
  geom_text(aes(label=channel),size = 3) +  
  scale_y_reverse() + 
  scale_fill_continuous(low = "white",high = "#53B400",na.value = "white", 
             limits = c(0,max(merged_out$value[which(merged_out$variable %in%  
    c("2d kbases (mean)", 
     "template kbases (mean)", 
     "complement kbases (mean)"))],na.rm = T))) + 
  labs(title = "Template reads - mean KBases / channel", 
   y = "Channel number", 
   fill="Kbases") + 
  theme_light() + 
  theme(panel.background = element_blank(), 
  plot.background = element_blank(), 
      panel.grid = element_blank(), 
  axis.line = element_blank(), 
      axis.title.x = element_blank(), 
  axis.ticks = element_blank(), 
      axis.text = element_blank(), 
  panel.border = element_blank() 
  ) 
} 
 
## channel temp function 
channel_stats_plot_temp <- function(input){ 
 
 numeric_cols_mean <-c("channel","heatsink_temp") 
 dat_mean <- input[which(colnames(input) %in% numeric_cols_mean)] 
 datm <- dat_mean %>% group_by(channel) %>% summarise_all(mean) 
  
 merged_channel <- merge(channel.layout,datm,by.x = "value", 
    by.y = "channel", 
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    all.x = T) 
 
 names(merged_channel) <- c("channel","Var1","Var2","temp (C)") 
  
 merged_out <- melt(merged_channel,id.vars = c("channel","Var1","Var2")) 
  
 ggplot(merged_out[merged_out$variable == "temp (C)",],aes(x = Var2,y = Var1)) + 
  geom_point(shape = 21, 
   size = 9, 
   color = "grey25", 
   stroke = 0.5, 
   aes(fill = value)) + 
  geom_text(aes(label=channel),size = 3) +  
  scale_y_reverse() + 
  scale_fill_continuous(low = "green", 
  high = "red", 
  na.value = "white", 
  limits = c(0,60)) + 
  labs(title = "Mean temperature / channel", 
  y = "Channel number", 
  fill="Temp (C)") + 
  theme_light() + 
  theme(panel.background = element_blank(), 
  plot.background = element_blank(), 
      panel.grid = element_blank(), 
  axis.line = element_blank(), 
      axis.title.x = element_blank(), 
  axis.ticks = element_blank(), 
      axis.text = element_blank(), 
  panel.border = element_blank() 
  ) 
} 
## Channel quality function 
channel_stats_plot_tmeanq <- function(input){ 
 
 numeric_cols_mean <-c("tmq","cmq","mq2d","channel") 
 dat_mean <- input[which(colnames(input) %in% numeric_cols_mean)] 
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 dat_mean[is.na(dat_mean)] <- 0 
 datm <- dat_mean %>% group_by(channel) %>% summarise_all(mean) 
 merged_channel <- merge(channel.layout,datm,by.x = "value", 
   by.y = "channel", 
   all.x = T) 
 names(merged_channel) <- c("channel","Var1","Var2", 
    "template quality (mean)", 
    "complement quality (mean)", 
    "2d quality (mean)") 
  
 merged_out <- melt(merged_channel,id.vars = c("channel","Var1","Var2")) 
  
 ggplot(merged_out[merged_out$variable == "template quality (mean)",], 
   aes(x = Var2,y = Var1)) + 
  geom_point(shape = 21,size = 9,color = "grey25", 
  stroke = 0.5, aes(fill = value)) + 
  geom_text(aes(label=channel),size = 3) +  
  scale_y_reverse() + 
  scale_fill_continuous(low = "grey95",high = "#53B400",na.value = "white", 
  limits = c(0,max(merged_out$value[which(merged_out$variable %in%  
  c("2d quality (mean)", 
  "template quality (mean)", 
  "complement quality (mean)"))], 
  na.rm = T))) + 
  labs(title = "Template reads - mean quality / channel", 
  y = "Channel number", fill="Quality") + 
  theme_light() + 
  theme(panel.background = element_blank(), 
  plot.background = element_blank(), 
      panel.grid = element_blank(), 
  axis.line = element_blank(), 
      axis.title.x = element_blank(), 
  axis.ticks = element_blank(), 
      axis.text = element_blank(), 
  panel.border = element_blank() 
  ) 
} 
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## Plotting 
png(filename = paste(project,"_channelQC_kb_events.png",sep = ""),width = 23.5, 
  height = 10, 
  units = "in", 
  res = 600) 
grid.arrange(channel_stats_plot_tkb(reads_info),channel_stats_plot_tevn(reads_info),ncol
=2) 
dev.off() 
png(filename = paste(project,"_channelQC_meanKB.png",sep = ""),width = 17.5, 
  height = 10, 
  units = "in", 
  res = 600) 
grid.arrange(channel_stats_plot_tmeankb(reads_info),ncol=1) 
dev.off() 
png(filename = paste(project,"_channelQC_meanQuality.png",sep = ""),width = 17.5, 
  height = 10, 
  units = "in", 
  res = 600) 
grid.arrange(channel_stats_plot_tmeanq(reads_info), ncol=1) 
dev.off() 
png(filename = paste(project,"_channelQC_temp.png",sep = ""),width = 6, 
  height = 10, 
  units = "in", 
  res = 600) 
channel_stats_plot_temp(reads_info) 
dev.off() 
png(filename = paste(project,"_readQC.png",sep = ""),width = 16, 
  height = 10, 
  units = "in", 
  res = 600) 
grid.arrange(qual_plot(reads_info),yield_plot(reads_info),rlength_plot(reads_info),nrow=
3) 
dev.off() 
write.table(reads_info,paste(project,"_qcdata.txt",sep = ""),append = FALSE, quote = F, 
  sep = "\t", 
  na = "NA", 
  row.names = T, col.names = T) 
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9.2 Chapter 3 Targeted Sanger and amplicon sequencing 
9.2.1 Sanger sequencing and long range PCR primers 
Gene Name Primer Name Forward Primer Reverse Primer TmF (°C) 
TmR 
(°C) 
PCR size (bp) Exons 
KMT2C KMT2C-Exon 1 
GTCACCATGCCA
GGCTAATT 
TTGCTGGTCCTTGT
AATGACA 
58.23 57.5 7909 1 
KMT2C KMT2C-Exon 2 
GCAAAACATGGG
TCTGAGAGA 
AGGAGTATGTTTGG
TGGGCT 
58.22 58.63 7950 2 
KMT2C KMT2C-Exon 3 
GATGATGAGGTT
GCGCAGTT 
CAGGAGAATCGCGC
GAAC 
58.91 59 7854 3 
KMT2C KMT2C-Exon 4-6 
CTGGTCTCGAAC
TTCCACCT 
TTTGAAAGCTTTGC
CTATGTTCT 
59.03 57.21 7457 4-6 
KMT2C KMT2C-Exon 7 
AAATTTGGAGCAT
GGGGAGC 
GAGGCAGGAGAAAT
CGCATG 
58.8 59.06 5668 7 
KMT2C KMT2C-Exon 8-9 
CCACCACACCCT
GCTAATTT 
AGGGGAGACAGAA
CAAGCT 
58.08 57.83 7826 8-9 
KMT2C KMT2C-Exon 10-14 
GTGCAGATTTTGT
GAGGCCA 
GCTTACCGTTCTAC
TAGTTGGC 
59.04 58.81 7896 10-14 
KMT2C KMT2C-Exon 15-16 
CCCCACTGCCTA
CCACTAAA 
CCCCACAAAGAAAA
TTTCAGGC 
59.01 58.6 7243 15-16 
KMT2C KMT2C-Exon 17-18 
TCGAACTCCTGA
TCCACCTG 
GAGGAGAGAGAATG
CGGGAA 
58.81 58.88 4806 17-18 
KMT2C KMT2C-Exon 19-20 
GCCAAAAGAAAC
AAAACAAGTGT 
TTACGTAGGGAGGG
CAGAAG 
57.39 58.52 6219 19-20 
KMT2C KMT2C-Exon 21-23 
TTCTTGGGACTCT
GGCTACT 
TGCAGGCCCACTTA
CATACA 
57.67 59.01 8008 21-23 
KMT2C KMT2C-Exon 24-27 
GGTGGGGAACTA
GATAGGAGC 
TGCCCACCAAAACC
AAAAGG 
59.03 59.46 9375 24-27 
KMT2C KMT2C-Exon 28-31 
GGATTGAAATTG
GACAGAGAACA 
TCCTTGAAACTGGT
CCCTGG 
57.04 59.23 7832 28-31 
KMT2C KMT2C-Exon 32-37 
GTTCACACCCTG
GGCTTTTG 
CTCCTGAGTAGCCG
CGAATA 
59.61 59.05 9205 32-37 
KMT2C KMT2C-Exon 38-41 
TCCCATCATCAAA
CCTGTGC 
GGGACCCCTGCAAA
TAACTAG 
58.16 58.07 9776 38-41 
KMT2C KMT2C-Exon 42-44 
ATGTAGTTTGGCT
TGTGGGTT 
TACCACCACGCCCA
GTAAAT 
58.04 59.01 9047 42-44 
KMT2C KMT2C-Exon 45-52 
ACTGTTAAGCTG
GGAGAGGT 
TCCCCAATGCAAAT
GACAGG 
57.97 58.44 9169 45-52 
KMT2C KMT2C-Exon 53-58 
AGTATGTGGAGC
TGCTTTCTT 
CCACACCTGAACTG
CTGAAG 
57.29 58.77 8924 53-58 
KMT2C KMT2C-Exon 59 
TCCTGGAAAGCT
GTCACTGA 
AACAAACTGCAAGC
ACCTGT 
58.58 58.81 8076 59 
KMT2D KMT2D-Exon 1-14 
GCACAGACTGGC
CTCTAGAA 
CACGATGGTCCTGA
ACTCCT 
59.1 59.1 8151 1-14 
KMT2D KMT2D-Exon 15-18 
GGAGGCCTAGTC
TCTGCATT 
AGACCATGGTGCCT
GATGAA 
57 57 1518 15-18 
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Gene Name Primer Name Forward Primer Reverse Primer TmF (°C) 
TmR 
(°C) 
PCR size (bp) Exons 
KMT2D KMT2D-Exon 19-34 
TTCACCGTGTTA
GCCAGGAT 
TCAATCAACTCTCCT
GCCTCA 
59.02 58.74 8880 19-34 
KMT2D KMT2D-Exon 35-47 
AGATCGCCTCAT
TGCACTCC 
CGCCTGGCTACTGT
TTTGTT 
58 56 8064 35-47 
KMT2D KMT2D-Exon 48-54 
AGATTGTGCCAC
TGGATCCA 
CCTGCGCTCTCAAA
CCTCTA 
59.01 59.47 9125 48-54 
CDKN2B CDKN2B-1A-PS 
TAGCATCTTTGG
GCAGGCTT 
CACCTTCTCCACTA
GTCCCC 
59.67 58.8 598 1 
CDKN2B CDKN2B-1B-PS 
CTAGGAAGGAGA
GAGTGCGC 
TCGTTGAAAGCAGA
CAGACA 
59.62 57.4 597 1 
CDKN2B CDKN2B-2A-PS 
GAGACCTGAACA
CCTCTGCA 
GTCGAGGGCCAGAT
AAGACA 
59.32 58.89 600 2 
CDKN2B CDKN2B-2B-PS 
CCGCCCACAACG
ACTTTATT 
CAGGGCTTCCAGAG
AGTGT 
58.84 58.63 595 2 
EPAS1 ORF-EPAS1-Ex12 
TGACACAGCCAA
GTCTGAGG 
ACATGGCTTGAGGT
GATTCC 
60.02 59.93 829 12 
EPAS1 ORF-EPAS1-Ex9 
TCCATGGCTCAC
ACACTTCT 
GGAGCGTGTGGTGT
TCTTTT 
58.94 58.98 565 9 
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9.2.2 Sequence identity comparisons 
KMT2C-BAGE2 gene 
Command line:  
matcher –auto –stdout –asequence emboss_matcher-I20160128-160222-0718-19876421-
oy.asequence –bsequence emboss_matcher-I20160128-160222-0718-19876421-oy.bsequence –
datafile EDNAFULL –gapopen 16 –gapextend 4 –alternatives 1 -aformat3 pair –snucleotide1 –
snucleotide2 
 Align format: pair | Aligned sequences: 2 
 ENSG00000055609 
 ENSG00000187172 
 Matrix: EDNAFULL | Gap penalty: 16 | Extend penalty: 4 | Length: 93385 | Identity: 80878/93385 
(86.6%) | Similarity: 80878/93385 (86.6%) | Gaps: 8361/93385 (8.0%) 
KMT2C-BAGE2 mRNA 
Command line:  
matcher –auto –stdout –asequence emboss_matcher-I20190325-143621-0347-48066866-
p2m.asequence –bsequence emboss_matcher-I20190325-143621-0347-48066866-
p2m.bsequence –datafile EDNAFULL –gapopen 16 –gapextend 4 –alternatives 1 -aformat3 pair –
snucleotide1 –snucleotide2 
Align format: pair | Aligned sequences: 2 
 NM_170606.3 
 NM_182482.2 
Matrix: EDNAFULL | Gap penalty: 16 | Extend penalty: 4 
Length: 2109 | Identity: 1539/2109 (73.0%) | Similarity: 1539/2109 (73.0%) | Gaps: 535/2109 
(25.4%) 
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9.2.3 Sequence alignment and quality metrics – KMT2C/KMT2C sequencing 
Read mapping percentages for KMT2C and KMT2D (orange) compared to off target mapping (blue). Figure A shows read 
mapping proportion of both KMT2C and KMT2D. Figure B shows read mapping proportion for KMT2C only. Figure C shows 
the read mapping proportion for KMT2D only and Figure D shows the read mapping proportion for BAGE2. 
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9.2.4 BAGE-family genes table 
 
 
  
Gene Loci 
Location/Scaffold 
(GRCh38) 
Lenth 
(bp) 
Length 
(AA) 
Aliases Notes 
BAGE 21p11.1 
NW_001839676.1 
Not in current 
release 
1,004 43 
BAGE1 
CT2.1 
B Melanoma Antigen 
Family, Member 1 
No full gene length - cDNA 
(132bp) reported far smaller than 
mRNA - 2 reported exons 
BAGE2 21p11.2 
chr21:10,413,477-
10,516,431 
102,955 109 
Cancer/Testis Antigen 
2.2 
CT2.2 
B Melanoma Antigen 
Family, Member 2 
Reported as protein producing, 
processed transcript & unknown 
locus type; 10 reported exons; 3 
Transcripts 
BAGE3 21p11.2 
NC_000021.8 
(Hg37) 
Not in current 
release 
1,891 109 
Cancer/Testis Antigen 
2.3 
CT2.3 
B Melanoma Antigen 
Family, Member 3 
8 exons reported - Full gene 
length unknown - orientation 
unknown - cDNA (330bp) far 
smaller than mRNA 
BAGE4 21p11.1 
AC_000153.1 
Not in current 
release 
1,840 39 
Cancer/Testis Antigen 
2.4 
CT2.4 
B Melanoma Antigen 
Family, Member 4 
2 exons reported - No full gene 
length - cDNA (120bp) far smaller 
than reported mRNA - protein 
coding (inference) 
BAGE5 13cen 
chr13:76,210-
170,143 
(NW_011332699.1) 
1,589 43 
Cancer/Testis Antigen 
2.5 
CT2.5 
B Melanoma Antigen 
Family, Member 5 
9 exons reported - Split build 
information for loci - mRNA 
sequence longer than reported 
gene 
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9.3 Chapter 4 Cancer gene panel sequencing 
9.3.1 Cancer gene panel target list 
SNPs (287) 
rs17401966 rs710521 rs3117582 rs4242384 rs110419 rs7176508 rs1327301 
rs9430161 rs2131877 rs204999 rs7837688 rs1945213 rs8034191 rs5945572 
rs7538876 rs798766 rs9268542 rs9642880 rs11228565 rs1051730 rs5945619 
rs11249433 rs1494961 rs6903608 rs2019960 rs7931342 rs8042374 rs5919432 
rs7412746 rs12500426 rs2395185 rs10088218 rs10896449 rs3803662 rs1321311 
rs3790844 rs17021918 rs2858870 rs891835 rs7130881 rs4784227 rs3824999 
rs6691170 rs1229984 rs674313 rs4295627 rs7105934 rs3112612 rs5934683 
rs6687758 rs971074 rs28421666 rs2294008 rs614367 rs9929218 rs2283873 
rs801114 rs7679673 rs2647012 rs7040024 rs1393350 rs391525 rs807624 
rs1465618 rs10069690 rs10484561 rs755383 rs1801516 rs258322 rs1027643 
rs7579899 rs2242652 rs9275572 rs3814113 rs3802842 rs1805007 rs3755132 
rs1432295 rs2736100 rs210138 rs7023329 rs498872 rs4785763 rs790356 
rs721048 rs2853676 rs10484761 rs2157719 rs735665 rs4795519 rs5955543 
rs10187424 rs4635969 rs339331 rs1412829 rs2900333 rs4430796 rs10974944 
rs17483466 rs4975616 rs2180341 rs1011970 rs718314 rs7501939 rs1210110 
rs12621278 rs401681 rs9485372 rs4977756 rs10875943 rs7210100 rs7555566 
rs2072590 rs31489 rs2046210 rs965513 rs11169552 rs1859962 rs1364054 
rs13016963 rs12653946 rs651164 rs865686 rs902774 rs17674580 rs6734275 
rs13393577 rs2255280 rs9364554 rs505922 rs995030 rs7238033 rs7584993 
rs3768716 rs13361707 rs7758229 rs10795668 rs3782181 rs4939827 rs17272796 
rs6435862 rs2121875 rs4487645 rs11012732 rs4474514 rs8170 rs1155741 
rs13387042 rs4415084 rs11978267 rs3123078 rs11066015 rs8102137 rs161792 
rs966423 rs889312 rs4132601 rs10993994 rs671 rs10411210 rs11940551 
rs13397985 rs10052657 rs6465657 rs10821936 rs4767364 rs8102476 rs9293511 
rs7584330 rs20541 rs1495741 rs7089424 rs2074356 rs11083846 rs9352613 
rs2292884 rs4624820 rs1512268 rs10822013 rs11066280 rs2735839 rs685449 
rs757978 rs10058728 rs2439302 rs10995190 rs4765623 rs961253 rs7808249 
rs4973768 rs872071 rs16892766 rs224278 rs1572072 rs910873 rs1106334 
rs1052501 rs12210050 rs1016343 rs704010 rs9510787 rs4925386 rs11017876 
rs2660753 rs4712653 rs1456315 rs3765524 rs753955 rs6010620 rs9572094 
rs9284813 rs6939340 rs16901979 rs2274223 rs9600079 rs4809324 rs4905366 
rs17181170 rs4324798 rs2456449 rs3781264 rs9573163 rs372883 rs4775699 
rs9841504 rs29232 rs16902094 rs17119461 rs9543325 rs2014300 rs1528601 
rs10934853 rs3129055 rs445114 rs12413624 rs7335046 rs45430 rs11655512 
rs6763931 rs2860580 rs13281615 rs11199874 rs944289 rs1547374 rs4793172 
rs6774494 rs2517713 rs1562430 rs2981579 rs116909374 rs738722 rs242076 
rs10936599 rs6457327 rs10505477 rs2981575 rs4444235 rs36600 rs6603251 
rs10936632 rs130067 rs6983267 rs1219648 rs4779584 rs2284063 AMG_mid100 
rs4488809 rs2894207 rs7014346 rs2981582 rs4924410 rs1014971 rs149617956 
rs10937405 rs2596542 rs1447295 rs3817198 rs4775302 rs5759167  
rs17505102 rs2248462 rs4242382 rs7127900 rs8030672 rs5768709 rs138213197 
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Genes (94) 
AIP CEBPA FANCA KIT PRF1 SLX4 
ALK CEP57 FANCB MAX PRKAR1A SMAD4 
APC CHEK2 FANCC MEN1 PTCH1 SMARCB1 
ATM CYLD FANCD2 MET PTEN STK11 
BAP1 DDB2 FANCE MLH1 RAD51C SUFU 
BLM DICER1 FANCF MSH2 RAD51D TMEM127 
BMPR1A DIS3L2 FANCG MSH6 RB1 TP53 
BRCA1 EGFR FANCI MUTYH RECQL4 TSC1 
BRCA2 EPCAM FANCL NBN RET TSC2 
BRIP1 ERCC2 FANCM NF1 RHBDF2 VHL 
BUB1B ERCC3 FH NF2 RUNX1 WRN 
CDC73 ERCC4 FLCN NSD1 SBDS WT1 
CDH1 ERCC5 GATA2 PALB2 SDHAF2 XPA 
CDK4 EXT1 GPC3 PHOX2B SDHB XPC 
CDKN1C EXT2 HNF1A PMS1 SDHC  
CDKN2A EZH2 HRAS PMS2 SDHD  
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9.3.2 Sanger sequencing primers – BRIP1 
Position 
(GRCh38) 
Variant 
(BRIP1) 
Forward primer Reverse primer 
Tm-F 
(°C) 
Tm-R 
(°C) 
Size 
(bp) 
chr17:61716051 p.Arg798* 
ACCAGTTCCTAT
GGTTCCAGT 
TGCTTGAGATCAC
ACAGCTG 
58.37 58.2 462 
chr17:61799278 
p.Gln388Thrfs*
7 
TCCCAAGAAGCC
TAGTTAACCA 
TGTAGAGCTGATAT
TTGGTTGGC 
58.75 58.8 498 
chr17:61780325 p.Ser624* 
TGCATCCCAAGT
GACTGGAT 
CAGACTCCTAGAC
TCAAGCGA 
59.01 58.64 467 
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9.4 Chapter 5 Whole exome sequencing 
9.4.1 WES gene lists 
Frequently somatically altered 
Gene Chr Start (bp) End (bp) Gene description 
ABCA13 chr7 48171458 48647497 ATP binding cassette subfamily A member 13 
ADGRV1 chr5 90529344 91164437 adhesion G protein-coupled receptor V1 
AHNAK2 chr14 104937244 104978374 AHNAK nucleoprotein 2 
ANK2 chr4 112818109 113383740 ankyrin 2 
ANK3 chr10 60026298 60733490 ankyrin 3 
ARID1A chr1 26693236 26782104 AT-rich interaction domain 1A 
ATM chr11 108222484 108369102 ATM serine/threonine kinase 
COL6A3 chr2 237324003 237414375 collagen type VI alpha 3 chain 
DNAH2 chr17 7717354 7833744 dynein axonemal heavy chain 2 
DNAH8 chr6 38715341 39030529 dynein axonemal heavy chain 8 
DNAH9 chr17 11598470 11969748 dynein axonemal heavy chain 9 
DST chr6 56457987 56954649 dystonin 
FAT1 chr4 186587794 186726722 FAT atypical cadherin 1 
HERC1 chr15 63608618 63833948 
HECT and RLD domain containing E3 
ubiquitin protein ligase family member 1 
KDM5C chrX 53191321 53225422 lysine demethylase 5C 
KDM6A chrX 44873177 45112602 lysine demethylase 6A 
KIAA1109 chr4 122152333 122362758 KIAA1109 
KIF1B chr1 10210805 10381603 kinesin family member 1B 
KMT2C chr7 152134922 152436005 lysine methyltransferase 2C 
KMT2D chr12 49018975 49059774 lysine methyltransferase 2D 
LRP1 chr12 57128493 57213351 LDL receptor related protein 1 
MACF1 chr1 39081316 39487177 microtubule-actin crosslinking factor 1 
MTOR chr1 11106535 11262507 mechanistic target of rapamycin kinase 
MUC17 chr7 101020072 101058745 mucin 17, cell surface associated 
NF2 chr22 29603556 29698598 neurofibromin 2 
NFE2L2 chr2 177227595 177392697 nuclear factor, erythroid 2 like 2 
OBSCN chr1 228208130 228378874 
obscurin, cytoskeletal calmodulin and titin-
interacting RhoGEF 
PIK3CA chr3 179148114 179240093 
phosphatidylinositol-4,5-bisphosphate 3-
kinase catalytic subunit alpha 
PKHD1 chr6 51615300 52087625 PKHD1, fibrocystin/polyductin 
RANBP2 chr2 108719482 108785809 RAN binding protein 2 
RYR1 chr19 38433699 38587564 ryanodine receptor 1 
RYR3 chr15 33310945 33866121 ryanodine receptor 3 
SETD2 chr3 47016429 47163967 
SET domain containing 2, histone lysine 
methyltransferase 
SMARCA4 chr19 10960825 11079426 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 4 
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Gene Chr Start (bp) End (bp) Gene description 
SMARCB1 chr22 23786931 23838008 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily b, 
member 1 
SRRM2 chr16 2752626 2772538 serine/arginine repetitive matrix 2 
STAG2 chrX 123960212 124422664 stromal antigen 2 
SYNE2 chr14 63852983 64226433 
spectrin repeat containing nuclear envelope 
protein 2 
TP53 chr17 7661779 7687550 tumor protein p53 
UBR4 chr1 19074510 19210266 
ubiquitin protein ligase E3 component n-
recognin 4 
XIRP1 chr3 39183210 39192620 xin actin binding repeat containing 1 
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TCA cycle genes 
Gene Chr Start (bp) End (bp) Gene description 
ACO1 chr9 32384603 32454769 aconitase 1 
ACO2 chr22 41469117 41528989 aconitase 2 
CS chr12 56271699 56300391 citrate synthase 
DLD chr7 107891162 107931730 dihydrolipoamide dehydrogenase 
DLST chr14 74881891 74903743 dihydrolipoamide S-succinyltransferase 
FH chr1 241497603 241519761 fumarate hydratase 
IDH1 chr2 208236227 208266074 
isocitrate dehydrogenase (NADP(+)) 1, 
cytosolic 
IDH2 chr15 90083045 90102504 
isocitrate dehydrogenase (NADP(+)) 2, 
mitochondrial 
IDH3A chr15 78131498 78171945 isocitrate dehydrogenase 3 (NAD(+)) alpha 
IDH3B chr20 2658395 2664219 isocitrate dehydrogenase 3 (NAD(+)) beta 
IDH3G chrX 153785766 153794523 isocitrate dehydrogenase 3 (NAD(+)) gamma 
MDH1 chr2 63588609 63607197 malate dehydrogenase 1 
MDH2 chr7 76048051 76067508 malate dehydrogenase 2 
OGDH chr7 44606572 44709066 oxoglutarate dehydrogenase 
OGDHL chr10 49734641 49762379 oxoglutarate dehydrogenase like 
SDHA chr5 218241 257082 succinate dehydrogenase complex subunit A 
SDHB chr1 17018722 17054170 succinate dehydrogenase complex subunit B 
SDHC chr1 161314257 161375340 succinate dehydrogenase complex subunit C 
SDHD chr11 112086824 112120013 succinate dehydrogenase complex subunit D 
SUCLA2 chr13 47745736 48037968 succinate-CoA ligase ADP-forming beta subunit 
SUCLG1 chr2 84423528 84460045 succinate-CoA ligase alpha subunit 
SUCLG2 chr3 67360460 67654614 
succinate-CoA ligase GDP-forming beta 
subunit 
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Known RCC genes 
Gene Chr Start (bp) End (bp) Gene description 
BAP1 chr3 52401013 52410350 BRCA1 associated protein 1 
BRIP1 chr17 61681266 61863521 BRCA1 interacting protein C-terminal helicase 1 
CDKN2B chr9 22002903 22009363 cyclin dependent kinase inhibitor 2B 
FH chr1 241497603 2.42E+08 fumarate hydratase 
FLCN chr17 17212212 17237188 folliculin  
MET chr7 116672390 1.17E+08 MET proto-oncogene, receptor tyrosine kinase 
MITF chr3 69739435 69968337 melanocyte inducing transcription factor 
PBRM1 chr3 52545352 52685917 polybromo 1 
PTEN chr10 87863113 87971930 phosphatase and tensin homolog 
SDHA chr5 218241 256700 
succinate dehydrogenase complex flavoprotein 
subunit A 
SDHB chr1 17018722 17054170 
succinate dehydrogenase complex iron sulfur 
subunit B 
SDHC chr1 161314257 1.61E+08 succinate dehydrogenase complex subunit C 
SDHD chr11 112086773 1.12E+08 succinate dehydrogenase complex subunit D 
TSC1 chr9 132891348 1.33E+08 TSC complex subunit 1 
TSC2 chr16 2047465 2089487 TSC complex subunit 2 
VHL chr3 10141008 10152220 von Hippel-Lindau tumor suppressor 
 
9.4.2 HapMap sample list 
Sample ID 
NA06985 NA07051 NA11832 NA11918 
NA06986 NA07056 NA11840 NA11919 
NA06989 NA10847 NA11881 NA11920 
NA06994 NA11829 NA11892 NA11931 
NA07000 NA11830 NA11893 NA11992 
NA07037 NA11831 NA11894  
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9.4.3a CNV pipeline - main 
Primary pipeline – xhmm_CNV.sh [BASH] 
CNV_xhmm.sh acts as a wrapper bash script for the XHMM C++ binary executable that acts to 
pass tar-get BAM alignment files in batches to GATK DepthOfCoverage and subsequently XHMM 
sub-programmes ‘xhmm –matrix’, ‘xhmm –normalize’, ‘xhmm –PCA’, ‘xhmm –discover’, and ‘xhmm 
–genotype’. 
#!/bin/bash 
## Generating work-environment folder 
if [ -d "${outputfolder}cnv_analysis" ]; then 
 echo -e "## CNV Pipeline ## - Root folder exists - folder not generated" 
else 
 mkdir ${outputfolder}cnv_analysis 
fi 
cp cnvPCA.R ${outputfolder}cnv_analysis/ 
cp cnvANNO.R ${outputfolder}cnv_analysis/ 
cp cnvPLOTS.R ${outputfolder}cnv_analysis/ 
cp ref_CNVs.txt ${outputfolder}cnv_analysis/ 
cd ${outputfolder}cnv_analysis 
 
### Output directory 
if [ -d "xhmm_analysis_${cohort}" ]; then 
 echo -e "## CNV Pipeline ## - Analysis folder exists - folder not generated" 
else 
 mkdir xhmm_analysis_${cohort} 
fi 
mv cnvPCA.R xhmm_analysis_${cohort}/temp 
mv cnvANNO.R xhmm_analysis_${cohort} 
mv cnvPLOTS.R xhmm_analysis_${cohort} 
mv ref_CNVs.txt xhmm_analysis_${cohort} 
cd xhmm_analysis_${cohort}/temp 
 
 
## folder setup 
cp ${int} xhmm.intervals 
vim -c "%s/\(\S\+\)\t\(\S\+\)\t\(\S\+\)\t\(\S\+\)/\1:\2-\3/g|wq" xhmm.intervals 
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interval="xhmm.intervals" 
ls ${inputfolder}*.bam > bam_list_xhmm 
 
## XHMM Analysis 
echo -e "## CNV Pipeline ## - XHMM started..." 
if [[ ${call} = "FALSE" ]]; then 
 echo -e "## XHMM ANALYSIS ## - Bam files split into 6 sets...(Stage 1 of 10)" 
 split -a 1 --numeric-suffixes=1 --additional-suffix=.list -n l/6 bam_list_xhmm 
 bam_chunk 
 
 
java -Xmx30g -jar ${gatk} -T DepthOfCoverage \   | 
 -I bam_chunk1.list \       | 
 -L ${interval} \       | 
 -R ${ref} \        | 
 -dt BY_SAMPLE \       | 
 -dcov 5000 \        | 
 -l INFO \       | 
 --omitDepthOutputAtEachBase \     | 
 --omitLocusTable \      | Process replicated 
6 
 --minBaseQuality 0 \      | times for 6 sample  
 --minMappingQuality 20 \     | chucks (one shown) 
 --start 1 \       | 
 --stop 5000 \       | 
 --nBins 200 \       | 
 --includeRefNSites \      | 
 --countType COUNT_FRAGMENTS \     | 
 --allow_potentially_misencoded_quality_scores \  | 
 -o bam_chunkOUT1 > /dev/null 2>&1 &    | 
## Allow for all child processes in parallel to complete 
 wait 
 sleep 5 
## Combines GATK Depth-of-Coverage outputs for multiple samples (at same loci): 
 xhmm --mergeGATKdepths -o xhmmCNV.mergeDepths.txt \ 
 --GATKdepths bam_chunkOUT1.sample_interval_summary \ 
 --GATKdepths bam_chunkOUT2.sample_interval_summary \ 
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 --GATKdepths bam_chunkOUT3.sample_interval_summary \ 
 --GATKdepths bam_chunkOUT4.sample_interval_summary \ 
 --GATKdepths bam_chunkOUT5.sample_interval_summary \ 
 --GATKdepths bam_chunkOUT6.sample_interval_summary > /dev/null 2>&1 
 
## calculates the GC Content of the exome intervals 
java -Xmx30g -jar ${gatk} -T GCContentByInterval \ 
 -L ${interval} \ 
 -R ${ref} \ 
 -o DATA_GC_percent.txt > /dev/null 2>&1 
 
## Concatenates and assess GC content (if less than 0.1 or more than 0.9 
cat DATA_GC_percent.txt | \ 
awk '{if ($2 < 0.1 || $2 > 0.9) print $1}' > extreme_gc_targets.txt 
 
## Centres the data about the mean and filters high/low GC intervals 
xhmm --matrix -r xhmmCNV.mergeDepths.txt --centerData --centerType target \ 
 -o xhmmCNV.filtered_centered.RD.txt \ 
 --outputExcludedTargets xhmmCNV.filtered_centered.RD.txt.filtered_targets.txt \ 
 --outputExcludedSamples xhmmCNV.filtered_centered.RD.txt.filtered_samples.txt \ 
 --excludeTargets extreme_gc_targets.txt --minTargetSize ${minTargetSize} \ 
 --maxTargetSize ${maxTargetSize} --minMeanTargetRD ${minMeanTargetRD} \ 
 --maxMeanTargetRD ${maxMeanTargetRD} --minMeanSampleRD ${minMeanSampleRD} \ 
 --maxMeanSampleRD ${maxMeanSampleRD} \ 
 --maxSdSampleRD ${maxSdSampleRD} > /dev/null 2>&1 
 
## Performs PCA to generate component variation 
xhmm --PCA -r xhmmCNV.filtered_centered.RD.txt \ 
 --PCAfiles xhmmCNV.mergeDepths_PCA > /dev/null 2>&1 
 
 
wd=$(pwd) 
Rscript cnvPCA.R ${wd} ${PVE_mean_factor} > /dev/null 2>&1 
 
## Normalises the mean centered data using the PCA data 
xhmm --normalize -r xhmmCNV.filtered_centered.RD.txt \ 
 --PCAfiles xhmmCNV.mergeDepths_PCA \ 
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 --normalizeOutput xhmmCNV.PCA_normalized.txt \ 
 --PCnormalizeMethod PVE_mean \ 
 --PVE_mean_factor ${PVE_mean_factor} > /dev/null 2>&1 
 
## Generates and asseses z-score distribution of mean centered-normalised 
## read depth data and filters inappropriate intervals 
xhmm --matrix -r xhmmCNV.PCA_normalized.txt \ 
 --centerData --centerType sample --zScoreData \ 
 -o xhmmCNV.PCA_normalized.filtered.sample_zscores.RD.txt \ 
 --outputExcludedTargets xhmmCNV.PCA_normalized.filtered_targets.txt \ 
 --outputExcludedSamples xhmmCNV.PCA_normalized..filtered_samples.txt \ 
 --maxSdTargetRD ${maxSdTargetRD} > /dev/null 2>&1 
 
 
 
## applies the normalisation and z-scoring to the standard non-normalised 
xhmm --matrix -r xhmmCNV.mergeDepths.txt \ 
 --excludeTargets xhmmCNV.filtered_centered.RD.txt.filtered_targets.txt \ 
 --excludeTargets xhmmCNV.PCA_normalized.sample_zscores.filtered_targets.txt \ 
 --excludeSamples xhmmCNV.filtered_centered.RD.txt.filtered_samples.txt \ 
 --excludeSamples xhmmCNV.PCA_normalized.sample_zscores.filtered_samples.txt \ 
 -o xhmmCNV.same_filtered.RD.txt > /dev/null 2>&1 
 
## assessment of the z-score to identify high levels of statistical deviation 
xhmm --discover -p ${params} \ 
 -r xhmmCNV.PCA_normalized.filtered.sample_zscores.RD.txt \ 
 -R xhmmCNV.same_filtered.RD.txt -c xhmmCNV.xcnv \ 
 -a xhmmCNV.aux_xcnv -s xhmmCNV > /dev/null 2>&1 
 
## genotypes indentified CNV during prior discovery steps 
xhmm --genotype -p ${params} \ 
 -r xhmmCNV.PCA_normalized.filtered.sample_zscores.RD.txt \ 
 -R xhmmCNV.same_filtered.RD.txt -g xhmmCNV.xcnv -F ${ref} \ 
 -v xhmmCNV.vcf > /dev/null 2>&1 
 
if (( $(cat xhmmCNV.xcnv | wc -l) < '2' )); then 
    echo -e "## CNV Pipeline ## - ERROR: No CNVs called" 
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    echo -e "## CNV Pipeline ## - XHMM analysis exiting" 
    exit 
fi 
mv xhmmCNV.xcnv ../xhmmCNV.xcnv 
mv xhmmCNV.vcf ../xhmmCNV.vcf 
mv bam_list_xhmm ../xhmm_samplelist.txt 
if [[ ${PCA_plot} == "TRUE" ]]; then 
 mv PCA_Scree.png ../PCA_Scree.png 
 mv PCA_summary.txt ../PCA_summary.txt 
fi 
mv xhmmCNV.aux_xcnv ../xhmmCNV.aux_xcnv 
mv cnv.log ../cnv.log 
cd ../ 
Rscript cnvANNO.R ${int} > /dev/null 2>&1 
XHMM annotation – cnvPCA.R [R] 
cnvPCA.R script uses GATK DepthOfCoverage output to generate a principle component graph 
used for dimensional reduction of variance in read depth across the read depth matrix, where the 
value of the i-th row and j-th column of the matrix correspond to the mean read depth at genomic 
target i in sample j. 
args = commandArgs(trailingOnly=TRUE) 
setwd(args[1]) 
PCA <- args[2] 
PCA <- as.numeric(PCA) * 100 
library(ggplot2) 
library(data.table) 
## read in filtered and centered read depth data from xhmm 
t <- fread("xhmmCNV.filtered_centered.RD.txt",sep = "\t",header = TRUE) 
t1 <- t[,-1]  
p <- prcomp(t1)  
 
## generate SVD eigen values from SD data in PCA output 
## Coerce into a dataframe with index values for each PC 
scr <- as.data.frame(p$sdev^2/sum(p$sdev^2)*100) 
scr$PC <- seq.int(nrow(scr)) 
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names(scr)[1] <- "Eigen" 
for(i in 1:nrow(scr)){ 
 c <- sum(scr$Eigen[1:i]) 
 if(c >= PCA){ 
  val <- i 
  break 
  } 
} 
 
## plot the data of eigen value against PC 
png("PCA_Scree.png", width = 5, height = 5, units = 'in', res = 600) 
ggplot(scr, aes(x=PC, y=Eigen)) + geom_line() + geom_point() +  
 geom_vline(xintercept=val, linetype = "dashed", color="red") + 
  scale_y_continuous(name="Eigen Value - Contributed Variance (%)", 
 breaks = pretty(scr$Eigen, n = 10)) + 
 scale_x_continuous(name="Princple Component", 
 breaks = pretty(scr$PC, n = 10)) + 
 ggtitle(label="PCA Scree Plot", subtitle="Cummulative Contributed Variance") + 
 geom_text(data=NULL, x=val+3, y=max(scr$Eigen),label="Contributed Variance cut off", 
 size=2.5) + 
 theme(panel.border = element_blank(),axis.line = element_line(colour="black")) + 
 theme(panel.background = element_blank(), 
 panel.grid.major = element_line(size = 0.1,colour = "grey50")) 
dev.off() 
XHMM annotation – cnvANNO.R [R] 
The cnvANNO.R script performs a secondary calling, annotation, and filtering steps on the default 
output files from XHMM. Utilising the .xcnv output file, the .aux_xcnv auxiliary calling file, and the 
target bed file, calling data from ‘xhmm –PCA’, ‘xhmm –discover’, and ‘xhmm –genotype’ sub-
programmes, cnvANNO.R converts from genomic region calls to target region resolution calls. 
Target calls are then annotated using the initial bed file to allow for gene/exon mapping and 
analysis. A series of filtering steps are also applied during this process to remove upstream and 
downstream targets with neutral copy changes, remove low quality calls (using the Q_SOME 
metric), and CNV allele frequency (internal and external). 
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Output is an 11+N column tab-delimited file (where N is the number of samples in the analysis set), 
each call being annotated with originating CNV identification number, original CNV call region, 
name of affected exon, genomic positions of target, non-normalised read depth and mean read 
depths, Quality score and mean quality score, and internal minor allele frequency for the 
associated call. 
args = commandArgs(trailingOnly=TRUE) 
options(digits=3) 
require(methods) 
library(ggplot2) 
library(stringr) 
library(tidyr) 
library(dplyr) 
 
int_af_value <- 0.05 
ref_af_value <- 0.05 
 
## Read in files for CNV annotation script 
cnv <- read.table("xhmmCNV.xcnv", sep = "\t", header = TRUE, stringsAsFactors = FALSE) 
intv <- read.table(args[1], sep = "\t", stringsAsFactors = FALSE) 
colnames(intv) <- c("chr","start","stop","exon") 
aux <- read.table("xhmmCNV.aux_xcnv", sep = "\t", header = TRUE, stringsAsFactors = 
FALSE) 
 
ref.list <- read.table("ref_CNVs.txt", sep = "\t", stringsAsFactors = FALSE) 
colnames(ref.list) <- c("EXON","CNV","AF_ref") 
f.aux <- aux[!aux$TARGET_IND == "U-2" & !aux$TARGET_IND == "U-1" & 
     !aux$TARGET_IND == "D+1" & !aux$TARGET_IND == "D+2",] 
intv$id <- paste(intv$chr,":", intv$start, "-", intv$stop, sep="") 
x <- merge(f.aux, intv, by.x = "TARGET", by.y = "id", all.x = TRUE) 
x$cnv_id <- as.numeric(as.factor(x$FULL_INTERVAL)) 
x <- cbind(x$cnv_id,x$SAMPLE,x$CHR,x$TARGET, 
 x$FULL_INTERVAL,x$CNV,x$exon,x[,8:10]) 
 
colnames(x) <- c("CNV_ID","SAMPLE","CHR","TARGET", 
"FULL_INTERVAL","CNV","EXON","POSTERIOR","RD","ORIG_RD") 
## Remove unmapped exons from interval files 
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x <- x[!is.na(x$EXON),] 
x <- droplevels.data.frame(x) 
 
## Add Q_SOME field from CNV file and number of targets per full interval 
q.value <- data.frame(x=rep(0,nrow(x))) 
for(i in 1:nrow(x)){ 
  q <- cnv[cnv$SAMPLE == as.character(x[i,2]) & 
     cnv$INTERVAL == as.character(x[i,5]),] 
  q.value[i,] <- q[10] 
} 
q.tar <- q.value 
colnames(q.tar) <- "Q_SOME" 
x <- cbind(x,q.tar) 
rm(q.value,q.tar,q,i) 
 
## Remove redundant columns 
x <- x[,-c(5,8:9)] 
 
## Conversion to vcf sytyle genotype annotation 
t <- unique(x[c("EXON","CNV")]) 
t <- cbind(t,seq.int(1,nrow(t),1)) 
colnames(t)[3] <- "EXON_CNV_ID" 
x <- merge(x,t,by.y = c("CNV","EXON"), all.x = TRUE) 
x$GT <- 1 
x <- x[!duplicated(x),] 
x <- spread(x,SAMPLE,GT,fill=0) 
x %>% mutate_if(is.factor, as.character) -> x 
#na replaced as 0 in ref genotype field 
x[is.na(x)] <- 0 
 
## Selecting columns with constant values across rows & collapsing 
x_const <- x[,c(8,1,2,4,5)] 
x_const <- x_const %>% group_by(EXON_CNV_ID) %>% 
       summarise_all(funs(paste(unique(.), collapse=","))) 
 
## Selecting columns with variable values and concatenating them into cells 
x_var <- x[,c(8,3,6,7)] 
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x_var <- x_var %>% group_by(EXON_CNV_ID) %>% 
      summarise_all(funs(paste(., collapse=","))) 
 
## Collapsing genotype information into single row for each unique "site" 
x_geno <- x[,c(8:ncol(x))] 
x_geno <- as.data.frame(x_geno %>% group_by(EXON_CNV_ID) %>% 
       summarise_all(funs(sum(as.numeric(.))))) 
## Confirming only 1 or 0 present 
x_geno[-1][x_geno[-1] > 0] <- 1 
 
## Reconstructing db into single dataframe 
x <- cbind(x_const,x_var,x_geno) 
x <- x[-c(6,10)] 
 
## Adding mean Q_some for each row 
x$Mean_Q_Some <- sapply(str_split(x$Q_SOME, ","), 
          function(x) mean(as.numeric(x))) 
x$Mean_Orig_RD <- sapply(str_split(x$ORIG_RD, ","), 
          function(x) mean(as.numeric(x))) 
x <- cbind(x[1:7],x[ncol(x)],x[9:ncol(x)-1]) 
x <- cbind(x[1:9],x[ncol(x)],x[11:ncol(x)-1]) 
 
## Addition of AF internal to file 
AF_all <- apply(x[11:ncol(x)],1, function(y) (sum(y == 1)/sum(y == 0))) 
x <- cbind(x[1:10],AF_all,x[11:ncol(x)]) 
 
## Adding REF_AF 
x <- merge(x, ref.list, by = c("EXON","CNV"), all.x = TRUE, fill = 0) 
x[is.na(x)] <- 0 
x <- cbind(x[1:11],x[ncol(x)],x[13:ncol(x)-1]) 
#remove commonly altered exons in ref Cohort 
x <- x[x$AF_ref < ref_af_value,] 
 
## String split Exon into gene and exon 
gene_exon <- as.data.frame(str_split(as.character(x$EXON), 
                    "_", 
                    simplify = TRUE), 
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              stringsAsFactors = FALSE) 
gene_exon <- gene_exon[-3] 
colnames(gene_exon) <- c("GENE","EXON") 
x <- x[-1] 
x <- cbind(gene_exon,x[1:ncol(x)]) 
 
## Make sure chr positions are unified as numeric - not containing "chr" 
x$CHR <- gsub("chr","",x$CHR) 
x$TARGET <- gsub("chr","",x$TARGET) 
## write output 
write.table(x, file="cnv_xhmm_annotated.tsv", sep="\t", 
       quote = FALSE, row.names = FALSE, col.names = TRUE, na = "-9") 
save.image(file="cnvANNO.RData") 
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9.4.3b CNV pipeline - Reference interval file generation 
While implemented in its standard deployment, XHMM was limited in its ability to call CNVs at the 
exon-level resolution and provided no reference files for exome target regions. Generation of an 
accurate and curated target file is critical to calculating accurate CNV calls from therefore a series 
of selection criteria were applied to all exome target regions. 
Reference intervals 
Exon bed file was downloaded from BioMart (1) in TSV format, returning unique entries for the 
following fields: 
 "Chromosome/scaffold name" 
 "Exon region start (bp)" 
 "Exon region end (bp)" 
 "Gene name" 
 "Exon rank in transcript" 
Exon intervals were reformatted to fit BED4 (chr, chromStart, chromEnd, Label) specifications. 
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Repeat region filtering 
An important component of the interval file used is that is appropriately filtered for regions that are 
of interest; this excludes regions overlapping low-complexity regions of the genome. These regions 
act to add excessive noise to CNV calling due to systemic sequencing bias and technical issue, so 
can be justifiably removed from genomic target lists. The site repeatmasker.org provides 
categorical fasta files for each type and span of these regions. 
Fasta files containing the type and genomic position of repeat-masked regions can be downloaded 
from repeatmasker.org. The repeat-mask fasta is not immediately appropriate for use so some 
minor pre-processing steps were required to allow for interval comparisons (i.e. delimiter 
alterations, repeat type selection, and sorting by chromosome and position). 
Generating list of overlapping intervals 
Filtering out intervals with any amount of repeat-mask overlap would be overly stringent so only 
exome intervals harbouring an overlap of 25% or more are excluded. The command below 
compares the exome interval set to the repeat-masked interval set generating a list of exons that 
are overlapped by repeat-masked regions by > 25% 
Nextera probe positions were downloaded from Illumina to match library preparation kit used for 
sequencing run and regions overlapping with 50% of matching targets from the library preparation 
probes were retained using Bedtools intersect. The preceding files are loaded into R for filtering 
and target merging, after which 10bp padding is applied to each target interval. This is intended to 
increase the fidelity of calls over target sets by incorporating more reads that align to the edges of 
target regions. The subsequent file is then sorted and merged to collapse overlapping intervals into 
a single interval, resulting in a final exome interval bed file containing only targets of interest. 
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XHMM reference interval – Exome_CNV_reference_intervals_1.sh [BASH] 
sed -i '1d' exons.txt 
sed -i 's/\(\S\+\)\t\(\S\+\)\t\(\S\+\)\t\(\S\+\)\t\(\S\+\)/\1\t\2\t\3\t\4_\5/g' > 
exons.txt 
 
sort -k1,1 -k2,2n exons.txt > exons.sorted.bed 
wget -c LINK_TO_REPEATMASKER_FA_FILE 
gunzip REPEATMASKER.fa.out.gz 
 
awk -v OFS="\t" '$1=$1' REPEATMASKER.fa.out > REPEATMASKER _tab.fa.out 
grep "Simple_repeat" REPEATMASKER _tab.fa.out >> lowcomplex_simpreps.REPEATMASKER.bed 
grep "Low_complexity" REPEATMASKER _tab.fa.out >> lowcomplex_simpreps.REPEATMASKER.bed 
cut -f5-7 lowcomplex_simpreps.REPEATMASKER.bed > 
lowcomplex_simpreps.cut.REPEATMASKER.bed 
 
sort -k1,1 -k2,2n lowcomplex_simpreps.cut.REPEATMASKER.bed > \ 
   lowcomplex_simpreps.sorted.REPEATMASKER.bed 
bedtools intersect -wb -v -F 0.25 -a exons.sorted.bed  
   -b lowcomplex_simpreps.sorted.REPEATMASKER.bed > exons.masked.bed 
sort -k1,1 -k2,2n exons.masked.bed > exons.masked.sorted.bed 
bedtools intersect -loj -wb -F 0.5 -b exons.masked.sorted.bed \ 
          -a nextera_exome_targets.bed > intersect.txt  
XHMM reference interval – Exome_CNV_reference_interval.R [R] 
library(dplyr) 
library(stringr) 
options(scipen = 999) 
 
# Load data and remove empty fields 
bed <- read.table("intersect.txt",sep="\t",comment.char = "",quote = "",fill = T, 
          stringsAsFactors = F) 
bed <- bed[bed$V1 != ".",] 
bed <- bed[bed$V4 != ".",] 
bed <- bed[,-c(4:6)] 
 
# Keep unique and remove misencoded exons 
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bed <- unique(bed) 
bed <- bed[which(!grepl(bed$V7,perl = T,pattern = "\\S+_\\S+_\\S+")),] 
 
 
# Collapse on genomic position 
bed_col <- bed %>% group_by(V1,V2,V3) %>% 
      summarise_all(funs(paste(unique(.),collapse = ","))) 
# Add padding 
bed_col$V2 <- bed_col$V2 - 10 
bed_col$V3 <- bed_col$V3 + 10 
# Write output 
write.table(bed_col, "cnv_targets_masked_pad_.bed",sep="\t",quote=FALSE, 
row.names=FALSE, 
      col.names=FALSE)  
XHMM reference interval – Exome_CNV_reference_intervals_2.sh [BASH] 
sort -k1,1 -k2,2n cnv_targets_masked_pad.bed > cnv_targets_masked_pad_sort.bed 
bedtools merge -i cnv_targets_masked_pad_sort.bed -c 4 \ 
   -o collapse > COLLAPSE.cnv_targets_masked_pad_sort.bed 
mv COLLAPSE.cnv_targets_masked_pad_sort.bed cnv_targets_masked_pad_sort.bed  
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9.4.4 Miscellaneous scripts 
Discordance – genotype_discord.sh [BASH] 
#!/bin/bash 
## Compress and index for bcftools format 
bgzip INPUT_1.vcf; tabix INPUT_1.vcf.gz 
bgzip INPUT_2.vcf ;tabix INPUT_2.vcf.gz 
 
## Calculate discordance with bcftools 
bcftools gtcheck -R ${REGION} -G 1 -g INPUT_1.vcf.gz INPUT_2.vcf.gz | \ 
  cut -f2,4 | tail -n1 > discord_out 
 
## Convert and calculate percentage of GTs discordant 
SCI_NUMER=$(cut -f1 discord_out) # removes scientific notation for calculations 
NUMER=$(printf "%.0f\n" ${SCI_NUMER}) 
DENOM=$(cut -f2 discord_out) 
PCT=$(bc <<< "scale=4; $NUMER / $DENOM * 100" | sed -r 's/^(-?)\./\10./' | \ 
   awk ' sub("\\.*0+$","") ') 
 
## Convert target file paths to useable sample names 
ECHO_1=$(echo ${INPUT1} | sed 's%\S\+/\(\S\+\)_\S\+%\1%') 
ECHO_2=$(echo ${INPUT2} | sed 's%\S\+/\(\S\+\)_\S\+%\1%') 
Population scripts – population.sh [BASH] 
#!/bin/bash 
cat ${VCF} | grep -m 1 "#C" | tr '\t' '\n' | sed -e '1,9d' > sample_list_pop 
bcftools view -h ${REF_VCF} | grep -m 1 "#C" | tr '\t' '\n' | \ 
sed -e '1,9d' >> sample_list_pop 
 
bgzip -c ${VCF} > ${NAME}.vcf.gz 
tabix ${NAME}.vcf.gz 
bcftools merge -Oz -o ${NAME}_REF.vcf.gz ${NAME}.vcf.gz ${REF_VCF} 
 
vcftools --gzvcf ${NAME}_REF.vcf.gz --thin 2000 --chr chr1 --chr chr2 --chr chr3 --chr 
chr4 \ 
  --chr chr5 --chr chr6 --chr chr7 --chr chr8 --chr chr9 --chr chr10 --chr 
chr11 \ 
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  --chr chr12 --chr chr13 --chr chr14 --chr chr15 --chr chr16 --chr chr17 \ 
  --chr chr18 --chr chr19 --chr chr20 --chr chr21 --chr chr22 --chr chrX \ 
  --min-alleles 2 --max-alleles 2 --non-ref-ac 2 --recode --out ${NAME}_REF 
 
plink1.90 --vcf ${NAME}_REF.recode.vcf --out ${NAME}_REF.maf0.05 --make-bed --maf 0.05 \ 
  --vcf-half-call 'm' --const-fid --biallelic-only --geno 0.05 
 
${ADMIXTURE} ${NAME}_REF.maf0.05.bed 5 
Rscript admixture_plotting.R ${NAME}_REF.maf0.05.5.Q 
Population scripts – admixture_plot.R [R] 
rm(list = ls()) 
## Enable cmd line args 
args = commandArgs(trailingOnly=TRUE) 
 
library(ggplot2) 
library(reshape2) 
library(plotly) 
library(RColorBrewer) 
 
q.table <- read.table(args[1]) 
colnames(q.table) <- c("SAS","EUR","EAS","AFR","AMR") 
 
sample.table <- read.table("sample_list_pop") 
colnames(sample.table) <- c("Sample") 
 
pop.table <- read.table("1KG_samplePopulations.tsv",header = T) 
 
plot.table <- cbind(sample.table,q.table) 
 
merge.table <- merge(plot.table,pop.table[,c(2,4)], 
by = "Sample",all.x = T,all.y = F,sort = F) 
merge.table$pred <- apply(merge.table[2:6],1,function(x) names(which.max(x))) 
 
lapply(sort(unique(merge.table$pred)), 
function(x){print(table(merge.table$Super_population[merge.table$pred == x]))}) 
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merge.table <- merge.table[with(merge.table, order(pred)),] 
merge.table$Sample <- factor(merge.table$Sample,levels = merge.table$Sample) 
 
merge.table.cases <- merge.table[is.na(merge.table$Super_population),] 
write.table(merge.table.cases[,-7],"admixture_unknowns.tsv", 
sep = "\t",quote = F,col.names = T,row.names = F) 
 
data.json <- t(merge.table.cases[,1:6]) 
data.json <- cbind(rownames(data.json),data.json) 
save(data.json,file = "admixture_pop.RData") 
 
melt.table <- melt(merge.table,id.vars = c("Sample","Super_population","pred")) 
names(melt.table) <- c("Sample","SuperPop","Pred","Population","Admixture") 
 
P <- ggplot(melt.table[is.na(merge.table$Super_population),], 
    aes(x = Sample, y = Admixture, fill = Population)) + 
       geom_bar(stat = "identity") + 
       ggtitle("Admixture population proportions") + 
       scale_fill_brewer(palette = "Set1") + 
       theme(panel.grid = element_blank(), 
       panel.background = element_blank(), 
       axis.line = element_line(), 
       axis.text.x = element_blank(),axis.ticks.x = element_blank()) + 
       scale_y_continuous(expand = c(0,0)) + 
       scale_x_discrete(expand = c(0,0)) 
png("admixture_unknowns.png",width = 12,height = 3,units = "in",res = 600) 
P 
dev.off() 
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9.4.5 Burden testing scripts 
Burden testing - Association_tests.sh [BASH] 
#!/bin/bash 
if [[ ! -d ${OUTPUT}${PROJECT} ]]; then 
 mkdir ${OUTPUT}${PROJECT} 
fi 
 
if [[ "$MODE" != "no_prep" ]]; then 
 cp tests/* ${OUTPUT}${PROJECT}/ 
 cp ${VCF} ${OUTPUT}${PROJECT}/input_file.vcf 
 mv assoc_log.txt ${OUTPUT}${PROJECT}/ 
 cd ${OUTPUT}${PROJECT}/ 
 VCF="input_file" 
 
## Further vcf filtering removing sites with >10% missing particularly 
 vcftools --vcf ${VCF}.vcf --hwe 0.05 --non-ref-ac-any 1 --minGQ ${MINGQ} \ 
    --minDP ${MINDP} --max-missing ${MISS} --minQ ${MINQ} \ 
   --recode --out ${VCF} 
 mv ${VCF}.recode.vcf ${VCF}.filt.vcf 
 
## Spliting multiallelics 
 java -Xmx30g -jar ${GATK} \ 
  -T LeftAlignAndTrimVariants \ 
  -R /data/Resources/References/${REFERENCE}/${REFERENCE}.fa \ 
  --variant ${VCF}.filt.vcf \ 
  -o ${VCF}.filt.bi.vcf \ 
  --splitMultiallelics 
 
## Generate list of chr files for 
 sed -n '/#CHROM/,$p' ${VCF}.filt.bi.vcf | cut -f1 | sort -u | \ 
   grep -v '#CHROM' > chr_list 
 cat chr_list | xargs -n1 -P${CORES} -I {} mkdir temp_{} 
 cat chr_list | xargs -n1 -P${CORES} -I {} vcftools --vcf ${VCF}.filt.bi.vcf \ 
        --chr {} --recode --recode-INFO-all 
\ 
       --out temp_{}/${VCF}.splt.{} 
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 cat chr_list | xargs -n1 -P${CORES} \ 
   -I {} ${ANNO}table_annovar.pl temp_{}/${VCF}.splt.{}.recode.vcf \ 
   ${ANNO}humandb/ -vcfinput -buildver hg38 -out temp_{}/${VCF}_{} \ 
   -remove -protocol refGene,exac03,dbnsfp30a -operation g,f,f -nastring . 
 
 cat chr_list | xargs -n1 -P${CORES} \ 
   -I {} mv temp_{}/${VCF}_{}.hg38_multianno.vcf 
${VCF}_{}.hg38_multianno.vcf 
 rm -r temp_* 
 sed '/#CHROM/,$d' ${VCF}.filt.bi.vcf > header 
 
 for i in `cat chr_list`; do 
  cat header ${VCF}_${i}.hg38_multianno.vcf > \ 
      ${VCF}_${i}.hg38_multianno.header.vcf 
 done 
 
 ls *.header.vcf > vcf_list 
 
 bcftools concat -o ${VCF}.FINAL.vcf -Ov -f vcf_list 
 
 rm *_multianno*.vcf 
 
## Remove header 
 sed -i -n '/#CHROM/,$p' ${VCF}.FINAL.vcf 
else 
 ## Run vcf processing script 
 mv assoc_log.txt ${OUTPUT}${PROJECT}/ 
 cd ${OUTPUT}${PROJECT}/ 
 VCF="input_file" 
fi 
 
Rscript vcf_prep.R ${VCF}.FINAL.vcf ${PED} ${CORES} ${AF_ref} ${AF_all} \ 
${AF_case} ${AF_cont} ${CONSEQS} 
 
 
Rscript SKAT_test.R 
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Burden testing – vcf_prep.R [R] 
args = commandArgs(trailingOnly=TRUE) 
library(stringr) 
library(stringi) 
library(tidyr) 
library(dplyr) 
library(data.table) 
library(parallel) 
options(scipen=999) 
 
## Load list of excluded samples 
samples_rm <- c() 
CONSEQS <- c("nonframeshift_deletion","nonframeshift_insertion", 
       "frameshift_deletion","stopgain","frameshift_insertion", 
       "splicing","nonsynonymous_SNV","synonymous_SNV","stoploss") 
CONSEQS <- CONSEQS[CONSEQS %in% as.character(unlist(strsplit(args[8],",")))] 
 
## Load column header from vcf file 
col_headers <- fread(args[1],nrows = 1,header = F,sep="\t") 
col_headers <- gsub(pattern = "#",replacement = "",col_headers) 
 
## Load vcf data and append to column headers 
vcf_file <- fread(input = args[1],skip = 1,stringsAsFactors = F, 
         header = F,,sep="\t") 
names(vcf_file) <- col_headers 
vcf_file <- as.data.frame(vcf_file) 
 
## Load case/control T/F data - Sort them into the same order as vcf 
samples <- read.table(args[2]) 
samples <- samples[match(names(vcf_file[10:ncol(vcf_file)]),samples$V1),] 
samples <- samples[!samples$V1 %in% samples_rm,] 
af_unaf <- as.logical(samples[,2]) 
 
## Converting genotypes 
out <- mclapply(vcf_file[10:ncol(vcf_file)],mc.preschedule = T,mc.cores = 2, 
function(x){ 
 x <- stri_replace_all_regex(x,pattern = "^0/0.*",replacement = 0) 
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 x <- stri_replace_all_regex(x,pattern = "^0/1.*",replacement = 1) 
 x <- stri_replace_all_regex(x,pattern = "^1/1.*",replacement = 2) 
 x <- stri_replace_all_regex(x,pattern = "^\\./\\..*",replacement = -9) 
}) 
vcf_file[10:ncol(vcf_file)] <- do.call(cbind.data.frame, out) 
 
## Coerce all genotype columns as.numeric 
vcf_file[,10:ncol(vcf_file)]<-as.data.frame(sapply(vcf_file[,10:ncol(vcf_file)], 
          function(f) as.numeric(as.character(f))),stringsAsFactors=F) 
 
## Adding internal AFs 
cases <- as.character(samples$V1[samples$V2 == TRUE]) 
controls <- as.character(samples$V1[samples$V2 == FALSE]) 
 
intAF <- data.frame(intAF_cases=as.numeric(seq_len(nrow(vcf_file))), 
          intAF_controls=as.numeric(seq_len(nrow(vcf_file))), 
          intAF_set=as.numeric(seq_len(nrow(vcf_file)))) 
 
intAF$intAF_cases <- signif(apply(vcf_file[, 
           which(names(vcf_file) %in% cases)], 
           1,function(x) sum(x != 0) / length(cases)),digits = 2) 
intAF$intAF_controls <- signif(apply(vcf_file[, 
           which(names(vcf_file) %in% controls)], 
           1,function(x) sum(x != 0) / length(controls)),digits = 2) 
intAF$intAF_set <- signif(apply(vcf_file[, 
           which(names(vcf_file) %in% c(cases,controls))], 
           1,function(x) sum(x != 0) / length(c(cases,controls))), 
           digits = 2) 
 
vcf_file <- cbind(intAF,vcf_file) 
## Retrieving annotation information on Allele freq, region function, and mutation 
consequence 
info_split <- as.data.frame( 
 str_split(string = 
 gsub(".*Func\\.refGene=(.*?);.*Gene\\.refGene=(.*?); 
 .*ExonicFunc\\.refGene=(.*?);.*ExAC_ALL=(.*?);.*", 
             replacement = "\\1#\\2#\\3#\\4", 
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             x = vcf_file$INFO), 
      pattern = "#", 
      simplify = T), 
 stringsAsFactors = F) 
 
## Naming annoation information - replacing uncoded 
names(info_split) <- c("FUNC","GENE","CONSEQ","AF") 
info_split$FUNC <- gsub(pattern = "\\\\x3b",replacement = ";",info_split$FUNC) 
info_split$GENE <- gsub(pattern = "\\\\x3b",replacement = ";",info_split$GENE) 
info_split$AF[info_split$AF == "."] <- 0 
info_split$AF <- as.numeric(info_split$AF) 
 
## bind new columns to vcf data 
vcf_file <- cbind(info_split,vcf_file) 
 
## Adding chr:pos ids to rsID column and replacing "." missing value 
vcf_file$ID[vcf_file$ID == "."] <- paste(vcf_file$CHROM[vcf_file$ID == "."], 
                  vcf_file$POS[vcf_file$ID == "."],sep = ":") 
calcID <- paste(vcf_file$ID,vcf_file$REF,vcf_file$ALT,sep = "_") 
vcf_file <- cbind(calcID,vcf_file) 
 
## Add splicing anntation to CONSEQ field 
vcf_file$CONSEQ[vcf_file$FUNC == "splicing" | 
               vcf_file$FUNC == "exonic;splicing"] <- "splicing" 
 
## PCA analysis 
vcf_file_PCA <- vcf_file[vcf_file$AF > 0.05,18:ncol(vcf_file)] 
vcf_file_PCA_t <- as.data.frame(t(vcf_file_PCA)) 
vcf_file_PCA_t <- vcf_file_PCA_t[,which(apply(vcf_file_PCA_t,2,var)!=0)] 
 
PCA.out <- prcomp(vcf_file_PCA_t,center = T, scale. = T) 
PCAs <- as.data.frame(PCA.out$x[,1:5]) 
rm(vcf_file_PCA,vcf_file_PCA_t,PCA.out) 
 
colours <- ifelse(af_unaf == T,"blue","grey") 
colours[which(abs(PCAs$PC1) > sd(PCAs$PC1)*3 & 
      abs(PCAs$PC2) > sd(PCAs$PC2)*3)] <- "red" 
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colours[which(abs(PCAs$PC2) > sd(PCAs$PC2)*3 & 
      abs(PCAs$PC3) > sd(PCAs$PC3)*3)] <- "red" 
 
png(filename = "association_test_PCA.png",width = 16, 
  height = 8,units = "in",res = 600) 
layout(matrix(c(1,2), 1, 2, byrow = TRUE)) 
plot(abs(PCAs$PC1),abs(PCAs$PC2),col=colours,xlab = "PC1", 
  ylab = "PC2", 
  main = "Association tests - PC1 ~ PC2",sub = "Red = Excluded") 
abline(v=sd(PCAs$PC1)*3, col="red") 
abline(h=sd(PCAs$PC2)*3, col="red") 
 
plot(abs(PCAs$PC2),abs(PCAs$PC3),col=colours,xlab = "PC2", 
  ylab = "PC3", 
  main = "Association tests - PC2 ~ PC3",sub = "Red = Excluded") 
abline(v=sd(PCAs$PC2)*3, col="red") 
abline(h=sd(PCAs$PC3)*3, col="red") 
dev.off() 
 
PCA_excluded <- unique(c(rownames( 
    PCAs[abs(PCAs$PC1) > sd(PCAs$PC1)*3 & abs(PCAs$PC2) > sd(PCAs$PC2)*3,]), 
    rownames( 
    PCAs[abs(PCAs$PC2) > sd(PCAs$PC2)*3 & abs(PCAs$PC3) > sd(PCAs$PC3)*3,])) 
    ) 
 
writeLines(PCA_excluded,sep = "\n",con = "PCA_excluded.samples") 
## Adjust Samples and data to remove samples 
PCAs <- PCAs[!rownames(PCAs) %in% PCA_excluded,] 
samples <- samples[!samples$V1 %in% PCA_excluded,] 
 
af_unaf <- as.logical(samples[,2]) 
 
vcf_file <- vcf_file[!colnames(vcf_file) %in% PCA_excluded] 
 
## Filtering vcf data on various traits - Rarity, Function, Consequence 
vcf_file <- vcf_file[vcf_file$CONSEQ %in% CONSEQS,] 
vcf_file <- vcf_file[vcf_file$AF < args[3],] # 0.005 
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vcf_file <- vcf_file[vcf_file$intAF_set < args[4],] # 0.05 
vcf_file <- vcf_file[vcf_file$intAF_cases < args[5],] # 0.2 
vcf_file <- vcf_file[vcf_file$intAF_controls < args[6],] #0.2 
 
save(vcf_file,PCAs,samples,af_unaf,file="association.RData") 
Burden testing – skat_test.R [R] 
## Script for SKAT-O implementation 
rm(list=ls()) 
library(stringr) 
library(stringi) 
library(tidyr) 
library(dplyr) 
library(data.table) 
library(parallel) 
library(SKAT) 
 
## Load data 
load("association.RData") 
## Set missing to 9 
vcf_file[vcf_file == -9] <- 9 
 
## Split by gene 
split_region <- split(vcf_file,as.factor(vcf_file$GENE)) 
 
## Weights 
allele_Freq <- vcf_file$AF 
weights <- Get_Logistic_Weights_MAF(MAF = allele_Freq) 
 
## Setting binary phenotype 
binary <- af_unaf 
binary[binary == T] <- 1 
binary[binary == F] <- 0 
 
## Generating matrix_list 
gene_matrix_list <- mapply(function(x, i){ 
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 mat <- as.data.frame(x) 
 if(nrow(mat) > 1){ 
 col.n <- colnames(mat[c(18:ncol(mat))]) 
 row.n <- as.character(mat[,1]) 
 mat <- as.matrix(t(mat[c(18:ncol(mat))])) 
 rownames(mat) <- col.n 
 colnames(mat) <- row.n 
 return(mat) 
 } 
}, split_region, names(split_region),SIMPLIFY = F) 
 
## SKAT null model 
obj <- SKAT_Null_Model(binary ~ PCAs$PC1, out_type="D") 
## Performing binary SKAT 
out <- mapply(function(x, i){ 
 tryCatchAdv({ 
 cat(paste("[ASSOCIATION TESTS][SKAT] Testing ",i," \n",sep = "")) 
 SKATBinary(as.matrix(x), obj, method = "SKAT", kernel = "linear.weighted") 
 }) 
}, gene_matrix_list, names(gene_matrix_list),SIMPLIFY = F) 
 
skat_results <- do.call(rbind,mapply(function(x, i){ 
  if(length(x$value) == 1){ 
   data.frame(gene=i,pvalue=NA,warning=x$status,description=x$message$message) 
  } else { 
  unique(data.frame(gene=i,pvalue=x$value$p.value,warning=x$status, 
      description=ifelse(!is.na(x$message),x$message$message,NA))) 
  } 
}, out, names(out),SIMPLIFY = F)) 
 
skat_results <- skat_results[order(skat_results$pvalue),] 
skat_results$q.value <- p.adjust(skat_results$pvalue,"fdr") 
 
write.table(skat_results,"skat_output.results", 
      quote=F,row.names=F,col.names=T,sep="\t") 
png(filename = "SKAT_QQ_PC1_MAFw.png", 
   width = 8, 
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   height = 8, 
   units = "in",res = 600) 
QQPlot_Adj( 
Pval = as.numeric(unlist( 
    lapply(out,function(x) if(length(x$value) > 1 ){x$value$p.value}))), 
MAP = as.numeric(unlist( 
    lapply(out,function(x) if(length(x$value) > 1 ){x$value$MAP})))) 
dev.off() 
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9.4.6 Burden testing results 
SKAT-O Burden association testing results (p < 0.01) 
Gene p value q value (FDR corrected) 
FBLIM1 2.55E-06 0.03563319 
SNX30 1.08E-05 0.054276049 
CTSV 1.17E-05 0.054276049 
SLPI 4.89E-05 0.170566669 
PNRC2 0.000134573 0.264815975 
FAM151B 0.000156261 0.264815975 
OR5K1 0.000173994 0.264815975 
SLC23A2 0.000188126 0.264815975 
PRAP1 0.000203361 0.264815975 
SLC19A2 0.000242856 0.264815975 
GPR65 0.000247932 0.264815975 
TBX19 0.000267781 0.264815975 
DPRX 0.000271117 0.264815975 
LILRB3 0.000292 0.264815975 
GFAP 0.00034382 0.264815975 
GSK3B 0.00038061 0.264815975 
OR10P1 0.000399109 0.264815975 
SMPD4 0.000402619 0.264815975 
SC5D 0.000412803 0.264815975 
FBXW4 0.000412876 0.264815975 
PACS1 0.000426772 0.264815975 
COX6A1 0.000433019 0.264815975 
TONSL 0.000436333 0.264815975 
ZNF346 0.000458236 0.266521319 
PRG3 0.000518547 0.289535762 
KCNJ8 0.000654497 0.349503469 
DMRTC2 0.000701635 0.349503469 
LAMTOR5 0.000728328 0.349503469 
CORO1C 0.000735446 0.349503469 
NGDN 0.000751136 0.349503469 
PRSS22 0.000979471 0.413986965 
TMED3 0.001010605 0.413986965 
SLC6A11 0.001012629 0.413986965 
KCNK7 0.001104079 0.413986965 
ZNF250 0.001152795 0.413986965 
CCL4,CCL4L1,CCL4L2 0.001154802 0.413986965 
SLC8B1 0.001170377 0.413986965 
TIGD3 0.001238785 0.413986965 
SH3RF2 0.001254344 0.413986965 
HMGB4 0.001261796 0.413986965 
ZFP57 0.001263514 0.413986965 
LFNG 0.001275334 0.413986965 
RP1L1 0.001323406 0.413986965 
FNDC5 0.001330022 0.413986965 
OR13C4 0.001334581 0.413986965 
VPS33A 0.001388261 0.420908624 
PTGR1 0.001429968 0.420908624 
TBX15 0.001447354 0.420908624 
PSMD8 0.001497021 0.424130617 
KCNN2 0.001519201 0.424130617 
KSR1 0.001570575 0.428019911 
TM9SF4 0.00166613 0.428019911 
ZNF714 0.00173174 0.428019911 
DET1 0.001735973 0.428019911 
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Gene p value q value (FDR corrected) 
ZNF416 0.001737172 0.428019911 
CALHM2 0.001738639 0.428019911 
XPNPEP1 0.00180327 0.428019911 
PANK1 0.001834203 0.428019911 
CLCA4 0.001867313 0.428019911 
CHRAC1 0.001882703 0.428019911 
DUSP6 0.001898997 0.428019911 
CD1E 0.001922296 0.428019911 
HCFC2 0.001931747 0.428019911 
KRTAP4-7 0.001991673 0.434402518 
SERPINB6 0.002032936 0.436580907 
CST8 0.002468087 0.522000314 
DMPK 0.002524601 0.525983717 
IFT88 0.002583276 0.530293297 
HIPK2 0.002741558 0.540888182 
HBP1 0.002774881 0.540888182 
GABRA3 0.002779539 0.540888182 
UBN1 0.002843189 0.540888182 
TEAD1 0.002881216 0.540888182 
PLEKHO1 0.002904529 0.540888182 
ZNF705A 0.002906126 0.540888182 
PKDREJ 0.002966456 0.544852105 
MRPL40 0.003009531 0.545585057 
KPTN 0.003255227 0.5750819 
HIF1A 0.003286868 0.5750819 
NUDT16 0.003322268 0.5750819 
MEDAG 0.00337031 0.5750819 
LRRC74B 0.003418878 0.5750819 
KBTBD4 0.003419428 0.5750819 
LYSMD4 0.003488999 0.579796832 
CTTN 0.003531331 0.579927579 
RRP15 0.003663402 0.580204652 
VAV2 0.003726035 0.580204652 
ITCH 0.00377388 0.580204652 
OR4F4 0.003802435 0.580204652 
FAAH 0.003879128 0.580204652 
PKNOX2 0.003890677 0.580204652 
PHF20L1 0.003900951 0.580204652 
C1QTNF7 0.003969547 0.580204652 
GIMAP7 0.003998001 0.580204652 
ACMSD 0.004026266 0.580204652 
OIT3 0.004037775 0.580204652 
MRPL39 0.004119993 0.580204652 
CLEC17A 0.004121411 0.580204652 
KRTAP5-8 0.004220275 0.580204652 
C17orf78 0.004270211 0.580204652 
PREP 0.004306123 0.580204652 
PPM1A 0.004327817 0.580204652 
SLC22A15 0.004388291 0.580204652 
HOXC10 0.004395015 0.580204652 
C4orf27 0.004403175 0.580204652 
LGALS12 0.004405881 0.580204652 
SLC5A1 0.004775543 0.618382577 
SPEG 0.004802565 0.618382577 
FYTTD1 0.004828691 0.618382577 
AMDHD1 0.004920644 0.621823193 
MS4A2 0.004982337 0.621823193 
CPA2 0.004989197 0.621823193 
CA14 0.005035638 0.622057282 
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Gene p value q value (FDR corrected) 
C10orf12 0.005226798 0.633847033 
ADGRD1 0.005236317 0.633847033 
AKR1C4 0.005269664 0.633847033 
TAOK3 0.005319086 0.633847033 
ZNF430 0.005409051 0.633847033 
KIF5C 0.005501874 0.633847033 
GPD1L 0.005573342 0.633847033 
REEP6 0.005585432 0.633847033 
SH2B2 0.005632483 0.633847033 
ST6GAL1 0.005812554 0.633847033 
B3GALT2 0.005854457 0.633847033 
SPAG16 0.005854845 0.633847033 
MYH1 0.005855493 0.633847033 
SEC22C 0.005857836 0.633847033 
PDE12 0.005923886 0.633847033 
FGD5 0.005942027 0.633847033 
ENTPD4 0.005963749 0.633847033 
RPUSD2 0.005966535 0.633847033 
SCGN 0.005993825 0.633847033 
ASB18 0.00607613 0.637719549 
TGFBI 0.006237223 0.646677384 
LRIT1 0.006254133 0.646677384 
ZFP42 0.006335164 0.647966604 
DMTF1 0.00635944 0.647966604 
DAPK2 0.006461977 0.65364307 
ARMC7 0.006550323 0.657812621 
A1CF 0.006613826 0.659445725 
NAV3 0.006892369 0.682344512 
CDCA3 0.007109488 0.698882698 
ADCY7 0.007281647 0.710800775 
DDX54 0.00742003 0.715038593 
RBM15 0.007427509 0.715038593 
SAMD7 0.007565645 0.720872629 
C5orf60 0.007591395 0.720872629 
TMA16 0.007668263 0.723251946 
STT3B 0.007736165 0.724759272 
BROX 0.00785703 0.72911864 
GOLIM4 0.007887163 0.72911864 
PADI1 0.008077093 0.733139724 
TRMT2A 0.008090709 0.733139724 
SLC36A4 0.008095321 0.733139724 
OR2AG1 0.008142547 0.733139724 
ADAMTS2 0.00825169 0.733139724 
MYL2 0.008371296 0.733139724 
CXCL1 0.008418193 0.733139724 
EPHB4 0.008434813 0.733139724 
APITD1,APITD1-CORT 0.008535441 0.733139724 
FCRL2 0.008538744 0.733139724 
LCN12 0.008551669 0.733139724 
CWC27 0.008560912 0.733139724 
MAEL 0.008794906 0.747131388 
CHPF 0.00883134 0.747131388 
VSIG10L 0.009300606 0.764899502 
AXIN1 0.009328601 0.764899502 
FPR3 0.009450124 0.764899502 
ZNF202 0.009477217 0.764899502 
SGPP2 0.009572906 0.764899502 
SLC35F1 0.009585344 0.764899502 
GAN 0.009703024 0.764899502 
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Gene p value q value (FDR corrected) 
WLS 0.009774578 0.764899502 
KCNB1 0.009842355 0.764899502 
LIPF 0.009844052 0.764899502 
PIGA 0.009867894 0.764899502 
OR1S2 0.009888138 0.764899502 
CHCHD2 0.009898729 0.764899502 
CNN1 0.009907776 0.764899502 
ENAH 0.009977957 0.764899502 
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9.5 Chapter 6 RCC-associated translocations 
9.5.1 Copy number and structural variant calling scripts 
Copy number calling – CANVAS.sh [BASH] 
Canvas CNV Caller (version 1.38.0.1598) was used to call copy number variation from WGS BAM 
files. Reference genomes and required supporting files were downloaded from http://canvas-cnv-
public.s3.amazonaws.com/ for GRCh38. The following command was used to generate copy 
number alterations; 
#!/bin/bash 
 
for SAMPLE in `cat /home/pss41/translocs_rcc/canvas_samples.list`; do 
 mkdir ${OUTPUT}${SAMPLE}_canvas 
 cd ${OUTPUT}${SAMPLE}_canvas 
##decoy VCF files 
 echo –e “${DECOY_VCF_HEADER" > ploidy.vcf 
dotnet ${CANVAS} SmallPedigree-WGS -b ${INPUT}${SAMPLE}${SUFFIX} \ 
   --population-b-allele-vcf ${CANVAS_RESOURCES}${BUILD}/dbsnp.vcf \ 
   -o ${OUTPUT}${SAMPLE}_canvas \ 
       -g ${CANVAS_RESOURCES}${BUILD}/Sequence/WholeGenomeFasta/ \ 
   -r ${CANVAS_RESOURCES}${BUILD}/Sequence/WholeGenomeFasta/genome.fa 
\ 
   -f ${CANVAS_RESOURCES}${BUILD}/filter13.bed \ 
   --ploidy-vcf ploidy.vcf 
 tabix CNV.vcf.gz 
 bcftools view -f "PASS" -o ${SAMPLE}_canvas.vcf -Ov CNV.vcf.gz 
 
sed -n '/#CHROM/,$p' ${SAMPLE}_canvas.vcf | grep -v '#CHROM' | \ 
 sed 's%\(\S\+\)[10]%\3\t\1|\2|\3|\4|\5|\6|\7|\8|\9%g' | \ 
 sed -r 's%Canvas:GAIN:%%g' | sed -r 's%Canvas:LOSS:%%g' | \ 
 sed -r 's%Canvas:REF:%%g' | \ 
 sed 's%\(\S\+\):\(\S\+\)-\(\S\+\)\t\(\S\+\)%\1\t\2\t\3\t\4%g' > 
${SAMPLE}_canvas.bed 
bedtools intersect -wa -wb -a ${SAMPLE}_canvas.bed -b ${BED} > 
${SAMPLE}_annotated_canvas.bed 
done 
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Structural variant calling – MANTA.sh [BASH] 
Manta Structural variant caller (version 1.3.1) was used to identify candidate chromosomal break 
points matching cytogenetic banding and assess if structural variants had impacted on known RCC 
predisposition genes (VHL, MET, FH, SDHB, SDHD, SDHC, BAP1, CDKN2B). The following 
command was used to generate SV calls using Manta; 
#!/bin/bash 
 
configManta.py --bam=${SAMPLE}.bam \ 
 --referenceFasta=${REFERENCE}.fa \ 
 --runDir=${OUTPUT_FOLDER} 
 
${OUTPUT_FOLDER}/runWorkflow.py -m local -j 8 
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9.5.2 IGV visualisations of translocation break point 
t(2;17)(q21;q11.2) 
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t(3;6)(p14.2;p12) 
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inv(3)(p21.1q12) 
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t(3;14)(q13.3;q22) 
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t(10;17)(q11.22;p12) 
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9.5.3 Sanger sequencing of translocation break points 
Translocation break point primers 
 
 
Translocation 
Pair one (5’ to 3’) Pair two (5’ to 3’) 
Left Right Left Right 
t(2;17)(q21;q11
.2) 
TTCTGGCAGCGGGTCC
A 
CAAAAGGGCAGCAATG
AACCA 
TTCAATGATGTCATACTAG
CAGCTT 
GTGGACTTCAGGGAGA
TGCG 
t(3;6)(p14.2;p1
2) 
TCACCTGAAGTCTCTTC
TTTCTT 
CTCCAGGAAGTGATAC
ATGGAA 
GTCCTGTTTCCCTAGTCC
TGC 
AGGGAGGCAAGAAGGA
AGTG 
inv(3)(p21.1q1
2) 
Failed to generate PCR products – 3 independent primer sets and nested primers 
t(3;14)(q13.3;q
22) 
CCCCAACAAACCCCAC
AACA 
TGGACTCTGTATTCTGT
TCCGT 
GAGCTGAGATCATGCCAT
TGT 
CTGAGTGGAGTCTGTAT
TTCCCA 
t(10;17)(q11.22
;p12) 
GGCCACAATACTATGT
CTCACC 
ATACATGCGCACACAA
GGTC 
GGGACAGTGGAGAACGC
AT 
AAATTAGCTGGGCATGG
TGG 
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